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Soluble lipopolysaccharide (LPS) inhalation challenge induced a dose-dependent
bronchoalveolar lavage fluid (BALF) neutrophilia in both heaves-susceptible and
control horses, and significant lung dysfunction in the heaves group. The response
thresholds were lower for the heaves group, yet were markedly greater than airborne
endotoxin exposure during the 5h dusty hay/straw challenge. In addition, there was no
significant difference in BALF neutrophil numbers between the 2 groups following
challenge with the middle and high LPS dose. There was a significant difference in
the airway inflammatory response of the heaves group to 2 separate hay/straw
exposures. This response was not related to the level of airborne endotoxin exposure.
These findings indicated that inhaled endotoxin is not solely responsible for the
induction of naturally occurring heaves.
Inhalation challenge of the heaves group with 3 incremental doses of soluble A.
fumigatus extract resulted in an increase in a BALF neutrophilia and lung
dysfunction, which plateaued following inhalation of the middle dose. Inhalation
challenge with LPS-depleted A. fumigatus extract resulted in a significant reduction
in airway neutrophil numbers, of a magnitude that was greater than predicted by
extrapolation from soluble LPS dose response inhalation experiments. These findings
indicated that inhaled endotoxin may act synergistically with mould antigens, and
contribute to the pulmonary inflammation observed in heaves.
Inhalation challenge with hay dust suspensions (FIDS), prepared from fine hay dust
particles, induced an airway neutrophilia, airway dysfunction and mucus hyper¬
secretion in the heaves group only. Inhalation challenge of the heaves group with the
soluble fraction of HDS (SUP) failed to induce the magnitude of response measured
following HDS challenge, despite containing almost all of the endotoxin activity of
the HDS. These findings supported the involvement of HDS components, other than
endotoxin, in the aetiopathogenesis of heaves. Inhalation challenge of the heaves
group with the particulate fraction of FIDS (WP) induced only a mild BALF
neutrophilia, however a combined challenge with SUP and WP induced a
neutrophilic response approaching the magnitude of that following HDS challenge.
These findings indicated a synergistic action between the soluble and particulate
fractions of HDS.
Inhalation challenge of the heaves group with LPS-depleted HDS resulted in a
significant reduction in BALF neutrophil numbers, of a magnitude that was greater
than predicted by extrapolation from soluble LPS dose response inhalation
experiments. Replacement of the depleted LPS resulted in the re-establishment of the
original level of BALF neutrophilia. Inhalation challenge of the heaves group with
WP reconstituted in LPS solution (containing an equivalent LPS activity to SUP)
resulted in a BALF neutrophilia that was not significantly different from that
following challenge with combination of WP and SUP. These findings indicated that
the endotoxin content of HDS acts synergistically with other HDS components, most
notably the particulate fraction.
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The domestication of the horse has resulted in the exposure of many horses to
environments that have proved to be detrimental to their health. Frequently horses
are housed in poorly ventilated environments (Clarke et al., 1987; Jones et al., 1987),
fed on poorly saved hay and bedded on poorly saved straw (Clarke, 1987b). As a
result the housed horse is frequently exposed to high levels of airborne pollutants
including inorganic dusts, ammonia (Clarke, 1987a), endotoxins (Dutkiewicz et al.,
1994; McGorum et al., 1998), bacteria (Clarke, 1987a), viruses (Clarke, 1987a), fungi
and actinomycetes (Clarke, 1987a; Clarke and Madelin, 1987; Clarke, 1993) and
forage mites. Consequently large numbers of housed horses develop environmental
pulmonary diseases, the most commonly recognised of which is heaves (previously
termed Chronic Obstructive Pulmonary Disease). While an association between
heaves and mouldy hay was documented in the veterinary literature over 200 years
ago (Clarke, 1788), there is increasing awareness that other forms of stable dust-
induced respiratory disease may also affect horses.
Over the past decade it has become increasingly evident that the clinical features of
equine heaves are consequences of pulmonary inflammation (Derksen, 1993).
Effective management of heaves therefore relies upon the reduction of the
inflammatory response, ideally by removing the inciting inhaled agents or by the use
of anti-inflammatory therapy. Improved understanding of the inhaled agents
responsible for inducing pulmonary inflammation is a prerequisite to the
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establishment of airborne dust safety threshold levels and the development of new
strategies to control this disease.
1.1 Equine Heaves
1.1.1 Aetiological agents
Heaves results from housing horses in certain environments. When horses are stabled
and fed hay, they are exposed to and inhale airborne dusts rich in organic material
(Crichlow et al., 1980; Clarke and Madelin, 1987; Clarke et al., 1987; Webster et al.,
1987; Woods et al., 1993), which induce pulmonary inflammation and airway
obstruction (Robinson et al., 1996). Clinical remission can be achieved by moving
the horses to pasture (Thomson and McPherson, 1984; Derksen et al., 1985a;
Derlcsen et al., 1985b). The relative importance of each organic dust component in
the aetiopathogenesis of heaves is unknown, and it is probable that more than one
component of organic dust has the potential to cause pulmonary disease when inhaled
in sufficient quantities. Indeed the inhalation of a combination of these agents may
result in complicated additive and synergistic activities.
1.1.1.1 Moulds (fungi and thermophilic actinomycetes)
A wide variety of airborne moulds have been identified in equine stables which
contain hay and straw (Clarke and Madelin, 1987), since, if baled with a moisture
content exceeding 20%, this herbage is rich in spores of fungi and actinomycetes such
as Aspergillus fumigatus, Faenia rectivirgida and Thermoactinomyces vulgaris
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(Clarke, 1987b). Although there is little or no difference between healthy and heaves
horses with respect to levels of serum antibodies to a number of different moulds
(Lawson et al., 1979; Madelin et al., 1991), heaves horses do have exaggerated local
pulmonary antibody (both IgG and IgE) responses to certain moulds including
A.fumigatus and F.rectivirgula (Halliwell et al., 1993; Crameri, 2001). McGorum et
al. (1993c) demonstrated that inhalation challenges with aqueous extracts of either A.
fumigatus or F. rectivirgula induced a neutrophilic pulmonary inflammatory response
and associated pulmonary dysfunction in asymptomatic heaves-affected horses, but
not in controls, thus indicating that these agents may contribute to the development of
naturally occurring heaves. However in this study, the severity of the pulmonary
inflammation induced by these challenges was significantly less marked than that
induced by long-term mouldy hay/straw exposure. Many differences exist between
the two types of challenge systems that may account for this difference. These include
a difference in the total quantity and duration of antigen challenge, a possible
difference in the proportion and location of antigen deposition within the respiratory
tract and the fact that the natural hay/straw challenge results in exposure to multiple
mould antigens. Additionally, the potential involvement of other agents present
within organic dust should not be overlooked, since these may act in an additive or
synergistic fashion with mould antigens, thus amplifying the inflammatory and lung
function changes. In contrast to the findings ofMcGorum et al (1993c), Derksen et al
(1988) demonstrated that inhalation challenge with F. rectivirgula induced a
bronchoalveolar lavage fluid (BALF) neutrophilia in both control horses and
asymptomatic heaves horses. The BALF neutrophilia reported in the control ponies
may indicate that F. rectivirgula inhalation challenges are not a good model of the
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disease, as control horses do not develop an airway neutrophilia following natural
exposure to a hay/straw environment. Alternatively, the concentration of extract used
by Derksen el al. (1988) may have been excessively high, thus inducing a non¬
specific inflammatory response. A similar induction of false positive results has been
reported in humans given inhalation challenges with excessively high concentrations
of antigen (Townley et al., 1965; Cavanaugh et al., 1977). An alternative explanation
for the finding of Derksen et al. (1988) may have been contamination of the inhaled
extract with other pro-inflammatory agents such as endotoxin.
1.1.1.2 Forage mites
Large numbers of forage mites may be present in poorly stored forage (Halls and
Gudmundsson, 1985). Horses with heaves do not have elevated BALF levels of
forage mite specific IgE and IgG, suggesting that pulmonary hypersensitivity
responses to forage mites are unlikely to be involved in the pathogenesis of the
disease (BC McGorum, personal communication).
1.1.1.3 Endotoxins
Further investigation is warranted with respect to the potential role of inhaled
endotoxin in the aetiopathogenesis of equine heaves, since there are many similarities
between equine heaves and endotoxin mediated lung diseases in other species
(McGorum et al., 1998). Both are characterised by reversible airway obstruction,
airway neutrophilia, bronchial hyper-responsiveness and increased mucus production,
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have similar time courses, and result in minimal permanent structural lung changes
such as emphysema and fibrosis (Rylander, 1990; Gordon and Harkema, 1995;
Robinson et al., 1996). In addition several studies have reported high concentrations
of airborne endotoxin in horse stables, often exceeding the recommended safety
levels for human exposure (Dutkiewicz et al., 1994; Rylander, 1997b; McGorum et
al., 1998; Tanner et al., 1998). The latter section of this review will give a more
detailed literature review on the potential involvement of inhaled endotoxin in the
aetiopathogenesis of heaves.
1.1.1.4 Other stimuli contributing to airway inflammation and dysfunction
Horses with symptomatic heaves have increased airway reactivity (Derksen et al.,
1985a), therefore other inhalants, including particulate matter, cold air, dry air and
noxious gases may exacerbate airway inflammation and obstruction in symptomatic
horses.
1.1.2 Pathogenesis of heaves
The exact mechanisms that result in pulmonary inflammation and dysfunction in
heaves are not fully understood, however both environmental observations and the
findings of several studies strongly support the involvement of a hypersensitivity
component (Robinson et al., 1996). Some studies have demonstrated an increased
frequency and magnitude of skin responses in heaves-susceptible horses following
intradermal injections of both stable dust and mould extracts (Halliwell et al., 1979;
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McPherson et al., 1979), with a significant difference from the response of control
horses at 30min and 4h (Halliwell et al., 1979). As well as supporting the
involvement of allergy in heaves, the study by Halliwell et al. (1979) also indicated
that both a type I (IgE-mediated) and type III (IgG-mecliated) hypersensitivity were
involved, at least with respect to the dermal response. However the limited value of
intradermal mould antigen testing was highlighted by McGorum et al. (1993a), who
demonstrated that there was no difference between controls and heaves horses with
respect to the intradermal end-point titres of various aqueous mould extracts. This
study also failed to demonstrate a significant correlation between the pulmonary and
dermal response to mould extracts (McGorum et al., 1993a), a finding which has also
been reported in human allergen inhalation and intradermal studies using recombinant
house dust mite allergens (van der Veen et al., 1998). Further support for IgE
mediation (type I hypersensitivity) in heaves has been advocated recently, where
bronchoalveolar lavage cells harvested from hay/straw challenged heaves horses,
when compared to those from control animals, had increased expression of
interleukin-4 (IL-4) and IL-5, and decreased expression of interferon-y (INF- y)
(Lavoie, 2001), a cytokine profile consistent with a local pulmonary T-helper cell 2
response. In addition, a recent study reported that compared with controls, heaves-
susceptible horses had a higher number of IgE positive cells in bronchioles and
pulmonary blood vessels following mouldy hay straw challenge (van der Haegen et
al., 2001). However, the significant difference between the 2 groups was largely due
to 2 individual heaves horses with excessively high IgE positive cells. The study
suggested that various immunological reactions are probably involved in heaves, and
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that IgE-mediated reactions are possibly only involved in some cases or in some
stages of the disease.
Certain studies have suggested that the mast cell may play a key role in the
pathogenesis of heaves (Mair et al., 1988), and mast cells have been identified in
greater numbers in lungs from horses with heaves (Winder and Vonfellenberg, 1990).
In addition, the pulmonary epithelial lining fluid (PELF) concentration of histamine
was found to be elevated in heaves horses following hay/straw challenge, and the
histamine concentration was found to correlate with the numbers of
metachromatically staining cells, presumed to be mast cells and/or basophils
(McGorum et al., 1993b). However, although the potential involvement of mast cells
and mast cell-derived mediators is also consistent with an IgE mediated
hypersensitivity response, it is possible that other factors such as bacteria, fungal
spores and endotoxin result directly in mast cell degranulation (Clementsen et al.,
1991; Norn et al., 1994; Larsen et al., 1996; Brown et al., 1998; Iuvone et al., 1999)
causing a non-IgE mediated mast cell-induced airway response (Mehlhop et al.,
1997). In addition, the sole involvement of a type I hypersensitivity in heaves is
unlikely given the usual clinical presentation of heaves susceptible horses following
exposure to mouldy hay/straw environments where an early (<lh) onset dyspnoea is
absent.
Therefore despite the evidence for a hypersensitivity response in heaves, it would
appear that this does not exclusively involve an IgE mediated type I response,
7
although the balance between the involvement of a type I and type III (and possibly
type IV) response may vary among individual subjects (Halliwell et al., 1979). The
involvement of a hypersensitivity response is further supported by the fact that only
certain susceptible individuals develop all the characteristic features of heaves,
namely airway neutrophilia, obstructive pulmonary disease and bronchial
hyperreactivity, when exposed to dusty environments, which have little or no effect
on the majority of the horse population. Of the above characteristics, airway
obstruction is the most likely to result in overt clinical signs and thus initiate further
diagnostic intervention. Therefore it is probable that less severely affected horses
remain undiagnosed, and that a larger spectrum of disease severity than is currently
appreciated likely exists. Upon consideration of the variety of components present in
stable dust, it is possible that the distinction between clinical and sub-clinical disease
may not only reflect variation in the degree of sensitivity to inhaled allergens, but also
variation in the response to other inhalants through non-allergenic mechanisms.
1.1.3 Pathology of heaves
The principal lesion in heaves-affected horses is bronchiolitis (Nicholls, 1978).
Airway wall thickness increases are due to increased thickness of the epithelium,
submucosa and smooth muscle. Mucus accumulates within the lumen of airways and
adjacent alveoli. Peribronchial accumulations of inflammatory cells, principally
lymphocytes, are accompanied by intraluminal accumulations of neutrophils, and
very rarely eosinophils (Derksen et al., 1985b; Yamashiro et al., 1985; McGorum et
al., 1993d). Alveolar epithelial changes include necrosis of type 1 alveolar epithelial
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cells with replacement by type II alveolar epithelium. Mucus cell metaplasia and
hyperplasia is seen, in addition to Clara cell degranulation and loss (Kaup et al.
1990a). Focal loss of ciliated cells occurs in the larger airways followed by
replacement by undifferentiated cells in a hyperplastic epithelium (Kaup et al.
1990b).
1.1.4 Pathophysiology of heaves
The airway dysfunction and resultant clinical abnormalities can largely be related to
the airway obstruction. This obstruction occurs both as a result of airway narrowing
associated with inflammation and to contraction of bronchial and bronchiolar smooth
muscle. Airway smooth muscle contraction is caused by the complex actions of
inflammatory mediators on smooth muscle and on the afferent and efferent neural
arcs which control airway calibre (Robinson et al., 1996).
Some of the clinicopathological changes associated with heaves are fully reversible
following a relatively short period (4-24 days) of exclusion from the causal agent(s)
(Thomson and McPherson, 1984). Consequently, animals in disease remission have
no clinically detectable pulmonary dysfunction, airway neutrophilia nor increased
airway reactivity, however some structural airway changes are longer lasting and
include epithelial metaplasia and hyperplasia and smooth muscle hyperplasia
(Robinson et al., 1996). Additionally it has recently been demonstrated that mucus
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hypersecretion persists for long periods after affected horses are moved to an allergen
free environment (Dixon et al. 1995b).
1.2 Organic Dusts and Occupational Lung Disease in Humans
1.2.1 Background
Organic dust has been defined as dust that originates from plant or animal matter
(Heederik et al., 2000). It has been well established that high levels of airborne
organic dust occur in many agricultural and industrial environments, including
poultry housing (Clark et al., 1983b; Wiegand et al., 1993), farm buildings
(Lundholm et al., 1986; Olenchock et al., 1986; Rylander, 1986), various animal
houses (Pickrell, 1991; Dutkiewicz et al., 1994), dairy farms (Malmberg, 1990;
Louhelainen et al., 1997; Kullman et al., 1998), compost plants (Clark et al., 1983a),
equine stables (Crichlow et al., 1980; Webster et al., 1987; Clarke, 1993; McGorum
et al., 1998), cotton mills (Rylander, 1987) and saw mills (Douwes et al., 2000a;
Mandryk et al., 2000). It is also well recognised that many agricultural and forestry
occupations are associated with a high incidence of respiratory symptoms such as
those reported amongst swine workers (Larsson et al., 1994; Zejda et al., 1994;
Preller et al., 1995a; Schwartz et al., 1995a; Reynolds et al., 1996; Cormier et al.,
1997; Wang et al., 1997; Nowak, 1998; Vogelzang et al., 1998; Vogelzang et al.,
2000), animal feed workers (Jorna et al., 1994; Smid et al., 1994; Kuchuk et al.,
2000), grain workers (Schwartz et al., 1995b), potato processing workers (Zock et al.,
1995), poultry workers (Zuskin et al., 1995; Donham et al., 2000), cotton workers
(Rylander, 1987; Rylander, 1990; Sigsgaard et al., 1992; Jacobs et al., 1993; Li et al.,
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1995; Christiani et al., 1999) trout workers (Sherson et al., 1989), sawmill workers
(Mandryk et al., 2000) and crop farmers (Monso et al., 2000).
It has recently been suggested that rather than linking clinical disease with a specific
environment, symptoms should be related to the relevant pulmonary cellular
reactions, particularly inflammation (Rylander, 1992). This has led to the realisation
that many of the reported clinical symptoms associated with a particular occupation
also occur in workers in other organic dust environments, thus identifying a common
link, namely airborne organic dust (Rylander, 1992). In addition to establishing a link
between agricultural occupations which result in a high organic dust exposure and
respiratory symptoms and/or a reduction in lung function, many studies have also
identified an association between certain agricultural occupations and an increase in
markers of inflammation in blood (Sigsgaard et al., 1992; Borm et al., 1996; Thorn et
al., 1998; Wang et al., 1998; Rylander et al., 1999; Sjogren et al., 1999), nasal lavage
fluid (Cormier et al., 1997; Larsson et al., 1997; Wang et al., 1997; Keman et al.,
1998; Borm et al., 2000; Douwes et al., 2000b), BALF (Cormier et al., 1997; Larsson
et al., 1997; Wang et al., 1997) and sputum (Thorn et al., 1998). Consequently
agriculture is considered one of the most hazardous occupations with respect to
human health (Kirkhorn and Garry, 2000). Furthermore, the changing patterns of
agriculture, such as increases in animal density within confinement houses, has
resulted in increased exposure to respiratory hazards in the workplace (Kirkhorn and
Garry, 2000).
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1.2.2 Organic dust inhalation studies
As part of the recent extensive investigation into the effects of organic dust
inhalation, new models for organic-dust induced disease have been established using
the criteria developed for disease among workers in cotton mills and swine
confinement buildings (Rylander, 1992; Castranova et al., 1996). Controlled acute
inhalation studies have been conducted using dry dust challenges in humans
(Cavagna et al., 1969; Wang et al., 1996a), pigs (Hoist et al., 1994; Urbain et al.,
1996b), guinea pigs (Rylander, 1988; Gordon, 1990; Frazer et al., 1993; Gordon,
1994) mice (Ryan et al., 1994; Shvedova et al., 1996) and rabbits (Cavagna et al.,
1969), and organic soluble aqueous dust extracts in humans (Clapp et al., 1994; von
Essen et al., 1995a; Blaski et al., 1996; Jagielo et al., 1996b; Jagielo et al., 1997;
Trapp et al., 1998), mice (Jagielo et al., 1996a; Jagielo et al., 1998; WohlfordLenane
et al., 1999) and rabbits (Cavagna et al., 1969). In addition, a few long-term dry dust
challenges have been conducted in animal models (Jolie et al., 1999). These models
have been successful in reproducing many of the clinical symptoms, and lung
dysfunction and inflammation, observed in agricultural workers exposed naturally to
organic dusts. In addition, they have improved the understanding of the underlying
disease mechanisms.
Inhalation of organic dusts or organic dust extracts results in an increase in the
numbers of granulocytes in blood (Jagielo et al., 1997) and BALF (Rylander, 1988;
Frazer et al., 1993; Clapp et al., 1994; Ryan et al., 1994; von Essen et al., 1995a;
Jagielo et al., 1996a; Jagielo et al., 1996b; Shvedova et al., 1996), an increase in
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vascular permeability (Gao et al., 1993) and airway oedema (Gordon, 1990). It also
results in an increased concentration and/or expression of inflammatory cytokines
(e.g. TNF-alpha, IL-6, IL-la, IL-ip, IL-8 and IFN-y) in serum (Shvedova et al., 1996;
Wang et al., 1996b), BALF (Clapp et al., 1994; Ryan et al, 1994; Jagielo et al.,
1996a; Jagielo et al., 1996b; Shvedova et al., 1996) and/or induced sputum (Park et
al., 1998), as well as increased expression of chemokines (e.g. MIP-2) in BALF cells
(WohlfordLenane et al., 1999) and increased neutrophil elastase in induced sputum
(Park et al., 1998). Both in vitro cell culture work and in vivo inhalation challenges
have provided evidence for the involvement of macrophages, epithelial cells,
neutrophils and mast cells in the local pulmonary production of cytokines and
mediators in response to organic dust extract (Becker et al., 1999).
1.3 The Role of Endotoxin in the Aetiology of Organic Dust-Induced Disease
It is generally accepted that organic dusts contain a wide variety of components, many
of which have been shown to induce either sensitisation or inflammation, when
inhaled (Rylander, 1994). However, endotoxins are universally present within all
types of organic dusts, and there is increasing evidence that inhaled endotoxin plays a
major role in organic dust-induced lung disease.
1.3.1 Endotoxin overview
Endotoxin is perhaps the most important cause of organic dust-induced pulmonary
disease (Jacobs, 1997a). It is present in the cell walls of gram-negative bacteria,
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which are commonly found in organic dusts (Jacobs et al., 1997). The terms
"endotoxin" and "lipopolysaccharide" (LPS) are often used interchangeably, however
the term lipopolysaccharide should be reserved to denote chemically pure substances,
free from other chemical compounds that can be found in gram-negative bacterial cell
walls. The term endotoxin refers to fragments of the gram-negative bacterial cell wall
that contain LPS as well as other naturally occurring compounds (Jacobs et al., 1997).
The LPS molecule contains a lipid region (lipid A), and a long covalently linked
heteropolysaccharide. The polysaccharide portion is divided into a "core" portion and
the O-specific chain, a division made on the basis of chemical composition, structure,
mode of biosynthesis and function (Jacobs et al., 1997). The lipid A molecule shows
the least variation of all the components of the LPSs in all bacterial families and is
primarily responsible for LPS toxicity, which is determined by the presence of 2 D-
glucosamine residues that are (3-( 1 -6)-linked, and the phosphoryl groups.
Additionally, the location of fatty acids, the number of acyl chains present, the acyl
length, and the configuration of the -OH fatty acids are of great importance to
endotoxin activity (Rietschel et al., 1987; Rietschel et al., 1990).
Structural variation of the core polysaccharide within a bacterial species tends to be
low, with only five known types in the family Enterobacteriaceae (Jacobs et al.,
1997). The O-specific chain shows the greatest structural diversity of all the
molecular components of LPS (Rietschel et al., 1990). It is composed of 20-40
repeated "oligosaccharide units", the number being dependant on both bacterial strain
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characteristics and growth conditions (Jacobs et al., 1997). In addition, the type of
monosaccharide and the nature, sequence and type of sugar linkage of the
monosaccharide units within the oligosaccharide units vary with each bacterial genus
and species (Rietschel et al., 1990).
Like other membrane molecules, LPS is amphipathic, i.e. has both hydrophobic and
hydrophilic parts (Taussig, 1984). Thus, in aqueous solution it forms large micelles
with the lipid on the inside. Although the lipid A component of LPS determines
toxicity, the antiphagocytic effect of LPS can be attributed to the very hydrophilic
nature of the O-side chains, thus contributing to virulence (Taussig, 1984). Therefore
LPS is a very heterogenous molecule, the biological effects of which are largely
dependant on molecular structure.
Various cell types can respond to endotoxins, including polymorphonuclear
leucocytes, lymphocytes, epithelial cells, endothelial cells and mast cells, although
monocytes/macrophages are the most investigated cell populations which respond to
endotoxins (Ulmer, 1997). Each individual cell type reacts in a typical way, however
in general these reactions involve mediator production, phagocytosis, proliferation
and/or differentiation (Ulmer, 1997). CD14 is the prominent LPS-binding structure
on monocytes/macrophages, and interaction of LPS with CD 14 is necessary for the
specific activation of monocytes or macrophages (Ulmer, 1997). This binding can be
catalysed by LPS binding protein (LBP) (Martin et al., 1992), which is traditionally
considered to be serum-derived. However, recent work has demonstrated that human
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respiratory epithelial cells can also produce this acute phase protein (Dentener et al.,
2000). The potential importance of LBP in the lung was highlighted by work which
demonstrated an enhanced LPS-induced TNF-alpha gene expression in human and
rabbit alveolar macrophages in vitro when LPS was complexed with LBP (Martin et
al., 1992). In addition, a cell surface co-receptor for CD14, termed the toll-like
receptor 4 (TLR 4) has recently been identified which permits LPS-mediated signal
transduction (Chow et al., 1999; Ingalls et al., 1999).
1.3.2 Airborne endotoxin in agricultural environments
Not surprisingly, high levels of airborne endotoxin have been detected in
environments which have high levels of organic dust, such as the farming industry
(Lundholm et al., 1986; Olenchock et al., 1986; Anon, 1989), particularly in pig
housing (Clark et al., 1983b; Dutkiewicz et al., 1994; Preller et al., 1995a; Preller
et al., 1995b; Schwartz et al., 1995a) and poultry housing (Clark et al., 1983b;
Wiegand et al., 1993). Elevated levels of airborne endotoxin have also been detected
in other working environments including the cotton industry (Christiani et al., 1993;
Li et al., 1995), linen industry (Buick et al., 1994), fibreglass industry (Milton et al.,
1995) and potato industry (Zock et al., 1995). Despite this apparent relationship
between organic dust and endotoxins and the potentially important biologic effects of
organic dusts which contain endotoxins, there is general agreement that the relative
amounts of endotoxins in different dusts may vary (Rylander, 1997b). Consequently,
several epidemiologic investigations have been conducted in order to determine
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whether a relationship existed between endotoxin exposure and disease in exposed
subjects.
1.3.3 Correlation between respiratory symptoms and airborne endotoxin exposure
Several studies have identified a correlation between airborne endotoxin exposure
and respiratory symptoms, airway inflammatory markers and/or lung dysfunction
(Sigsgaard et al., 1992; Rylander and Bergstrom, 1993; Teeuw et al., 1994; Reynolds
et al., 1996; Douwes and Heederik, 1997; Wang et al., 1997; Keman et al., 1998;
Vogelzang et al., 1998; Donham et al., 2000; Douwes et al., 2000b). In most
instances, the airborne endotoxin is in airborne organic dust. However, the role of
airborne endotoxin in disease induction is further supported by many studies, which
have found that despite a good correlation with endotoxin exposure, respiratory
symptoms are poorly correlated or unrelated to the total level of atmospheric dust
(Jorna et al., 1994; Smide/u/., 1994; Zejda et al., 1994; Schwartz et al., 1995b).
Despite this relationship, these studies did not prove causality, which requires the
following requirements to be met: (a) endotoxin must be identified in all
environments that cause similar symptoms, (b) endotoxin must be capable of
producing the signs and symptoms of the disease in subjects challenged with pure
LPS, (c) there must be a demonstrable relationship between the prevalence of the
disease and the exposure levels, and (d) there must be a decrease of symptoms after
reduction in endotoxin exposure (Rylander, 1997b). The reasons for caution in
attributing too much significance to the relationship between endotoxins and clinical
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symptoms includes the fact that organic dusts contain many other biologically potent
agents, such as bacterial enzymes, tannins, mycotoxins, and P-D-glucan (Rylander,
1997b). It is therefore possible that endotoxin may either act as a surrogate marker for
some of these agents, or act in combination with them, either in an additive or
synergistic fashion, to result in pulmonary disease.
1.3.4 Endotoxin tolerance
It is well recognised that many of the symptoms experienced by persons working in
the cotton industry, who are exposed to cotton dust on a daily basis throughout the
working week, are more severe on the first workday of the week (Rylander, 1988;
Rylander, 1994). It has been proposed that this reduction in symptom severity
throughout the week may reflect a degree of tolerance to inhaled endotoxin, a
phenomenon that has recently been demonstrated experimentally in both rats and
mice following repeated exposure to inhaled endotoxin (Elder et al., 2000a; Shimada
et al., 2000). This information therefore further supports the role of inhaled endotoxin
in organic dust induced disease.
1.3.5 Inhalation challenges
1.3.5.1 Endotoxin inhalation challenges
Endotoxin inhalation/instillation challenges have been conducted in humans
(Rylander et al., 1989; Sandstrom et al., 1992; Sandstrom et al., 1994; Michel et al.,
1995a; Michel et al., 1995b; Rolla et al., 1997) guinea pigs (Snella et al., 1987;
Gordon, 1994; Hsieh et al., 1994; Uno et al., 1996; Uno et al., 1997), pigs (Urbain et
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al., 1996a), rats (Gordon and Harkema, 1993; Ulich et al., 1993; Gordon and
Harkema, 1994), hamsters (Lantz et al., 1991) and mice (Ryan et al., 1994; Chignard
and Balloy, 2000). These studies invariably show a neutrophil influx into the airways
following LPS inhalation (Sandstrom et al., 1992; Caillaud et al, 1996; Michel,
1997), as detected by cytological evaluation of BALF (Sandstrom et al., 1994;
Chignard and Balloy, 2000; Larsson et al., 2000) or induced sputum (Nightingale et
al., 1998; Thorn and Rylander, 1998b; Michel, 2000). The influx of neutrophils into
the airway occurs in a dose-dependant manner (Gordon, 1992; Urbain et al., 1996a;
Michel et al., 1997), and may be mediated in part by the intrapulmonary release of
cytokines such as IL-l-P and IL-8, the concentration of which correlate with
neutrophil numbers following LPS inhalation (Wesselius et al., 1997). An increase in
the concentration of TNF-a also appears to be related to neutrophil influx (Ulich et
al., 1993), however functional blockade of TNF-alpha in mice failed to prevent a
neutrophilic inflammatory response following LPS inhalation (Moreland et al., 2001).
In addition, an increased mRNA message for the chemokines MIP-1 and MIP-2 in
BALF cells following LPS challenge is supportive of their involvement in neutrophil
recruitment (Johnston et al., 1998).
Other markers of inflammation which increase after LPS inhalation include elastase
(Nagai et al., 1991; Kawabata et al., 2000), collagenase (Nagai et al., 1991), platelet
activating factor (Rylander and Beijer, 1987; Lantz et al., 1991; Dallal and Chang,
1992), fibronectin (Sandstrom et al., 1992; Sandstrom et al., 1994), nitric oxide (NO)
(Rolla et al., 1997) and NO metabolites (Toward and Broadley, 2000). Also several
studies have demonstrated an increase in airway epithelial and pulmonary
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microvascular permeability (Li et al., 1998; Chignard and Balloy, 2000), mucus cell
metaplasia (Gordon and Harkema, 1993; Gordon et al., 1996) and increased mucin
secretion (Tesfaigzi et al., 2000) following inhaled/instilled endotoxin challenge. In
addition to the induction of local pulmonary inflammation, LPS inhalation also
results in systemic inflammation (Michel et al., 1992a; Michel et al., 1995a; Michel
et al., 1997; Michel et al., 2000) and symptoms [e.g. chest tightness, airway irritation]
(Rylander et al., 1989; Michel, 2000), reduced lung function (Rylander et al., 1989;
Michel et al., 1992a; Michel et al., 2000) and an increase in bronchial
responsiveness/reactivity (Nagai et al., 1991; Vincent et al., 1993; Jarreau et al.,
1994; Rylander, 1996; Michel, 2000; Toward and Broadley, 2000).
The mechanisms involved in this LPS induced increase in bronchial
responsiveness/reactivity are unclear, however NO, platelet-derived products
(Vincent et al., 1993), collagenase and elastase (Nagai et al., 1991), TNF (Uno et al.,
1996) and tachykinins (Loeffler et al., 1997) have all been proposed as playing a
regulatory role. However, even within a healthy population, an LPS response
phenotype exists, whereby LPS inhalation results in the distinct separation of the
population into sensitive, intermediate and hyporesponsive individuals with respect to
both lung obstruction and in vitro LPS-induced cytokine release from blood
monocytes and lung macrophages (Kline et al., 1999). It has recently been
demonstrated that LPS hyporesponsiveness in humans is related to mutations in TLR
4 (Arbour et al., 2000), a phenomenon which has previously been identified in LPS
tolerant/hyporesponsive mice (Hoshino et al., 1999; Qureshi et al., 1999).
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1.3.5.2 Similarities between endotoxin and organic dust extract inhalation challenges
Upon comparison of the results of separate endotoxin inhalation challenges and
organic dust extract inhalation challenges, it can be concluded that the responses to
both challenge systems are similar, namely they are both characterised by a
predominantly neutrophilic, obstructive airway disease which is associated with a
degree of bronchial hyperreactivity. Although such a comparison suggests a role for
inhaled endotoxin in organic dust-induced disease in man, this hypothesis has been
further supported by other studies, which have directly compared the effects of
endotoxin inhalation and organic dust extract inhalation (Clapp et al.t 1993; Jagielo et
al., 1996b; WohlfordLenane et al.t 1999). These studies demonstrated that at
equivalent LPS exposure levels, challenge with both soluble LPS and corn dust
extract resulted in similar symptoms, changes in airflow, and increases in BALF
inflammatory cells and mediators.
1.3.5.3 The role ofendotoxin in the response to inhaled organic dust/organic dust
extract
A few studies have further highlighted the specific role of endotoxin in organic dust-
induced disease using mice which were either genetically resistant to endotoxin, or
which were rendered endotoxin tolerant by daily injections of increasing doses of
LPS (Ryan et al., 1994; Schwartz et al., 1994; George et al., 2001). These mice
developed significantly less severe pulmonary inflammation than controls following
both acute and chronic inhalation challenge with corn dust extract (Schwartz et al.,
1994; George et al., 2001) and exposure to airborne cotton dust (Ryan et al., 1994).
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In addition, although both endotoxin-sensitive and endotoxin-resistant mice
developed airway hyperreactivity following chronic corn dust extract inhalation
challenge, this hyperreactivity persisted only in the endotoxin-sensitive mice (George
et al., 2001). In support of these findings, the in vitro release of TNFa from alveolar
macrophages in response to wool dust leachates was significantly reduced if the
macrophages were harvested from mice which were genetically resistant to endotoxin
(Brown and Donaldson, 1996). Furthermore, depletion of endotoxin activity from
corn dust extract significantly reduced the pulmonary inflammatory response
following inhalation challenge in mice (Jagielo et al., 1996a). Similarly, intratracheal
pretreatment of mice with the relatively biologically inactive partial agonist of LPS,
diphosphoryl lipid A, before exposure to corn dust extract significantly reduced
pulmonary inflammation (Jagielo et al., 1998).
The aforementioned evidence indicates that the inflammatory response to inhaled
organic dusts is largely attributable to the dust endotoxin activity. However with the
exception of Ryan et al's. (1994) study, which only evaluated the pulmonary
inflammatory and not the functional response to cotton dust exposure, all studies
investigating the role of endotoxin have used a soluble extract of organic dust. This
may be a criticism since such a model does not permit the evaluation of the role of
the particulate components of airborne organic dust in the overall pulmonary
inflammatory and functional response.
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1.3.6 Interaction between endotoxins and other organic dust components
Despite the overwhelming evidence for the major contribution of inhaled endotoxin
in the response to inhaled organic dust, it would be naive, given the presence of other
agents present within these dusts, to consider that endotoxins are solely responsible
for pulmonary disease induction. Indeed many other organic dust components have
pro-inflammatory properties, including plant tannins, proteins, (3-D-glucan, mould
spores, bacteria, proteases and mycotoxins (Rylander, 1994; Milanowski et al.,
1995a; Milanowski et al., 1995b). Furthermore, there is sufficient evidence that
additional endotoxin independent mechanisms exist by which organic dusts can cause
pulmonary inflammation (von Essen et al., 1995b). It is therefore likely that many of
these components act in an additive fashion, resulting in an inflammatory response in
the host, which is related to the relative composition of the inhaled organic dust
particles. In addition both in vitro and in vivo studies have provided evidence to
support a complex interaction and/or synergistic relationship between endotoxin and
various other organic dust components such as P-D-glucan (Fogelmark et al., 1994;
Rylander, 1994; Fogelmark et al., 2001), fungal spores (Shahan et al., 1994) and
carbonaceous particles (Oberdorster, 2000).
23
1.4 The response to inhaled endotoxins/organic dusts in subjects with allergic
respiratory disease
1.4.1 The response of human asthmatics to inhaled/airborne grain dust or endotoxin
Despite some conflicting reports in the literature, it is generally accepted that
asthmatic subjects can demonstrate higher sensitivity to inhaled LPS than normal
subjects (Alexis et al., 2001), and consequently safety guidelines for endotoxin
exposure levels are based on values for subjects with histories of atopy or asthma
(Rylander, 1997b). Although it is generally accepted that organic dust-induced
pulmonary disease represents a non-allergic inflammatory response, primarily to
endotoxin, some studies have shown that organic dust exposure results in a
significantly greater degree of pulmonary dysfunction in subjects with a history of
respiratory allergy compared to healthy subjects (Jacobs et al., 1993). Furthermore,
inhalation challenge of asthmatic and non-asthmatic subjects with endotoxin has
demonstrated a difference in their response. Asthmatic subjects developed a slight but
significant bronchial obstruction and an increase in non-specific bronchial reactivity
following inhalation of 22.2pg LPS, but no change in reactivity or pulmonary
mechanics was noted in the non-asthmatic group (Michel et al., 1989; Michel et al.,
1995a). However, conflicting views exist regarding the association between allergy
and the response to endotoxin and organic dust, since other studies have indicated
that the lung function response of human subjects to inhaled grain dust extract is
independent of pre-existing asthma (Clapp et al., 1994). Furthermore, other studies
found that LPS-induced bronchial obstruction is associated with non-specific
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responsiveness but not with atopy (Michel et al., 1992b), and that the atopic status of
an individual was not a significant determinant of airflow obstruction or lower airway
inflammation following organic dust inhalation (Blaski et al., 1996).
1.4,2 Mechanisms of enhanced response of asthmatics to inhaled endotoxin/organic
dust
The mechanisms involved in the enhanced response of asthmatics to inhaled grain
dust and/or endotoxin are unclear, particularly in light of some conflicting results. In
those studies that identified an enhanced response in asthmatics, it is possible that this
resulted from a degree of pre-existing subclinical pulmonary disease in these subjects
at the time of the endotoxin inhalation challenges and/or organic dust exposures. It is
also possible that the organic dust also contained allergens to which the individual
was sensitive. Alternatively, an inherent increased sensitivity to endotoxin may exist
in atopic/asthmatic subjects. Consistent with this, peripheral blood leucocytes from
asthmatics were more susceptible to LPS than those from healthy individuals with
respect to sulpholeukotriene release (KrausFilarska et al., 1998). Furthermore, an
increased level of constitutive CD 14 expression, as demonstrated in atopics, may
contribute to an increased LPS sensitivity in asthmatic subjects, as the constitutive
sCD14 expression was a good predictor of the magnitude of neutrophil response in
induced sputum following LPS inhalation (Alexis et al., 2001).
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1.4.3 The role of combined allergen and endotoxin as a determinant of disease
severity
In most natural environments, instead of being exposed to single airborne agents,
allergic asthmatics are exposed to a combination of allergen and endotoxin (Michel et
al., 1991). Studies in humans have shown that endotoxin exposure exacerbates
asthmatic symptoms in subjects who are allergic to house dust mites and other
allergens (Michel, 1996; Rizzo et al., 1997). Additionally, the concentration of
endotoxin in house dust is a more important determinant of asthma severity in house
dust mite-sensitized subjects than the concentration of house dust mite allergen
(Michel et al., 1991; Michel et al., 1996). Endotoxin exposure has also been shown to
increase the risk of wheezing during the first year of life in children with a familial
predisposition to asthma or allergy (Park et al., 2001). It has also been speculated that
the increased incidence of asthma may not only reflect the increase in environmental
allergen concentrations but also increased concentrations of dust components, such as
endotoxins, that enhance the response of the lungs to foreign proteins (PlattsMills et
al., 1997). There is some evidence to suggest that the increased severity of disease in
asthmatics co-exposed to allergen and endotoxin is related primarily to an increase in
pulmonary inflammation. For example the pulmonary inflammatory response of
ovalbumin (OVA) sensitised mice exposed to a combination of OVA and LPS was
significantly greater than that induced by OVA alone (Goldsmith et al., 1999; Tulic et
al., 2000). It is interesting to note that this OVA/LPS combination did not increase
the degree of airway hyperresponsiveness, and in one study, LPS inhalation abolished
the OVA-induced hyperresponsiveness (Tulic et al., 2000).
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Sufficient evidence now exists to indicate that airway exposure of atopic asthmatics
to combined allergen and endotoxin results in greater pulmonary inflammation and
possibly severity of symptoms than those observed with either stimulus alone
(Eldridge and Peden, 2000).
1.4.4 Mechanisms of enhanced response to combined allergen and endotoxin
stimulus
Several possibilities exist as to the mechanisms by which inhaled endotoxin may
enhance the response to inhaled allergen, and thus influence the severity of asthmatic
lung disease. Firstly, ragweed antigen inhalation in ragweed allergic asthmatics
results in a profound increase in the concentration of the accessory molecules LBP
and soluble CD 14 in BALF, thus enhancing the capacity of inhaled LPS to activate an
inflammatory cascade (Dubin et al., 1996). Although respiratory epithelial cells are
now recognised as a potential source of LBP (Dentener et al., 2000), the increased
BALF levels of this protein following allergen challenge is likely to result from the
allergen induced increase in pulmonary epithelial permeability (Folkesson et al.,
1998). In support of the role of LBP, allergen-sensitised LBP-deficient mice failed to
develop substantial inhaled allergen-induced airway reactivity compared with
allergen sensitised wild type mice (Strohmeier et al., 2001).
In addition, endotoxins can act as adjuvants for delayed hypersensitivity and IgE
production, and enhance antigen-specific mediator release (Norn, 1994; Williams and
Halsey, 1997). Inhaled endotoxin also down-regulates repeated, antigen exposure-
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induced IgE isotype-specific tolerance, thus potentiating allergen-specific airway
inflammation (Wan et al., 2000). Furthermore, inhalation of LPS-stimulated allergen
(OVA)-specific antibody production in sensitised guinea pigs (Rylander and Holt,
1998). Therefore is possible that as well as allergen potentially increasing the
inflammatory response to LPS, LPS may also increase the inflammatory response to
allergen. In fact, it is probable that both of these mechanisms occur resulting in a
synergistic effect between inhaled allergen and endotoxin.
1.4.5 The possible role of endotoxin in determining the predominant airway
inflammatory cell type in asthma and heaves
Despite the proposed similarities between heaves and allergic lung disease in humans,
one major difference between these diseases is the predominant inflammatory cell
recruited to the airways. Heaves is characterised by an airway neutrophilia (Robinson
et al., 1996). In contrast, allergic asthma is characterised by an airway eosinophilia
(Coyle et al., 1996), although there is a late neutrophilic response to intra-bronchial
allergen challenge that may reflect a response to endotoxin (Hunt et al., 1992). It
should be noted however that in the studies by Goldsmith et al. (1999) and Tulic et
al. (2000), which investigated the response to inhaled LPS and allergen in sensitised
mice, the predominant inflammatory cell type was the neutrophil. In addition, the
neutrophilic response following inhaled allergen challenge in some human asthmatics
resulted from endotoxin contamination of the allergen extract (Hunt et al., 1994).
Also, the predominantly neutrophilic influx noted in acute, fatal asthma may be due
to inhalation of endotoxin-coated mould spores (Sur et al., 1993).
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In addition to inducing a direct neutrophilic inflammatory response LPS, may inhibit
eosinophil migration following allergen challenge, as demonstrated in the mouse
peritoneum (Schimming et al., 1997). Also, inhalation of (3-D-glucan, a component of
fungal cell walls which is likely to be present in high quantities in mouldy stable dust,
decreased the allergen-induced airway eosinophilia associated with OVA inhalation
in sensitised guinea pigs (Rylander and Holt, 1998). Furthermore, the P-D-glucan-
induced BALF eosinophilia, reported in guinea pigs following a 5week exposure, was
absent when animals were co-exposed to LPS (Fogelmark et al., 2001).
Therefore, possible reasons why heaves is characterised by an airway neutrophilia
include the fact that dusty stables almost invariably contain high levels of endotoxin
(Dutkiewicz et al., 1994). Alternatively, neutrophil recruitment in heaves may result
from the fact that active nuclear factor-xB (NF- kB) in bronchial epithelial and BAL
cells from heaves-affected horses is mainly p65 homodimers, rather than classical
p65-p50 heterodimers (Bureau et al., 2000; Lekeux et al., 2001). The p65
homodimers induce intercellular adhesion molecule-1 (ICAM-1) (Ledebur and Parks,
1995) and IL-8, a potent neutrophil chemo-attractant (Schulte et al., 2000), and not
eotaxin, an eosinophilic chemo-attractant which is under p65-p50 control (Matsukura
et al., 1999). However there is evidence to suggest that LPS-induced expression of at
least ICAM-1 may also be dependent on the binding of p65 homodimers to the same
kB binding site, suggesting that the endotoxin content of stable dust may still be
partly responsible for the neutrophil influx in heaves (Ledebur and Parks, 1995). In
addition, since mast cell derived tryptase directly stimulates IL-8 expression and
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upregulates ICAM-1 expression (Cairns and Walls, 1996), mast cell degranulation
may also play a critical role in neutrophil recruitment in heaves, following either IgE-
mediated mechanisms and/or direct stimulation by endotoxin (Norn et al., 1994) or
fungal spores (Larsen et al., 1996).
1.5 Possible interactions between different potential components of stable
dust
Certain airborne stable dust components, including proteases, fungal antigens and
glucan, may directly induce pulmonary inflammation by non-endotoxin-mediated and
non-allergenic mechanisms (Milanowski, 1996; Milanowski, 1997; Iadarola et al.,
1998; Milanowski, 1998; Schuyler et al., 1998). In addition, these agents may also
potentiate the effects of other dust components such as endotoxin and allergen. For
example, fungal spores and endotoxin have a synergistic effect on superoxide anion
release from guinea pig BALF cells (Shahan et al., 1994). In addition, other
components of organic dusts, including mould spores, bacteria and endotoxins have a
synergistic effect on histamine release from human basophil cells via non-
immunological mechanisms (Norn et al., 1994). Furthermore, the type of pulmonary
inflammation induced by inhalation of a combination of glucan and endotoxin
differed histologically from that following inhalation of each individual component,
with the former inducing granuloma formation (Fogelmark et al., 1994).
Although little information exists relating to the synergism between organic dust
particles and endotoxin, extensive research has been carried out on the potentiating
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effects between urban air particles and endotoxin. For example, endotoxin markedly
increased cytokine expression of rat and human alveolar macrophages exposed to
urban air particles (Dong et al., 1996; Soukup and Becker, 2001), and pre-exposure
of rats to LPS, or pre-incubation of rat or human lung derived macrophages with LPS,
amplifies lung inflammation and TNF production in response to air particles and
ultrafine carbon particles (Imrich et al., 1999a and b; Elder et al., 2000b).
Additionally, synergism between air pollutants and allergen has also demonstrated
whereby inhalation challenge with leachate of residual oil fly ash (a surrogate of
ambient air particles) significantly increased allergen (OVA)-induced airway
hyperresponsiveness and inflammation in sensitised mice (Iadarola et al., 1998).
The level of gaseous pollution in equine stables is largely unknown, however levels
of ammonia and hydrogen sulphide do tend to rise where deep litter management of
bedding is practiced and when there is poor drainage of urine (Clarke, 1987a).
Although the safety levels for noxious gases are unknown, it is possible that
excessively high levels may result in respiratory inflammation, either directly or
indirectly, via interaction with dust components. For example, ozone-pretreatment of
bovine alveolar macrophages had an additive effect on TNF release following LPS
stimulation (Mosbach et al., 1996). In addition, work on animal models of allergic
asthma has shown that exposure to air pollutants such as nitrogen dioxide and ozone
may increase levels of serum and pulmonary allergen-specific antibody thus
exacerbating immune-mediated lung disease (Gilmour, 1995).
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Therefore there is much potential for numerous additive and synergistic interactions
to occur, between many different airborne components which may be present within
stables. It is probable that what ultimately determines the severity of disease is largely
dependent on the relative quantities of these different agents within the airborne
environment, in addition to the subjects degree of "sensitivity" to each component.
Many of these interactions may involve endotoxin, therefore although the direct
response to inhaled endotoxin may be inflammatory, the co-exposure to endotoxin
and other agents present in organic dusts may result in an amplified response
involving both immunological and non-immunological mechanisms.
1.6 Hypotheses
There are many similarities between equine heaves and organic-dust mediated lung
disease in humans and animal models; namely both conditions are characterised by a
reversible pulmonary neutrophilia and obstructive lung dysfunction following
exposure to certain environments. It is now generally accepted that organic-dust
mediated lung disease in humans is due largely to the inhalation of endotoxin. This
has been demonstrated firstly by the association between respiratory symptoms in
subjects suffering from organic dust-mediated lung disease and the levels of
endotoxin exposure, and secondly, by the similarities between the physiological and
inflammatory effects of endotoxin and organic dust inhalation.
Upon consideration of the similarities between these two diseases, it is therefore
highly probable that endotoxin inhalation contributes to the aetiopathogenesis of
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heaves, particularly as equine stables contain relatively high levels of airborne
endotoxin. Despite the evidence for an underlying pulmonary hypersensitivity to
moulds in heaves, it is probable that endotoxin inhalation contributes to the severity
of disease, particularly as an exaggerated response to inhaled endotoxin occurs in
some humans with pre-existing allergic respiratory disease.
Consequently, following consideration of the above information, the work detailed in
this thesis was initiated to investigate two initial hypotheses:
(1) Exposure to high levels of airborne endotoxin will result in non-specific
pulmonary inflammation and dysfunction in both heaves-susceptible and healthy
horses. In consideration of the difference in response between healthy human
subjects and asthmatics, heaves horses may exhibit a lower response threshold to
such challenges.
(2) Exposure to airborne endotoxin will increase the severity of pulmonary
inflammation and dysfunction in symptomatic heaves horses that are co-exposed
to other components of stable dust.
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CHAPTER 2: DOSE-RESPONSE RELATIONSHIP TO INHALED SOLUBLE
LIPOPOLYSACCHARIDE (LPS) IN ASYMPTOMATIC HEAVES HORSES
AND CONTROLS AND COMPARISON WITH NATURAL ENDOTOXIN
EXPOSURE
2.1 Summary
To investigate whether inhaled endotoxin contributes to airway inflammation and
dysfunction in horses and to compare the responses of control horses (n=6) and
heaves-susceptible horses (n=7), both groups were given inhalation challenges with
20, 200 and 2000pg of soluble Salmonella typhimurium Ra60 lipopolysaccharide
(LPS). LPS inhalation induced a dose-dependent neutrophilic airway inflammatory
response in both groups. Inhalation with 2000pg of LPS also induced detectable lung
dysfunction in the heaves group, albeit of mild severity. LPS inhalation did not alter
clinical score, tracheal secretion score or airway reactivity in either group. The no-
response thresholds were lower for the heaves group (<20pg for airway
inflammation; 200 to 2000pg for lung dysfunction) than for the control group (20 to
200pg for airway inflammation; >2000pg for lung dysfunction). To enable
comparison of these threshold levels with airborne endotoxin concentrations in
stables, horses also received a 5h duration hay/straw challenge, during which the total
and respirable airborne endotoxin concentrations were determined. Comparison of the
effects of acute LPS inhalation and hay/straw challenges suggest that inhaled
endotoxin is not the sole cause of heaves. However, it is likely that it contributes to
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airway inflammation, both in heaves horses in concert with other inhalants, and in
normal horses when they are exposed to high levels in poor stable environments.
2.2 Introduction
Inhaled endotoxins are an important cause of human pulmonary disease (Jacobs,
1997a), with the severity of pulmonary inflammation and clinical symptoms
experienced by subjects exposed to organic dusts being related to the endotoxin
concentration of the inhaled dust (Rylander and Bergstrom, 1993; Smid et al., 1994;
Zejda et al., 1994; Schwartz et al., 1995b; Vogelzang et al., 1998). Additionally, the
severity of human asthma has been related to the level of endotoxin exposure (Michel
et al., 1991; Michel, 1996; Michel et al., 1996; PlattsMills et al., 1997; Rizzo et al.,
1997), suggesting that inhaled endotoxin may potentiate the inflammatory response to
allergens in atopic subjects. In man, considerable efforts have been made to establish
no-response threshold levels for inhaled endotoxin (Michel et al., 1997), and to
identity safety guidelines for occupational endotoxin exposure (Rylander, 1997b).
Since horse stables contain high concentrations of airborne endotoxin (Olenchock et
al., 1992; Dutkiewicz et al., 1994; McGorum et al., 1998; Tanner et al., 1998), and
given the similarities between heaves and inhaled endotoxin mediated lung disease in
other species (McGorum et al., 1998), it is surprising that the role of endotoxin in
heaves is unknown. The aims of the present study were (a) to investigate the response
of control and heaves horses to increasing doses of inhaled LPS, (b) to determine no-
response threshold levels for both control and heaves horses, and (c) to compare no-
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response threshold levels of inhaled soluble LPS with airborne endotoxin levels
encountered in equine stables.
2.3 Materials and methods
2,3.1 Subjects
2.3.1.1 Heaves horses
The heaves group consisted of 7 horses (3 geldings, 4 mares; median age 17 years,
range 8-28; median weight 434 kg, range 323-594) with a history and clinical
diagnosis of heaves. The disease status of all subjects was confirmed by hay/straw
challenge. A 5h hay/straw challenge (2.3.4.2) induced BALF neutrophilia (>20%),
increased volume of tracheal secretions bronchoscopically, and a reduction in PaC>2 in
all heaves horses. A more prolonged challenge induced increased maximum
transpulmonary pressure (dPplmax), isovolumetric and expiratory lung resistance
(RLiso and RLe, respectively) and work of breathing (Wb), and decreased dynamic
compliance (Cdyn). In all cases dPplmax exceeded 15cm FLO at variable time points
following exposure to the hay/straw environment. All of the above clinical and
laboratory abnormalities reverted to normal when the heaves horses were moved to a
controlled environment (2.3.2.1). These criteria are consistent with the definition of
heaves horses as determined by the International Workshop on Equine Chronic
Airway Disease (Robinson, 2001).
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2.3.1.2 Control horses
The control group consisted of 6 healthy horses with no detectable respiratory tract
disorders (all female, median age 6 years, range 4-9; median weight 320 kg, range
316-356). A 5h-hay/straw challenge (2.3.4.2) did not induce detectable pulmonary
inflammation or detectable tracheal secretions in control horses. A more prolonged
hay/straw challenge did not induce significant lung dysfunction in this group, with the
maximum transpulmonary pressure not exceeding 8 cm H2O.
2.3.2 Stable environment
2.3.2.1 Controlled environment
Throughout the study all horses were kept in a low dust environment. This refers to a
hay and straw free environment, which would be expected to contain minimal levels
of allergens implicated in the aetiology of heaves. This consisted of large (length 5m
x width 4m) ventilated stables (Fig. 2.1) with spaced boarding sections {height lm x
width 4m) at the top of the back wall (1.75m from ground level) and at the top of the
front wall (3m from ground level). The front wall also incorporated a door with a
permanently open top section {width 1.5m x height lm) and an open grille/feed
hopper {width 2.5m x height 0.5m). Florses in this accommodation were bedded on
dry wood shavings and fed haylage and occasionally concentrate feed. Damp bedding
and faeces were removed three times daily. These stables were 150m from the closest
hay and straw storage area and sheltered from the prevailing wind.
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During summer, the horses were occasionally kept at pasture, 300m from the closest
hay and straw storage area. Supplementary haylage was provided when necessary.
2.3.2.2 Hay/straw challenge environment
This refers to a poorly ventilated environment in which the horses were exposed to
dusty hay and straw. This consisted of a smaller stable (length 3.4m x width 2.6m)
than the controlled environment, which had no wall or roof vents. All doors
remained closed during the challenge period. Bedding consisted of deep litter straw,
which had accumulated for several weeks, during which time other livestock
(including horses and sheep) were kept in the stable. Feeding in this environment
consisted of dusty hay with grossly visible fungal contamination. Microscopic
examination of the respirable fraction of dust collected following agitation of this hay
revealed large numbers of fungal spores, dust mites and dust mite faeces.
Fig 2.1: The well ventilated stables used as the "controlled environment".
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2.3.3 Inhalation challenge material
2.3.3.1 Lipopolysaccharide (LPS) solution
All horses received 3 separate increasing doses (20, 200 and 2000pg) of purified
Salmonella typhimurium Ra60 LPS (kindly donated by Professor Ian Poxton,
Department of Medical Microbiology, University of Edinburgh). LPS was diluted
from a stock solution (8.89mg/ml) in sterile isotonic saline, immediately prior to
nebulisation.
2.3.3.2 Negative (placebo) control
Prior to the LPS inhalation challenges, all horses received an initial control inhalation
challenge with sterile isotonic saline (Vetivex, [Sodium Chloride 0.9% w/v], Ivex
Pharmaceuticals, Larne, UK) as a placebo and vehicle control challenge.
2.3.4 Inhalation challenges
2.3.4.1 Nebulised inhalation challenges
To facilitate nebulisation, horses were sedated with 20pg/kg romifidine (Sedivet,
Boehringer Ingelheim Ltd., Bracknell, Berkshire, UK) and 10pg/kg butorphanol
(Torbugesic, Fort Dodge Animal Health, Southampton, UK), intravenously. Although
randomisation of the inhalation challenges was considered, the following order was
chosen for safety reasons, due to the unknown effects of LPS inhalation in the horse.
Several procedures were performed to minimise potential carry-over effects of a
preceding challenge on a subsequent challenge. Firstly, inhalation challenges were
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conducted a minimum of 14 days apart. Secondly, all horses were shown to have
normal BALF cytology at least 7 days prior to challenges, and normal clinical
findings immediately prior to each inhalation challenge. In order to assess any carry¬
over effects, all baseline lung function, arterial blood gas and venous blood leucocyte
data were compared with each other. Additionally, 6 heaves and 4 control horses
received a repeat inhalation challenge of 200pg LPS following completion of the
other challenges. As well as permitting the assessment of any carry-over effects,
comparison of the response to this challenge with that to the original 200pg LPS
challenge also determined the repeatability of LPS inhalation challenge.
The aerosol was generated using a compressor (Parimaster, PARI Medical Ltd., West
Byfleet, Surrey, UK), with a calibrated output of 71/min, connected to a nebuliser cup
(Sidestream, Medic-Aid Ltd., Bognor Regis, West Sussex, UK) whose manufacturers
state that 80% of aerosol is in the respirable range (<5pm). The nebuliser cup
contained 2ml of challenge solution. The delivery system is represented in Fig. 2.2.
The challenge solution was nebulised into a section of corrugated tubing (length
185cm, dead space 0.51), that communicated with the inspiratory arm of the Y-piece
delivery system (length 220cm, dead space 4.11), distal to a one-way inspiratory
valve. During inspiration, the aerosol was inhaled via the one-way valve and an
airtight facemask. To account for aerosol losses within the corrugated tubing, pilot
studies showed it was necessary to aerosolise 1.05ml solution from the nebuliser cup
to achieve delivery of 1ml to the inspiratory arm of the delivery device. Any further
losses between the inspiratory arm and the subject nostrils were not accounted for.
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During expiration, expired breath passed via a one-way valve on the expiratory arm
of the delivery system and was vented to the external environment.
Fig. 2.2: Delivery system used for nebulised inhalation
challenges, showing compressor (c), neuliser cup (n),
inspiratory (i) and expiratory (e) arms of Y-piece delivery
system, with the position of the one way valves marked (v).
2.3.4.2 Hay/straw challenges
For the hay/straw challenge, horses were housed for 5h in the hay/straw challenge
environment previously described (2.3.2.2). This environment had previously been
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shown to induce airway inflammation, clinical signs and lung dysfunction in heaves
horses (McGorum et al., 1993c). During this challenge, time zero (t-0) represented
the time when the horse entered the stable.
2.3.5 Dust collection
During the hay/straw challenge, total and respirable stable dusts were collected using
a personal sampler (AFC 124 High Flow Personal Sampler, Casella Ltd., Kempston,
UK) and total and respirable sampling heads (Casella Ltd., Kempston, UK), onto
25mm diameter, 0.8pm pore size, cellulose acetate filters (Millipore, Bedford, USA).
Respirable dust refers to dust particles of sufficiently small aerodynamic size (<7pm)
and shape to allow deposition within the lower airways. The sampling heads were
attached on either side of the subjects head collar, approximately 15cm from the
nostrils (Figs. 2.3-2.5).
Fig. 2.3: Personal samplers (s) were attached on either side of a girth
strap and connected to dust sampling heads (h).
42
Fig. 2.4: A sampling head designed for collection of total airborne dust
(t) was attached to to the right side of the head-collar in order to collect




Fig. 2.5: A sampling head designed for collection of respirable airborne
dust (r) was attached to to the left side of the head-collar in order to
collect from the horses breathing zone
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This ensured the collection of airborne dust present in the subjects breathing zone,
thus providing a more accurate indication of the amount inhaled of dust compared
with remote sampling (Woods et al., 1993). The sampling period was 5h, and the
pump flow rate (2 1/min) was calibrated before and at the end of each sampling period
using a calibrated rotameter (Casella Ltd., Kempston, UK).
2.3.6 Analysis of dust
2.3.6.1 Calculation ofairborne dust concentration
The mass of collected dust was determined by weighing the filters before and after
dust collection. To minimise the effects of variable moisture content on filter mass,
filters were conditioned overnight in a partially open container in the laboratory at
room temperature prior to weighing (Anon 1993). The dust concentration per m3 of
air sampled was then calculated using the following equation:
1000 (i.e. number of litres in lm3)
airborne dust (mg/m3) = dust collected (mg) x
600 (i.e. litres collected over 5h @ 21/min)
After weighing, sample filters were stored in individual sterile universal containers at
-20°C, prior to endotoxin analysis.
2.3.6.2 Measurement ofendotoxin in airborne dust
The endotoxin content of filters was determined using an endotoxin specific Limulus
amoebocyte lysate assay (Endospecy, Seikagaku Co, Tokyo, Japan). Samples were
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prepared by adding 5ml and 10ml of sterile water (water for injection, Animalcare
Ltd., Dunnington, York, UK) to the respirable dust and total dust fractions,
respectively. Containers were rotated end-over-end, at room temperature for lh to
elute endotoxin. To remove particulate matter, which could interfere with the assay,
the eluates were centrifuged at 1600g for 15min. Following centrifugation, the
supernatant was decanted, transferred to another sterile container and frozen at -80°C
until analysis.
For analysis, all reagents, samples and standards were brought to room temperature.
Samples and standards were mixed vigorously for 30s with a vortex mixer. Serial
dilutions of the samples were then made in order to ensure a final sample
concentration that did not exceed the endotoxin standard (E.coli 0111:B4) provided
with the kit. Serial dilutions (1:1, 1:2, 1:4 and 1:8) of the standard were also made to
provide a standard curve. lOpl of standard, sample or distilled endotoxin free water
(negative control) was pipetted into a sterile 96 well microplate. lOOpl of Limulus
amoebocyte lysate substrate solution was immediately added to each well. The
microplate was then incubated at 37°C for 30min, following which the reaction was
stopped by the addition of 200pl of 0.6M acetic acid to each well. The absorbance of
the resulting colour reaction was read photometrically (Microplate Autoreader, Bio-
Tek Instruments Inc., Winooski, VT, USA) at 405nm, and compared to a standard
curve, prepared during each analysis. All samples were analysed in duplicate and the
mean value calculated. Analysis was repeated if (a) the paired values differed from
their mean by >10% of the mean, (b) either of the paired values exceeded the value of
undiluted standard solution, or (c) either of the paired values were less than the value
45
obtained from a 1:8 dilution of the standard solution. In addition, the sterile water
used to dilute the samples was tested as a sample and compared with the endotoxin-




The endotoxin concentration per m of air sampled was then calculated using the
following equation:
1000
Airborne endotoxin (ng/ m3) = endotoxin per sample (ng) x inverse of dilution factor x
600
In addition, the endotoxin content of the dust was calculated using the following
equation:
endotoxin per sample (ng) x inverse of dilution factor
Endotoxin content of dust (ng/mg) =
dust collected (mg)
2.3.7 Monitoring the response to challenges
The timing and method of the assessment of the response to challenges is summarised
in Fig. 2.6.
Fig. 2.6: Study design. For the 5h hay/straw challenges, the horses entered
the stable at t=0.
BAL = bronchoalveolar lavage; LF = lung function evaluation; Clin Ex = clinical examination; Art BG =
Arterial blood gas analysis; Haem = haematological analysis; A React = airway reactivity evaluation.
Clin Ex Clin Ex
Art BG INHALATION <?linnE^ 9'!^ if ^BG
Haen CHALLENGE ArtBG ^ BAL Haan,
t - 7 days t - 30min to t + 90min t +4h t +5h t + 6h t + 24h
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2.3.7.1 Clinical examination
The clinical response to challenge was assessed using the clinical scoring system
summarised in Table 2.1.
Table 2.1: Clinical scoring system


















































2.3. 7.2 Arterial blood gas analysis
Arterial blood samples were collected by carotid puncture using a 21 gauge 4cm
needle into heparinised plastic syringes (Arterial Blood Sampler, Bayer Ltd.,
Halstead, Essex, UK). Samples were analysed either immediately or following less
than 30min storage at 4°C, for PaC>2, PaCC>2 and arterial pH, using an AYL Opti CCA
blood gas analyser (AVL Medical Instruments UK Ltd, Stone, Staffs), at an altitude
of 170m. Blood gas tensions data were corrected to the rectal temperature of the
horse.
47
2.3.7.3 Pulmonary mechanics testing
All horses unfamiliar with this procedure were given 2 training periods prior to the
collection of data in order to minimise anxiety, which may influence lung function
(Deegan and Klein 1985). All measurements were performed on standing unsedated
horses restrained in stocks only with a headcollar (Fig. 2.7). No sedation was
administered immediately prior to or during pulmonary mechanics testing to avoid
any drug induced effects on pulmonary function (Reitmeyer et al., 1986; Broadstone
et al., 1992; Lavoie et al., 1992). Sedation was however administered immediately
following baseline measurements to ensure subject safety and compliance during the
nebulised challenge. Therefore when assessing the pulmonary function responses to
challenge, a period of 5h had elapsed following the intravenous administration of a
sedative drug. Recording commenced immediately after the horses were connected to
the apparatus, and 2 separate 60s periods of data were collected.
Fig. 2.7: Horse restrained in stocks, wearing an airtight facemask
with attached pneumotachograph (p) connected to pressure
transducer (t). The oesophageal (o) and mask catheters (m) are
also connected to pressure transducers (t).
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Respiratory flow was measured using a heated pneumotachograph (A. Fleish No.4,
Bilthoven, Holland), mounted on an airtight facemask and connected to 2 pressure
transducers, the output of which were conditioned, amplified as necessary, and
converted from analog to digital form, using appropriate hardware (National
Instruments Co., Austin, Texas). Custom-designed computer software (Labview,
National Instruments Co., Austin, Texas) was used to facilitate integration of the flow
signal to yield volume. The part of the facemask into which the horse's muzzle was
inserted was composed of taught flexible rubber with a central opening (12cm x
12cm) (Fig. 2.8). The flexible rubber margins of the opening conformed to the
contours of the horse's face caudal to the position of the lip commisures, thus
providing an airtight seal. The mask was secured by means of a woven strap, which
passed behind the horse's poll.
Fig. 2.8: Facemask with attachment for mask catheter (mc),
portal for oesophageal catheter (oc) and opening in rubber seal,
into which the horse's muzzle was placed (o).
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An oesophageal balloon catheter, consisting of a latex condom secured over the end
of a polythene catheter (length 2550mm, O.D. 4mm, I.D. 2mm, ARCO, Linlithgow,
UK), which had a series of spirally arranged holes distally, and a mask catheter (O.D.
4mm, I.D. 2mm, ARCO), were connected to separate pressure tranducers to permit
measurement of transpulmonary pressure (Ptp). The output of the transducers were
conditioned, amplified as necessary, and converted from analog to digital form, using
appropriate hardware (National Instruments Co., Austin, Texas, USA). The
oesophageal catheter was positioned at a point within the thoracic oesophagus,
initially estimated by holding the tubing at the side of the horse, and then repositioned
to a point which gave the greatest recording of Ptp, without any recorded artefacts
consistent with pulsatile/rhythmic cardiac movement. The catheter was passed to the
same position for each individual horse. The catheter balloon assembly was filled
with 4ml air, this volume being within the range of high compliance of the balloon
(Appendix 2.1).
The output of the data acquisition equipment was directed to an electronic flow and
pressure time trace, permitting real time assessment of the quality of data recorded
(Fig. 2.9). In addition, raw data was electronically transferred to a spreadsheet format
(Excel, Microsoft Co., Redmond, WA, USA), which recorded all flow and pressure
data over time for both 60s periods of data collection. Measurements were performed
at an altitude of 170m above sea level.
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Fig. 2.9: Example of flow and pressure traces, which permitted real-time
assessment of the quality of data recorded.
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Flow and pressure calibrations were made using, respectively a rotating vane flow
meter (Rotameter KDG Mobrey 2000, KDG Mobrey Ltd., Crawley, Sussex, England,
UK) and a water manometer (Fisher Scientific, Loughborough, Leicesteshire, UK).
All outputs were linear over the working ranges (Appendices 2.2 and 2.3). The
frequency response characteristics of the flow and pressure recording systems were
phase matched up to 8Hz (Appendix 2.4), using standard techniques (Macklem
1974).
Following collection of both 60s periods of data, the recorded electronic traces were
visually assessed. From each period, a series of consecutive breaths, devoid of
artefacts, were selected for further analysis (Fig. 2.10). A minimum of 6 total
representative breaths was selected for analysis.
Fig.2.10: Example of use of electronic callipers (c) to select representative
breaths devoid of artefacts for further analysis.
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For each breath, custom designed software (Labview, National Instruments Co.,
Austin, Texas) was used to derive the following lung function indices from flow, Ptp
and tidal volume (Vt): dynamic compliance (Cdyn); maximum transpulmonary
pressure change (dPplmax); isovolumetric lung resistance (RLjS0); lung resistance at
25%, 50% and 75% inspired volume (RLi25o/0, RLi50%, RLi75%, respectively); lung
resistance at 25%, 50% and 75% expired volume (RLe25%, RLe5o% and RLe75%>
52
respectively); total, resistive and elastic work of breathing (Wbt, Wbres and Wbei,
respectively), expiratory and inspiratory resistive work of breathing (WBeres and
WBires, respectively), inspiratory total work of breathing (WBitot), maximum
inspiratory and expiratory flow (V'Emax and V'imax, respectively), respiratory rate
(RR), time for expiration and inspiration (Te and Ti, respectively) and the ratio of Ti
to Te (Ti:Te). A mean of the values obtained from the selected breaths was calculated
to give a single value for the baseline measurement and for the 5h response
measurement.
Airway reactivity was assessed immediately following collection of the 5h lung
function data. To ensure safety and subject co-operation, horses were sedated for this
procedure by the intravenous administration of 20pg/kg romifidine (Sedivet,
Boehringer Ingelheim Ltd., Bracknell, Berkshire, UK) and 10pg/kg butorphanol
(Torbugesic, Fort Dodge Animal Health, Southampton, UK). Two minutes following
the administration of sedative, subjects received a lmin duration aerosol challenge
with saline, using the method described above, followed immediately by 2min of lung
function data recording. Data obtained throughout this 2min period were used to
calculate baseline measurements. This process (lmin aerosol challenge and 2min data
collection) was then repeated during and following nebulisation of doubling
concentrations ofmethacholine chloride (Sigma Aldrich Co. Ltd., Poole, Dorset, UK)
dissolved in saline, starting with 0.4mg/ml. The increasing concentrations (0.4, 0.8,
1.6, 3.2, 6.4, 12.5, 25 and 50mg/ml) ofmethacholine chloride solution were prepared
from a stock solution of lOOmg/ml, immediately prior to the assessment of airway
reactivity. Airway reactivity was assessed by measuring the concentration of inhaled
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methacholine chloride solution required to reduce the dynamic compliance to 70% of
the baseline value recorded following saline inhalation (PCCdyn70). PCCdyn70 was
used to assess airway reactivity, as in the majority of cases the 30% reduction in this
variable preceded any significant increase in lung resistance following methacholine
chloride inhalation (personal observation). The data acquisition software permitted
real time calculations of mean dynamic compliance values calculated over a 20s
recording period, however final PCCdyn70 values were calculated following the
analysis of selected breaths as previously described.
2.3.7.4 Tracheal secretion scoring
The volume of tracheal secretions detected during endoscopy was graded 0-5 as
previously described (Dixon et al. 1995) as summarised in Table 2.2.
Table 2.2: Tracheal secretion grading system (as described by Dixon etal. [1995a])
GRADE ENDOSCOPIC FINDINGS
0 No respiratory secretions seen
1 A few droplets of respiratory secretions present
2 Small pool of respiratory secretions present
3 Moderate pool of respiratory secretions present
4 Large pool of respiratory secretions present
5 Very large pool (> 20ml) of respiratory secretions present
2.3.7.5 Bronchoalveolar lavage fluid (BALF) collection
Transendoscopic bronchoalveolar lavage (BAL) was performed under sedation using
intravenous 20pg/kg romifidine and 10pg/kg butorphanol. Horses were also
i
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restrained with a headcollar and nose twitch. A 14mm diameter endoscope (Olympus
CF Type 200HL, 1.7m working length, Olympus Optical Co. Ltd., Tokyo, Japan)
introduced via the rhino-pharyngeal route into the larynx and trachea, was passed
distally until it "wedged" in a third or fourth generation bronchus. The t-7d and 6h
BALF samples were both collected from the right accessory lung lobe, and the 24h
BALF samples were collected from the left ventral segment. Room temperature
sterile saline (300ml) was instilled via the biopsy channel of the endoscope into the
occluded bronchus and immediately aspirated using sterile 60ml plastic syringes.
Instillation and recovery of BALF took less than 45s. The collected BALF was
immediately processed.
2.3.7.6 Bronchoalveolar lavage fluid (BALF) processing
Total unfiltered BALF cell counts were performed using a haemocytometer
(Neubauer haemocytometer, Fischer Scientific UK Ltd., Loughborough, Leics.).
Duplicate cytospin glass slide preparations, prepared by centrifuging lOOpl BALF at
300rpm (lOg) for 3min (Shandon Cytospin 3, Shandon Scientific Ltd., Runcorn,
Cheshire) were air-dried and stained using a Leishmans stain (Fischer Scientific UK
Ltd., Loughborough, Leics.). Differential counts of 500 nucleated cells were made on
both slides by light microscopy (Leica Microsystems UK Ltd., Milton Keynes) under
xlOOO magnification, and a mean value for each cell type was calculated. Absolute
BALF cell counts were determined for each cell type by multiplying the cell ratio (%)
by the total BALF cell count /100.
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The remaining BALF was immediately centrifuged at 600g for 5min, after which the
supernatant was decanted into another sterile plastic universal container. The
remaining cell pellet was resuspended in the residual supernatant retained by surface
tension. A pre-calculated volume of lysis buffer (Buffer RLT, Quiagen, Crawley, W.
Sussex, UK), containing 10pl/ml beta mercaptoethanol (Sigma-Aldrich Co. Ltd.,
Poole, Dorset, UK) was added to the re-suspended cell pellet resulting in a
concentration of 8.6 x 106 cells/ml lysis buffer. This lysed cell sample was then
aliquoted into 350pl volumes, each containing the lysed contents of 3 x 106 cells, and
immediately frozen at -80°C. The decanted supernatant was further centrifuged at
1600g for 15min, and the resulting supernatant was decanted, aliquoted and frozen at
-80°C.
2.3.7.7 Venous blood collection and analysis
Venous blood was collected by jugular venipuncture into plain, heparinised and
ethylenediaminetetraacetic acid (EDTA) coated vacutainers. The heparinised samples
were immediately centrifuged at 1600g for lOmin, and the plasma was aliquoted into
sterile eppendorfs, and stored at -80°C. Following fibrin clot formation in the plain
vacutainers, the samples were centrifuged at 1600g for lOmin, and the serum was
aliquoted into sterile eppendorfs, and stored at -80°C. The samples containing EDTA
were submitted for a total and differential leucocoyte count, performed using an
electronic cell counter (Baker System 9120 plus CP, Biochem Immunosystems,
Allentown, PA, USA) and microscopic examination of a blood smear, respectively.
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2.4 Statistical analysis
Non-parametric tests were used, as the data were either not normally distributed
and/or the groups of compared data did not have equal variance. The effects of each
challenge were determined primarily by performing within-group analyses.
To check for the presence of any carry-over effects of one challenge on a subsequent
challenge, pre-challenge (baseline) measurements of arterial blood gases, lung
mechanics and peripheral blood leucocytes were compared using a Friedman test, and
when significant, a Wilcoxon Rank Sum test was performed on paired data.
To check for any effects of challenge where pre-challenge measurements were made
at t-30min (arterial blood gas analyses, peripheral blood leucocyte and neutrophil
counts, and lung mechanics), the post-challenge values were expressed as % of
baseline value, except for clinical scores where actual values were used. As saline
was the vehicle for LPS delivery, the effect of LPS challenge was assessed by pairing
and subtracting post-LPS (% of baseline value) and post-saline (% of baseline value)
data. Where no pre-challenge data was collected (BALF cytology), comparisons were
made with saline (placebo) challenge data at equivalent time points. A Friedman test
was performed on sets of paired data to reduce the risk of type 1 errors, and when
significant, a Wilcoxon Rank Sum test was performed on paired data.
Between group (heaves vs. controls) analyses were performed for BALF neutrophil
numbers, using the Mann Whitney test.
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Significance was assumed if P<0.05. Following correction for any effect of saline
inhalation, changes from baseline are expressed as increase/decrease or change in
median values, with 95% confidence interval for the difference in median, calculated
for non-parametric data as described by Campbell and Gardner (1994).
The two separate 200pg LPS inhalation challenges were compared using a Wilcoxon
Rank Sum test, and as an indication of repeatability, the differences in paired values
were plotted against their mean as described by Bland and Altman (1986). Good
repeatability was assumed if the calculated differences in paired values fell within 2
standard deviations of the mean of the differences (British Standards Institution,
1979). Results are expressed as median and range.
2.5 Results
2,5.1 Dust and endotoxin exposure during hay/straw challenge
Total and respirable airborne dust endotoxin concentrations, and dust endotoxin
content, in the hay/straw challenge stable are given in Table 2.3. The estimated
biologically active endotoxin exposure received during the 5h challenge was
calculated using the following formula:
D(ng) = Ea(ng/m3) x V(m3/h) x T(h) x C
D = 5h exposure to biologically active endotoxin
Ea = airborne endotoxin concentration (calculated either from the total or respirable dust
fraction)
V = average ventilation rate of both groups (total 13 horses) immediately following hay/straw
challenge (3.1 m3/h)
T = duration of challenge (h)
C = correction factor of 3 for approximate three-fold underestimation of biologically active
endotoxin content in organic dust by the Limulus amoebocyte lysate method (Rylander et at.
1989).
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Table 2.3: Total and respirable airborne dust endotoxin concentrations, and
dust endotoxin content, in the hay/straw challenge stable.




Airborne dust concentration (mg/m3) 2.83(0.83-6.83)
0.50
(0.17-0.83)





Airborne endotoxin concentration (ng/m3) 160.00(86.88-580.56)
3.95
(1.75-61.39)










2.5.2 Response to challenge
2.5.2.1 Clinical examination
All horses had a clinical score of zero prior to all challenges. When compared with
baseline values, no significant increase in clinical scores was detected in either group
following any of the challenges (Appendix 2.5).
2.5.2.2 Arterial blood gases andpH analyses
Raw data for arterial blood gas measurements are presented in Appendix 2.6. There
was no significant difference in the baseline blood gas indices prior to each of the
challenges, indicating a lack of any carry-over effects. The percent change in arterial
blood gases and pH measurements from baseline is presented in Table 2.4. Following
correction for saline inhalation, LPS challenges did not significantly alter arterial pH,
PaC>2 or PaCC>2 when compared with baseline values in either group. In the heaves
group, hay/straw challenge reduced PaC>2 at 90min (decrease in median 6%, 95%
confidence interval (CI) 1-17; P<0.05), and increased arterial pH at 4h (increase in
median 0.2%, 95% CI 0.1-0.6; P<0.05). PaCC>2 was reduced in the control group at
24h following hay/straw challenge (decrease 9%, 3-15; P<0.05).
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2.5.2.3 Lung mechanics and airway reactivity
Raw data for lung function measurements are presented in Appendix 2.7. There was
no significant difference in the baseline lung function measurements prior to each of
the challenges, indicating a lack of any carry-over effects. The percent change in lung
function measurements from baseline is presented in Table 2.5. Following correction
for saline inhalation, LPS inhalation challenges had no significant effect on lung
function of controls. The heaves group had significantly increased RLE50% (increase
in median: 106%, 95% CI 18-2017; P<0.05) and RLe75% (increase in median 116%,
95% CI 34-595; P<0.05) at 5h following inhalation of 2000pg when compared with
baseline values (Table 2.5, Fig. 2.11 and 2.12).
Fig. 2.11: Percent (%) of baseline RLE50% in
heaves horses (n=7) at 5h following inhalation
challenge with saline, 20, 200 and 2000pg LPS
minus percent of baseline RLE5o%, at 5h







SALINE 20|ig LPS 200^ig LPS 2000|ug LPS
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Fig. 2.12: Percent (%) of baseline RI_e75% in
heaves horses (n=7) at 5h following inhalation
challenge with saline, 20, 200 and 2000pg LPS
minus percent of baseline RLE75%, at 5h






SALINE 20(.ig LPS 200ng LPS 2000^g LPS
PCCdyn values following challenge are presented in Appendix 2.8. None of the
challenges altered airway reactivity in either group when compared with saline
inhalation challenge. There was no significant difference in airway reactivity between
the first (median 6.9mg/ml, range 1.5-19.4) and second (5.2mg/ml, 2.8-17.1) 200pg
LPS inhalation challenges. There was good agreement of PCCdyn70 between these 2
challenges, with all the calculated differences in paired values falling within 2
standard deviations of the mean of the differences.
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2.5.2.4 Tracheal secretion score
Compared with saline challenge, LPS challenges did not significantly increase
tracheal secretion score at 6h in either group, however 2 horses in the heaves group
had increased tracheal secretions following inhalation of 200 and 2000pg LPS.
Heaves horses had significantly (P<0.05) increased tracheal secretions score after
hay/straw challenge, when compared with saline (Table 2.6).
Table 2.6 Tracheal secretion scores (median and range) in heaves (n=7) and
control (n=6) horses, 6h following inhalation challenge with saline, 20, 200
and 2000pg LPS, and hay/straw challenge.
























Examination of BALF revealed neutrophils, macrophages, lymphocytes, ciliated
columnar epithelial cells, non-ciliated cuboidal epithelial cells, lymphocytes,
eosinophils, mast cells and "basophiloid cells".
Pooled pre-challenge BALF cytology for both groups (n=13) is presented in Table
2.7. There was no significant difference in the pre-challenge BALF cytology prior to
each of the challenges, indicating a lack of any carry-over effects. Saline inhalation
did not significantly alter BALF cytology in either group. The BALF neutrophil
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counts and ratios at 6h and 24h after each challenge are presented in Appendix 2.9,
and summarised in Table 2.8.
Table 2.7: Baseline total and differential BALF cell counts (x105/ml) (median
and range) at t-7d in both control (C; n=4) and heaves horses (H; n=6) prior to
inhalation challenge with 20, 200 and 2000pg LPS and mouldy hay/straw
challenge (H/S). TCC = total cell count.


















































































































































Table 2.8: BALF neutrophil counts (x105/ml) and ratios (%) (median and range)
in control (n=6) and heaves (n=7) horses at 6 and 24h following inhalation
challenge with saline, 20, 200 and 2000pg LPS and mouldy hay/straw
challenge (H/S).
BALF neutrophil count (x105/ml) BALF neutrophil ratio (%)
Heaves Controls Heaves Controls


























































































LPS induced a dose-dependent BALF neutrophilia in both groups (Figs. 2.13-2.16).
In the heaves group, when compared with saline inhalation, absolute BALF
neutrophil count was significantly (P<0.05) increased at both 6 and 24h after 20pg,
200pg and 2000pg LPS inhalation. These significant increases were also seen in the
BALF neutrophil ratio with the exception of the 24h values following 20pg LPS
inhalation.
In controls, BALF neutrophil count and ratio were significantly (P<0.05) increased at
6h after inhalation of 200pg and 2000pg LPS, and at 24h after inhalation of 2000pg
LPS. BALF neutrophil count and ratio were significantly (P<0.05) increased in the
heaves group at 6h (Figs. 2.13 and 2.14) and 24h after hay/straw challenge. No
increase in BALF neutrophil count was seen in the control group at 6h or 24h after
hay/straw challenge (Fig. 2.15), however a slight, yet significant (P<0.05) increase in
BALF neutrophil ratio was noted in this group at 6h (Fig. 2.16). Absolute BALF
neutrophil count was significantly greater (PO.Ol) at both 6h and 24h in the heaves
group compared with the control group, following inhalation of 20pg LPS and after
hay/straw challenge (Fig. 2.17). In addition, the heaves group also had a significantly
greater BALF neutrophil ratio following 20pg LPS inhalation (P<0.05 at 6h, PO.Ol
at 24h) and hay/straw challenge (PO.Ol) (Fig 2.18).
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Fig. 2.13: BALF neutrophil counts (x10b/ml) in
heaves (n=7) horses at 6h following inhalation
challenge with saline, 20, 200 and 2000pg LPS














1 1 1 T
20(j.g LPS 200ng LPS 2000|jg LPS H/S
Fig. 2.14: BALF neutrophil ratio (%) in heaves
(n=7) horses at 6h following inhalation challenge
with saline, 20, 200 and 2000pg LPS and
mouldy hay/straw challenge (H/S). * = statistical
outlier.
SALINE 20ng LPS 200|^g LPS 2000|.ig LPS
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Fig. 2.15: BALF neutrophil counts (x10 /ml) in
control (n=6) horses at 6h following inhalation
challenge with saline, 20, 200 and 2000pg LPS
and mouldy hay/straw challenge (H/S).
i 1 r
SALINE 20(ag LPS 200ng LPS 2000ng LPS H/S
Fig. 2.16: BALF neutrophil ratio (%) in control
(n=6) horses at 6h following inhalation challenge
with saline, 20, 200 and 2000pg LPS and
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Fig. 2.17: BALF neutrophil counts (x105/ml) in
heaves (n=7) and control (n=6) horses at 6h
following inhalation challenge with saline, 20,
200 and 2000pg LPS and mouldy hay/straw








































SALINE 20|4j LPS 200pg LPS 2000ng LPS H/S
Fig. 2.18: BALF neutrophil ratio (%) in heaves
(n=7) and control (n=6) horses at 6h following
inhalation challenge with saline, 20, 200 and
2000pg LPS and mouldy hay/straw challenge










































There was no significant difference in BALF neutrophil counts between the first (1.3
x 105/ml, 0.3-2.2), and the second (0.9 x 105/ml, 0.6-1.5) 200pg LPS inhalation
challenges. Nine of the 10 calculated differences in paired values fell within 2
standard deviations of the mean of the differences. As the data point falling out with
this range was a clear statistical outlier (out with the lower limit defined as: first
quartile minus 1.5 x [third quartile minus first quartile]), repeatability was considered
good (Bland and Altman 1986) (Fig. 2.19).
Fig. 2.19: Difference between BALF neutrophil
counts (x105/ml) plotted against the mean of the
BALF neutrophil counts (x105/ml) in heaves
(n=6) and control (n=4) horses at 6h following
both 200pg LPS inhalation challenges. Solid line
= mean of the differences; dotted line = mean of
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Difference in BALF neutrophil counts (x10b/ml)
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Due to the influence of a BALF neutrophilia on the ratio of other BALF cell types,
other BALF cell types were considered only as absolute numbers. The absolute
number of other BALF cell types at 6h following all challenges is summarised in
Table 2.9.
Table 2.9: Total and differential BALF cell counts (x105/ml) (median and range)
in heaves (H; n=7) and control (C; n=6) horses at 6h following inhalation
challenge with saline, 20, 200 and 2000pg LPS and mouldy hay/straw challenge
(H/S). *












































































































































Reduced absolute BALF macrophage (P<0.05) and mast cell (P<0.05) numbers
followed 2000pg LPS inhalation only in controls at 6h (Figs. 2.20 and 2.22), with
heaves horses showing a similar but non-significant reduction (Figs. 2.21 and 2.23)
when compared with saline inhalation. None of the challenges induced significant
changes in BALF total cell count, or absolute lymphocyte, epithelial cell, basophiloid
or eosinophil counts. There was no difference between the 6h and 24h BALF total or
absolute cell counts following all challenges, although there was a trend towards a


















Fig. 2.20: BALF macrophage count (x105/ml) in
control (n=6) horses at 6h following inhalation
challenge with saline and 2000pg LPS.
3 —I
SALINE 2000ng LPS
Fig. 2.21: BALF macrophage count (x10/ml) in
heaves (n=7) horses at 6h following inhalation








































Fig. 2.22: BALF mast cell count (x10 /ml) in
control (n=6) horses at 6h following inhalation























Fig. 2.23: BALF mast cell count (x10 /ml) in
heaves (n=7) horses at 6h following inhalation








Fig. 2.24: BALF neutrophil count (x105/ml) in
heaves (n=7) horses at 6 and 24h following
inhalation challenge with saline, 20, 200 and
2000pg LPS and hay/straw challenge. * =
2000jag LPS, A = hay/straw challenge, x =




Fig. 2.25: BALF neutrophil count (x105/ml) in
control (n=6) horses at 6 and 24h following
inhalation challenge with saline, 20, 200 and
2000|ag LPS and hay/straw challenge. * =
2000pig LPS, A = hay/straw challenge, x =










Raw data for peripheral blood total leucocyte and neutrophil counts are presented in
Appendix 2.10. There was no significant difference in the baseline peripheral blood
total leucocyte or neutrophil values prior to each of the challenges, indicating a lack
of detectable carry-over effects. The percent of baseline peripheral blood total
leucocyte and neutrophil values is presented in Table 2.10. Following correction for
the effects of saline inhalation, challenge with 2000pg LPS significantly reduced
peripheral blood total leucocyte counts at 4h when compared with baseline in both
groups (heaves: reduction in median 14%, 95% CI 5-24; P<0.05; controls: reduction
in median 23%, 95% CI 12-36; P<0.05).
Control horses also had a significant, but minor, reduction in peripheral blood total
leucocyte counts at 90min following inhalation of 200pg LPS (reduction in median
8%, 95% CI 0-17; P<0.05). Compared with baseline values, hay/straw challenge
significantly increased peripheral blood total leucocyte counts in the controls at
90min (increase in median 13%, 95% 1-24; P<0.05). A marked and significant
increase in peripheral blood neutrophil counts was also noted in the heaves group at
24h following hay/straw challenge (increase in median 34%, 95% CI 13-75; P<0.05).
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The systemic and pulmonary effects of inhalation with soluble LPS in control and
asymptomatic heaves horses are reported for the first time. Consistent with endotoxin
inhalation studies in man and other species (Gordon, 1992; Schwartz et al., 1994;
Urbain et al., 1996a; Michel et al., 1997), inhalation of 20, 200 and 2000pg soluble
Salmonella typhimurium Ra60 LPS induced a dose-dependent airway neutrophilia,
with BALF neutrophil numbers increasing approximately 50-fold in heaves horses at
6h after the highest dose (2000pg) challenge. Pulmonary recruitment of neutrophils
may have been induced by a variety of alveolar macrophage derived cytokines,
including tumour necrosis factor-alpha, interleukin 1 (IL-1), IL-6 and IL-8, which are
present in increased concentrations in BALF following endotoxin inhalation in other
species (Derochemonteixgalve et al., 1991; Ryan et al., 1994; Schwartz et al., 1994;
Jagielo et al., 1996a; Jagielo et al., 1996b; Ulmer, 1997; Wesselius et al., 1997).
After inhalation of 2000pg LPS, absolute BALF macrophage and mast cell numbers
were significantly reduced in controls, and non-significantly reduced in the heaves
group. Reduced BALF macrophage numbers have been reported following LPS
inhalation in other species, possibly due to LPS-induced macrophage apoptosis
(Michel et al., 1997), or to migration of macrophages from the lung following
antigenic stimulation or for clearance of apoptotic neutrophils (Brazil, 2000) and
possibly other apoptotic inflammatory cells. The significance of the reduction in
BALF mast cell numbers is unclear, but may be artefactual and reflect failure to
identify (and count) degranulated mast cells on cytospin preparations, as endotoxin
78
has been shown in rat skin to directly stimulate mast cell degranulation (Iuvone et al.,
1999).
Peripheral blood total leucocyte counts were reduced at 4h following inhalation of
2000pg LPS in both groups, consistent with a combined systemic and pulmonary
response. This reduction probably reflects margination and pulmonary recruitment of
leucocytes, as occurs following LPS inhalation in guinea pigs (Fogelmark et al.,
1992). As found in this study, the circulating leucocyte response to inhaled endotoxin
was similar in healthy and asthmatic humans, whereas only the asthmatic group had
significant lung dysfunction (Michel et al., 1992a; Michel et al., 1995a). There was
no significant alteration in peripheral blood neutrophil counts in either group, at the
time points studied, in contrast to hay/straw challenge, which induced a peripheral
blood neutrophilia in the heaves group at 24h.
LPS inhalation challenges had no significant effect on clinical score in either group.
This is not surprising, since many of the clinical symptoms reported by humans
following LPS inhalation, including chest tightness, headaches, joint pain and
tiredness (Rylander et al., 1989; Rylander et al., 1999) are subjective, and would
therefore be difficult to detect in horses.
Heaves horses showed a significant deterioration in lung function (as determined by
lung mechanics testing), only after inhalation of 2000pg LPS. Similarly in healthy
humans, high doses (>80-200pg) of inhaled LPS are required to produce combined
79
restrictive and obstructive lung dysfunction, albeit moderate and inconsistent
(Cavagna et al., 1969; Rylander et al., 1989; Michel et al., 1995a; Michel, 1997).
While the increased RLeso% and RLe75% noted in the heaves group is consistent with
an obstructive component, the relative insensitivity of pulmonary mechanics testing
in the horse (performed on tidal breathing) may have prevented detection of mild
restrictive dysfunction. As in humans, where lung dysfunction is more pronounced in
atopics and asthmatics (Michel et al., 1989; Rylander, 1996), control horses had no
significant lung dysfunction, even after inhalation of 2000p.g LPS.
The difference between the 2 groups with respect to lung mechanics cannot be
explained solely by the possible atopic status of the heaves group. The effects of
endotoxin are inflammatory in nature, and not IgE-mediated (Michel, 1997), and
studies in humans have demonstrated that the bronchial obstruction induced by LPS
inhalation is associated with non-specific responsiveness but not with atopy (Michel
et al., 1992b). However, the exaggerated lung dysfunction noted in the heaves group
may reflect a degree of undetected pre-existing airway inflammation in this group,
despite them having been maintained in a dust free environment for several weeks
prior to the challenges, thus magnifying the response to inhaled LPS. No alteration in
airway reactivity was detected in either group, in contrast to the increased airway
reactivity noted at 6h after endotoxin inhalation in human asthmatics (Michel et al.,
1989; Michel et al., 1992a). Failure to detect increased airway reactivity may be due
to insufficient dose of LPS, or to attenuation of the methacholine induced
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bronchconstriction by the bronchodilatory effects of the a2-agonist drug (Broadstone
et ah, 1992) used to sedate horses for this procedure.
LPS challenges did not significantly increase tracheal mucus score in either group at
the 6h or 24h time points, although the heaves group did show a trend for increased
mucus volume with increasing doses of LPS. In other species, inhaled endotoxin
induces (Gordon and Harkema, 1994; Gordon et al., 1996), or is correlated with,
airway mucus hypersecretion (Rylander et al., 1999).
The role of inhaled endotoxin in human occupational respiratory diseases is well
documented (Douwes and Heederik, 1997; Jacobs, 1997a), and the necessity for
dose-response experiments as a prerequisite to establishing no-response safety
thresholds has been recognised (Michel et ah, 1997). As a result of this series of
inhalation challenges, comparisons can be made between the levels of airborne
endotoxin detected in equine environments and the minimal threshold exposures of
soluble LPS required for induction of lung inflammation and dysfunction in the
horse. However the lack of information on the deposition of inhaled aerosolised
solution compared with inhaled organic dust in the horse greatly reduces the accuracy
of any such comparisons. The response threshold of LPS for inducing airway
inflammation was lower in the heaves group (20pg), than controls (200pg), and the
magnitude of BALF neutrophilia was, albeit insignificantly, more marked in heaves
horses than controls. The reason for this difference in LPS response between the 2
groups is unclear. However human studies have identified a similar phenomenon
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when asthmatics are compared with healthy controls, whereby both the atopic status
and the increased neutrophilic response to LPS inhalation in asthmatics was
associated with the constitutive expression of CD 14, the principal receptor in
mediating LPS responses (Alexis et al., 2001).
The response thresholds for lung dysfunction in the heaves (2000pg LPS) and control
(>2000ug LPS) groups were higher than the response thresholds for inflammation as
assessed by BALF cytology. Consistent with this finding, in other species, markers of
inflammation (e.g. BALF and/or sputum neutrophils, myeloperoxidase, tumour
necrosis factor-alpha, eosinophil cationic protein and lactate dehydrogenase) were
more sensitive indices of the effects of inhaled endotoxin than lung dysfunction
(Gordon, 1992; Herbert et al., 1992; Michel et al., 1997).
In this study, the 5h duration hay/straw challenge was estimated to result in an
exposure to biologically active endotoxin equivalent to 0.18 (0.08-2.85)pg as
calculated from respirable dust and biologically active endotoxin equivalent to 7.44
(4,04-27.00)pg, as calculated from total dust. These exposures are mostly lower than
the thresholds for lung inflammation and dysfunction in both groups. Similarly, in
man, while the role of endotoxin in occupational lung disease is well recognised, with
respect to the induction of clinical symptoms, the threshold exposure for soluble LPS
(20pg) (Michel et al., 1989; Michel et al., 1995a) exceeds that for endotoxin present
in airborne organic dust (1.8-3.Opg) collected from swine housing environment
(Larsson et al., 1994). This apparent discrepancy may be explained by several factors
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that limit direct comparison of the threshold exposures for inhaled endotoxin in acute
experimental LPS inhalation challenges and in organic dust exposure, as follows:
(a) Other agents present in stable dust, such as moulds and glucans, may potentiate
the response to endotoxin (Fogelmark et al., 1994; Hunt et al., 1994). Pre-exposure of
human asthmatics to allergen potentiates their response to LPS (Martin et al., 1992)
by increasing vascular permeability and extravasation of LPS binding protein and
soluble CD14 receptors from the pulmonary circulation (Dubin et al., 1996).
Consequently, guidelines for safe environmental levels are based on values for
persons with histories of atopy or asthma (Rylander, 1997b). Possibly, concomitant
mould allergen exposure could increase LPS responsiveness to a greater extent in
heaves horses than in controls.
(b) The biologically active endotoxin content of the stable dust may have been
underestimated by the Limulus amoebocyte lysate assay used in this study, since this
method detects mainly soluble endotoxin and underestimates the biologically active
particulate endotoxin (Rylander et al., 1989). While the recommended correction
factor of 3 (Rylander et al., 1989) was applied when calculating the biologically
active endotoxin content of stable dust, this correction factor may be incorrect given
the probable variation in the proportions of soluble and particulate endotoxin in dusts
from different sources. The method and duration of elution of endotoxin from the
filters may have had an effect on amount of "biologically available" endotoxin
detected by the Limulus amoebocyte lysate assay. Although there is no consensus
regarding the most effective method for extraction of endotoxin from filters, the
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method employed in the current study was chosen to reflect those methods most
frequently described in the literature (Jacobs, 1997b). An example of the influence of
extraction methods is the reported sevenfold difference in detected endotoxin when
0.05% Tween is used as a diluent (Douwes et al., 1995), presumably resulting in the
disruption of micelles, thus resulting in the exposure of the lipid A component of
LPS.
(c) Short duration challenges, as used for soluble LPS inhalation, may produce less
effect than longer duration exposure (e.g. 5h hay/straw challenge). Similarly with
intravenous LPS challenges, slow infusion is frequently preferred to bolus
administration, owing to the ability of the mononuclear phagocyte system to
neutralise circulating endotoxins (Urbain et al., 1996a). As the increased content of
stored mucosubstances in rat airways following endotoxin inhalation is duration-
dependant (Gordon and Harkema, 1994; Gordon et al., 1996), this may explain why
there was significant mucus hypersecretion following hay/straw challenge but not
following LPS inhalation.
(d) The acute LPS and hay/straw challenges likely differed with respect to the
efficacy of delivery and deposition of aerosol and dust particles, the anatomical site in
which they were deposited, and the mechanisms and rate by which they were cleared.
While in the order of 7% of the LPS aerosol generated by the jet nebuliser may have
been deposited in the lung (Votion et al., 1997), the proportion of respirable and total
airborne stable dust reaching the lungs during the hay/straw challenge cannot be
determined. Therefore, without a detailed knowledge of the aerodynamic prperties of
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the challenge aerosol (particulate or aqueous) the exposure level in the breathing zone
may not accurately reflect the "dose" delivered to the target cells within the lung.
Finally, it is unclear whether the endotoxin concentration in respirable or total
airborne stable dust should be considered when making a comparison with the
threshold exposure of soluble LPS. In the hay/straw challenge the majority of
endotoxin in respirable stable dust likely reached the lower airways, however the
endotoxin in the non-respirable fraction may have caused inflammation and
dysfunction of the larger airways (Jacobs, 1997b) and may have contributed to the
response to challenge.
(e) It could be argued that there was a difference between the LPS present within the
organic dust (comprised a variety of LPS types) and that present within the LPS
solution used in the LPS inhalation challenges (S. typhimurium Ra60 mutant), with
respect to virulence within the lung. Given the inability to produce a pure endotoxin
mix which is representative of those types of LPS encountered in equine stables, the
choice of the S. typhimurium Ra60 mutant LPS was considered appropriate. It was
considered likely that Enterobacteriaceae largely contribute to endotoxin present on
airborne dust in equine stables. Although the shortened polysaccharide chain of the S.
typhimurium Ra60 mutuant is more representative of respiratory tract-derived LPS
than gastrointestinal-derived LPS (Makela and Stocker, 1984), it did contain a
complete core oligosaccharide plus lipid A. This structure is responsible for a major
part of the biological activity of LPS and is shared by many Enterobacteriaceae
including all Escherichia coli and Salmonella species (Prof. IR Poxton, personal
communication). However, truncation of the polysaccharide chain may have resulted
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in an alteration of its virulence due to a reduction in phagocytosis in the lung
(Taussig, 1984). One major advantage of the LPS used in the inhalation challenges
was the homogenous nature of the preparation, compared with the very heterogenous
nature ofwild type LPS and even some commercially available preparations (Prof. IR
Poxton, personal communication).
Despite the aforementioned problems in comparing endotoxin levels in the hay/straw
challenge and the threshold exposure for soluble LPS inhalations, several
observations suggest that inhaled endotoxin was not the sole cause of lung
inflammation and dysfunction in the heaves group following hay/straw challenge.
Firstly, the total estimated exposure of endotoxin encountered in the hay/straw
challenge (7.44pg) was markedly lower than the threshold exposure of soluble LPS
(200-2000pg) required to induce a similar degree of BALF neutrophilia. Secondly,
the hay/straw challenge did not induce a BALF neutrophilia in controls, while
inhalation of >200pg LPS induced BALF neutrophilia in both groups. Thirdly, in
contrast to LPS inhalation, hay/straw challenge significantly increased tracheal mucus
score in the heaves group.
However, it is likely that endotoxin per se causes airway inflammation in horses in
stables with very poor air hygiene, since respirable endotoxin concentrations in such
stables may be as high as 3437ng/m (Dutkiewicz et al., 1994). A 5h exposure to this
concentration would equate to an LPS exposure of 160pg, which exceeds the
threshold exposure of LPS which causes inflammation in horses with asymptomatic
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heaves (20pg), and possibly that which causes inflammation in control horses
(between 20 and 200pg).
In this study, as in human studies (Michel et al., 1997), all horses were given LPS in
increasing rather than randomised doses. This order was selected for safety reasons,
given the absence of data on the effects of acute LPS inhalation in horses, and given
the potential for significant individual-dependent variability in the response (Michel
et al., 1992b). It could be argued that randomisation of challenge order may have
minimised potential carry-over effects from prior challenges. Carry-over effects could
include potentiation due to persistence of inflammation, early-phase tolerance
(Ulmer, 1997), and late-phase (occurring after several weeks) tolerance due to
production of anti-endotoxin antibodies (Johnston and Greisman, 1985; Ulmer,
1997). Daily exposure of rats to LPS did result in a gradual reduction in chemokine
and neutrophil concentration in recovered BALF (Shimada et al., 2000) However, the
excellent repeatibility of inflammatory (BALF neutrophilia) and functional
(PCCDyn70) changes following repeated 200ug LPS challenge, suggests that carry¬
over effects were insignificant in this study. Further, since early-phase tolerance to
inhaled endotoxin lasts no more than 2 days (Johnston and Greisman, 1985), it was
unlikely to have influenced the response to subsequent challenges that were separated
by at least 2 weeks.
In conclusion, inhaled endotoxin induces neutrophilic airway inflammation and
dysfunction in horses. While this study suggests that inhaled endotoxin is not the sole
cause of heaves, it suggests that it may contribute to disease aetiopathogenesis.
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Acceptance of the dose-response data described is a prerequisite to the development
of acceptable endotoxin exposure levels for horse accommodation. Control or heaves-
affected horses housed in stables with poor air hygiene may be exposed to airborne
endotoxin levels exceeding the threshold dose levels that induce airway
inflammation. While further work is required to determine the effect of inhaled
endotoxin on subclinical pulmonary dysfunction and thus on exercise performance,
potentially detrimental effects may be minimised by optimising air hygiene in stables.
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CHAPTER 3: COMPARISON OF TWO DIFFERENT HAY/STRAW
CHAFLENGE SYSTEMS WITH RESPECT TO DISEASE INDUCTION IN
ASYMPTOMATIC HEAVES HORSES AND AIRBORNE DUST AND
ENDOTOXIN EXPOSURE
3.1 Summary
To determine whether the pulmonary inflammatory response of heaves-susceptible
animals to organic dust challenge was related to airborne endotoxin exposure, 6
heaves horses were exposed to 2 different hay/straw challenge environments. Both
challenges consisted of a 5h exposure to dusty hay and straw, however one of the
challenge environments used hay with obvious visible mould contamination. The
severity of airway disease, as indicated by the BALF neutrophilia and arterial
hypoxaemia, was significantly different despite airborne dust and endotoxin
concentrations in the horses' breathing zones being similar in both challenges.
Furthermore, the environment that induced the greater disease severity had a higher
airborne concentration of P-D-glucan, albeit non-significantly. This likely reflected
the greater degree of visible mould contamination of the hay used during this
challenge. Inhaled endotoxin appears, therefore, not to be the main determinant of
disease severity. As the BALF neutrophilia was greater in horses exposed to mouldy
hay, mould exposure may be a more important determinant of disease severity.
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3.2 Introduction
The experimental LPS dose-response inhalation experiments detailed in Chapter 2
established that the induction of heaves in susceptible horses does not appear to be
entirely due to inhaled endotoxin (Chapter 2). However several problems were
highlighted regarding the comparison of endotoxin exposure in an environment
containing high levels of organic dust and during soluble LPS nebulisation. These
included the following: (a) the presence of other potentially pro-inflammatory or
allergenic agents present in stable dust, such as moulds and glucans, which may
potentiate the response to endotoxin (Fogelmark et al., 1994; Hunt et al., 1994); (b)
the probable underestimation of the biologically active endotoxin content of stable
dust using the Limulus amoebocyte lysate assay (Rylander et al., 1989); (c) the
different duration of the two challenges, and (d) the differences between the two
challenge systems with respect to the efficacy of delivery and deposition of aerosol
and the mechanisms and rate of particle clearance.
In addition, the finding that inhaled soluble LPS did induce some of the features of
heaves, and that heaves susceptible horses responded to a lower concentration of LPS
than controls, indicates that further investigation of the role of endotoxin in this
disease is warranted. Numerous studies in human occupational environments
containing high concentrations of organic dust have established that the incidence of
respiratory disease is correlated to the level of endotoxin exposure (Sigsgaard et al.,
1992; Teeuw et al., 1994; Milton et al., 1995; Preller et al., 1995a; Schwartz el al.,
1995a; Schwartz et al., 1995b; Reynolds et al., 1996; Keman et al., 1998; Donham et
al., 2000) often more so than to the level of dust exposure (Rylander and Bergstrom,
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1993; Zejda et al., 1994). In addition, several studies have shown that the clinical
severity of asthma in house dust mite-sensitive humans was correlated with endotoxin
exposure, yet poorly correlated with exposure to house dust mite allergens (Michel et
al., 1991; Michel et al., 1996; Rizzo et al., 1997).
To overcome the problems associated with a comparison of the endotoxin exposure
during an acute challenge (soluble LPS inhalation) with a more chronic challenge (5h
hay/straw challenge), comparisons were made between 2 different hay/straw
challenges of equal duration. Heaves susceptible horses received two separate 5h
hay/straw challenges, which differed only with respect to the source of hay used for
feeding. Both hay sources were dusty, however only one had visual evidence of
mould contamination. The systemic and pulmonary responses of heaves horses to
both challenges were measured and compared. These responses were than related to
the airborne dust, endotoxin and P-D-glucan (an indicator of airborne fungal content)
exposure to establish whether the severity of disease in heaves-susceptible horses was
related to specific dust components.
3.3 Materials and methods
3.3.1 Subjects
Six horses (3 geldings, 3 mares; median age 17 years, 8-28; median weight 434 kg,
323-594) with a history and clinical diagnosis of heaves were used. The disease status




Hay/straw challenge B (H/S A): Six heaves horses were housed for 5h in a small (3.7
x 3.7m) poorly ventilated stable with the doors and air vents closed. Horses were
bedded on deep litter straw, and fed a mixture of good quality and dusty hay.
Hay/straw challenge A (H/S B): For comparison, the same 6 heaves horses were
housed for 5h in an environment identical to that above, with the exception that the
dusty hay used for feeding contained visible mould growth. This hay/straw challenge
has been shown to induce heaves only in susceptible horses (McGorum et al.t 1993c),
and is described previously (2.3.2.2).
3.3.2.2 Challenge protocol
All 6 horses received H/S A challenge first, followed by H/S B. Several procedures
were performed to minimise potential carry-over effects of H/S A challenge on H/S B
challenge. Firstly, challenges were conducted a minimum of 14 days apart. Secondly,
all horses were shown to have normal BALF cytology at least 7 days prior to
challenges, and normal clinical findings immediately prior to each inhalation
challenge. In order to assess any carry-over effects, the 2 sets of baseline lung
function, arterial blood gas and pH, and venous blood leucocyte values were
compared.
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3.3.3 Stable dust collection
Throughout the 5h duration of both hay/straw challenges, total and respirable dust
was collected from the horse's breathing zones, as described previously (2.3.5).
3.3.4 Analysis of dust
3.3.4.1 Calculation ofairborne dust concentration
The collected dust was weighed (2.3.6.1) and sample filters were then stored in
individual sterile universal containers at -20°C, prior to endotoxin and p-D-glucan
analyses.
3.3.4.2 Measurement ofendotoxin in airborne dust
The endotoxin content of filters was determined using an endotoxin specific Limulus
amoebocyte lysate assay as previously described (2.3.6.2).
3.3.4.3 Measurement of/3-D-glucan in airborne dust
The p-D-glucan content of filters collected from the respirable dust samplers was
determined using a glucan-specific Limulus amoebocyte lysate assay (Gluspecy,
Seikagaku Co, Tokyo, Japan). Samples were prepared as described for endotoxin
analysis. For analysis, all reagents, samples and standards were brought to room
temperature. Samples and standards were mixed vigorously for 30s with a vortex
mixer. Serial dilutions of the samples were then made in order to ensure a final
sample concentration that did not exceed the P-D-glucan standard provided with the
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kit. Serial dilutions (1:1, 1:2, 1:4 and 1:8) of the standard were also made to provide a
standard curve. 50pl of standard, sample or p-D-glucan-free distilled water (negative
control) was pipetted into a sterile 96 well microplate. 50pl of Limulus amoebocyte
lysate substrate solution was then quickly added to each well. The microplate was
then incubated at 37°C for 30min and the reaction was stopped by adding 200pl of
0.6M acetic acid to each well. The absorbance of the resulting colour reaction was
read photometrically (Microplate Autoreader, Bio-Tek Instruments Inc., Winooski,
VT, USA) at 405nm, and compared to a standard curve, prepared during each
analysis. All samples were analysed in duplicate and the mean value calculated.
Analysis was repeated if (a) the paired values differed from their mean by >20% of
the mean, (b) either of the paired values exceeded the value of undiluted standard
solution, or (c) either of the paired values was less than the value obtained from a 1:8
dilution of the standard solution.
The P-D-glucan concentration per m3 of air sampled was then calculated using the
following equation:
1000
Airborne p-D-glucan (ng/ m3) = P-D-glucan per sample (ng) x inverse of dilution factor x
600
In addition, the P-D-glucan content of the dust was calculated using the following
equation:
p-D-glucan per sample (ng) x inverse of dilution factor
P-D-glucan content of dust (ng/mg) =
dust collected (mg)
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3.3.5 Monitoring the response to challenges
The response to challenges was assessed using clinical scoring, arterial blood gases
and pH analyses, venous blood haematology, lung mechanics, airway reactivity and
BALF cytology as previously described (2.3.7). The timing of the assessment of the
response to challenges is summarised in Fig. 3.1.
Fig. 3.1: Study design.
BAL = bronchoalveolar lavage; LF = lung function evaluation; Clin Ex = clinical examination; Art BG =


















t - 7 days t-30min to t + 90min t +4h t + 5h t +6h
3.4 Statistical analysis
Responses to the 2 hay/straw challenges and the airborne concentration of dust,
endotoxin and p-D-glucan of the 2 challenges were compared by performing within-
group, paired analyses. Where pre-challenge measurements were made at t-30min
(arterial blood gases and pH analyses, and lung mechanics) the post-challenge values
were expressed as % of baseline value, except for clinical scores where actual values
were used. A Wilcoxon Rank Sum test was performed on paired sets of data; namely
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horses' response data collected from identical time points, or airborne dust, endotoxin
and (3-D-glucan concentrations within the challenge stable.
To check for the presence of any carry-over effects of the first challenge on the
second challenge, pre-challenge (baseline) measurements of arterial blood gases and
pH, lung mechanics and blood leucocytes were compared using a Wilcoxon Rank
Sum test. Significance was assumed if P<0.05.
3.5 Results
3.5.1 Dust, endotoxin and (3-D-glucan exposure
There was no significant difference in airborne dust, endotoxin or (3-D-glucan
exposure between the 2 hay/straw challenges (Table 3.1). The respirable dust
endotoxin concentration was non-significantly (P=0.059) higher during H/S A (Fig.
3.2), and the respirable dust [3-D-glucan concentration was non-significantly
(P=0.059) higher during H/S B (Fig 3.3).
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Table 3.1: Airborne respirable and total dust, endotoxin and (3-D-glucan
concentrations during H/S A (n=6) and H/S B (n=6) challenges (median and
range).
H/S A H/S B
Total dust concentration (mg/m3) 1.2(0.7-1.7)
1.5
(0.5-1.9)
Respirable dust concentration (mg/m3) 0.1(0.1-0.6)
0.2
(0.1-0.3)
Airborne endotoxin concentration (ng/m3)
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Fig. 3.2: Airborne endotoxin concentration
(ng/m3) in respirable dust during hay/straw


























Fig. 3.3: Airborne p-D-glucan concentration
(ng/m3) in respirable dust during hay/straw
challenges H/S A (n=6) and H/S B (n=6).
H/S A H/SB
3.5.2 Response to challenges
3.5.2.1 Clinical examination
All horses had a clinical score of zero prior to all challenges. When compared with
baseline values, no significant increase in clinical scores was detected in either group
following H/S A or H/S B (Appendix 3.1).
3.5.2.2 Arterial blood gas analysis
Raw data for arterial blood gases and pH measurements are presented in Table 3.2.
There was no significant difference in the baseline blood gas indices prior to each of
the challenges, indicating a lack of detectable carry-over effects. H/S B induced a
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significant (P<0.05) arterial hypoxaemia at 90 min (median decrease in PaC>2 4%,
95% CI 1-19), with a similar but non-significant (P=0.059) reduction at 4h post
challenge.
Table 3.2: Arterial blood gases (mmHg) and pH measurements (median and
range) in heaves (n=6) horses at 0, 1.5, 4 and 24h following hay/straw




























































3.5.2.3 Lung mechanics and airway reactivity
Raw data for lung mechanics measurements are presented in Appendix 3.2. PCCdyn
values following challenge are presented in Appendix 3.3. There was no significant
difference in baseline lung function measurements between the 2 challenges,
indicating a lack of detectable carry-over effects. Neither of the challenges altered
lung function when compared with baseline values, and the challenges did not
significantly differ from one another with respect to airway reactivity.
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3.5.2.4 BALF cytology
The BALF cytology data following both challenges are presented in Appendix 3.4,
and summarised in Table 3.3. H/S B induced a significantly (P<0.05) higher BALF
neutrophil count and ratio than H/S A at 6h (Table 3.3, Figs. 3.4 and 3.5). There was
no difference between H/S A and H/S B with respect to numbers of other BALF cell
types.
Table 3.3: Total and differential BALF cell counts (x105/ml) (median and range)
in heaves (n=6) horses at 6h following hay/straw challenges H/S A and H/S B.
TCC = total BALF cell count; Lymph = lymphocytes.









































Fig. 3.4: BALF neutrophil counts (x105/ml) in
heaves (n=6) horses at 6h following hay/straw
challenges H/S A and H/S B.
10 H
H/S A H/S B
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Fig. 3.5: BALF neutrophil ratio (%) in heaves
(n=6) horses at 6h following hay/straw

















H/S A H/S B
3.6 Discussion
The results of this study suggest that the pulmonary response of heaves-susceptible
horses to housing in a dusty environment is not solely related to the magnitude of
airborne endotoxin exposure. This is consistent with the findings of the study
described in Chapter 2, whereby the pulmonary functional and inflammatory
responses of heaves horses to high concentrations of inhaled LPS was not
significantly different from that of controls. Despite the pulmonary neutrophilic
inflammation being significantly greater following H/S B challenge, there was no
significant difference between the 2 challenge systems with respect to airborne
concentration of total or respirable dust, or the endotoxin and (3-D-glucan
concentration of these 2 dust fractions within the horses breathing zone. In fact, the
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H/S A challenge resulted in a non-significantly greater endotoxin exposure as
calculated from the respirable dust fraction, yet induced only minor pulmonary
neutrophilic inflammation and no alteration in lung mechanics or arterial blood gas
tension compared with H/S B challenge.
In addition, H/S B resulted in a non-significantly greater exposure to the mould cell
wall component (l-3)-p-D-glucan as calculated from the respirable dust fraction. As
airborne (l-3)-p-D-glucan has been shown to reflect mould exposure (Douwes et al.,
1998; Rylander et al., 1998; Chew et al., 1999; Dillon et al., 1999; Mandryk et al.,
2000; Wouters et al., 2000), this finding supports previous studies that have
identified an association between mould exposure and clinical signs in heaves-
susceptible horses (McPherson and Thomson, 1983; Thomson and McPherson, 1984;
Derksen et al., 1988; McGorum et al., 1993c; Robinson et al., 1996). Furthermore, as
several human studies have identified an association between respiratory symptoms
or airway responsiveness and (l-3)-p-D-glucan exposure (Rylander, 1997a and c;
Rylander, 1998; Thorn et al., 1998; Thorn and Rylander, 1998a; Rylander et al.,
1999), it is possible that as well as reflecting the degree of mould exposure, (l-3)-P-
D-glucan inhalation may in itself result in respiratory inflammation and dysfunction.
The pro-inflammatory effects of (l-3)-P-D-glucan have been demonstrated both in
vivo, by means of inhalation studies in humans and laboratory animals (Fogelmark et
al., 1992; Rylander and Fogelmark, 1994; Fogelmark et al., 1997; Schuyler et al.,
1998; Beijer et al., 1999; Sigsgaard et al., 2000; Fogelmark et al., 2001), and in vitro
following challenge of lung derived macrophages (Milanowski et al., 1995b;
Ljungman et al., 1998).
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The dust concentrations measured during both challenges were similar yet lower than
previously reported levels in which personal samplers were used to collect from the
breathing zone of horses housed in a confined hay and straw environment (Bartz and
Hartung, 1993; Woods et al., 1993; McGorum et al., 1998). The greater airborne dust
concentration in the study by McGorum et al (1998) is somewhat surprising
considering the better ventilation provided in that study in which the top door of the
stable remained open during the sampling period.
Despite this finding, the endotoxin concentrations were greater in the current study
compared with those reported by McGorum et al. (1998) in which the dust collection
procedure was identical. This likely reflects the higher endotoxin content of the dust
in the current study, a finding that is supported by other studies in which a poor
correlation between dust levels and endotoxin levels (Kullman et al., 1998; Douwes
et al., 2000a) has been reported. It is possible that the actual endotoxin content of the
dust was greater than that measured using the Limulus amoebocyte lysate assay due to
its reported underestimation of particulate endotoxin which would have been
pelletted by centrifugation prior to analysis (Rylander et al., 1989). However this
underestimation would have applied to both H/S A and H/S B challenges to a similar
degree, considering the similar respirable dust levels measured in both systems.
Numerous human studies have identified an association between pulmonary function,
inflammation or symptoms and endotoxin exposure in workers exposed to organic
dusts (Sigsgaard et al., 1992; Rylander and Bergstrom, 1993; Teeuw et al., 1994;
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Milton et ah, 1995; Preller et ah, 1995a; Schwartz et ah, 1995a; Schwartz et al.,
1995b; Vogelzang et al., 1998). In many cases either a poor association, or no
association at all, has been identified between respiratory symptoms and dust
exposure (Rylander and Bergstrom, 1993; Jorna et al., 1994; Smid et al., 1994; Zejda
et al., 1994; Wang et al., 1996a). However other studies have identified an
association between pulmonary function and dust levels (Christiani et al., 1999), and
no correlation between pulmonary function and endotoxin exposure (Allermann and
Poulsen, 2000). The reason for the disagreement between some of these studies is
unclear, however it may reflect the complex nature of organic dusts (Kullman et al.,
1998), many components of which have been implicated in a range of respiratory
diseases (Lacey, 1993).
It has already been established that endotoxin inhalation in the horse results in
pulmonary inflammation and dysfunction (Chapter 2), however the level of soluble
LPS exposure required to induce these effects greatly exceeds the degree of endotoxin
exposure encountered in both H/S A and H/S B challenges. Although there are
limitations in making such direct comparisons, the lack of association between
endotoxin exposure and pulmonary inflammation in the current study may simply
reflect the fact that the level of endotoxin exposure was below the response threshold
for the horse. However in both challenges the airborne endotoxin concentration
greatly exceeded the recommended safety levels for human workers (Rylander,
1997b).
104
Although the greater severity of pulmonary inflammation detected following H/S B
challenge appeared to relate to the higher level of mould exposure, it may also have
been partly related to endotoxin exposure. It is possible that exposure to moulds in
H/S B challenge resulted in a greater inflammatory response to co-inhaled endotoxin.
Co-exposure to endotoxin and either purified (l-3)-P-D-glucan or allergen has been
reported to induce an exaggerated inflammatory pulmonary response (Fogelmark et
al., 1994; Wan et al., 2000), and it is likely that a complex interaction exists between
the microbial components of organic dusts with respect to their combined pro¬
inflammatory properties (Fogelmark et al., 2001). In order to investigate this
possibility further, a third challenge system would have been required in which horses
were exposed to airborne mould in the absence of endotoxin. However as endotoxins
are prevalent in many forms of organic dust (Jacobs, 1997a), such a dry dust
challenge system would be difficult to create. As inhalation models can be used to
determine which components of a mixture are the most important for inducing the
observed adverse outcome (Thorne, 2000), further studies require an inhalation
challenge system which is representative of some or all of the components of hay dust
and which permits the selective manipulation of those components. This would
further the understanding of the relative contribution of each allergenic or pro¬
inflammatory agents present in hay dust to the overall pulmonary inflammatory and
functional response.
In summary, this chapter support the findings of Chapter 2, namely that inhaled
endotoxin does not appear to be solely responsible for the pulmonary inflammatory
and functional response of heaves-susceptible horses to organic dust exposure.
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However, it remains possible that inhaled endotoxin contributes to this overall
pulmonary response when inhaled in concert with other organic dust components
such as mould spores.
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CHAPTER 4: DOSE-RESPONSE RELATIONSHIP TO INHALED SOLUBLE
ASPERGILLUS FUMIGATUS EXTRACT IN ASYMPTOMATIC HEAVES
HORSES
4.1 Summary
Previous studies showed a shortfall in response of heaves horses to inhaled mould
extract compared with natural disease (McGorum et al., 1993c). To investigate
whether insufficient dose delivery was responsible for this shortfall, the response of 6
heaves horses to inhalation of saline (placebo), and 3 doses of soluble Aspergillus
fumigatus extract was assessed. Inhalation challenge with 0.5, 1.6 and 5mg A.
fumigatus extract significantly increased BALF neutrophil ratios compared with
saline. Only 1.6 and 5mg A. fumigatus extract inhalation caused significant lung
dysfunction compared with saline. There was no significant difference in the
pulmonary inflammatory or functional response to 1.6 and 5mg extract inhalation. A
good agreement was found between the response to these 2 doses with respect to
airway neutrophil numbers and lung function, indicating that a plateau was attained
for both measured responses. As the magnitude of the response was less than that of
natural disease, this study therefore supports a role for other inhalants, in addition to
the soluble components ofA. fumigatus, in the aetiopathogenesis of heaves.
4.2 Introduction
The results presented in both Chapters 2 and 3 indicate that inhaled endotoxin is not
the sole inhalant responsible for the response of heaves susceptible horses during
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dusty hay/straw exposure. Indeed, the results of the challenge experiments presented
in Chapter 3 are more supportive of a role for inhaled moulds in disease
aetiopathogenesis. However considering the myriad of inhalants to which horses are
exposed when housed in dusty environments, it is possible that endotoxin plays a
contributing role when co-presented to the lung along with other inhalants, such as
moulds.
Mould extract inhalation challenges have been used previously in the investigation of
heaves (Derksen and Robinson, 1981; Derksen et al., 1988; McGorum et al., 1993c).
Although such studies have implicated a hypersensitivity to inhaled moulds in disease
pathogenesis (McPherson et al., 1979; Derksen et al., 1988; McGorum et al., 1993c),
little attention has been given to the additional role of other inhaled components.
Although experimental mould extract (.Aspergillus fumigatus, Faenia rectivirgula)
inhalation results in pulmonary neutrophilic inflammation and dysfunction, consistent
with the natural disease, the magnitude in response is less than that observed
following dusty hay/straw exposure (McGorum et al., 1993c). While one suggested
reason for this shortfall in response is that there was insufficient dose delivery during
the experimental inhalation challenges, no dose-response inhalation challenges have
been reported. To establish whether insufficient dose delivery is responsible for this
response shortfall following mould extract inhalation, a series of dose-response
inhalation experiments was conducted in 6 heaves horses, using a soluble A.
fumigatus extract.
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4.3 Materials and methods
4.3.1 Subjects
6 horses (3 geldings, 3 mares; age 17 years, 8-28; weight 434 kg, 323-594) with a
history and clinical diagnosis of heaves were used as previously described (3.3.1).
The disease status of all subjects was confirmed by mouldy hay/straw challenge as
previously described (2.3.4.2). All horses were kept in a low dust environment
(2.3.2.1) throughout the duration of the study.
4.3.2 Aspergillus fumieatus extract
Soluble Aspergillus fumigatus extract (AFE) prepared from both the cellular
(somatic) and extracellular (culture filtrate) components of A. fumigatus culture was
kindly donated by Dr. John Edwards, MRC Immunology Lab., Sully ITospital,
Penarth, Wales. Doses of 0.5mg, 1.6mg and 5mg AFE were used in the inhalation
challenges, being prepared from a stock solution of lOmg/ml and diluted in
physiologic saline immediately prior to use. A constant 1ml volume of challenge
solution was delivered to the facemask for all challenges.
4.3.3 Inhalation challenges
4.3.3.1 Inhalation challenge protocol
To facilitate subject compliance, horses were sedated with intravenous 20pg/kg
romifidine and 1 Opg/kg butorphanol immediately prior to each inhalation challenge.
The aerosol was generated and delivered as previously described (2.3.4.1). The order
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of challenges in all horses was constant i.e. 5mg followed by 0.5mg, followed by
1.6mg. To minimise potential carry-over effects of a preceding challenge on
subsequent challenges, inhalation challenges were conducted a minimum of 14 days
apart and all horses were shown to have normal clinical findings immediately prior to
each inhalation challenge. In order to assess any carry-over effects, all baseline lung
function and arterial blood gases and pH values were compared statistically.
4.3.3.2 Positive (hay/straw exposure) and negative (saline) control challenges
To compare the AFE responses with those of placebo and a conventional hay/straw
challenge, comparisons were made with saline inhalation and a 5h-duration
conventional hay/straw challenge in the same horses, as previously described
(2.3.4.2).
4.3.3 Monitoring the response to challenges
The method and timing of assessment of response to each challenge is summarised in
Fig. 4.1. Responses to the AFE, hay/straw and saline challenges (Chapter 2) were
assessed using clinical scoring, lung mechanics, airway reactivity, blood gases and
pH analyses and BALF cytology, as previously described (2.3.7).
Fig. 4.1: Study design.
BAL = bronchoalveolar lavage; LF = lung function evaluation; Clin Ex = clinical examination;











t- 30min to t + 4h t + 5h t + 6h
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4.4 Statistical analysis
As the data were either not normally distributed and/or the groups of compared data
did not have equal variance, non-parametric tests were used. The effects of each
challenge were determined by performing within-group analyses.
To check for the presence of any carry-over effects of one challenge on a subsequent
challenge, pre-challenge (baseline) measurements of arterial blood gases and pH and
lung mechanics were compared using a Friedman test, and when significant, a
Wilcoxon Rank Sum test was performed on paired data.
To check for any effects of challenge, where pre-challenge measurements were made
at t-30min (arterial blood gas analyses and lung mechanics), the post-challenge values
were expressed as % of baseline value, except for clinical scores where actual values
were used. As saline was the vehicle for AFE delivery, the effect of AFE challenge
was assessed by pairing and subtracting post-AFE (% of baseline value) and post-
saline (% of baseline value) data. Where no pre-challenge data was collected (BALF
cytology), comparisons were made with saline (placebo) challenge data at an
equivalent time point. A Friedman test was performed on sets of paired data to reduce
the risk of type 1 errors, and when significant, a Wilcoxon Rank Sum test was
performed on paired data.
Significance was assumed if P<0.05. Following correction for any effect of saline
inhalation, changes from baseline are expressed as increase/decrease or change in
median values (% baseline following AFE challenge minus % baseline following
ill
saline), with 95% confidence interval for the difference in median, calculated for non-
parametric data (Campbell and Gardner 1994). Results in tables are expressed as
median and range.
To assess the level of agreement in neutrophil response to 1.6 and 5mg AFE
challenges, the differences in paired values were plotted against their mean (Bland
and Altman 1986), for BALF neutrophil counts. Good agreement was assumed if the
calculated differences in paired values fell within 2 standard deviations of the mean
of the differences (British Standards Institution, 1979).
4.5 Results
4.5.1 Dose-response to AFE inhalation challenge.
4.5.1.1 Clinical examination
All horses had a clinical score of zero prior to all challenges. When compared with
baseline values, no significant increase in clinical scores was detected at 4h following
any of the AFE challenges (Appendix 4.1).
4.5.1.2 Arterial blood gases andpH analyses
Raw data for arterial blood gases and pH measurements are presented in Appendix
4.2. There was no significant difference in the baseline blood gas or pH indices prior
to any of the inhalation challenges, indicating a lack of detectable carry-over effects.
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When compared with baseline values, no significant change in blood gas or pH
values was detected at 4h following any of the AFE challenges.
4.5.1.3 Lung mechanics and airway reactivity
Raw data for lung mechanics measurements are presented in Appendix 4.3. With the
exception of respiratory rate and inspiratory resistive work of breathing (Wbires), there
was no significant difference in the baseline lung mechanics measurements prior to
each of the challenges, indicating a lack of detectable carry-over effects. The
percentage change in lung mechanics measurements from baseline is presented in
Table 4.1. PCCdyn values following challenge are presented in Appendix 4.4.
Following correction for any effects of saline inhalation, a dose dependant alteration
in lung mechanics was detected following AFE challenge (Fig. 4.2). Both 1.6mg and
5mg, but not 0.5mg, AFE inhalation resulted in a significant (P<0.05) increase in
Rle25% (l-6mg - increase in median 94%, 95% CI 14-678; 5mg - increase in median
114%, 95% CI 12-578) at 5h.
Fig. 4.2: Percent (%) of baseline RLe25% in
heaves horses (n=6) at 5h following inhalation
challenge with saline, 0.5, 1.6 and 5mg AFE
minus percent of baseline RLe75%, at 5h
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There was no significant difference between the 1.6mg and the 5mg FE challenges
with respect to Rle25%- In addition, as all of the 6 calculated differences in Rle25%
values for the 1.6 and 5mg AFE challenges fell within 2 standard deviations of the
mean of the differences and the mean of the differences approximated zero (Fig. 4.3),
agreement was considered good (Bland and Altman 1986). Both of these findings
suggested that there was a plateau in the lung function response following 1.6 and
5mg AFE inhalation. None of the AFE doses induced a significant alteration in
airway reactivity at 5h.
Fig. 4.3: Difference plotted against mean of
percent (%) of baseline RLe25% in heaves horses
(n=6) at 5h following inhalation challenge with
1.6 and 5mg AFE minus percent of baseline
RLe75%, at 5h following inhalation challenge with
saline.
Solid line = mean of the differences; dotted line = mean of
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BALF neutrophil counts and ratios following saline and AFE challenges are
presented in Appendix 4.5, and summarised in Table 4.2.
Table 4.2: BALF neutrophil counts (x105/ml) and ratios (%) (median and range)
in heaves (n=6) horses at 6h following inhalation challenge with saline, 0.5, 1.6
and 5.0mg AFE.





















When compared with saline inhalation, both 1.6mg and 5mg AFE inhalation
challenges resulted in a significant (P<0.05) increase in BALF neutrophil count
(1.6mg - increase in median 0.84 x 105/ml, 95% CI 0.65-2.02: 5.0mg - increase in
median 0.95 x 105/ml, 95% CI 0.31-1.76) and neutrophil ratio (Table 4.2; Figs 4.4
and 4.5). Although inhalation of 0.5mg AFE did not significantly increase the BALF
neutrophil count, it did induce a slight, yet significant (P<0.05) increase in BALF
neutrophil ratio (Table 4.2, Fig. 4.5). When compared with 0.5mg AFE inhalation,
both 1.6mg and 5mg AFE inhalation resulted in a significantly (P<0.05) greater
BALF neutrophil count (1.6mg - difference in median 0.78 x 105/ml, 95% CI 0.37-
1.89: 5.0mg - difference in median 0.85 x 105/ml, 95% CI 0.29-1.35) and neutrophil
ratio. A 5h-hay/straw challenge (2.5.2.6) induced a significantly (P<0.05) greater
BALF neutrophil count and ratio than 0.5mg AFE, and a greater BALF neutrophil
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count and ratio than 1.6mg and 5mg which approached significance (P=0.059) (Figs.
4.4 and 4.5).
Fig. 4.4: BALF neutrophil counts (x10 /ml) in
heaves (n=6) horses at 6h following inhalation
challenge with saline, 0.5, 1.6 and 5.0mg AFE
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Fig. 4.5: BALF neutrophil ratio (%) in heaves
(n=6) horses at 6h following inhalation challenge
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There was no significant difference in the neutrophil count or ratio between the
1.6mg and 5mg AFE challenges. In addition, as all of the 6 calculated differences in
total BALF neutrophil number values for the 1.6 and 5mg AFE challenges fell within
2 standard deviations of the mean of the differences and the mean of the differences
approximated zero, agreement was considered good (Bland and Altman 1986) (Fig.
4.6). Both of these findings were indicative of a plateau in the neutrophilic response
at higher doses ofAFE.
Fig. 4.6: Difference between BALF neutrophil
counts (x105/ml) plotted against the mean of the
BALF neutrophil counts (x105/ml) in heaves
(n=6) horses at 6h following inhalation challenge
with 1.6 and 5.0mg AFE.
Solid line = mean of the differences; dotted line = mean of
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Due to the influence of a BALF neutrophilia on the ratio of other BALF cell types,
the latter cells were considered only as absolute numbers. The absolute number of
other BALF cell types 6h following challenge is summarised in Table 4.3.
Table 4.3: Total (TCC) and differential BALF cell counts (x105/ml) (median and
range) in heaves (n=6) horses at 6h following inhalation challenge with saline,
0.5, 1.6 and 5.0mg AFE.
TCC





















































When compared with saline inhalation, both 1.6mg and 5mg AFE inhalation resulted
in a significant (P<0.05) reduction in absolute BALF basophiloid numbers (1.6mg -
decrease in median 0.02, 95% CI 0.00-0.11; 5mg - decrease in median 0.02, 95% CI
0.01-0.11) at 6h (Fig. 4.7). In addition, inhalation of 1.6mg AFE resulted in a
significant (P<0.05) reduction in BALF mast cell count (reduction in median 0.08 x
105/ml, 95% CI 0.04-0.12) (Fig. 4.8). A similar reduction albeit non-significant
(P=0.059) occurred following 0.5mg (reduction in median 0.09 x 105/ml, 90% CI
0.04-0.14) and 5mg (reduction in median 0.09 x 105/ml, 90% CI 0.03-0.13) AFE
inhalation (Fig 4.8). Interestingly, a significant (P<0.05) increase in BALF
eosinophils was noted following 5mg AFE inhalation (increase in median 0.08 x
















Fig. 4.7: BALF basophiloid cell counts (x105/ml)
in heaves (n=6) horses at 6h following inhalation















Fig. 4.8: BALF mast cell counts (x10 /ml) in
heaves (n=6) horses at 6h following inhalation




SALINE 0.5mg AFE 1.6mg AFE 5.0mg AFE
120
Fig. 4.9: BALF eosinophil counts (x105/ml) in
heaves (n=6) horses at 6h following inhalation
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4.6 Discussion
This study reports the results of a series of dose-response inhalation experiments in
heaves-susceptible horses using a soluble aqueous Aspergillus fumigatus extract
(AFE). In agreement with other studies, AFE inhalation resulted in both pulmonary
inflammation and dysfunction (McPherson et al., 1979; McGorum et ah, 1993c).
However a plateau was demonstrated in both of these measured indices with the 2
higher AFE doses, as indicated by the agreement between the responses to the 1.6 and
5mg doses. This plateau in response could have been further supported if higher
challenge doses than used in the study also failed to result in an increasing response,
however this work was not possible due to unavailability of sufficient quantity of the
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same batch of AFE. It is however likely that the observed plateau was a real
phenomenon, considering that it was reached at an exposure (1.6mg AFE) less than
3.15-fold higher than the response threshold for neutrophilic inflammation (i.e.
>0.5mg AFE) and was maintained following a further 3.15-fold increase in the AFE
exposure.
Although randomisation of the challenge doses would have been more appropriate, it
is unlikely that a carry over effect of the 5mg AFE challenge resulted in an
exaggerated response to the 1.6mg AFE challenge. Firstly all horses received a 0.5mg
AFE challenge following the 5mg AFE challenge, yet only a minor response to this
low exposure was detected. Secondly, a lack of carry-over effects was supported by
the failure to detect any significant differences between the baseline data for both
lung function and arterial blood gas and pH measurements prior to all challenges.
Although the reason for the plateau in the neutrophilic and lung function response is
unclear, a similar plateau in skin reactivity has been reported in children with allergic
eczema following atopy patch testing with house dust mite and grass pollen allergens
(Darsow et al., 1999). This phenomenon has also been demonstrated in a guinea pig
model of dust mite antigen-induced asthma whereby the degree of airway
eosinophilia induced following inhalation of a low dose of crude dust mite extract did
not increase with increasing doses of inhaled extract (Hsiue et al., 1997). As previous
studies have proposed the involvement of a type I hypersensitivity response in the
pathogenesis of heaves (McPherson et al., 1979; Derksen et al., 1988; McGorum et
al., 1993b), with a suggested role for pulmonary mast cells (McGorum et al., 1993b),
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it is feasible that the observed plateau in response may reflect a state of "allergen
saturation". Under such circumstances the maximal capacity for allergen-specific
IgE-mediated mast cell degranulation may have been reached following challenge
with the middle dose of AFE. It is possible to attribute the plateau in both the
pulmonary neutrophilic and functional response to such a phenomenon (Cairns and
Walls, 1996).
It has been suggested that a reduction in BALF mast cells and basophiloid cells may
reflect mast cell/basophiloid cell degranulation, with subsequent failure to identify
the degranulated cells on BALF cytospin preparations stained using Leishmans' stain.
Therefore the hypothesis of "allergen saturation" may be supported by the significant
reduction in BALF basophiloid cells following 1.6mg and 5mg AFE challenges and
the reduction in BALF mast cell numbers following all 3 challenges, although this
only approached significance following 0.5mg and 5mg AFE challenge. However, the
data presented in Figs. 4.7 and 4.8 suggest that the magnitude of the reduction in the
mast cell and basophiloid numbers did not appear to increase with increasing doses of
AFE.
Also of interest was the increase in BALF eosinophil numbers detected following the
5mg AFE challenge. While this was statistically significant, it was only a small
increase, which probably has little biological significance. However, despite the
eosinophil being classically associated with allergic responses in the lung (Coyle et
al., 1996; Ohkawara et al., 1997), following all AFE challenges, the neutrophil was
the most abundant polymorphonuclear inflammatory cell detected in BALF,
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consistent with previous mould extract inhalation studies (Derksen et al., 1988;
McGorum et al., 1993c) and naturally occurring heaves (Derksen, 1993; Fairbairn et
al, 1993).
The plateau in response to increasing doses of mould extract may explain the results
of previous mould inhalation studies where the severity of pulmonary inflammation
and dysfunction associated with the natural disease was not reproduced (McGorum et
al., 1993c). Although only the 0.5mg AFE dose resulted in significantly lower BALF
neutrophil count than the hay/straw challenge performed in the same horses (Chapter
3), the difference between the BALF neutrophilic response to hay/straw challenge and
both the 1.6 and 5.0mg doses approached significance. This failure to achieve
statistical significance in both cases resulted from the same horse, which developed a
BALF neutrophilia following hay/straw challenge of equivalent magnitude to that
following both 1.6mg and 5.0mg AFE challenge (H/S - BALF neutrophil ratio =
27%, 1,6mg AFE - 31%, 5.0mg AFE 28%).
Proposed explanations for this reduced response compared with hay/straw challenge
include variations between responses to short-term and long-term inhalation
challenge, the involvement of other inhalants in the natural disease and insufficient
dosage of extract (McGorum et al., 1993c). Flowever it would appear from the
current study that the latter explanation is unlikely. The plateau in response may
therefore support the role of inhalants other than those present within AFE in the
natural disease. This is perhaps not surprising considering the myriad of likely
inhalants present within stable dust (6.4.1), many of which have pro-inflammatory
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properties (Clarke, 1987a; Clarke and Madelin, 1987) including endotoxin (Chapters
2 and 3). It is possible that the combined exposure to fungal allergens and endotoxin
could result in an increase in disease severity in susceptible horses, even if the
underlying susceptibility reflects the individuals' hypersensitivity response to fungal
allergen, as opposed to their endotoxin responsiveness. Another explanation for the
reduced response to soluble mould extract inhalation compared with hay/straw
exposure is that the AFE contains only soluble and not particulate components.
Particulates, such as mould spores, have been shown in vitro to significantly enhance
IgE-mediated histamine release from suspensions ofBAL cells (Larsen et al., 1996).
In conclusion, the current study supports the role of other inhalants in addition to
soluble mould allergens in the aetiopathogenesis of heaves. Considering the wide
variety of inhalants to which stabled horses are exposed, the clinical features of this
disease may reflect a hypersensitivity to inhaled mould allergens, which results in a
magnification in the host response to other pro-inflammatory components of stable
dust, such as endotoxin. Consequently, further work was performed to investigate
whether, in heaves horses, inhaled endotoxin could potentiate the pulmonary
inflammatory and functional response to AFE (Chapter 5).
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CHAPTER 5: EFFECT OF CONTAMINANT LPS ON THE RESPONSE TO
INHALED SOLUBLE ASPERGILLUS FUM1GATUS EXTRACT
5.1 Summary
To investigate the role of endotoxin contamination of fungal extract in the response
of heaves horses following inhalation challenge, the response of 6 heaves horses to
inhalation of 1.6mg soluble A. fumigatus extract (AFE) was assessed before and after
lipopolysaccharide (LPS) depletion. LPS depletion of AFE resulted in a significant
reduction in airway (BALF) neutrophil numbers and increase in arterial oxygen
tension when compared with AFE. There was no significant difference between
saline and the LPS-depleted AFE challenges with respect to BALF neutrophil count
and lung function. The reduction in airway neutrophil numbers was greater than
predicted by extrapolation from soluble LPS dose-response inhalation experiments.
While it was not determined whether the reduction in effect was due entirely to
removal of LPS and not other AFE components, this study supports the potentiating
role of LPS in this AFE-induced model of heaves. This study also supports the role of
inhaled endotoxin in the pulmonary inflammation and dysfunction in naturally
occurring heaves, given the high concentration of both A. fumigatus and endotoxin in
stable dust.
5.2 Introduction
The study described in Chapter 4 suggested that insufficient dose delivery was
unlikely to explain the reduced pulmonary inflammatory response following fungal
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extract inhalation as compared to that following mouldy hay/straw exposure. It
appeared more likely that additional components of the airborne dust contributed to
this pulmonary inflammation, and this thesis has concentrated on the potential role of
endotoxin in this respect for 2 main reasons. Firstly, stable dust contains relatively
high quantities of endotoxin (Olenchock et al., 1992; Dutkiewicz et al., 1994;
McGorum et al., 1998; Tanner et al., 1998), and secondly, LPS inhalation challenges
in horses results in neutrophilic airway inflammation (2.5.2.6) and mild obstructive
lung dysfunction (2.5.2.3), both features of naturally occurring heaves. Despite the
proposed similarities between heaves and human allergic asthma (Derksen, 1993),
unlike asthma, eosinophil infiltration into the airways is not a feature of heaves
(Derksen et al., 1985b; Fairbairn et al., 1993). However in asthma, endotoxin
contamination of inhaled allergens can alter the predominant cell population recruited
to the airways from eosinophils to neutrophils (Hunt et al., 1992; Hunt et al., 1994).
Indeed endotoxin contamination of inhaled allergens has been proposed as a cause of
the predominantly neutrophilic lung infiltration in sudden-onset fatal asthma (Sur et
al., 1993). It is therefore possible that the high concentration of inhaled endotoxin to
which horses are exposed may be a major contributor to the neutrophilic
inflammation in heaves. This chapter describes the pulmonary inflammatory and
functional response to inhalation challenge with LPS depleted fungal extract.
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5.3 Materials and methods
5.3.1 Subjects
6 horses (3 geldings, 3 mares; age 17 years, 8-28; weight 434 kg, 323-594) with a
history and clinical diagnosis of heaves were used (3.3.1). The disease status of all
subjects was confirmed by mouldy hay/straw challenge as previously described
(2.3.4.2). All horses were kept in a low dust environment (2.3.2.1) throughout the
duration of the study.
5.3.2 Inhalation challenge material
5.3.2.1 Evaluated challenge
Endotoxin-depleted 1.6mg soluble A. fumigatus extract (AFE-LPS) was used. The
AFE was of the same batch as that previously described (4.3.2).
5.3.2.2 Positive (1.6mgAFE) and negative (saline) control challenges
To relate the AFE-LPS responses with those of a negative and positive challenge,
comparisons were made with saline inhalation (Chapter 2) and 1.6mg AFE challenges
(Chapter 4) performed in the same horses.
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5.3.2.3 Endotoxin analysis ofAFE
Endotoxin analysis of 1.6mg AFE and AFE-LPS was performed using an endotoxin-
specific Limulus amoebocyte assay (2.3.6.2), following appropriate dilution of the
extract to reduce the contaminating endotoxin concentration to a level between the
standard supplied with the assay and a 1:8 dilution of that standard.
5.3.2.4 Endotoxin depletion ofAFE
Polymixin-coated agarose beads suspended in 50% glycerol (polymixin B-agarose,
Sigma Aldrich Co. Ltd., Poole, Dorset) were used to achieve endotoxin depletion of
AFE (Molig and Baek, 1987). The binding capacity of the polymixin-coated bead
suspension is reported as 200-500p.g LPS from Escherichia coli serotype 0128:B 12
per ml. 10ml of the polymixin-coated bead suspension was added to 5ml of the stock
solution of AFE (lOmg/ml) in a sterile conical tube. The tube was rotated for 30min
and the resulting mixture was centrifuged (1600g; 15min) to pellet the beads. The
LPS-depleted supernatant (AFE-LPS) was decanted and frozen at -80°C until diluted
in saline to a concentration of 1,6mg/ml and used for the inhalation challenges.
5.3.3 Inhalation challenges
For all challenges, 1ml of challenge substance was delivered to the facemask. To
facilitate subject cooperation, horses were sedated immediately prior to each
inhalation challenge as previously described (2.3.4.1). The aerosol was generated and
delivered as previously described (2.3.4.1).
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To minimise potential carry-over effects of a preceding on subsequent challenge,
inhalation challenges were conducted a minimum of 14 days apart and all horses were
shown to have normal clinical findings immediately prior to each inhalation
challenge. In order to assess any carry-over effects from previous inhalation
challenges in the same horses, baseline lung function and arterial blood gas values
prior to AFE and AFE-LPS challenge were compared.
5.3.4 Monitoring the response to challenges
The method and timing of assessment of response to each challenge is summarised in
Fig. 5.1. Responses to the AFE-LPS, 1.6mg AFE (Chapter 4) and saline (Chapter 2)
challenges were assessed using clinical scoring, lung mechanics, airway reactivity,
blood gas analyses and BALF cytology, as previously described (2.3.7).
Fig. 5.1: Study design.
BAL = bronchoalveolar lavage; LF = lung function evaluation; Clin Ex = clinical examination;











t- 30min to t +4h t + 5h t +6h
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5.4 Statistical analyses
As the data were either not normally distributed and/or the groups of compared data
did not have equal variance, non-parametric tests were used. The effects of each
challenge were determined by performing within-group analyses.
To check for the presence of any carry-over effects of one challenge on a subsequent
challenge, pre-challenge (baseline) measurements of arterial blood gases and pH and
lung function were compared for the 3 challenges using a Friedman test, and when
significant, a Wilcoxon Rank Sum test was performed on paired data.
To assess the effects of challenge where pre-challenge measurements were made at t-
30min (arterial blood gases and pH analyses and lung mechanics), the post-challenge
values were expressed as % of baseline value, except for clinical scores, where actual
values were used. As saline was the vehicle for AFE and AFE-LPS delivery, the
effect of AFE challenge was assessed by pairing and subtracting post-AFE/AFE-LPS
(% of baseline value) and post-saline (% of baseline value) data. Where no pre-
challenge data was collected (BALF cytology), comparisons were made with saline
(placebo) challenge data at an equivalent time point. A Friedman test was performed
on sets of paired data to reduce the risk of type 1 errors, and when significant, a
Wilcoxon Rank Sum test was performed on paired data.
Significance was assumed if P<0.05. Following correction for any effect of saline
inhalation, changes from baseline are expressed as increase/decrease or change in
median values, with 95% confidence interval for the difference in median, calculated
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for non-parametric data as described by Campbell and Gardner (1994). Results in
tables are expressed as median and range.
5.5 Results
5.5.1 LPS depletion from AFE
Following mixing of 5ml AFE (lOmg/ml) with 10ml the polymixin bead suspension
and centrifugation to pellet the beads, the volume of the resulting supernatant was
10ml, as the 5ml glycerol in which the beads were suspended was not separated by
centrifugation. Therefore the concentration of AFE in the final stored supernatant was
5mg/ml (1:2 dilution of lOmg/ml) and this was used as the stock solution for
subsequent dilution and nebulisation.
The endotoxin content of the original AFE (lOmg/ml) was shown to be 13.1pg/ml.
The endotoxin content of the LPS depleted AFE (5mg/ml) was 2.1 pg/ml. Both the
AFE-LPS and the AFE were diluted in physiologic saline, to result in a final
challenge concentration equivalent to 1.6mg/ml AFE. Therefore polymixin treatment
reduced the endotoxin concentration in the final 1.6mg AFE challenge from 2.1 pg/ml
(13.1pg/ml x [1.6/10]) to 0.66pg/ml (2.1pg/ml x [1.6/5]), i.e. a reduction of
1.44pg/ml, equating to a 69% reduction in endotoxin activity.
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5.5.2 Response to inhalation challenge with saline, AFE and AFE-LPS
The responses to inhalation challenge with saline and 1.6mg AFE are previously
described (2.5.2 and 4.5.1, respectively).
5.5.2.1 Clinical examination
All horses had a clinical score of zero prior to all challenges, and when compared
with baseline values, no significant increase in clinical scores was detected at 4h
following AFE-LPS challenge (Appendix 5.1).
5.5.2.2 Arterial blood gases andpH analyses
Raw data for arterial blood gas and pH measurements are presented in Appendix 5.2.
There was no significant difference in the baseline blood gases or pFl when AFE-LPS
and AFE challenges were compared, indicating a lack of detectable carry-over effects.
When compared with baseline values, no significant change in blood gases or pH
values were detected at 4h following AFE-LPS challenge. AFE challenge induced a
significantly (P<0.05) greater decrease in median arterial oxygen tension at 4h than
AFE-LPS (difference in median - 11%, 95% CI 4-27).
5.5.2.3 Lung mechanics and airway reactivity
Raw data for lung mechanics measurements are presented in Appendix 5.3. With the
exception of RLe50%> RLe75% and Wbnres, there was no significant difference in the
baseline lung mechanics measurements prior to AFE and AFE-LPS challenges,
indicating a lack of detectable carry-over effects. The percentage change in lung
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function measurements from baseline is presented in Table 5.1. PCCdyn70 values
following challenge are presented in Appendix 5.4.
Following correction for the effects of saline inhalation, the significant (P<0.05)
increase in Rle25% at 5h following 1.6mg AFE challenge (4.5.1.3) was not detected
following AFE-LPS challenge. AFE-LPS challenge did not induce a significant
alteration in airway reactivity at 5h. There was no significant difference in PCCdyn70
values when the AFE-LPS and 1.6mg AFE challenges were compared.
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BALF neutrophil counts and ratios following saline, 1.6mg AFE and AFE-LPS
challenges are fully presented in Appendix 5.5, and summarised in Table 5.2.
Table 5.2: BALF neutrophil counts (x105/ml) and ratios (%) (median and
range) in heaves (n=6) horses at 6h following inhalation challenge with
saline, 1.6mg AFE and 1.6mg AFE-LPS.
BALF neutrophil count
















Inhalation challenge with AFE-LPS resulted in a significant (P<0.05) reduction in
BALF neutrophil count (decrease in median 0.43 x 105/ml, 95%C1 0.10-0.65) and
ratio at 6h when compared with AFE challenge (Table 5.2; Figs. 5.2 and 5.3). In
addition, the BALF neutrophil count following AFE-LPS challenge was not
significantly different from that following saline challenge (Table 5.2; Fig. 5.2). For
comparison, previous inhalation challenges in the same 6 horses with 20pg soluble
LPS resulted in an increase in BALF neutrophil numbers (increase in median 0.20,
95% CI 0.06-0.48), compared with saline at 6h (calculated from data of study in
Chapter 2).
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Fig. 5.2: BALF neutrophil counts (x10b/ml) in
heaves (n=6) horses at 6h following inhalation






Fig. 5.3: BALF neutrophil ratio (%) in heaves
(n=6) horses at 6h following inhalation challenge
with saline, 1.6mg AFE and 1.6mg AFE-LPS.
SALINE AFE AFE-LPS
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Due to the influence of a BALF neutrophilia on the ratio of other BALF cell types,
they were considered only as absolute numbers. The absolute number of other BALF
cell types at 6h following challenge are summarised in Table 5.3.
Table 5.3: Total and differential BALF cell counts (x105/ml) (median and range)
in heaves (n=6) horses at 6h following inhalation challenge with saline, 1.6mg
AFE and 1.6mg AFE-LPS.
TCC = total BALF cell count.
TCC Lymphocytes
■











































LPS depletion also resulted in a significant (P<0.05) increase in the BALF mast cell
count (increase in median 0.03 x 105/ml, 0.01-0.06) at 6h, compared with 1.6mg AFE
challenge (Fig 5.4). BALF mast cell and basophiloid cell numbers at 6h following
AFE-LPS challenge did not significantly differ from those following saline challenge.
Compared with saline inhalation, AFE-LPS challenge did not result in a significant
alteration in total BALF cell numbers or absolute lymphocyte, macrophage,
eosinophil or epithelial cell numbers (Table 5.3).
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Fig. 5.4: BALF mast cell counts (x105/ml) in
heaves (n=6) horses at 6h following inhalation




















In addition to supporting the role of inhaled fungi in the aetiopathogenesis of heaves,
the results presented in Chapter 4 also supported a role for other inhalants in
determining the severity of the pulmonary inflammatory response. Comparing the
inhalation responses to standard doses of AFE and endotoxin, with the response to
inhalation of a combination of these components would have provided a valid method
of determining the relative role of each component. However the finding that the
AFE, used in the dose-response inhalation challenges reported in Chapter 4, was
contaminated with LPS offered a suitable alternative to further investigate the
combined effects of these 2 components. Considering the relatively high airborne
concentrations of both moulds and endotoxin in stable dust (Clarke, 1987a; Clarke,
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1987b; Clarke and Madelin, 1987; Clarke et al., 1987; Webster et al., 1987;
Olenchock et al., 1992; Dutkiewicz et al., 1994; Raymond et al., 1994; McGorum et
al., 1998; Tanner et al., 1998), this system also potentially offered an insight into the
role of inhaled endotoxin in the aetiopathogenesis of naturally occurring heaves. The
successful depletion of LPS (estimated 69% reduction) from inhalation challenge
material using polymixin-coated agarose beads was previously employed to
investigate the role of inhaled endotoxin in a mouse model of organic dust-induced
lung disease (Jagielo et al., 1996a). The failure to achieve complete depletion in this
study may have resulted from the LPS molecules forming micelles in the AFE, thus
preventing exposure and consequently binding of the polymixin to cations on the
lipid A component of the LPS molecules (Makela and Stocker, 1984).
The reduction in the neutrophilic response and improvement in lung function
following LPS depletion of AFE was greater than would have been predicted by
extrapolation of previous LPS dose-response inhalation experiments (Chapter 2).
Polymixin treatment of AFE resulted in a reduction in delivery to the facemask
equivalent to only 1.44pg LPS. However the difference in the median BALF
neutrophil count when the AFE and AFE-LPS challenges were compared was greater
than that induced following 20pg LPS inhalation (data presented in 5.5.2.4). This
finding suggests that the LPS content of the inhaled extract contributed to the
pulmonary inflammatory response to a greater degree than predicted if the
contribution was solely additive to that of AFE, or that polymixin treatment also
removed other AFE components which had a greater effect than LPS.
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Despite the fact that the AFE-LPS challenge consistently resulted in a BALF
neutrophil count not significantly different from saline challenge, it is unlikely that
the neutrophilic response to AFE (4.5.1.4) could entirely be attributed to the activity
of LPS. Firstly, previous LPS dose-response experiments have demonstrated that a
significantly higher dose of LPS than that present within both the 1.6mg and 5mg
AFE (2.1 and 6.6pg, respectively) is required to induce an equivalent airway
neutrophilia and lung dysfunction (2.5.2). Secondly, the dose response curves
following AFE inhalation and LPS inhalation in heaves horses are quite different,
with the inflammatory response to LPS continuing to increase at exposures 100-fold
greater than the response threshold (<20pg) (2.5.2.6; Pirie et al., 2001b). This
compares with a plateau in the neutrophilic inflammatory response to increasing
doses of AFE only at a dose 3.2-fold greater than the response threshold (4.5.1.4).
It could be argued that the endotoxins present in AFE may be of a different LPS type
to those present within the Salmonella R60 mutant used in the LPS challenges.
However the Salmonella R60 mutant LPS represents a structure shared by many of
the Enterobacteriaccae and is responsible for a major part of the biological activity of
LPS (Prof. IR Poxton, personal communication). It would have been interesting to
determine the effect of challenge with AFE-LPS following the addition of LPS from
the Salmonella R60 mutant at a dose equivalent to that removed during the original
depletion. Re-establishment of the neutrophilic response to a degree similar to that
following challenge with AFE would have supported the theory that the depleted LPS
and the Salmonella R60 mutant had similar biological activities. This would also
have provided confirmation that the reduction in response resulted entirely from LPS
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depletion, and was not due to any alteration in the activity of other agents present
within AFE, nor due to contamination of the AFE-LPS with glycerol.
This study therefore demonstrates that the LPS contamination contributes markedly
to the response to AFE challenge in horses. The phenomenon of disease severity
being related to exposure to other inhalants, in addition to allergen, has been
documented in human asthma, whereby endotoxin exposure can be a greater
determinant of disease severity than allergen exposure (Michel et al.t 1991; Michel,
1996; Michel et al., 1996; Rizzo et ah, 1997). In addition, inhalation challenge
studies in a murine model of asthma have shown that co-exposure of mice to LPS and
allergen results in a greater degree of airway neutrophilia when compared with
allergen challenge alone (Goldsmith et ah, 1999).
It is possible that the presence of LPS contamination in the current AFE model
resulted in a magnification in the response to mould allergens present within the
extract, consistent with previous studies which have demonstrated an augmentation of
the immunoglobulin responses to allergen by LPS (Rylander and Holt, 1998; Slater et
ah, 1998; Tulic et ah, 2000). Alternatively, the response to inhaled LPS may have be
magnified by the co-presence of allergen, perhaps via an increase in the concentration
of lipopolysaccharide binding protein and soluble CD14 receptors in the
bronchoalveolar compartment after allergen challenge, as has been demonstrated in
human asthma (Martin et ah, 1992; Dubin et ah, 1996).
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Interestingly, an alteration of the type of cellular response to inhaled allergen has been
demonstrated in man following endotoxin contamination of allergen, whereby
neutrophils instead of eosinophils were the predominant cell type detected within the
airways (Hunt et al., 1992; Hunt et al., 1994). It is possible therefore that endotoxin
contamination of mould extracts used in previous investigations of heaves
contributed significantly to the reported neutrophil influx in the airways (Derksen et
al., 1988; McGorum et al., 1993c). Although reduction in the LPS content of AFE in
the current study did not alter the type of inflammatory cell recruited to the airways
from neutrophils to eosinophils, complete LPS depletion was not achieved.
Consequently, the level of endotoxin contamination in the AFE-LPS challenge, albeit
reduced, may have contributed to the neutrophilic influx.
Also of interest was the increased BALF mast cell count following AFE-LPS
challenge when compared with AFE challenge. It has been hypothesised that the
reduction in the BALF mast cell count following AFE challenge when compared with
saline inhalation resulted from a failure to identify degranulated mast cells on
cytospin preparations (Derksen et al., 1988). Consequently, the higher BALF mast
cell count following challenge with AFE-LPS compared with AFE may support a role
for LPS in mast cell degranulation, as has been demonstrated previously in studies on
rat skin and colon (Brown et al., 1998; Iuvone et al., 1999). In addition, endotoxin
has been shown to enhance histamine release from human pulmonary mast cells in
vitro by both immunological and non-immunological mechanisms (Norn et al.,
1994).
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In conclusion, this work has further supported a potentiating role of endotoxin in the
pulmonary inflammatory and functional response to inhaled AFE. Ideally an add-back
experiment would have been done to confirm if the difference in response to AFE and
AFE-LPS was due solely to LPS.
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CHAPTER 6: PRODUCTION AND CHARATERISATION OF A HAY DUST
SUSPENSION (HDS), FOR USE IN INHALATION CHALLENGES IN
HEAVES-SUSCEPTIBLE SUBJECTS
6.1 Summary
Currently, heaves is investigated by exposing susceptible horses to dusty hay.
Consequently, the response will be dependent on the organic dust content and
composition of the hay, as well as other factors including stable ventilation. It was
hypothesised that the use of a nebulised hay dust suspension (HDS) would reduce the
variability of these challenges and thus standardise experimental protocols.
Furthermore, analysis of HDS would also permit further investigation of the organic
dust components responsible for the pulmonary inflammatory and functional
response.
Three hay dust suspensions (HDS-1, 2 and 3) were prepared from 3 batches of dusty
hay. HDS-1 and 3 were analysed for endotoxin, P-D-glucan and protein
concentrations, general protease activity, and enumeration and size distribution of
particulates. Protease activity was mainly attributable to a 28kDa serine protease and
to 85kDa and 160kDa metalloproteases. The particulate and soluble components of
HDS could be aerosolised by jet nebulisation. It was therefore concluded that detailed
analysis of HDS is possible, that such a challenge system provides a method of
standardising experimental protocols within and among laboratories, and that all




The diagnosis of heaves may be problematic, especially in horses with mild disease
(Clarke, 1987c). In such cases, the diagnosis is frequently based upon the induction of
pulmonary inflammation and dysfunction by exposure to mouldy hay/straw, with
subsequent resolution of signs when this exposure ceases (Robinson et al., 1996).
However, no standardised hay/straw challenge protocol exists, and the variable and
undefined composition of airborne dust in a conventional hay/straw challenge system
(Clarke, 1993), and variation in stable ventilation can result in poor reproducibility of
the responses to such challenges (Chapter 3). There is thus a requirement for a
standardised and repeatable inhalation challenge that induces the functional and
inflammatory responses of heaves in susceptible horses, but not in controls.
Theoretically, a standardised, prolonged duration, dry dust challenge, as used in other
species (Rylander, 1988; Jolie et al., 1999), may best reproduce the dust challenge
encountered naturally in a dusty stable. However, the potential benefits of such a
technique may be outweighed by practical problems associated with standardised and
prolonged delivery of dry dust to horses. In addition, manipulation of the individual
components of dry dust would be problematic. Soluble aqueous extracts of various
organic dusts have been used extensively to investigate dust related respiratory
disease in man and other species (Gao et al., 1993; Schwartz et al., 1994; Blaski et
al., 1996; Jagielo et al., 1996a; Deetz et al., 1997; Jagielo et al., 1997; Jagielo et al.,
1998; Trapp et al., 1998). However, these extracts do not contain dust particulates
(eg. spores, mite debris, inorganic dust, plant fragments) which may directly
contribute to pulmonary inflammation (Kurup et al., 1997), and/or affect the
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pulmonary distribution of soluble components. Therefore only the response to soluble
dust components (eg. proteases and soluble fungal antigens, endotoxins and glucans)
can be assessed. Surprisingly, there are apparently no reports of the use of aqueous
hay dust suspensions (HDS), which contain both soluble and particulate dust
components, in the investigation of dust related disease in any species. This chapter
describes the production and analysis of HDS, to be used in the diagnosis and
investigation of heaves.
6.3 Materials and methods
6.3.1 Production of HDS
6.3.1.1 Collection ofdust particles
Three different HDS (HDS-1, 2 and 3) were produced from 3 visibly mouldy batches
of hay. Only HDS-1 was produced from a batch of hay known to induce heaves in
susceptible horses (2.3.2.2). To harvest hay dust, hay was agitated manually onto a
clean surface and the large stems were manually removed. The resultant dust was
sieved (grid size 3x2mm) twice to remove larger plant debris. The remaining dust
was spread evenly on a flat surface in an unventilated area (Fig. 6.1) and left for lh to
allow airborne dust to settle. The dust was then aspirated using a dual vortex
household vacuum (DC01, Dyson Appliances Ltd., Malmesbury, Wiltshire, UK) (Fig.
6.2), which collected coarse dust in the outer dust collection drum (Fig. 6.3) and fine
dust (Fig. 6.4) in a separate central compartment. The fine dust was transferred to
sterile containers and stored at -20°C until required.
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Fig 6.1: Following sieving, hay dust was spread on a flat clean
surface in an unventilated room
Fig. 6.2: A dual vortex household vacuum was used to aspirate the
settled dust
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Fig. 6.3: Coarse dust was separated from fine dust. The coarse
dust, collected in the outer dust collection drum, was discarded.
Fig. 6.4: Fine dust particles collected from the separate central
compartment were used to prepare FIDS.
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6.3.1.2 Production ofsuspension
To prepare the HDS, 10ml sterile physiologic saline (Vetivex, 0.9% w/v Sodium
Chloride, Ivex Pharmaceuticals, Larne, UK) was added to each gram of dust. The
suspension was then vortexed for 30s, shaken for 30min and rolled for 30min. It was
then filtered through 60pm pore size nylon gauze mesh (Nytex gauze, Nytex, UK),
aliquoted into 1.8ml eppendorfs and stored at -80°C.
6.3.2 Characterisation of HDS
6.3.2.1 Microscopic analysis
All three suspensions were examined microscopically (Leica Microsystems UK Ltd.,
Milton Keynes) under 400x magnification (Fig. 6.5) and the particulates sized using
an eyepiece graticule and compared with their microscopic appearance prior to
filtration (Fig. 6.6).
Fig. 6.5: Photomicrograph of HDS following filtration through 60pm pore
size nylon gauze showing mainly small fungal spores (2-4pm diameter) in
addition to occasional "fair weather air spora" (e.g. Alternaria spore [A], rust
uredospore [r]), mite faeces [m] and small fragments of plant/vegetable
debris, x 400 magnification.
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Fig. 6.6: Photomicrograph of HDS prior to filtration
through 60pm pore size nylon gauze showing larger
plant and non-defined particles, x 400 magnification.
6.3.2.2 Particulate loss duringfiltration
To determine the mass of particulates in the final suspensions, and consequently
particulate loss during filtration, a sample of HDS-1 was weighed before and after
evaporation of solution (including a correction for the mass of the sodium chloride).
6.3.2.3 Particulate count
Particulate counts for HDS-1 and HDS-3 were determined both manually using a
haemocytometer (Neubauer haemocytometer, Fischer Scientific UK Ltd.,
Loughborough, Leics., UK) and by the impedence principle using an electronic cell
counter (Baker System 9120 plus CP, Biochem Immunosystems, Allentown, PA,
USA). This equipment also calculated the frequency distribution of the different sized
particles. Counts were obtained for particulates in the 0-40, and the 40-300 pm
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ranges (Fig. 6.7), which, if particles were spherical, corresponded to particulate
diameters of 0-4.2 and 4.2-8.3pm, respectively. The particulate count as assessed
using the haemocytometer was calculated as a mean of 10 separate counts.
Fig. 6.7: Printout of electronic cell counter data indicating frequency distribution
of different sized particles. Two distinct peaks can be seen at the 2 most
abundant particle volumes (arrows).
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6.3.2.4 Analysis ofendotoxin and glucan content
Endotoxin and glucan concentrations in HDS-1 and HDS-3 were determined using
endotoxin-specific and glucan-specific assays, respectively. HDS samples were
diluted in sterile water prior to analysis, and the particulates were not removed by
centrifugation. Endotoxin analysis was then performed as previously described
(2.3.6.2). For glucan analysis, an equal volume of 3M NaOH was added to the diluted
sample prior to analysis to unwind the triple helical structure of the (3-D-glucan as
recommended for particulate samples by Thorn (1999). Otherwise P-D-glucan
analysis was performed as previously described (3.3.4.3).
6.3.2.5 Analysis ofprotein content
The protein concentrations of HDS-1 and HDS-3 were measured using a commercial
kit (Urinary Protein, Randox Laboratories Ltd., Co. Antrim, UK) by the method of
Pesce and Kaplan (1987).
6.3.2.6 Analysis for general protease activity
General proteolytic activity was measured in HDS-1 and HDS-3 using a commercial
assay (Universal protease substrate, Roche Diagnostics GmbH, Mannheim,
Germany), employing the method of Twining (1984), using resorufm-coupled casein
as a general protease substrate. For this assay, lmg casein from cow's milk was
coupled with 9pg activated resorufin (N-[resorufin-4-carbonyl]piperidine-4-carbonic
acid N'-hydroxysuccinimide ester) and purified by gel chromatography. Protease
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activity releases resorufin-labelled peptides from casein which are not precipitated by
trichloroacetic acid. Following treatment with trichloroacetic acid and centrifugation
to pellet precipitates, the concentration of these resorufin-labelled peptides in the
supernatant is used as a quantitative assessment of the proteolytic activity present.
For the assay, 75pl substrate solution (0.4% resorufin labelled casein in distilled
water) or 75pi distilled water (assay blank) was added to 75pi incubation buffer
(0.2M Tris-HCl pH 7.8, 0.02M CaCl2) and 150pl sample (1:10 dilution of HDS) or
150pl distilled water (sample blank). Following incubation at 37°C for 15min, 50pl
mixture was transferred to a sterile eppendorf and the remainder returned to the
incubator. 120pl of stop reagent (5% w/v trichloroacetic acid in distilled water) was
added to the 50pl aliquot, this mixture was incubated for a further lOmin, then
centrifuged for 5min, and lOOpl supernatant pipetted into a well of a 96 well
microtitre plate. 150pl assay buffer (0.5M Tris-HCl, pH 8.8) was added and the
absorbance read at 570nm. This procedure was repeated at 15min intervals whereby a
further 50pl aliquot was transferred from the original mixture. A 1:10 dilution of the
HDS was used as this provided a linear curve for absorbance over time during the
first 60min period, prior to the development of a plateau in absorbance units due to
substrate depletion. As the assay measured general protease activity, results could not
be expressed in actual units of protease activity, however comparisons could be made
between HDS samples.
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6.3.2.7Analysis for specific protease activity
To identify specific protease mechanistic classes, the assay was repeated on HDS-1
following the addition of, and co-incubation with, a variety of broad spectrum
(Complete Protease Inhibitor Cocktail Tablets [EDTA-free], Roche Diagnostics
GmbH) and group-specific (ethylenediaminetetraacetic acid [EDTA], Sigma-Aldrich
Co. Ltd., Dorset, UK; Aprotinin, Roche Diagnostics GmbH; Pepstatin, Roche
Diagnostics GmbH; E-64, Roche Diagnostics GmbH) protease inhibitors. Each
inhibitor was pre-incubated with the sample at 37°C for lh prior to analysis as
described above. A variety of concentrations of inhibitors were used: EDTA lmg/ml
and lOmg/ml; Aprotinin lmg/ml and lOmg/ml; Pepstatin 0.2mg/ml and 2mg/ml; E-
64 0.5mg/ml and 5mg/ml. For the Complete Protease Inhibitor Cocktail Tablets
[EDTA-free], 1 tablet per 10ml extraction solution is recommended for protease
inhibition. They were added to the HDS (1:10) from a stock solution of 1 tablet per
1,5ml to give final concentrations in the HDS equivalent to 1 tablet per 40ml, 20ml,
10ml, 5ml and 2.5ml.
6.3.2.8 Identification ofprotease activity by modified SDS-page electrophoresis
Proteolytic activities of HDS-1 and HDS-3 were also characterised using sodium
dodecyl sulfate (SDS)-page electrophoresis (Lundy et al 1995), using lmg/ml
azocasein incorporated into a 12% agarose gel as the general protease substrate.
Undiluted, diluted (1:10) and lOx concentrated HDS samples were analysed.
Concentration of the samples was achieved by centrifugation through filters with a
lOkDa cut-off (Centron-10, Amicon Ltd., Stonehouse, Gloucestershire, UK). Prior to
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loading of the wells in the gel, HDS samples were diluted 1:2 with sample buffer
(distilled water, 0.5M Tris-HCl [pH 6], glycerol, 10% SDS, 0.05% bromophenol
blue). Following electrophoresis, gels were washed twice for 45min with 2.5%
Triton-X 100 solution and incubated overnight at 37°C in phosphate buffered saline.
To ensure preservation of protease activity, samples were non-denatured prior to
electrophoresis. Following staining with Coomassie blue, specific bands of protease
activity were identified as clear areas against the blue background of the stained
azocasein substrate. These bands were compared with broad-range SDS-page
molecular weight markers (Molecular weight standards, Bio-Rad, Hercules,
California, USA).
This procedure was then repeated, following lh pre-incubation at 37°C of HDS with
broad spectrum (Complete Protease Inhibitor Cocktail Tablets [EDTA-free]) and 2
group-specific (EDTA and Pefabloc [Pentapharm AG, Basel, Switzerland]) protease
inhibitors. For pre-incubation, EDTA was added to the HDS at a concentration of
lOmg/ml, Complete Protease Inhibitor Cocktail Tablets [EDTA-free] were added at a
concentration equivalent to 1 tablet per ml, and Pefabloc was added to the HDS at a
concentration of 25mg/ml. With the exception of Pefabloc, which is an irreversible
inhibitor, all other inhibitors were also incorporated into the 2.5% Triton-X 100
washing solution and PBS incubation stage. EDTA was incorporated into both steps
at a concentration of 5mg/ml, and Complete Protease Inhibitor Cocktail Tablets
[EDTA-free] were incorporated into the 2.5% Triton X 100 washing stage at a
concentration of 1 tablet per ml, and into the PBS incubation stage at a concentration
of 0.5 tablets per ml.
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6.3.3 Efficiency of nebulisation of HPS particulates
In order to assess the efficiency of particulate nebulisation, HDS-1 was nebulised as
previously described (2.3.4.1) into an impinger chamber (All glass impinger,
Millipore, Hertfordshire, UK) containing 5ml saline (Fig. 6.8). 1ml HDS was
nebulised from a total volume of 2ml, as assessed by a lg reduction in mass of the
nebuliser cup. The particulate concentration of the suspension retained within the
impinger was measured as previously described (6.3.2.3.). This concentration was
multiplied by the final volume of suspension within the impinger, which gave the
total number of particulates aerosolised from 1ml HDS. Comparison of the total
particulate count of the nebulised suspension and the suspension collected within the
impinger permitted the calculation of the efficiency of particle nebulisation. In
addition, measurement of the frequency distribution of different sized particulates in
both aliquots permitted calculation of the relative efficiency of nebulisation of
particulates within the 0-40, and the 40-300 pm3 ranges.
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Fig 6.8: Apparatus for the assessment of the
efficiency of particulate nebulisation. 1ml of HDS
within the nebuliser cup (n) was nebulised into an all






6.3.4 Fractionation of HDS
HDS-1 was centrifuged at 1600g for 15 min to yield HDS supernatant (SUP) and
particulate debris. The particulates, which comprised mainly mould spores, were
washed 3 times with separate aliquots of sterile physiologic saline, by repeated re-
suspension and centrifugation (15 min, 1600g). The washed particulates (WP) were
then re-suspended in saline, to the volume of the original HDS. This washing
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procedure was repeated on a further sample of HDS-1, but the same aliquot of saline
(a volume equivalent to the decanted HDS supernatant) was used for all 3 washes.
Following the 3 washes, the resultant supernatant, which contained saline and soluble
components washed from the surface of the particulates, was collected and termed the
"wash fraction" (WF). All 3 fractions were aliquoted into 1.8ml ependorfs and stored
at -80°C.
6.3.5 Characterisation of FIDS fractions
6.3.5.1 Analysis for endotoxin and glucan content
The endotoxin and glucan concentrations of the 3 fractions (SUP, WP and WF) were
determined using endotoxin-specific and glucan-specific assays, respectively, as
previously described (6.3.2.4).
6.3.5.2 Analysis for generalprotease content
General proteolytic activity was measured in the 3 fractions using a commercial assay




6.4.1 Analysis of HPS
6.4.1.1 Microscopic analysis
All 3 HDS samples contained particulates which comprised predominantly fungal
spores 2-4pm in diameter (Fig. 6.5). Less abundant particulate constituents included
mite exoskeleton fragments, mite faeces, larger mould spores (e.g. Alternaria), plant
and other unidentifiable debris. It was not possible to differentiate the 3 HDS samples
by microscopic examination.
6.4.1.2 Particulate loss duringfiltration
4ml of HDS weighed 3.9654g (lml=0.99g). Following evaporation of solution from
4ml HDS, the resulting weight of particulates (including NaCl crystals) was 0.1234g.
Following subtraction of the weight ofNaCl in 4ml HDS (0.036g), the weight of dust
within 4ml HDS was calculated as 0.0874g. Hence the weight of dust particles within
lml HDS was calculated as 0.0219g (21.9mg), indicating that approximately 78% of
the original dust (lOOmg/ml) was removed by filtration through the 60pm pore size
nylon gauze.
6.4.1.3 Particulate count, endotoxin, glucan andprotein concentrations ofHDS
The particulate, endotoxin, glucan and protein concentrations ofHDS are summarised
in Table 6.1. Unfortunately, only limited assay of HDS-2 was possible due to
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insufficient sample quantity. The co-efficient of variance of the 10 counts using the
haemocytometer was 9.3%.
Table 6.1: Particulate, protein, endotoxin and p-D-glucan concentrations of HDS.
NP = not performed.
HDS-1 HDS-2 HDS-3
Particulate concentration (x10 /ml)
(0-40|.im3 range) 553 NP 929
Particulate concentration (x106/ml)
(40-300pm3 range) 181 NP 187
Mean total particulate concentration (x106/ml)
(manual count using haemocytometer)
710 NP NP
Protein concentration (mg/ml) 0.47 NP 0.46
Endotoxin concentration (gg/ml) 21.6 18.2 15.2
(3-D-glucan concentration (pg/ml) 184 NP 596
6.4.1.4 Protease activities ofHDS
HDS-1 and HDS-3 had similar general proteolytic activities (Fig. 6.9). A dose-
dependant reduction in protease activity was observed when HDS-1 was co-incubated
with the Complete Protease Inhibitor Cocktail Tablets [EDTA-free], however
significant protease activity remained even following co-incubation with a high
concentration of inhibitor (Fig 6.10). Protease activity was reduced when HDS-1 was
co-incubated with the metalloprotease inhibitor EDTA or the serine protease inhibitor
aprotinin (Fig. 6.11), but not with the aspartate protease inhibitor pepstatin, or the
cysteine protease inhibitor E-64.
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Fig. 6.9: Casein-resorufin hydrolysis (A570nm)
by HDS-1 (1:10 and 1:100 dilution) and F1DS-3
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Fig 6.10: Casein-resorufin hydrolysis (A570nm)
by FIDS-1 (1:10 dilution) co-incubated with
doubling Complete Protease Inhibitor Cocktail
Tablets [EDTA-free] plotted against incubation
time (min).
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O - HDS and no inhibitor
HDS and EDTA (1mg/ml)
X -
HDS and aprotinin (1mg/ml)
* - HDS and EDTA (10mg/ml)
+ " HDS and aprotinin (10mg/mt
Fig. 6.11: Casein-resorufin hydrolysis (A570nm)
by HDS-1 (1:10 dilution) co-incubated with
aprotinin (10mg/ml and 1mg/ml) and EDTA
(10mg/ml and 1mg/ml) plotted against
incubation time (min).
0 10 20 30 40 50 60 70 80 90
Time (mins)
6.4.1.5 SDS-page electrophoresis
Following electrophoresis of 1:10 diluted samples of HDS, faint bands of protease
activity were visible. Following electrophoresis of lOx concentrated samples, HDS-1
had distinct bands of protease activity at 160 and 85kDa and HDS-3 had a broad area
of protease activity extending from 200 to 85kDa (Figs. 6.12 and 6.13), which
following sample dilution, revealed 2 distinct bands at approximately 160 and 85kDa.
A band of protease activity in the 28kDa region was present in both HDS, but was
more marked in HDS-3 (Figs. 6.12 and 6.13).
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Thirty minute pre-incubation at 37°C of both lOx concentrated HDS samples with
Pefabloc®, reduced the intensity of the 28kDa band, revealed a faint band of activity
in the 21kDa region, but did not affect the protease activity in the higher molecular
weight regions (Figs. 6.12 and 6.13). Pre-incubation with EDTA, and its subsequent
incorporation in the wash and incubation steps, removed the 160 and 85kDa bands of
activity in HDS-1, and markedly reduced the intensity of the broad area of activity in
the 200 to 85kDa range in HDS-3 (Figs. 6.12 and 6.13). Interestingly, EDTA
markedly enhanced the 28kDa band and revealed a faint band of activity at 21kDa
(Figs. 6.12 and 6.13). The modified gel electrophoresis data supported the results of
the general protease activity assay, indicating that protease activity of HDS-1 was
mainly due to 28kDa serine protease, and 85 and 160kDa metalloproteases.
Fig. 6.12: Modified SDS-PAGE electrophoresis of
10 x concentrated samples of HDS-1 and HDS-3
with and without pre- and co-incubation with
pefabloc (HDS-1/P; HDS-3/P) and EDTA (HDS-
1/E; HDS-3/E).







Fig. 6.13: Negative image of modified SDS-PAGE
electrophoresis of 10 x concentrated samples of
HDS-1 and HDS-3 with and without pre- and co-
incubation with pefabloc (HDS-1/P; HDS-3/P) and
EDTA (HDS-1/E; HDS-3/E).
6.4.2 Efficiency of nebulisation ofHPS particulates
Following nebulisation of 1ml HDS, the final volume in the impinger was 5.9ml
(original volume 5ml). Following comparison of the total number of particulates in
the impinger with those in the 1ml of nebulised HDS, it was calculated that 26% of
3 • 3
particulates in the 0-40pm range, and 8% of particulates in the 40-300pm range,
were successfully aerosolised.
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6.4.3 Endotoxin and P-D-glucan content, and protease activity of HPS fractions
6.4.3.1 Endotoxin and (3-D-glucan content
The endotoxin and P-D-glucan concentrations of the 3 HDS fractions (SUP, WP and
WF) are summarised in Table 6.2. The endotoxin concentration of SUP and FIDS
were comparable, and markedly greater than that of WP and WF. The glucan
concentration of WP and HDS were comparable and markedly greater than that of
SUP and WF.






21.6 17.9 0.8 2.3
p-D-glucan concentration
(pg/mi)
183.7 3.0 166.8 1.4
6.4.3.2 Protease activity ofHDSfractions
The protease activities of the HDS fractions (SUP, WP and WF) are summarised in






Fig. 6.12: Casein-resorufin hydrolysis (A570nm)







This chapter describes the production and characterisation of saline suspensions of
hay dust (HDS), which contain both soluble and particulate dust components, and
which could be used as a tool for the diagnosis and investigation of heaves. There are
apparently no previous reports of organic dust suspensions being used for this
purpose in any species.
When preparing the HDS, a dual-cyclone vacuum was specifically used to collect
large quantities of dust containing a high proportion of respirable dust particles. This
was considered important since respirable particles are more likely to deposit in the
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lower airways and induce pulmonary disease (Jacobs, 1997b). In addition, the
collection of large dust particles would have resulted in an appreciable
overrepresentation of certain soluble dust components in the final suspensions
following filtration. Although it is possible to collect particles entirely within the
respirable range (<5pm), such a practice would not have been feasible on such a large
scale. Despite this, the method used in this report to ensure the collection of very fine
dust in the final yield did employ the principle of separating particles according to
their inertial properties under centrifugal forces. This principle is well recognised and
is utilised by cyclone personal air samplers, which are in common use as a
preclassifier for sampling respirable dust fractions, as previously described (2.3.5).
Microscopic examination of the resultant HDS indicated that the majority of particles
were mould spores, as described by Clarke and Madelin (1987), with the two most
abundant spore types being approximately 2 and 4 pm in diameter. An electronic
counter employing the impedence principle was used to further evaluate the
concentration and size range of the particles. Although this equipment is designed for
haematological analysis, it proved accurate in determining the particulate
concentration when compared with a haemocytometer count. In addition, the
electronic counter provided particle size frequency distributions, indicating the
presence of 2 peaks of particle volumes, which corresponded with the diameters of
the two most abundant spore sizes as determined microscopically, assuming that
spores were spherical. Given that these spores were predominantly in the 2-4pm
diameter size range, they were likely to be respirable (Clarke, 1987a).
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The HDS glucan concentration (an indicator of total fungal content [Douwes et al.,
1998; Dillon et al., 1999; Douwes et al., 1999]), was approximately 3-fold greater in
HDS-3 than in HDS-1. While this likely reflected the higher concentration of mould
spores in HDS-3, this difference may alternatively reflect a difference in mould
species, since different fungi may contain varying amounts of glucan (Fogelmark and
Rylander, 1997). Previous mould inhalation studies have supported a role for inhaled
moulds in heaves (McPherson et al., 1979; Derksen et al., 1988; McGorum et al.,
1993c). All three HDS preparations contained similar endotoxin concentrations,
however it is possible that the levels are higher than the determined values since the
Limulns amoebocyte lysate assay employed mainly detects soluble endotoxin and
underestimates particulate endotoxin (Rylander et al., 1989). Interestingly, the
endotoxin concentrations detected exceeded those of soluble grain dust extracts
(Schwartz et al., 1994; Jagielo et al., 1996b), which were also produced by mixing lg
dust per ml of diluent. The high endotoxin content of HDS is consistent with reports
that equine stable dust contains relatively high endotoxin concentrations (Dutkiewicz
et al., 1994; McGorum et al., 1998), and supports the need for further investigation
into the contribution of inhaled endotoxin in the aetiopathogenesis of heaves.
The detection of proteases in HDS-1 and HDS-3 is of interest, since inhaled proteases
can induce respiratory epithelial damage, inflammatory cell recruitment and mucus
hypersecretion, ultimately resulting in airway inflammation and bronchoconstriction
(Suzuki et al., 1996). The source of the proteases in the HDS is unclear, however
possibilities include fungi (Chow et al., 2000), pollens (Tomee et al., 1998; Widmer
et al., 2000), bacteria (Milanowski et al., 1995b) and mites (Stewart et al., 1998). Of
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particular interest is the detection of serine proteases in HDS-1 and HDS-3, since
Aspergillus fumigatus is a common component of dust from mouldy hay (Clarke and
Madelin, 1987) and serine proteases of Aspergillus fumigatus origin can degrade
pulmonary epithelium (Iadarola et al., 1998). Furthermore, the serine proteases
trypsin and chymotrypsin contribute to the allergenicity of house dust mites (Stewart
et al., 1991; Stewart et al., 1994), an important cause of human allergic asthma
(PlattsMills et al., 1997). Storage mites, which were identified microscopically in the
collected hay dust, also produce a similar protease profile (Stewart et al., 1998), and
thus may be a source of proteases in the HDS. While the importance of inhaled
storage mite products in equine pulmonary inflammation is unclear (Robinson et al.,
1996), they have been implicated in acute airway obstruction in farmers exposed to
organic dusts (Vanhagehamsten and Johansson, 1998).
As expected, the soluble components of HDS were more effectively aerosolised by
the jet nebuliser than the particulates. However, as 26% and 8% of particles in the 0-
40pm and 40-300pm size range, respectively, were aerosolised, this means that
HDS can be used to investigate the potential important role of particulates in heaves.
The importance of inhaled particulates was highlighted by Kurup et al (1997), who
demonstrated enhancement of the murine pulmonary inflammatory response to
inhaled soluble Aspergillus fumigatus by co-exposure with inert polystyrene beads,
resulting in a magnitude of response similar to that following exposure to whole
Aspergillusfumigatus spores.
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In conclusion, the production and analysis of HDS provides a potentially useful
standardised and characterised tool for the diagnosis and investigation of heaves. As
both soluble and particulate components of HDS may be successfully nebulised, this
enables assessment of the role of stable dust particulates in heaves.
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CHAPTER 7: RESPONSE TO INHALED HAY DUST SUSPENSION IN
ASYMPTOMATIC HEAVES HORSES AND CONTROLS
7.1 Summary
To evaluate inhaled hay dust suspensions (HDS) as a tool for the diagnosis and
investigation of heaves, the pulmonary inflammatory and functional consequences of
inhalation challenge with 3 different HDS were determined in 6 control and 7
asymptomatic heaves horses. Heaves horses given HDS challenge developed the
characteristic features of heaves, including airway neutrophilia, obstructive airway
dysfunction and airway mucus hyper-secretion. While HDS challenge induced mild
airway neutrophilia in controls, the no-response threshold for controls was greater
than that of heaves horses, and there was no overlap in BALF neutrophil counts of
controls and heaves horses post challenge. Furthermore, HDS challenge did not
induce pulmonary dysfunction or mucus hyper-secretion in controls. Thus HDS
challenges enabled differentiation of control and heaves horses. Interestingly, in both
groups, the airway neutrophilia was a dose dependent, rather than an "all or nothing",
response. This study suggests that inhalation challenge with HDS is of value in the
diagnosis and investigation of heaves.
7.2 Introduction
The traditional method of inducing heaves, for diagnostic and research purposes,
involves housing horses in a poorly ventilated stable containing mouldy hay or straw
(McGorum et al., 1993c). However there is no standardised challenge protocol, and
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the variable and undefined composition of airborne dust in this challenge system
(Clarke, 1993) and differences in ventilation rates can result in poor reproducibility of
the responses to such challenges (Chapter 3). In order to develop a more standardised,
repeatable and defined challenge system, hay dust suspensions (HDS) were produced
and characterised (Chapter 6), with a view to their use as a model of disease induction
in susceptible horses. If successful, such a model would serve to improve the
diagnosis of heaves. Additionally, a HDS-induced model would also broaden
research potential by permitting selective manipulation of its constituents, thus
allowing some assessment of their individual contribution to the clinicopathological
features of heaves, a process which is not possible using the current methods of
disease induction. This chapter describes the pulmonary inflammatory and functional
response of control and heaves horses to inhalation challenge with 3 different HDS.
7.3 Materials and methods
7.3,1 Subjects
Six previously described healthy, control horses with no detectable respiratory tract
disorders (2.3.1.2) and 7 previously described horses with a history and clinical
diagnosis of heaves (2.3.1.1) were used, as previously described. Throughout the
study all horses were kept in a low dust environment, as previously described
(2.3.2.1).
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7.3.2 Inhalation challenge material
The origin, production and characterisation of the 3 HDS (HDS-1, HDS-2 and HDS-
3) have been previously described (6.3.1 and 6.3.2).
7.3.2.1 Dose-response relationship to HDS-1 challenge
To determine the dose-response relationship, four doses of HDS-1 were used in the
inhalation challenges, namely; HDS-1 [31], HDS-1 [57], HDS-1 [100] and HDS-1
[316] (Table 7.1). The number in parenthesis relates to the original weight (mg) of
dust used to produce 1ml of HDS prior to filtration through nylon gauze (60pm pore
size) (6.3.1.2). As the stock solution was HDS-1 [100], the HDS-1 [31] and HDS-1
[57] doses were prepared by appropriate dilution with saline immediately prior to
inhalation challenge, thus ensuring that the volume of the final challenge substance
was constant. HDS-1 [316] equated to 3.16 x volume of HDS-1 [100] challenge.
7.3.2.2 Effect ofchallenge with HDSfrom different dust sources
To investigate whether the response to HDS inhalation was dependent on the batch of
hay dust used, the response to inhalation challenge with HDS-2 [100] and HDS-3
[100] was also determined.
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7.3.3 HPS inhalation challenges
7.3.3.1 Inhalation challenge protocol
The challenges given to each group are summarised in Table 7.1. Each group
received 3 separate dose of HDS-1. The heaves group received inhalation challenge
with HDS-1 [31], HDS-1 [57] and HDS-1 [100], The control group received
inhalation challenge with HDS-1 [57], HDS-1 [100] and HDS-1 [316], Both
groups also received inhalation challenge with HDS-2 [100], and the heaves group
also received inhalation challenge with HDS-3 [100],
For all challenges, 1ml of challenge substance was delivered to the facemask, except
for HDS-1 [316], when 3.16ml was used (7.3.2.1). To facilitate subject cooperation,
horses were intravenously sedated with 20pg/kg romifidine and 1 Opg/kg butorphanol
immediately prior to each inhalation challenge. The aerosol was generated and
delivered as previously described (2.3.4.1). The challenges were not randomised, with
the exception of the HDS-1 [31] and HDS-1 [57] challenges in the heaves group. The
order in which the challenges were given is summarised in Table 7.1.
To minimise potential carry-over effects of a preceding challenge on subsequent
challenges, inhalation challenges were conducted a minimum of 14 days apart and all
horses were shown to have normal clinical findings immediately prior to each
challenge. In order to assess any carry-over effects, all measured baseline lung
function and arterial blood gases and pH values were compared. In addition,
following completion of the other challenges, heaves horses received a repeat
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inhalation challenge of HDS-2 [100] (termed HDS-2R [100]) which, as well as
confirming the absence of any carry over effects, allowed an assessment of
repeatability of the response to challenge.
Table 7.1: Summary of the various HDS challenges given to heaves (n=7) and









































7.3.3.2 Positive (hay/straw exposure) and negative (saline) control challenges
To relate the HDS responses with those of placebo and a conventional hay/straw
challenge, comparisons were made with saline inhalation (negative control) and a 5h-
duration conventional hay/straw challenge (positive control) in the same horses, as
previously described (2.3.4.2).
7.3.4 Monitoring the response to challenges
The timing and method of assessment of response to each challenge is summarised in
Fig. 7.1. Responses to the HDS-1 [100], HDS-2 [100] and HDS-3 [100] inhalation
challenges as well as the hay/straw (Chapter 2) and saline (Chapter 2) challenges
were assessed using clinical scoring, lung mechanics, airway reactivity, blood gases
and pH analyses and BALF cytology, as previously described (2.3.7). The quantity of
tracheal mucus was also blindly scored following HDS-1 [100] and hay/straw
challenges as previously described (2.3.7.4). Responses to all other challenges were
assessed solely by clinical scoring and BALF cytology.
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Fig. 7.1: Study design.
BAL = bronchoalveolar lavage (all challenges); LF = lung function evaluation (HDS-1 [100], HDS-
2 [100]; HDS-2R [100], HDS-3 [100]); Clin. Ex. = clinical examination (all challenges); Art BG =
Arterial blood gases and pH analysis (HDS-1 [100], HDS-2 [100]; HDS-2R [100], HDS-3 [100]); A











t - 30min to t + 4h t + 5h t +6h
7.4 Statistical analysis
As the data were either not normally distributed and/or the groups of compared data
did not have equal variance, non-parametric tests were used. The effects of each
challenge were determined mostly by performing within-group analyses.
To check for the presence of any carry-over effects of one challenge on a subsequent
challenge, pre-challenge (baseline) measurements of arterial blood gases and pH and
lung mechanics were compared using a Friedman test, and when significant, a
Wilcoxon Rank Sum test was performed on paired data.
To check for any effects of challenge where pre-challenge measurements were made
at t-30min (arterial blood gas and pH analyses and lung mechanics), the post-
challenge values were expressed as % of baseline value, except for clinical scores
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where actual values were used. As saline was the vehicle for HDS delivery, the effect
of HDS challenge was assessed by pairing and subtracting post-HDS (% of baseline
value) and post-saline (% of baseline value) data. Where no pre-challenge data was
collected (BALF cytology), comparisons were made with saline (placebo) challenge
data at equivalent time points. A Friedman test was performed on sets of paired data
to reduce the risk of type 1 errors, and when significant, a Wilcoxon Rank Sum test
was performed on paired data.
Between group (heaves v.v controls) analyses were performed for BALF neutrophil
numbers, using the Mann Whitney test.
Significance was assumed if P<0.05. Following correction for any effect of saline
inhalation, changes from baseline are expressed as increase/decrease or change in
median values, with 95% confidence interval for the difference in median, calculated
for non-parametric data (Campbell and Gardner 1994).
The two separate HDS-2 [100] inhalation challenges were compared using a
Wilcoxon Rank Sum test, and as an indication of repeatability, the differences in
paired values were plotted against their mean (Bland and Altman 1986). Good
repeatability was assumed if the calculated differences in paired values fell within 2
standard deviations of the mean of the differences (British Standards Institution,
1979). Results in tables are expressed as median and range.
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7.5 Results
7.5.1 Response to inhalation challenge with 3 separate HPS doses
7.5.1.1 Clinical examination
All horses had a clinical score of zero prior to all challenges, and when compared
with baseline values, no significant increase in clinical scores was detected in either
group following any of the challenges (Appendix 7.1).
7.5.1.2 Tracheal secretion score
Only the heaves group had significantly (P<0.05) increased tracheal secretion scores
after HDS-1 [100] (Table 7.2) when compared with saline (2.5.2.4). This response
was comparable to the response to hay/straw challenges (2.5.2.4).
Table 7.2 Tracheal secretion scores (median and range) in heaves (n=7) and
control (n=6) horses, 6h following inhalation challenge with HDS-1 [100] and
hay/straw challenge.
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The BALF neutrophil counts and ratios following challenge with saline and all HDS-
1 doses are fully presented in Appendix 7.2, and summarised in Table 7.3.
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Table 7.3: BALF neutrophil counts (x105/ml) and ratios (%) (median and range)
in control (n=6) and heaves (n=7) horses at 6h following inhalation challenge
with saline, HDS-1 [31], HDS-1 [57], HDS-1 [100] and HDS-1 [316].
NP = not performed.
BALF neutrophil count (x105/ml) BALF neutrophil ratio (%)











































When compared with saline, absolute BALF neutrophil counts and ratios were
significantly (P<0.05) increased in heaves horses following inhalation challenge with
HDS-1 [57] and HDS-1 [100] and in controls following inhalation challenge with
HDS-1 [100] and HDS-1 [316] (Table 7.3). The BALF neutrophilia induced by HDS-
1 in both groups was dose-dependent (Figs. 7.2 to 7.5). When compared with saline
inhalation, the BALF neutrophilia following HDS-1 [100] inhalation challenge was
significantly greater (P<0.01) in heaves horses (34-fold increase in median count)
than controls (5-fold increase in median count) (Figs. 7.6 and 7.7). There was no
overlap in BALF neutrophil ratios between the 2 groups following HDS-1 [100]
challenge (Fig. 7.7).
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Fig. 7.2: BALF neutrophil counts (x105/ml) in
heaves (n=7) horses at 6h following inhalation
challenge with saline, FIDS-1 [31], FIDS-1 [57],
FIDS-1 [100] and mouldy hay/straw challenge
{HIS). NP = not performed.
outlier - 9.8





Fig. 7.3: BALF neutrophil counts (x105/ml) in
control (n=6) horses at 6h following inhalation
challenge with saline, HDS-1 [57], HDS-1 [100],
HDS-1 [316] and mouldy hay/straw challenge
(H/S). * = outlier. NP = not performed.
SALINE HDS-1 HDS-1 HDS-1 HDS-1 H/S
[31] [57] [100] [316]
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Fig. 7.4: BALF neutrophil ratio (%) in heaves
(n=7) horses at 6h following inhalation challenge
with saline, HDS-1 [31], HDS-1 [57], HDS-1
[100] and mouldy hay/straw challenge (H/S). NP
= not performed.





Fig. 7.5: BALF neutrophil ratio (%) in control
(n=6) horses at 6h following inhalation challenge
with saline, HDS-1 [57], HDS-1 [100], HDS-1
[316] and mouldy hay/straw challenge (H/S). NP
= not performed.
SALINE HDS-1 HDS-1 HDS-1 HDS-1 H/S
[31] [57] [100] [316]
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Fig. 7.6: BALF neutrophil counts (x105/ml) in
heaves (n=7) and control (n=6) horses at 6h



























Fig. 7.7: BALF neutrophil ratio (%) in heaves
(n=7) and control (n=6) horses at 6h following
inhalation challenge with FIDS-1 [100].
CONTROLS HEAVES
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Due to the influence of a BALF neutrophilia on the ratio of other BALF cell types,
the latter were considered only as absolute numbers. The absolute numbers of other
BALF cell types were not significantly affected by any of the challenges and are
summarised in Table 7.4.
Table 7.4: Total and differential BALF cell counts (x105/ml) (median and
range) in heaves (H; n=7) and control (C; n=6) horses at 6h following
inhalation challenge with saline, HDS-1 [31], HDS-1 [57], HDS-1 [100] and
HDS-1 [316],
NP = not performed, TCC = total cell count.
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7.5.2 Response to inhalation with HPS from separate dust sources
7.5.2.1 Clinical examination
All horses had a clinical score of zero prior to all challenges, and when compared
with baseline values, no significant increase in clinical scores was detected in either
group following any of the challenges (Appendix 7.3).
7.5.2.2 Arterial blood gases andpH analyses
Arterial blood gas measurements raw data are presented in Appendix 7.4. There was
no significant difference in the baseline blood gas indices prior to each of the
challenges, indicating a lack of any carry-over effects. Following correction for saline
inhalation, none of the challenges significantly altered arterial PaC>2, PaC02 or pH
when compared with baseline values in either group.
7.5.2.3 Lung mechanics and airway reactivity
Raw data for lung mechanics measurements are presented in Appendix 7.5. With the
exception of respiratory rate in both groups, there was no significant difference in the
baseline lung function measurements prior to each of the challenges, indicating a lack
of any carry-over effects. The percent of baseline lung function measurements
following challenge is presented in Table 7.5. PCCdyn70 values following challenge
are presented in Table 7.6.
Heaves group: Following correction for any effects of saline inhalation, HDS-1 [100]
inhalation significantly increased RLeso% (median increase 39%, 95% confidence
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interval 4-75; P<0.05) when compared with baseline (Fig. 7.8). Following correction
for any effects of saline inhalation, HDS-2 [100] inhalation significantly increased
RLE5o% (increase in median 88%, 95% CI 25-303; P<0.05) (Fig. 7.8) and RLe75%
(increase in median 58%, 95% CI 49-347; P<0.05) (Fig. 7.9) when compared with
baseline. Following correction for any effects of saline inhalation, HDS-3 [100]
inhalation increased RLe5o% (increase in median 119%, 95% CI 21-355; P<0.05) (Fig.
7.8), RLE75% (increase in median 150%, 95% CI 48-252; P<0.05) (Fig. 7.9) and Rliso
(increase in median 93%, 95% CI 17-189; P<0.05) (Fig. 7.10) when compared with
baseline. HDS-3 [100] induced a significantly (P<0.05) greater increase in Rliso than
HDS-1 [100] (Fig. 7.10). Hay/straw challenge had no significant effect on lung
function (Chapter 2).
Control group: Lung mechanics of controls were unaffected by HDS-1 [100] and
HDS-2 [100] challenges. Hay/straw challenge had no significant effect on lung
function in controls (Chapter 2).
Only HDS-2R [100] challenge in the heaves group significantly increased airway
reactivity, as indicated by a reduced PCCdyn70 when compared with saline
(3.0mg/ml, 0.4-4.1 vs 5.6mg/ml, 2.5-10.5; P<0.05) (Table 7.6). Airway reactivity did
not significantly differ between HDS-2 [100] (8.0mg/ml, 1.4-32.8) and HDS-2R
[100] (3.0mg/ml, 0.4-4.1) challenges. Although all the calculated differences in these
paired values for airway reactivity fell within 2 standard deviations of the mean of the
differences, indicative of good agreement, the mean of the differences was
sufficiently different from zero to render the assessment of repeatability invalid.
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Fig. 7.8: Percent of baseline RLe5o% in heaves
horses (n=7) at 5h following inhalation challenge
with saline, HDS-1[100], HDS-2 [100] and HDS-
3 [100] minus percent of baseline RLeso% at 5h
following inhalation challenge with saline. * =
outlier.
SALINE HDS-1 HDS-2 HDS-3
Fig. 7.9: Percent of baseline RLE75% in heaves
horses (n=7) at 5h following inhalation challenge
with saline, HDS-1 [100], HDS-2 [100] and HDS-3
[100] minus percent of baseline RLe75% at 5h







SALINE HDS-1 HDS-2 HDS-3
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Fig. 7.10: Percent of baseline RLiso in heaves
horses (n=7) at 5h following inhalation challenge
with saline, HDS-1[100], HDS-2 [100] and HDS-
3 [100] minus percent of baseline RLiso at 5h
following inhalation challenge with saline. * =
outlier.
SALINE HDS-1 HDS-2 HDS-3
Table 7.6 PCCdyn70 (mg/ml methacholine chloride) (median and range) in
control (n=6) and heaves (n=7) horses at approximately 5h following inhalation
challenge with saline, HDS-1[100], HDS-2[100], HDS-2R [100] and HDS-3[100],
























The BALF neutrophil counts and ratios following challenge with saline, HDS-2
[100], HDS-2R [100] and HDS-3 [100] are fully presented in Appendix 7.4, and
summarised in Table 7.7.
Table 7.7: BALF neutrophil counts (x105/ml) and ratios (%) (median and range)
in control (n=6) and heaves (n=7) horses at 6h following inhalation challenge
with saline, HDS-1[100], HDS-2 [100], HDS-2R [100] and HDS-3 [100],
NP = not performed.
BALF neutrophil count (x105/ml) BALF neutrophil ratio (%)








































When compared with saline, absolute BALF neutrophil counts and ratios were
significantly (P<0.05) increased in heaves horses following inhalation challenge with
HDS-2 [100], HDS-2R [100] and HDS-3 [100] (Figs. 7.11 and 7.12). When
compared with saline, absolute BALF neutrophil counts and ratios were significantly
(P<0.05) increased in controls following inhalation challenge with HDS-2 [100]
(Figs. 7.13 and 7.14). When compared with saline, the BALF neutrophilia following
HDS-2 [100] challenge was significantly greater (P<0.01) in heaves horses (77-fold
increase in median count) than controls (3-fold increase in median count). There was
no overlap in BALF neutrophil ratio and count between the groups following HDS-2
[100] challenge (Figs. 7.15 and 7.16).
In comparison to all other inhalation challenges, HDS-3 [100] challenge in the heaves
group induced a markedly greater BALF neutrophil count (134-fold increase in






















Fig. 7.11: BALF neutrophil count (x10b/ml) in
heaves (n=7) horses at 6h following inhalation
challenge with saline, HDS-1[100], HDS-2 [100]
and HDS-3 [100] and in heaves (n=6) horses at
6h following inhalation challenge with FIDS-2R
[100]. * = outlier.
SALINE HDS-1 HDS-2 HDS-3 HDS-2R
Fig. 7.12: BALF neutrophil ratio (%) in heaves
(n=7) horses at 6h following inhalation challenge
with saline, HDS-1 [100], HDS-2 [100] and HDS-
3 [100] and in heaves (n=6) horses at 6h
following inhalation challenge with HDS-2R
[100], * = outlier.


















Fig. 7.13: BALF neutrophil count (x105/ml) in
control (n=6) horses at 6h following inhalation




Fig. 7.14: BALF neutrophil ratio (%) in control
(n=6) horses at 6h following inhalation challenge
with saline, HDS-1[100] and HDS-2 [100].
SALINE HDS-1 HDS-2
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Fig. 7.15: BALF neutrophil count (x10 /ml) in
heaves (n=7) and control (n=6) horses at 6h



























Fig. 7.16: BALF neutrophil ratio (%) in heaves
(n=7) and control (n=6) horses at 6h following
inhalation challenge with HDS-2 [100],
CONTROLS HEAVES
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Due to the influence of a BALF neutrophilia on the ratio of other
the latter were considered only as absolute numbers. The absolute
BALF cell types are summarised in Table 7.8.
BALF cell types,
numbers of other
Table 7.8: Total and differential BALF cell counts (x105/ml) (median and
range) in heaves (n=7) and control (n=6) horses at 6h following inhalation
challenge with saline, HDS-1[100], HDS-2 [100] and HDS-3 [100] and in
heaves (n=6) horses at 6h following inhalation challenge with HDS-2R [100],
NP = not performed, C = control group, H = heaves group, TCC = total cell count.
Basophiloid
cells
. „ : ;
TCC Lymphocytes Macrophages Mast cells Eosinophils
3.85 1.59 1.98 0.25 0.02 0.03
SALINE
(2.00-9.60) (0.99-6.22) (0.73-2.80) (0.06-0.39) (0.00-0.22) (0.00-0.06)
H
3.80 2.09 1.58 0.13 0.01 0.01
(1.30-5.60) (0.80-3.33) (0.34-2.96) (0.09-0.19) (0.00-0.11) (0.00-0.01)
4.65 1.49 2.18 0.14 0.02 0.01
HDS-1 (1.60-8.00) (0.66-2.29) (0.51-4.19) (0.11-0.24) (0.00-1.04) (0.00-0.23)
[100]
H
4.10 1.19 1.16 0.07 0.00 0.01
2.10-7.00) (0.61-1.86) (0.41-1.75) (0.02-0.14) (0.00-0.10) (0.00-0.13)
2.90 1.10 1.41 0.14 0.04 0.04
HDS-2 (1.70-4.30) (0.92-2.37) (0.30-1.62) (0.06-0.33) (0.00-0.09) (0.00-0.15)
[100]
H
7.90 1.53 1.19 0.08 0.02 0.00
(3.70-9.10) (0.51-2.34) (0.39-1.78) (0.04-0.29) (0.00-0.06) (0.00-0.25)
HDS-2R
C NP NP NP NP NP NP
[100]
H
7.70 1.28 1.68 0.08 0.01 0.03
(4.00-21.80) (0.49-2.24) (0.83-2.27) (0.00-0.12) (0.00-0.07) (0.00-0.15)
HDS-3
C NP NP NP NP NP NP
[100]
H
10.10 1.17 0.72 0.06 0.00 0.01
(8.10-19.00) (0.36-2.14) (0.24 1.93) (0.00-0.09) (0.00-0.03) (0.00-0.21)
Heaves horses had significantly (P<0.05) increased total BALF cell counts after
HDS-2 [100] and HDS-3 [100], when compared with saline (Fig. 7.17). HDS-3 [100]
also significantly (P<0.05) reduced macrophage and mast cell numbers in heaves
horses when compared with saline (Figs. 7.18 and 7.19). Absolute numbers of the
other BALF cell types were not significantly affected by any of the challenges.
195
Fig. 7.17: BALF total cell count (x105/ml) in
heaves (n=7) horses at 6h following inhalation
challenge with saline, HDS-1[100], HDS-2 [100]
and HDS-3 [100].
SALINE HDS-1 HDS-2 HDS-3
Fig. 7.18: BALF macrophage count (x105/ml) in
heaves (n=7) horses at 6h following inhalation
challenge with saline, HDS-1 [100], HDS-2 [100]
and HDS-3 [100], * = outlier.
SALINE HDS-1 HDS-2 HDS-3
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Fig. 7.19: BALF mast cell count (x105/ml) in
heaves (n=7) horses at 6h following inhalation
challenge with saline, FIDS-1[100], FIDS-2 [100]
















SALINE HDS-1 HDS-2 HDS-3
There was no significant difference in the counts of any BALF cell type in heaves
horses between the HDS-2 [100] and HDS-2R [100] challenge. Furthermore, the
mean of the differences in paired values for BALF neutrophil counts following these
2 challenges approximated to zero, and all of the calculated differences in paired
values fell within 2 standard deviations of the mean of the differences (Fig. 7.20).
Consequently, the agreement between the neutrophilic response to both challenges






Fig. 7.20: Difference between BALF neutrophil
counts (x105/ml) plotted against the mean of the
BALF neutrophil counts (x105/ml) in heaves
(n=6) horses at 6h following both HDS-2
inhalation challenges. Solid line = mean of the
differences; dotted line = mean of the

























In this study, asymptomatic heaves horses given inhaled hay dust suspension (HDS)
developed the neutrophilic airway inflammation, obstructive airway dysfunction and
mucus hypersecretion that characterise heaves. While high doses of HDS also
induced BALF neutrophilia in controls, the magnitude of the neutrophilia was
markedly lower than that of heaves horses, and there was no overlap in the neutrophil
ratios for the two groups. Furthermore, HDS did not induce lung dysfunction or
increase tracheal mucus volume in controls. These findings suggest that HDS is a
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valuable tool for the diagnosis and investigation of heaves. Indeed the HDS
challenges were more effective in reproducing the airway dysfunction than a 5h
duration conventional hay/straw challenge, which induced significant airway
neutrophilia but no significant alteration in pulmonary mechanics (Chapter 2).
Previous experiments (2.5.1) showed a standard hay/straw challenge protocol resulted
in a mean total airborne dust exposure of 2.8mg/m3, and a mean hourly ventilation
rate in the challenged horses of 3.1m /h. Therefore, as each HDS [100] challenge
originated from lOOmg of dust, this equates approximately to the dust exposure
encountered during an 11.5h conventional hay/straw challenge. When the
repeatability was assessed, there was good reproducibility with respect to airway
neutrophilia.
Interestingly, in both groups, the neutrophilic response to HDS-1 inhalation was dose-
dependent, rather than being an all or nothing response. This feature has been
previously noted in endotoxin-sensitive mice following inhalation of corn dust
extract, whereby the dose-dependent inflammatory response was related to the
endotoxin concentration of the extract (Schwartz et al., 1994). Interestingly, a
significant inflammatory response was not observed in endotoxin resistant mice until
high concentrations of extract were administered (Schwartz et al., 1994). In this
study, the no-response threshold dose for inducing airway neutrophilia was lower for
the heaves group (between HDS-1 [57] and HDS-1 [100]), than for the control group
(between HDS-1 [31] and HDS [57]). However, the finding that an extremely high
dose of HDS (HDS-1 [316]) induced a marked BALF neutrophilia in controls
suggests that even horses without pulmonary disease may develop significant
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pulmonary inflammation when exposed to very high airborne dust levels, as may be
encountered when they are housed in stables with particularly poor air hygiene. This
further emphasises the benefits of a standard, defined challenge protocol for use in
the diagnosis of heaves.
The magnitude of the airway neutrophilia and dysfunction in the heaves group was
shown to be dependent on the source of dust used to prepare the HDS, with the order
of potency being HDS-3 > HDS-2 > HDS-1. Although the order of inhalation
challenges was not randomised, it is unlikely that this variable potency resulted from
carry-over effects. Firstly, there were no significant differences in baseline lung
function prior to the 3 HDS inhalations. Secondly, there was good repeatability of
airway neutrophilia between the two separate HDS-2 inhalation challenges. Lastly,
the slight, yet significant BALF neutrophilia noted in the control group following
HDS-1 [100] challenge was greater than following HDS-2 challenge, despite the
HDS-1 [100] challenge being performed first.
It is probable that the potencies of the 3 different HDS reflect their content of pro¬
inflammatory agents. The greater potency of HDS-3 compared with HDS-1 may be
due to its approximately 3 fold higher [3-D-glucan content and/or higher level of
particulates (mostly mould spores) in the 0-40pm range (6.4.1.3). As these two
features reflect a higher fungal content, this finding supports the role of inhaled
moulds in the aetiopathogenesis of heaves (McPherson et al., 1979; Derksen et al.,
1988; McGorum et al., 1993c). In contrast, the potency of the 3 different HDS
preparations did not appear to relate to their endotoxin content (HDS-1 - 21.6pg/ml;
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HDS-2 - 18.2(j.g/ml; HDS-3 - 15.2pg/ml) (6.4.1.3). However, it is possible that the
greater glucan and/or particulate content in HDS-3 acted synergistically with, and so
magnified the response to, endotoxin and other inflammatory agents in the HDS
(Fogelmark et al., 1992; Rylander, 1994; Brown and Donaldson, 1996; Kurup et al.,
1997). The differing potencies of HDS-1 and HDS-3 did not appear to relate to their
protease content, because they exhibited similar general protease activity (6.4.1.4).
In conclusion, this study demonstrated the successful use of HDS inhalation
challenges in reproducing the neutrophilic airway inflammation and dysfunction and
mucus hyper-secretion that characterise heaves, and in differentiating heaves-
susceptible horses from controls.
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CHAPTER 8: RESPONSE TO INHALATION CHALLENGE WITH
SEPARATE FRACTIONS OF HAY DUST SUSPENSION IN
ASYMPTOMATIC HEAVES HORSES AND CONTROLS
8.1 Summary
To investigate the relative importance of inhaled particulate and soluble components
in the pulmonary response to inhaled hay dust suspension (HDS), 6 control and 7
asymptomatic heaves horses were given inhalation challenges with fractionated HDS.
The HDS fractions included supernatant (SUP), washed particulates (WP) and wash
fraction (WF). Inhalation of SUP induced a significant airway neutrophilia in both
groups, with a significantly greater response occurring in heaves horses. SUP induced
significantly less airway neutrophilia than HDS in both groups, despite the endotoxin
and protease content of HDS and SUP being comparable. WP and WF induced a
slight airway neutrophilia in heaves horses. These findings suggest that endotoxins
and proteases are not the sole determinants of the magnitude of response. A combined
challenge with SUP and WP induced a neutrophilic response approaching the
magnitude of that following HDS challenge in the heaves group, indicating that dust
particulates contribute to the pulmonary recruitment of neutrophils in heaves.
Consequently, inhalation challenge with HDS, which contains both particulates and
soluble dust components, may be a more useful tool for the diagnosis and




Although aqueous fungal extract inhalation challenges have established a role for
inhaled moulds in the aetiopathogenesis of heaves (McPherson et al., 1979; Derksen
et al., 1982; Derksen et al., 1988; McGorum et al., 1993c), these challenges have
failed to fully reproduce the naturally occurring disease (McGorum et al., 1993c), and
some have resulted in a significant airway neutrophilia in control animals (Derksen et
al., 1988). This has led to speculation that other inhaled dust components, including
inhaled endotoxins, contribute to the aetiopathogenesis of this disease (McGorum et
al., 1993c). Unfortunately, the traditional method of disease induction, namely
conventional hay/straw challenge, does not permit the investigation of the potential
role of the individual inhalants in this disease. Although the use of aqueous soluble
extracts of organic dusts has greatly improved the understanding of human organic
dust-related respiratory disease (Schwartz et al., 1994; Blaski et al., 1996; Jagielo et
al., 1996a; Jagielo et al., 1996b; Jagielo et al., 1997), it has only permitted evaluation
of the role of soluble dust components. The successful use of an inhaled HDS
(Chapter 7), which contains both soluble and particulate dust components (Chapter
6), to induce the clinical, inflammatory and functional features of heaves, has enabled
the investigation of the role of different dust fractions in the aetiopathogenesis of this
disease. This chapter describes the response of control and heaves horses to
inhalation challenge with different HDS fractions.
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8.3 Materials and methods
8.3.1 Subjects
Six previously described healthy control horses (2.3.1.2) with no detectable
respiratory tract disorders and 7 previously described horses with a history and
clinical diagnosis of heaves (2.3.1.1) were used. The disease status of all subjects was
confirmed by mouldy hay/straw challenge as previously described (2.3.4.2).
Throughout the study all horses were kept in a low dust environment (2.3.2.1).
8.3.2 Inhalation challenge material
8.3.2.1 HDSfractions in isolation
The production and characterisation of the 3 fractions of HDS-1, namely SUP,
WP and WF has been previously described (6.3.4 and 6.3.5). A 1ml volume of
challenge substances was delivered to the facemask for all inhalation
challenges unless stated otherwise.
8.3.2.2 HDSfractions given in combination
To determine the importance of inhaled dust particulates in the aetiopathogenesis of
heaves, heaves horses received 2 combined WP and SUP challenges. The first
combined challenge consisted of a mixture of WP and SUP, prepared by re-
suspending pelleted WP in SUP, thus the final proportion of WP to SUP was
comparable to that in the non-fractionated HDS. This challenge was termed mixed
WP/SUP challenge (WP/SUP[m]), with a 1ml volume used in each challenge. The
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second combined challenge consisted of a WP challenge and SUP challenge given
consecutively. The WP challenge was given first (taking approximately lOmin) and
was followed immediately by the SUP challenge (also taking approximately lOmin).
This challenge was termed the separate WP/SUP challenge (WP/SUP[s]). The
volume of each individual challenge (WP and SUP) was 1ml, therefore the total
volume of the WP/SUP [s] challenge was 2ml.
8,3.3 Inhalation challenges
8.3.3.1 Inhalation challenge protocol
The challenges given to each group are summarised in Table 8.1. The heaves group
received separate inhalation challenges with SUP, WP and WF, and both combined
challenges (WP/SUP[m] and WP/SUP[s]). The control group received inhalation
challenge with SUP only.
To facilitate subject cooperation, horses were sedated with intravenous 20pg/kg
romifidine and 10pg/kg butorphanol immediately prior to each inhalation challenge.
The aerosol challenge was generated and delivered as previously described (2.3.4.1).
The order in which the individual challenges were given is summarised in Table 8.1.
The SUP, WP and WF challenges in the heaves group were not randomised.
Following completion of the individual challenges, the combined challenges were
given. The order of the combined challenges was randomised.
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To minimise potential carry-over effects of a preceding challenge on subsequent
challenges, inhalation challenges were conducted a minimum of 14 days apart and all
horses were shown to have normal clinical findings immediately prior to each
challenge. In order to assess any carry-over effects, all measured baseline lung
function and arterial blood gases and pH values were compared. In addition, prior to
the combined challenges, 6 heaves horses received a repeat inhalation challenge with
WP (termed WP[R]) which, as well as confirming the absence of any carry over
effects, allowed an assessment of repeatability of the response to WP challenge.
Table 8.1 Summary of the order in which heaves (n=7) and control (n=6)
horses received inhalation challenges with the individual and combined HDS
fractions.
WP WP[R] SUP WF WP/SUP[m] WP/SUP[s]














7.3.3.2 Positive (hay/straw exposure) and negative (saline) control challenges
To compare the responses with those of placebo and non-fractionated HDS,
comparisons were made with saline (negative control) and HDS-1[100] (positive
control) challenge in the same horses, as previously described in Chapters 2 and 7.
8.3.4 Monitoring the response to challenges
The method and timing of assessment of response to each challenge is summarised in
Fig. 8.1. Responses to SUP and WP were assessed using clinical scoring, lung
mechanics, airway reactivity, blood gases and pH analyses and BALF cytology as
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previously described (2.3.7), while the response to the other single (WF, WP[R]) and
combined (WP/SUP[m] and WP/SUP[s]) challenges were assessed solely by BALF
cytology.
Fig. 8.1 Study design.
BAL = bronchoalveolar lavage (all challenges); LF = lung function evaluation (SUP, WP); Clin Ex
= clinical examination (SUP, WP); Art BG = Arterial blood gases and pH analysis (SUP, WP); A










t - 30min to t + 4h t + 5h t +6h
8.4 Statistical analysis
As the data were either not normally distributed and/or the groups of compared data
did not have equal variance, non-parametric tests were used. The effects of each
challenge were determined mostly by performing within-group analyses.
To check for the presence of any carry-over effects of one challenge on a subsequent
challenge, pre-challenge (baseline) measurements of arterial blood gases and pFl and
lung mechanics were compared using a Friedman test, and when significant, a
Wilcoxon Rank Sum test was performed on paired data.
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To check for any effects of challenge, where pre-challenge measurements were made
at t-30min (arterial blood gases and pH analyses and lung mechanics), the post-
challenge values were expressed as % of baseline value, except for clinical scores
where actual values were used. As saline was the vehicle for delivery of all HDS
fractions, the effect of challenge was assessed by pairing and subtracting post-HDS
fraction (% of baseline value) and post-saline (% of baseline value) data. Where no
pre-challenge data was collected (BALF cytology), comparisons were made with
saline (placebo) challenge data at equivalent time points. A Friedman test was
performed on sets of paired data to reduce the risk of type 1 errors, and when
significant, a Wilcoxon Rank Sum test was performed on paired data.
Analyses, for response to SUP challenge, between groups (heaves vs controls), were
performed for BALF neutrophil numbers, using the Mann Whitney test.
Significance was assumed if P<0.05. Following correction for any effect of saline
inhalation, changes from baseline are expressed as increase/decrease or change in
median percent values, with 95% confidence interval for the difference in median,
calculated for non-parametric data (Campbell and Gardner 1994).
The two separate WP inhalation challenges were compared using a Wilcoxon Rank
Sum test, and as an indication of repeatability, the differences in paired values were
plotted against their mean (Bland and Altman 1986). Good repeatability was assumed
if the calculated differences in paired values, fell within 2 standard deviations of the
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mean of the differences (British Standards Institution, 1979). Results are expressed as
median and range.
8.5 Results
8.5.1 Response to inhalation challenge with SUP, WP and WF given in isolation
8.5.1.1 Clinical examination
All horses had a clinical score of zero prior to all challenges. When compared with
baseline values, no significant increase in clinical scores was detected in the heaves
group following SUP or WP challenge, or in the control group following SUP
challenge (Appendix 8.1).
8.5.1.2 Arterial blood gases andpH analyses
Raw data for arterial blood gases and pH measurements are presented in Appendix
8.2. There was no significant difference in the baseline blood gas or pH values prior
to the SUP and WP challenges in the heaves group, indicating a lack of any carry¬
over effects. The percent of baseline arterial blood gases and pH measurements is
presented in Table 8.2. Following correction for saline inhalation, SUP challenge did
not significantly alter PaC>2, PaCC>2 or arterial pH when compared with baseline
values in both groups. WP challenge did not significantly alter arterial PaC>2, PaCC>2
or pH when compared with baseline values in the heaves group.
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8.5.1.3 Lung mechanics and airway reactivity
Raw data for lung mechanics measurements are presented in Appendix 8.3. There
was no significant difference in the baseline lung function measurements prior to the
WP or SUP challenges in the heaves group, indicating a lack of any carry-over
effects. The percent of baseline lung function measurements are presented in Table
8.3. PCCdyn70 values following challenge are presented in Appendix 8.4.
Following correction for any effects of saline inhalation, no alteration in lung
mechanics was detected following WP or SUP challenge in the heaves group, or
following SUP challenge in the controls. For comparison, following correction for
any effects of saline inhalation, FIDS-1 [100] inhalation significantly increased
RLe5o% (median increase 39%, 95% confidence interval 4-75; P<0.05) in the heaves
group when compared with baseline (7.5.2.3).
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The BALF neutrophil counts and ratios following challenge with FIDS fractions are
presented in Appendix 8.5, and summarised in Table 8.5, with data from saline and
HDS-1 [100] challenge being included for comparison.
Table 8.5 BALF neutrophil counts (x105/ml) and ratios (%) (median and range)
in control (n=6) and heaves (n=7) horses at 6h following inhalation challenge
with saline, WP, SUP, WF, WP/SUP[s], WP/SUP[m] and HDS-1[100], np = not
performed.
BALF neutrophil count (x105/ml) BALF neutrophil ratio (%)





















































Heaves horses developed a significant (P<0.05) BALF neutrophilia following
challenge with all HDS fractions (Table 8.5; Figs. 8.2 and 8.3). When compared with
saline inhalation, the BALF neutrophilia in the heaves group following HDS (36-fold
increase in median count) (7.5.1.4) was significantly greater (P<0.05) than following
SUP (8-fold increase), WP (3-fold increase) and WF (6-fold increase) challenges
(Table 8.5; Figs. 8.2 and 8.3). Controls developed a significant (P<0.05) increase in
BALF neutrophil count and ratio following SUP (Table 8.5, Figs. 8.4 and 8.5). In
controls, when compared with saline inhalation, the increase in BALF neutrophil
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count was also significantly (P<0.05) greater following HDS (5-fold increase in














Fig. 8.2: BALF neutrophil counts (x10 /ml) in
heaves (n=7) horses at 6h following inhalation
challenge with saline, SUP, WP, WF and PIDS-





SALINE SUP WP WF HDS-1
Fig. 8.3: BALF neutrophil ratio (%) in heaves
(n=7) horses at 6h following inhalation challenge
with saline, SUP, WP, WF and HDS-1[100], * =
outlier.
SALINE SUP WP WF HDS-1
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Fig. 8.4: BALF neutrophil counts (x105/ml) in
control (n=6) horses at 6h following inhalation















Fig. 8.5: BALF neutrophil ratio (%) in control
(n=6) horses at 6h following inhalation challenge
with saline, SUP, and HDS-1 [100],
SALINE SUP HDS-1
215
Following inhalation of SUP, heaves horses had a significantly higher BALF
neutrophil count (P<0.01) and ratio (P<0.05) than controls, with no overlap in the












Fig. 8.6: BALF neutrophil counts (x105/ml) in
heaves (n=7) and control (n=6) horses at 6h
following inhalation challenge with SUP.
CONTROLS HEAVES
Fig. 8.7: BALF neutrophil ratio (%) in heaves
(n=7) and control (n=6) horses at 6h following













Due to the influence of a BALF neutrophilia on the ratio of other BALF cell types,
the latter were considered only as absolute numbers. The absolute number of other
BALF cell types are summarised in Table 8.6.
Table 8.6: Total and differential BALF cell counts (x105/ml) (median and range)
in heaves (H; n=7) and control (C; n=6) horses at 6h following inhalation
challenge with saline, SUP, WP, WF, WP/SUP[s], WP/SUP[m] and HDS-1[100],
NP = not performed.

















































































































































SUP and WP significantly (P<0.05) increased total BALF cell counts in heaves
horses, when compared with saline (Fig. 8.8). Fleaves horses had a significant
(P<0.05) increase in BALF eosinophil count after SUP (Fig 8.9), however median
eosinophil numbers were always <1% of the median total BALF cell count following
this challenge. None of the challenges significantly altered absolute BALF
lymphocyte, macrophage or mast cell numbers, when compared with saline. In
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comparison, BALF absolute counts of all of these cell types were significantly
(P<0.05) lower following HDS challenge when compared with SUP and WP
challenge.
Fig. 8.8: BALF total cell counts (x105/ml) in
heaves (n=7) horses at 6h following inhalation
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Fig. 8.9: BALF eosinophil counts (x10 /ml) in
heaves (n=7) horses at 6h following inhalation
challenge with saline, SUP, WP, WF and
HDS[100]. * = outlier.
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There was no significant difference in BALF cytology between the repeated WP
challenges, with the increase in median BALF neutrophil numbers following the two
challenges being almost identical (3.0-fold vs 3.3-fold increases). Since the mean of
the differences in paired values approximated to zero, and all of the 6 calculated
differences in paired values fell within 2 standard deviations of the mean of the
differences (Fig 8.10), the agreement between the neutrophilic response to both
challenges was considered good (Bland and Altman 1986). In addition, no evidence





Fig. 8.10: Difference between BALF neutrophil
counts (x105/ml) plotted against the mean of the
BALF neutrophil counts (x105/ml) in heaves
(n=6) horses at 6h following both WP inhalation
challenges. Solid line = mean of the differences;
dotted line = mean of the differences + 2














8.5.2 Response to inhalation challenge with combined WP/SUP
8.5.2.1 BALF cytology
When compared with saline inhalation, the BALF neutrophilia in the heaves group
following the combined WP/SUP (21-fold increase in median) challenges was
significantly greater (P<0.05) than that following SUP (8-fold increase in median),
WP (3-fold increase in median) and WF (6-fold increase in median) challenges
(Table 8.5; Figs. 8.11 and 8.12). There was no significant difference in BALF
neutrophil counts following HDS and both the combined WP/SUP and separate
WP/SUP challenges (Figs 8.11 and 8.12).
The absolute numbers of other BALF cell types are summarised in Table 8.6. Both
WP/SUP[m] and WP/SUP[s] challenges resulted in significantly greater (P<0.05)











Fig. 8.11: BALF neutrophil counts (x10 /ml) in
heaves (n=7) horses at 6h following inhalation













SUP WP WP/SUP[s] WP/SUP[m] HDS-1
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Fig. 8.12: BALF neutrophil ratio (%) in heaves
(n=7) horses at 6h following inhalation challenge





Fig. 8.13: BALF lymphocyte counts (x105/ml) in
heaves (n=7) horses at 6h following inhalation
challenge with SUP, WP, WP/SUP[s],






















Fig. 8.14: BALF macrophage counts (x10 /ml) in
heaves (n=7) horses at 6h following inhalation
challenge with SUP, WP, WP/SUP[s],
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8.6 Discussion
In addition to being a useful tool for the diagnosis of heaves (Chapter 7), hay dust
suspensions (HDS) proved valuable in this study to investigate the relative
importance of the soluble and particulate components of hay dust in inducing
pulmonary inflammation in heaves horses. Inhalation challenges with each of the 3
HDS fractions induced airway neutrophilia in heaves horses, with the potency of the
fractions being SUP > WF » WP. The latter observation suggests that the soluble
components of HDS are more important than particulates for inducing pulmonary
neutrophil recruitment in heaves. While endotoxins and proteases may contribute to
the pro-inflammatory effect of SUP (6.3.5.1 and 6.3.5.2) as they were present at only
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low levels in WF (6.3.5.1 and 6.3.5.2), which also caused significant pulmonary
inflammation, other soluble components appear also to be involved in the
aetiopathogenesis of heaves.
It was considered likely that dust particulates also contributed to airway neutrophil
recruitment since the magnitude of the airway neutrophilia induced by each of the 3
fractions was less marked than that induced by HDS, and unlike HDS, none of the
fractions induced detectable pulmonary dysfunction. Consistent with the possibility
that dust particulates potentiate the neutrophilic response to SUP, the combined
WP/SUP challenges induced a neutrophilia of a magnitude approaching that induced
by HDS. Although there was no significant difference between the neutrophil count
following HDS (36-fold increase) and that following the mixed WP/SUP challenge
(23-fold increase), the HDS challenge did result in an non significant greater median
BALF neutrophil count and ratio. In addition, both the mixed and separate WP/SUP
challenges differed significantly from HDS challenge with respect to the reduction in
BALF macrophage (HDS - 1.16 x 105/ml, WP/SUP[m] - 1.46 x 105/ml, WP/SUP[s]
- 1.78 x 105/ml) and lymphocyte counts (HDS - 1.19 x 105/ml, WP/SUP[m] - 2.33 x
105/ml, WP/SUP[s] - 2.42 x 105/ml). These findings suggest that fractionation and
subsequent reconstitution of HDS may have resulted in a reduction in its overall pro¬
inflammatory properties. Alternatively, the fact that the WF fraction was not included
in the reconstituted HDS (combined WP/SUP), may have resulted in a reduction in its
pro-inflammatory capacity, despite the relatively low endotoxin, P-D-glucan and
protease concentration ofWF (6.3.5.1).
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The importance of inhaled particulates, both organic and inorganic, in determining
the type and magnitude of the pulmonary inflammatory response has previously been
demonstrated in rodent inhalation studies (Kurup et al., 1997; Li et al., 1997),
however the mechanism involved is unclear. Inhaled particulates may be pro¬
inflammatory per se, as evidenced by the mild airway neutrophilia induced by WP
alone. However, it is possible that the pro-inflammatory effect ofWP was partly due
to adherent or particulate endotoxin not removed during the wash protocol, and
undetected by the Limulus ameobocyte lysate assay, which mainly detects soluble
endotoxin and underestimates particulate endotoxin content (Rylander et al., 1989).
Interestingly, in the present study the combined WP/SUP challenge was more potent
than the separate WP/SUP challenge. This is possibly because in the combined
WP/SUP challenge the particulates were coated with soluble components, resulting in
enhanced activation of pulmonary inflammatory cells (Ning et al., 2000), and/or
increased pulmonary deposition, or reduced pulmonary clearance of pro¬
inflammatory dust components.
Consistent with these findings, pre- or co-exposure of rodent lungs in vivo or rodent
lung derived cells in vitro to airborne particulates, such as concentrated airborne
particles and residual oil fly ash, can alter the inflammatory response to pro¬
inflammatory agents, with the type of particulate determining the alteration in
response (Goldsmith et al., 1999; Hamada et al., 1999; Imrich et al., 1999b; Yang et
al., 1999; Ning et al., 2000). In contrast, there is limited information available on the
modulatory effects of inhaled mould spores. However, in one study the magnitude of
the pulmonary eosinophilia induced in mice by inhaled soluble Aspergillus fumigatus
224
antigen was potentiated when the antigen was coupled to inert 3pm diameter
polystyrene beads, resulting in a degree of eosinophilia comparable with that induced
by inhalation ofA. fumigatus spores (Kurup et al., 1997).
Other possible reasons for the magnified response to combined WP/SUP may include
an endotoxin-mediated enhanced neutrophilic response to allergen on the surface of
spores, an effect which has previously been demonstrated in guinea pigs following
chronic exposure to LPS and ovalbumin (Rylander and Holt, 1998). It is unlikely that
the high |3-D-glucan content of WP (6.3.5.1) was responsible for the magnified
response when WP was combined with SUP, as (3-D-glucan has been shown to
markedly reduce the airway neutrophilic response to inhaled endotoxin following
acute exposure in other species (Fogelmark et al., 1994).
While there was no overlap in the BALF absolute neutrophil counts following SUP
challenge in control and heaves horses, the magnitude of the difference between the
two groups was less marked than after non-fractionated HDS challenge. This
indicates that HDS is more useful than SUP as a diagnostic tool for differentiating
heaves and control horses.
In summary, this study identified an important role for inhaled particulates in the
inflammatory response of heaves horses. As the majority of particulates in HDS were
mould spores (6.3.2.1) their involvement in the aetiopathogenesis of heaves may
reflect not only their role as an antigenic source, but also the importance of their
particulate structure which may potentiate the pulmonary inflammatory response to
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other inhalants. Additionally, it is clear from this study that while aqueous dust
extracts may aid the investigation of heaves, the inclusion of particulates in the
challenge substance is important in optimising the resulting pulmonary inflammatory
response.
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CHAPTER 9: CONTRIBUTION OF LPS TO THE PULMONARY RESPONSE
TO INHALED HDS
9.1 Summary
This chapter investigated the relative contribution of inhaled endotoxin and organic
dust particulates (primarily mould spores) in the aetiopathogenesis of heaves.
Depletion of endotoxin from an aqueous hay dust suspension (HDS) attenuated the
airway neutrophilia and abrogated the airway dysfunction induced in heaves horses by
inhaled HDS. The airway response was re-established by adding back LPS,
confirming that the attenuation in airway response was specifically due to endotoxin
depletion. Interestingly, the magnitude of alteration in airway response following
endotoxin depletion and add-back was greater than that which could be attributed
solely to endotoxin per se, suggesting that the activity of LPS was enhanced by other
dust components. This indicates that inhaled organic dust components (soluble and/or
particulates) and LPS have a synergistic pro-inflammatory action in heaves. It was
concluded that inhaled endotoxin contributes to induction of airway inflammation
and dysfunction in heaves, and that the airway response to inhaled endotoxin is
synergised by co-challenge with other organic dust components.
9.2 Introduction
While previous work suggested that heaves is a hypersensitivity response to inhaled
moulds (Halliwell et al., 1979; Lawson et al., 1979; McPherson et al, 1979;
McGorum et al., 1993b), experimental aqueous mould extract inhalation induced
227
pulmonary neutrophilic inflammation and dysfunction, consistent with, but less
severe than the natural disease (McGorum et al., 1993c). This shortfall in response
may reflect insufficient dose of mould, although the findings of Chapter 5 make this
unlikely. Alternatively the shortfall in response may reflect a difference in the
duration of challenge and/or the involvement of additional dust components, such as
endotoxin (McGorum et al., 1993c). Inhaled endotoxin is a likely candidate for
involvement in heaves (Pirie et al., 2001b) for the reasons highlighted earlier (2.2).
However as the exposure level of inhaled LPS required to induce airway
inflammation and dysfunction in short-term experimental inhalation challenges
greatly exceeds that encountered in the stable, it is unlikely that LPS acts alone in
disease induction (Chapter 2; Pirie et al., 2001b).
Chapter 7 described the successful use of a nebulised aqueous hay dust suspension
(HDS) to reproduce the features of heaves in susceptible horses and also to
differentiate susceptible horses from control horses. Chapter 8 described the use of
the same model to demonstrate the relative importance of both soluble and particulate
components in the induction of heaves (Pirie et al., 2001a, c and d). This HDS
experimental model was also used in the present study, since it provided a method for
investigating the relative importance of dust components, including endotoxin, in
heaves. This chapter describes a series of inhalation challenge experiments performed
to determine the importance of inhaled endotoxin in heaves. The effect of LPS
depletion of HDS was studied to establish whether endotoxin contributes to the
pulmonary functional and inflammatory response of heaves susceptible and control
horses to inhaled HDS. In addition, heaves horses received a further series of
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inhalation challenges following "LPS add-back" i.e. the addition of LPS to the LPS-
depleted HDS, at a concentration equivalent to that which was previously removed.
9.3 Materials and methods
9.3.1 Subjects
Six previously described healthy control horses with no detectable respiratory tract
disorders (2.3.1.2) and 6 previously described horses with a history and clinical
diagnosis of heaves (3.3.1) were used. The disease status of all subjects was
confirmed by mouldy hay/straw challenge as previously described (2.3.4.2).
Throughout the study all horses were kept in a low dust environment (2.3.2.1).
9.3.2 Inhalation challenge material
The nebulised challenge material was endotoxin-depleted HDS-1[100] (HDS-LPS),
prepared and characterised as described previously (Chapter 6).
9.3.2.1 Endotoxin analysis ofHDS
Endotoxin analysis of HDS and HDS-LPS was performed using an endotoxin-
specific Limulus amoebocyte assay as previously described (6.3.2.4).
9.3.2.2 Endotoxin depletion ofHDS
Polymixin-coated agarose beads suspended in 50% glycerol were used to achieve
endotoxin depletion, using a modification of the method previously described for
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endotoxin depletion of A. fumigatus extract (5.3.2.2). 10ml HDS was centrifuged
(1600g; 15min) to pellet the particulates, and the supernatant, which contained 83%
of the HDS endotoxin activity (6.4.3.1), was decanted. 20ml of the polymixin-coated
bead suspension was added to 25ml HDS supernatant in a sterile conical plastic tube.
The LPS content of 25ml HDS-1[100] was calculated to be 540pg (25 x 21.6
[endotoxin content in 1ml HDS-1; 6.4.1.3]), and 20mls of polymixin-coated bead
suspension was calculated to have the capacity to remove between 4000 and lOOOOpg
LPS. The tube was rotated for 30min and the resulting mixture was then centrifuged
(1600g; 15min) to pellet the beads. The LPS-depleted supernatant (HDS-LPS) was
decanted, and used to re-suspend the previously pelleted HDS particulates to yield
HDS-LPS, which was frozen at -80°C until used for the inhalation challenges. As it
was not possible to pellet the glycerol along with the polymixin-coated beads, LPS
depletion of 25ml HDS resulted in a final volume of 35ml of HDS-LPS, due to the
added presence of 10ml glycerol in the final suspension.
9.3.2.3 Add-back ofdepleted LPS
The re-establishment of the original LPS concentration of HDS was achieved by
adding back soluble LPS (.Salmonella typhimurium Ra60) from a stock solution of
8.89mg/ml to HDS-LPS, at a quantity equivalent to that which had been removed
during the depletion. This challenge material was termed HDS-LPS+LPS.
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9.3.3 Inhalation challenges
9.3.3.1 Inhalation challenge protocol
Both the control and the heaves group received inhalation challenges with HDS-LPS.
To ensure that any alteration in response following endotoxin depletion was due
solely to depletion of endotoxin, heaves horses also received inhalation challenge
with HDS-LPS+LPS. Because of the glycerol content of HDS-LPS and HDS-
LPS+LPS (10ml glycerol per 25ml HDS), for these challenges, 1.4ml (35/25) of the
suspension was nebulised in order to deliver the same quantity of soluble and
particulate HDS components.
To facilitate subject cooperation, horses were sedated immediately prior to inhalation
challenges as previously described (2.3.4.1). The aerosol was generated and delivered
as previously described (2.3.4.1). The challenges were not randomised, therefore to
minimise potential carry over effects of preceding challenges, all inhalation
challenges on any one subject were conducted a minimum of 14 days apart and all
horses were demonstrated to have normal clinical findings immediately prior to each
inhalation challenge. In order to assess any carry-over effects, all baseline lung
function values were compared.
9.3.3.2 Positive (HDS) and negative (saline) control challenges
To compare the HDS-LPS and HDS-LPS+LPS responses with those of placebo and
HDS, comparisons were made with saline and HDS-1[100] challenge in the same
horses. As only 6 heaves horses were used in this study, the response data of this
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group to saline and HDS is presented fully in this chapter instead of referring to the
results of Chapters 2 and 7 (where 7 heaves horses were used).
9.3.4 Monitoring the response to challenges
The method and timing of assessment of response to each challenge is summarised in
Fig. 9.1. The response to challenges was assessed using clinical scoring, lung
mechanics, airway reactivity and BALF cytology as previously described (2.3.7).
Fig. 9.1: Study design.
BAL = bronchoalveolar lavage; LF = lung function evaluation; Clin Ex = clinical examination; A
React = airway reactivity evaluation.
Clin Ex INHALATION Clin Ex LF BAL
LF CHALLENGE A React
t-30min tO t + 4h t + 5h t + 6h
9.4 Statistical analysis
As the data were either not normally distributed and/or the groups of compared data
did not have equal variance, non-parametric tests were used. The effect of each
inhalation challenge was determined by performing within-group analyses.
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To check for the presence of any carry-over effects of one challenge on a subsequent
challenge, pre-challenge (baseline) measurements of lung mechanics were compared
using a Friedman test, and when significant, a Wilcoxon Rank Sum test was
performed on paired data.
To check for any effects of challenge, where pre-challenge measurements were made
at t-30min (lung mechanics), the post-challenge values were expressed as % of
baseline value, except for clinical scores where actual values were used. As saline
was the vehicle for delivery of all challenges, the effect of challenge was assessed by
pairing and subtracting post HDS-LPS or HDS-LPS+LPS (% of baseline value) and
post saline (% of baseline value) data. Where no pre-challenge data were collected
(BALF cytology), comparisons were made with saline challenge data at equivalent
time points. A Friedman test was performed on sets of paired data to reduce the risk
of type 1 errors, and when significant, a Wilcoxon Rank Sum test was performed on
paired data. Between group (heaves vs controls) analyses, for response to HDS-LPS,
were performed for BALF neutrophil numbers, using the Mann Whitney test.
Significance was assumed if P<0.05. Following correction for any effect of saline
inhalation, changes from baseline are expressed as increase/decrease or change in
median values, with 95% confidence interval for the difference in median, calculated
for non-parametric data (Campbell and Gardner 1994). Results in tables are expressed
as median and range.
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9.5 Results
9.5.1 LPS depletion of HPS
The endotoxin content of HDS was 21.6 pg/ml (6.4.1.3), while the endotoxin content
of the HDS-LPS was 9.1|_ig/ml. Therefore polymixin treatment reduced the final
endotoxin exposure present within the facemask from 21,6pg for HDS to 12.8pg for
HDS-LPS (9.1 pg x 1.4ml), equating to a 41% reduction in the endotoxin exposure.
9.5.2 Response to inhalation challenge
9.5.2.1 Clinical examination
All horses had a clinical score of zero prior to all challenges. When compared with
baseline, no significant change in clinical scores was detected in either group
following any of the challenges (Appendix 9.1).
9.5.2.2 Lung mechanics and airway reactivity
Raw data for lung mechanics measurements are presented in Appendix 9.2. There
was a significant difference among the baseline data before the 3 challenges (HDS,
HDS-LPS, HDS-LPS+LPS) with respect to dPpl, VT, RLE75%, RL125%, TE, V'E,
Wbei, Wbres, WbEres, Wbires and Wbitot, indicative of a slightly greater degree of
pulmonary dysfunction prior to the HDS-LPS challenge. The percentage of baseline
lung mechanics measurements are presented in Table 9.1. PCCdyn70 values
following challenge are presented in Appendix 9.3.
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Following correction for any effects of saline inhalation, HDS-LPS challenge did not
result in detectable lung dysfunction in either group, however HDS-LPS+LPS
induced a significant (P<0.05) increase in both Rle25% (increase in median 142%,
95% CI 32-363) (Fig. 9.2) and Rle75% (increase in median 103%, 95% CI 15-192)
(Fig. 9.3) in the heaves group. For comparison in the same 6 heaves horses, HDS
induced a significant (P<0.05) increase in expiratory resistive work of breathing
(Wbe res) (increase in median 66%, 95% CI 8-157) (Fig. 9.4), and a non-significant
(P=0.059) increase in Rle75%-
Fig. 9.2: Percent of baseline RI_e25% in heaves
horses (n=6) at 5h following inhalation challenge
with saline HDS-1[100], HDS-LPS and HDS-
LPS+LPS minus percent of baseline RLg25%, at
5h following inhalation challenge with saline.
SALINE HDS HDS-LPS HDS-LPS+LPS
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Fig. 9.3: Percent of baseline RI_e75% in heaves
horses (n=6) at 5h following inhalation challenge
with saline HDS-1[100], HDS-LPS and HDS-
LPS+LPS minus percent of baseline RLe75%, at
5h following inhalation challenge with saline.
200 H
SALINE HDS HDS-LPS HDS-LPS+LPS
Fig. 9.4: Percent of baseline WBE_res in heaves
horses (n=6) at 5h following inhalation challenge
with saline HDS-1[100], HDS-LPS and HDS-
LPS+LPS minus percent of baseline WBE_res at
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The BALF neutrophil counts and ratios following challenge with HDS-LPS and
HDS-LPS+LPS are presented in Appendix 9.4, and summarised in Table 9.2, with
data from saline and HDS-1[100] challenge included for comparison.
Table 9.2: BALF neutrophil counts (x105/ml) and ratios (%) (median and
range) in control (n=6) and heaves (n=6) horses at 6h following inhalation
challenge with saline, HDS and HDS-LPS and in heaves (n=6) horses at 6h
following inhalation challenge with HDS-LPS+LPS. NP = not performed.
BALF neutrophil count (x105/ml) BALF neutrophil ratio (%)

































When compared with saline inhalation, heaves horses had significantly (P<0.05)
increased BALF neutrophil ratios and counts after FIDS (difference in median count
2.25 x 105/ml, 95% CI 0.76-3.74; 34-fold increase), HDS-LPS (difference in median
count 0.92 x 105/ml, 95% CI 0.29-2.40; 8-fold increase) and HDS-LPS+LPS
(difference in median count 1.68 x 105/ml, 95% CI 0.53-4.21; 27-fold increase)
(Table 9.2, Figs. 9.5 and 9.6). While BALF neutrophil counts and ratios after HDS
and HDS-LPS+LPS did not differ, they were significantly (P<0.05) higher than those
after HDS-LPS (differences in median counts 1.27 x 105/ml, 95% CI 0.13-0.62 and
0.82 x 105/ml, 95%CI 0.07-2.65, respectively) (Table 9.2, Figs. 9.5 and 9.6).
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Fig. 9.5: BALF neutrophil count (x10b/ml) in
heaves (n=6) horses at 6h following inhalation
challenge with saline, FIDS, FIDS-LPS and HDS-
LPS+LPS.
SALINE HDS HDS-LPS HDS-LPS+LPS
Fig. 9.6: BALF neutrophil ratio (%) in heaves
(n=6) horses at 6h following inhalation challenge
with saline, HDS, HDS-LPS and HDS-LPS+LPS.
SALINE HDS HDS-LPS HDS-LPS+LPS
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After HDS challenge, controls had a slight, yet significant (P<0.05) increase in BALF
neutrophil count and ratio, when compared with saline (difference in median count
0.26 x 105/ml, 95%CI 0.06-0.49). Controls also showed an increase in BALF
neutrophil count and ratio, which approached significance (P=0.059), when compared
with HDS-LPS (difference in median count 0.23 x 105/ml, 90% CI 0.03-0.49) (Table
9.2; Figs. 9.7 and 9.8). The BALF neutrophil count and ratio of controls following
HDS-LPS and saline challenges did not differ significantly (Table 9.2; Figs. 9.7 and
9.8). The heaves group had a significantly (P<0.01) greater BALF neutrophil count
and ratio following HDS-LPS challenge when compared with saline (Fig 9.9 and
9.10).
Fig. 9.7; BALF neutrophil count (x10 /ml) in
control (n=6) horses at 6h following inhalation






















Fig. 9.8: BALF neutrophil ratio (%) in control
(n=6) horses at 6h following inhalation challenge
with saline, HDS and HDS-LPS.
SALINE HDS HDS-LPS
Fig. 9.9: BALF neutrophil count (x10 /ml) in
heaves (n=6) and control (n=6) horses at 6h




















Fig. 9.10: BALF neutrophil ratio (%) in heaves
(n=6) and control (n=6) horses at 6h following
inhalation challenge with FIDS-LPS.
CONTROLS HEAVES
Due to the influence of a BALF neutrophilia on the ratio of other BALF cell types,
the latter were considered only as absolute numbers. The absolute number of other
BALF cell types 6h following challenge is summarised in Table 9.3.
Table 9.3: Total and differential BALF cell counts (x105/ml) (median and range)
in heaves (C; n=6) and control (H; n=6) horses at 6h following inhalation
challenge with saline, HDS and HDS-LPS and in heaves (n=6) horses at 6h
following inhalation challenge with HDS-LPS+LPS.









































































































In heaves horses, absolute BALF macrophage numbers after HDS-LPS+LPS were
significantly (P<0.05) lower than those after saline (differences in median 0.85 x
105/ml, 95%CI 0.14-1.58) and HDS-LPS (difference in median 0.40 x 105/ml, 95%CI
0.01-1.10), but not significantly different from HDS (Fig. 9.11). In heaves horses,
absolute BALF mast cell counts were significantly (P<0.05) reduced following
challenge with HDS (difference in median 0.07 x 105/ml, 95% CI 0.03-0.14) and
HDS-LPS (difference in median 0.08 x 105/ml, 95% CI 0.01-0.15), compared with
saline (Fig. 9.12). In heaves horses, absolute BALF lymphocyte counts were reduced
by HDS-LPS+LPS (difference in median 0.97 x 105/ml, 95% CI 0.58-1.30), and non-
significantly (P=0.059) reduced by HDS (difference in median 0.91 x 105/ml, 90% CI
0.34-1.45), compared with saline (Fig. 9.13).
Fig. 9.11: BALF macrophage count (x10 /ml) in
heaves (n=6) horses at 6h following inhalation






















SALINE HDS HDS-LPS HDS-LPS+LPS
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Fig. 9.12: BALF mast cell count (x10 /ml) in
heaves (n=6) horses at 6h following inhalation








Fig. 9.13: BALF lymphocyte count (x105/ml) in
heaves (n=6) horses at 6h following inhalation








SALINE HDS HDS-LPS HDS-LPS+LPS
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9.6 Discussion
This study investigated the contributing role of inhaled LPS to airway neutrophilic
inflammation and dysfunction in equine heaves. Reduction of the LPS content of
aqueous HDS significantly attenuated the airway neutrophilia and dysfunction
induced by HDS inhalation challenge in heaves horses, and non-significantly reduced
the airway neutrophilia in controls. The airway inflammatory and functional response
was re-established in heaves horses after adding back endotoxin, confirming that the
attenuation was due specifically to reduction in endotoxin and not to a reduction in
other soluble components of HDS, or to the effect of glycerol contamination of the
depleted suspension.
The attenuation of the pulmonary functional response was difficult to interpret
considering that mild but significant pulmonary dysfunction was present prior to the
HDS-LPS challenge. It is possible that this finding resulted in an underestimation of
the degree of improvement in lung function following LPS depletion. Also, as percent
change in baseline lung function, and not individual post-challenge lung function
values were statistically analysed, it is equally possible that an overestimation of the
effects the LPS depletion on lung function occurred. Mild pre-existing pulmonary
obstruction may have resulted in a reduction in the percentage change of baseline
lung function measurements at 5h following challenge. However, the improvement in
RLe25% noted following HDS-LPS challenge, despite there being no statistical
difference between baseline measurements, is supportive of the attenuation in lung
function following LPS depletion.
246
The reduction in airway neutrophilic inflammatory response following endotoxin
depletion of HDS was less marked than that reported following endotoxin depletion
of corn dust extract in a mouse model of organic dust-induced disease (Jagielo et al.,
1996a). Jagielo et al. (1996a) described that the LPS-depleted extract (initially
suspended in pyrogen free water) was lyophilised and reconstituted in Hanks
balanced salt solution (HBSS). It is therefore possible that the salts within the HBSS
may have altered the solubility and biological activity of the LPS, resulting in a
reduced biological effect in mice following inhalation (Galanos and Luderitz, 1984).
However, despite this potential for a reduction in toxicity, the salt content should not
affect the results of the Limulus amoebocyte lysate assay (Galanos and Luderitz,
1984), which did detect an 89% reduction in LPS activity in the Jagielo et al. study,
compared with 41% in the present study. This greater depletion more likely explains
the more marked reduction in neutrophilic response in the Jagielo et al. study. The
reason for the difference between the two studies with respect to the efficiency of
LPS-depletion is unclear. It may, however reflect a greater degree of LPS aggregation
in sodium salt solution in the present study compared with pyrogen free water in
Jagielo et als.' study, thus reducing exposure of the lipid A component of LPS to the
polymixin-coated beads (Galanos and Luderitz, 1984; Makela and Stocker, 1984).
Other pro-inflammatory agents, such as dust particulates, which were present in
HDS-LPS but not in the soluble corn dust extract, may have contributed to the airway
response in the present study. HDS, containing both soluble and particulate dust
components, was used since particulates have been shown to contribute to the airway
response to HDS (Chapter 8). Endotoxin could only be removed from the HDS
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supernatant and not from the particulates, since the removal of polymixin-coated
beads following mixing with solution/suspension required centrifugation, a process
which would also have removed the HDS particulates. This was not considered
problematic since the supernatant contained 83% of the endotoxin activity of HDS
(Chapter 6), although the particulate endotoxin content may have been
underestimated (Rylander et al., 1989).
Horses received an estimated total exposure of 12.8pg endotoxin during the HDS-
LPS challenge, compared with 21.6pg during the HDS and HDS-LPS+LPS
challenges. Interestingly, in the endotoxin depletion and add-back experiments, the
magnitude of the airway response was altered to a greater extent than could be solely
attributed to the direct action of 8.8pg (i.e. 21.6-12.8) LPS. Indeed, extrapolation
from previously described data (2.5.2.6) indicates that inhalation of 20jug soluble LPS
in these same heaves horses induced only mild airway neutrophilia (0.28 x 105/ml,
0.18-0.53). This equated to an increase in median neutrophil count of 0.20 x 105/ml
(95% CI 0.06-0.48) neutrophils without airway dysfunction as compared with saline.
Despite its limitations, this comparison suggests that other components of HDS
enhance the activity of the LPS, resulting in a more severe airway response than
would have resulted from inhalation of LPS alone. Therefore considering the
apparent synergy between LPS and other HDS components described in this study,
more significance may be attributed to airborne endotoxin when inhaled in concert
with other dust components.
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The endotoxin activity removed from HDS by polymixin adsorption likely comprised
a variety of LPS types, in contrast to the S. typhimurium Ra60 mutant used in the LPS
challenges (2.3.3.1) and this current "add-back" experiment. The S. typhimurium
Ra60 mutant LPS (i.e. complete core oligosaccharide plus lipid A) was chosen
because it was not possible to produce a pure endotoxin mix that is representative of
those types of LPS encountered in equine stables. However, the complete core
oligosaccharide plus lipid A is responsible for a major part of the biological activity
of LPS and is likely to be present in high concentrations in HDS, since it is shared by
many Enterobacteriaceae including all Escherichia coli and Salmonella species (Prof.
IR Poxton, personal communication). It could however be argued that the
homogenous preparation of S. typhimurium Ra60 mutant LPS may have a lower
virulence following inhalation due to the truncated polysaccharide chain, resulting in
a reduction in antiphagocytic properties (Taussig, 1984). However the measured
responses to HDS and HDS-LPS+LPS inhalation were comparable, indicating that, as
well as having similar activity in the Limulus amoebocyte lysate assay, the soluble
LPS used for the add-back had similar biologic activity in vivo to the various
endotoxins removed by the polymixin beads.
In conclusion, this study has demonstrated that inhaled endotoxin contributes
markedly to the airway inflammatory and functional response to HDS inhalation in
heaves. In addition, the response to inhaled endotoxin is enhanced when co-presented
to the lung with other organic dust components. This may have major implications
when response thresholds for endotoxin exposure in dusty environments are
calculated by direct extrapolation from soluble LPS dose-response inhalation
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experiments. Under such circumstances, consideration should also be given to the
presence of other organic dust components, which may magnify the pulmonary
response to a given dose of endotoxin. Such dust components appear to have greater
significance when considering exposure levels in heaves-susceptible horses, possibly
due to their exaggerated pulmonary response to specific agents, such as mould
allergens.
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CHAPTER 10: POTENTIATION OF THE RESPONSE TO INHALED LPS BY
HAY DUST SUSPENSION PARTICULATES
10.1 Summary
This study investigated the relative contribution of inhaled LPS and organic dust
particulates (primarily mould spores) in heaves. Washed particulates harvested from
HDS enhanced the airway response to inhaled LPS in heaves horses. This indicates
that inhaled organic dust particulates and LPS have a synergistic pro-inflammatory
action in heaves. Interestingly, the magnitude of the enhancement in airway response
following the addition of LPS to washed particulates was greater than that which
could be attributed solely to LPS per se, indicating that the activity of LPS was
enhanced by the dust particulates. It was concluded that inhaled endotoxin contributes
to induction of airway inflammation and dysfunction in heaves and that the airway
response to inhaled endotoxin is synergised by co-challenge with organic dust
particulates.
10.2 Introduction
As with human organic dust-induced diseases (Popendorf, 1986; Rylander, 1988;
Milanowski, 1997), the relative importance of different dust components in inducing
heaves is unknown (Derksen, 1993; McGorum et al., 1993c), and warrants further
study (Robinson, 1998). A nebulised aqueous hay dust suspension (HDS)-induced
disease model has successfully reproduced heaves in susceptible horses,
differentiated susceptible horses from control horses and demonstrated the
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importance of both soluble and particulate hay dust components in the induction of
heaves (Chapters 7 and 8; (Pirie et al., 2001a, c and d). In addition, synergy between
the LPS content of HDS and other HDS components has been shown using the same
model (Chapter 9). This chapter describes a further series of inhalation experiments
performed to determine whether the particulate components HDS alone could
potentiate the airway response to inhaled LPS in heaves-susceptible horses. This
involved co-challenge with washed dust particulates harvested from HDS (WP as
previously described 6.3.4) and soluble LPS.
10.3 Materials and methods
10.3.1 Subjects
Seven previously described horses with a history and clinical diagnosis of heaves
(2.3.1.1) were used. Throughout the study all horses were kept in a low dust
environment (2.3.2.1). The disease status of all subjects was confirmed by the
previously described mouldy hay/straw challenge (2.3.4.2).
10.3.2 Inhalation challenge material
To determine whether co-inhalation with dust particulates enhanced the pulmonary
inflammatory and functional response to inhaled endotoxin, heaves horses received a
combined inhalation challenge with LPS and washed particulates (WP). This
challenge was referred to as WP+LPS. WP was prepared from HDS as previously
described (6.3.4). LPS, from a stock solution of 8.89mg/ml (as previously described
2.3.3.1), was added to the WP to give a final LPS concentration of the WP+LPS of
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20pg/ml. This LPS concentration was comparable to that of the non-fractionated
HDS (6.3.2.4). A constant 1ml volume of challenge substance was used for all
challenges.
10.3.3 Inhalation challenges
10.3.3.1 Inhalation challenge protocol
To facilitate subject cooperation, horses were sedated immediately prior to inhalation
challenge as previously described (2.3.4.1). The aerosol was generated and delivered
as previously described (2.3.4.1). To minimise potential carry-over effects of
preceding challenges, inhalation challenges on any one subject were conducted a
minimum of 14 days apart and all horses were shown to have normal clinical findings
immediately prior to each inhalation challenge. In order to assess any carry over
effects, all baseline lung function values were compared those of any challenges to
which comparisons were made, and 6 heaves horses received a repeat challenge with
WP+LPS after completion of all other challenges. As well as assessing any potential
carry-over effects, this also determined the repeatability of this challenge.
10.3.3.2 Positive (HDS) and negative (saline) control challenges
Comparisons of the responses to WP+LPS were made with previously described
responses to inhalation challenge with saline and 20pg LPS (Chapter 2), HDS-1[100]
(Chapter 7), WP (Chapter 8) and WP/SUP[m] (Chapter 8) in the same horses.
253
10.3.4 Monitoring the response to challenges
The method and timing of assessment of response to each challenge is summarised in
Fig. 10.1. The response to WP+LPS was assessed using lung mechanics, airway
reactivity and BALF cytology as previously described (2.3.7).
Fig. 10.1: Study design.
BAL = bronchoalveolar lavage; LF = lung function evaluation; A React = airway reactivity evaluation
INHALATION LF
LF CHALLENGE A React BAL
t - 30min to t + 5h t +6h
10.4 Statistical analysis
As the data were either not normally distributed and/or the groups of compared data
did not have equal variance, non-parametric tests were used. The effect of each
inhalation challenge was determined by performing within-group analyses.
To check for the presence of any carry-over effects of one challenge on a subsequent
challenge, pre-challenge (baseline) measurements of lung mechanics were compared
using a Friedman test, and when significant, a Wilcoxon Rank Sum test was
performed on paired data.
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To check for any effects of challenge, where pre-challenge measurements were made
at t-30min (lung mechanics), the post-challenge values were expressed as % of
baseline value. As saline was the principle vehicle for delivery of all challenges, the
effect of challenge was assessed by pairing and subtracting post-WP+LPS (% of
baseline value) and post-saline (% of baseline value) data. Where no pre-challenge
data was collected (BALF cytology), comparisons were made with saline (placebo)
challenge data at equivalent time points. A Friedman test was performed on sets of
paired data to reduce the risk of type 1 errors, and when significant, a Wilcoxon Rank
Sum test was performed on paired data.
Significance was assumed if P<0.05. Following correction for any effect of saline
inhalation, changes from baseline are expressed as increase/decrease or change in
median values, with 95% confidence interval for the difference in median, calculated
for non-parametric data (Campbell and Gardner 1994).
The two separate WP+LPS inhalation challenges were compared using a Wilcoxon
Rank Sum test, and as an indication of repeatability, the differences in paired values
were plotted against their mean (Bland and Altman 1986)(Bland and Altman, 1986).
Good repeatability was assumed if the calculated differences in paired values fell
within 2 standard deviations of the mean of the differences (British Standards
Institution, 1979). Results are expressed as median and range.
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10.5 Results
10.5.1 Response to inhalation challenge
10.5.1.1 Lung mechanics and airway reactivity
Lung function measurements raw data are presented in Appendix 10.1. With the
exception of RLe25%, there was no significant difference in the baseline lung function
measurements prior to each of the challenges, indicating a lack of carry-over effects.
The percentage of baseline lung function measurements following challenge are
presented in Table 10.1. PCCdyn70 values following challenge are presented in
Appendix 10.2.
Following correction for any effects of saline inhalation, WP+LPS inhalation induced
airway dysfunction as evidenced by a significant increase in Rle25% (increase in
median 103%, 95% CI 30-191) (Fig. 10.2), but did not alter airway reactivity.
Fig. 10.2: Percent of baseline RLe75% in heaves
horses (n=7) at 5h following inhalation challenge
with saline, 20pg LPS, WP, WP+20pg LPS and
HDS[100] minus percent of baseline RLE75% at
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The BALF neutrophil counts and ratios in heaves horses 6h following challenge with
WP+LPS are presented in Appendix 10.3, and summarised in Table 10.2. Data from
saline, 20pg LPS, HDS-1, WP and WP/SUP[m] challenge are included for
comparison.
Table 10.2: BALF neutrophil counts (x105/ml) and ratios (%) (median and
range) heaves (n=7) horses at 6h following inhalation challenge with saline,
WP, SUP, 20(.ig LPS, WP+20pg LPS, WP/SUP[m] and HDS.
BALF neutrophil count




































WP+LPS induced an airway neutrophilia in heaves horses, which was significantly
(P<0.05) greater than that for saline (increase in median count 0.89 x 105/ml, 95% CI
0.42-1.45), 20pg LPS (increase in median count 0.70 x 105/ml, 95% CI 0.13-1.27)
and WP (0.67 x 105/ml, 95% CI 0.18-1.21), yet significantly (P<0.05) lower than that
for HDS (Table 10.1; Figs. 10.3 and 10.4).
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Fig. 10.3: BALF neutrophil count (x105/ml) in
heaves (n=7) horses at 6h following inhalation
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Fig. 10.4: BALF neutrophil ratio (%) in heaves
(n=7) horses at 6h following inhalation challenge
with saline, 20pg LPS, WP, WP+20pg LPS and
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There was no significant difference in BALF neutrophil numbers or ratio following














Fig. 10.5: BALF neutrophil count (x105/ml) in
heaves (n=7) horses at 6h following inhalation


















Fig. 10.6: BALF neutrophil ratio (%) in heaves
(n=7) horses at 6h following inhalation challenge
with WP/SUP[m] and WP+20pg LPS.
WP/SUP[m] WP+20fxg LPS
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Due to the influence of a BALF neutrophilia on the ratio of other BALF cell types,
the latter were considered only as absolute numbers. The absolute numbers of these
cells are summarised in Table 10.3. The responses of other BALF cells to HDS and
WP+LPS did not differ significantly.
Table 10.3: Total and differential BALF cell counts (x105/ml) (median and range) in
heaves (n=7) horses at 6h following inhalation challenge with saline, WP, SUP,
































































































There was no significant difference in the number of any BALF cell type between the
first and second WP+LPS challenges, except for a significant (P<0.05) elevation in
macrophage count after the second challenge. As all of the 6 calculated differences in
paired neutrophil values fell within 2 standard deviations of the mean of the
differences, and the mean of the differences approximated zero (Fig 10.7),
repeatability was considered good (Bland and Altman 1986).
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Fig. 10.7: Difference between BALF neutrophil
counts (x105/ml) plotted against the mean of the
BALF neutrophil counts (x105/ml) in heaves
(n=6) horses at 6h following both WP+LPS
inhalation challenges. Solid line = mean of the
differences; dotted line = mean of the
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10.6 Discussion
In agreement with the results of the study described in Chapter 9, this study highlights
the contributing role of inhaled LPS to airway inflammation and dysfunction in
equine heaves. Following LPS depletion (HDS-LPS) the residual neutrophilic
response to HDS-LPS inhalation challenge (9.5.2.3) may have resulted from
incomplete removal of LPS. However, it may also have resulted from the presence of
other HDS pro-inflammatory agents present in HDS-LPS. The addition of 20pg
soluble LPS to washed particulates (predominantly washed fungal spores) harvested
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from HDS permitted the investigation of the potential synergistic effects of both of
these components in the absence of the other soluble components of HDS.
The addition of LPS, at a concentration comparable to that present within the HDS
supernatant (SUP; 6.3.5.1), enhanced the airway inflammatory response to WP
harvested from HDS, to a greater extent than could be attributed to the effects of
inhalation of 20ug LPS per se. Previous inhalation challenges with 20pg soluble LPS
in the same heaves horses induced only mild airway neutrophilia (0.28 x 105/ml,
[0.18-0.53]), equating to an increase in median neutrophil count of 0.20 x 105/ml
(95% CI 0.06-0.48) compared with saline challenge (2.5.2.6). This finding of
synergism is in agreement with previous in vivo and in vitro studies which
demonstrate that particulates enhance the response to pro-inflammatory agents such
as LPS, and conversely that the airway response to inhaled particulates is enhanced by
LPS priming (Imrich et al., 1999b; Yang et al., 1999; Ning et al., 2000; Oberdorster,
2000).
Synergy between LPS and particulates may be due to binding of LPS to the organic
particulates, resulting in a more focal and concentrated LPS challenge, in comparison
to the more likely diffuse pulmonary deposition of a solution with dilution throughout
the respiratory tract (Urbain et al. 1996a). Alternatively, while challenges with WP
alone induced only a mild airway neutrophilia (0.19 x 105/ml [0.10-0.65]), equating
to an increase in median of 0.15 x 105/ml (95% CI 0.04-0.48) (8.5.1.4), they may
prime target cells thereby enhancing LPS responsiveness. Both in vitro and in vivo
priming of guinea pig alveolar macrophages has been reported following fungal
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antigen and glucan challenge (Milanowski, 1996; Milanowski, 1997), both
components of HDS (6.3.2) (Pirie et al., 2001d).
In light of the results of previous inhalation studies (Eyre, 1972; Halliwell et al.,
1979; McPherson et al., 1979; McPherson and Thomson, 1983; Robinson et al.,
1996), which have proposed that heaves is a hypersensitivity response, it is possible
that the mould spores within the washed particulates acted as a source of allergen.
Consequently mould spore inhalation may have resulted in an allergen-associated
increase in LPS binding protein and soluble CD 14 receptors in the airways as
reported in asthmatic humans, thus magnifying the response to LPS (Martin et al.,
1992; Dubin et al., 1996). This synergy may in part explain why the exposure level of
experimentally inhaled LPS necessary to induce airway inflammation and dysfunction
in heaves horses is markedly greater than that to which horses are exposed naturally
(Pirie et al., 2001b).
While this study has confirmed a major role for endotoxin in heaves, other findings
indicate that other soluble dust components are also involved. For example, the
airway response to LPS may have been partly enhanced by other soluble HDS
components such as proteases (Pirie et al., 200Id), since the response to WP+LPS
was significantly less than that to HDS. However, as WP+LPS (0.71 x 105/ml [0.4-
1.62]; 12-fold increase in median neutrophil count) resulted in an airway neutrophilic
response approaching that following WP/SUP[m] (1.36 x 105/ml [0.43-4.55]; 23-fold
increase in median), compared with saline, it is likely that LPS and particulates play a
significant combined role compared with other HDS components. This combined
264
effect would have been further supported had BALF neutrophil ratios, rather than
BALF neutrophil numbers, been used as the sole indicator of airway neutrophilia,
since both WP+LPS and WP/SUP[m] resulted in almost identical BALF neutrophil
ratios (25.3% and 25.7%, respectively).
The endotoxin activity removed from HDS by removal of HDS supernatant from the
challenge material used in this reported study likely comprised a variety of LPS types,
in contrast to the single S. typhimurium R.60 mutant LPS which was used in the
WP+LPS challenge. This Ra chemotype LPS was chosen for reasons highlighted
previously (9.6), and although there are limitations with respect to the direct
comparison of the in vivo effects of the two different sources of LPS, the LPS used in
the WP+LPS challenges was considered to be representative of the LPS types
encountered in equine stables.
In conclusion, this study has demonstrated that inhaled endotoxin and particulates
contribute markedly to the airway inflammatory and functional response in heaves. In
addition, the response to inhaled endotoxin is enhanced when co-presented to the
lung with other organic dust components, especially hay dust particulates. This work
has important implications for organic dust-induced disease in all species since it
highlights the importance of quantifying both endotoxin and dust particulate
exposure, and not considering each component in isolation.
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CHAPTER 11: CONCLUDING ADDENDUM
The aim of this concluding addendum is to summarise the role of inhaled endotoxin
in the aetiopathogenesis of equine heaves, in light of the findings of this study.
11.1 Heaves does not result solely from the inhalation of airborne endotoxin
The findings of the present study have demonstrated that the development of
pulmonary inflammation and dysfunction associated with heaves in susceptible
horses is not solely due to the inhalation of endotoxin. This evidence for this
conclusion is based upon consideration of the following results:
The dose-response experiments detailed in Chapter 2 revealed that LPS inhalation did
reproduce some of the features of heaves, namely airway neutrophilia and pulmonary
dysfunction in heaves susceptible horses. However, in contrast to mouldy hay/straw
exposure, none of the inhaled LPS doses induced a significant increase in the tracheal
secretion score in susceptible horses. Although the tracheal secretion score was
increased in 2 of the 7 heaves horses following the high doses of LPS, the increase
was not significant when the data for the whole group was considered. These doses of
LPS greatly exceeded the level encountered during a 5h exposure to mouldy hay and
straw, which did significantly increase tracheal secretion score in all 7 heaves horses.
Furthermore a significant increase in tracheal secretion score was detected in all 7 of
the heaves group following HDS inhalation.
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Despite the finding that the response threshold was lower in the heaves group for both
pulmonary inflammation and dysfunction, following inhalation of the 2 higher doses
of LPS, there was no statistically significant difference from controls with respect to
airway neutrophilia. This is in contrast to 5h housing in a mouldy hay/straw
environment, which induced a significantly greater airway neutrophilia in the heaves
group. Furthermore, the soluble LPS exposure required to induce a similar degree of
airway neutrophilia in the heaves group to that measured following a 5h mouldy
hay/straw challenge was markedly greater than the endotoxin exposure encountered
during this challenge.
There are, however, certain problems in making comparisons between a natural long-
term endotoxin exposure and a short-term aerosolised purified LPS challenge. These
include the likely underestimation of particulate endotoxin collected during the
hay/straw challenge, a possible difference in the deposition and clearance of
endotoxin/LPS between the 2 challenge systems, and the possible difference in
biological activity of the variety of endotoxins in the stable dust compared with the
pure LPS used in the aerosolised challenge.
The experiments detailed in Chapter 3 were conducted to overcome some of the
highlighted problems associated with comparing the aforementioned challenge
systems. These experiments involved measuring the pulmonary inflammatory and
functional response of heaves horses to 2 separate dusty hay/straw exposures of equal
duration. The results of this study indicated that disease severity did not relate to the
level of endotoxin exposure. In fact, the challenge which resulted in a lesser degree of
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pulmonary inflammation resulted in an, albeit non-significantly, greater exposure to
airborne endotoxin within the respirable dust.
The response to HDS inhalation in the heaves group was dependent on the source of
the stable dust used to produce the suspension. HDS-3 resulted in a greater degree of
pulmonary inflammation and dysfunction, despite having a lower concentration of
endotoxin than HDS-1 and HDS-2. This finding was further supported by the
significantly lesser response to the soluble fraction of HDS (SUP) in the heaves
group, compared with the non-fractionated HDS, despite the SUP containing almost
all of the endotoxin activity.
The pulmonary inflammatory response to HDS inhalation was dose-dependent in
both groups. However, the magnitude of response in the heaves group following
inhalation of each dose of HDS could not be attributed purely to the endotoxin
activity within the HDS, although it is likely that the particulate endotoxin
concentration of the HDS was underestimated by the Limulus amoebocyte lysate
assay. However, while the LPS dose response experiments demonstrated a 12-fold
increase in median BALF neutrophil count over a 100-fold increase in LPS dose, a
similar increase (15-fold) was seen with only a 3-fold increase in HDS dose.
11.2 Evidence for the role of inhaled moulds in heaves aetiopathogenesis
The challenges detailed in Chapter 2 indicated that a greater degree of pulmonary
inflammation followed exposure to hay with visible mould contamination. The
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presence of mould contamination of this hay was supported by the (albeit non-
significantly) higher P-D-glucan concentration of the respirable dust collected
throughout the challenge with the visibly mouldy hay.
In agreement with the findings of the studies detailed in Chapter 3, the response of
heaves horses to HDS inhalation was also shown to be related to the P-D-glucan
content of the HDS, which probably reflected the higher particulate (predominantly
mould spores) content.
11.3 Evidence that endotoxin, in the presence of other inhalants, contributes
to heaves aetiopathogenesis
Although there was sufficient evidence to indicate that inhaled endotoxin was not
solely responsible for the induction of heaves in susceptible horses, it was considered
likely that it would contribute to disease severity in the presence of other inhaled
agents. Consequently, it was considered important to evaluate the response of heaves
susceptible horses to inhalation of LPS in conjunction with other stable dust
components.
The results of the inhalation challenges detailed in Chapter 5 suggested that LPS
contamination of A. fumigatus extract contributed to the pulmonary neutrophilia
induced by experimental inhalation challenge with A. fumigatus extract. However,
this could only have been confirmed definitively had a further series of inhalation
challenges been conducted following "add back" of the depleted LPS. Interestingly,
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extrapolation from the LPS dose-response experiments detailed in Chapter 2
indicated that the reduction in the airway neutrophilia following depletion of LPS
could not be solely attributed to the LPS activity removed during depletion, indicating
that these agents acted in a synergistic fashion.
Inhalation challenge with fractionated HDS revealed that none of the fractions
induced a neutrophilic response in the heaves group of the same magnitude to that
induced by HDS. Given that previous challenges had indicated that the severity of
response was related to P-D-glucan exposure (Chapters 3 and 7), this was an
interesting finding as the particulate fraction contained almost all of the HDS P-D-
glucan activity.
This work indicates that the response to HDS was dependent upon the presence of
both the SUP and the WP, with a synergistic activity between these 2 fractions, as
also demonstrated between the A. fumigatus extract and LPS (Chapter 5).
To establish whether the endotoxin content of the SUP acted in a synergistic fashion
with the other components of the HDS, HDS was partially depleted of LPS as
detailed in Chapter 9. LPS depletion resulted in a reduction in the pulmonary
inflammation and dysfunction in the heaves group. Interestingly, the reduction in
airway neutrophilia could not be attributed to the endotoxin activity that was removed
if the contribution of the endotoxin activity to the response to HDS inhalation was
solely additive. The re-establishment of the response following "add-back" of LPS, at
a quantity equivalent to that which was removed, was an important finding. Firstly
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this demonstrated that the reduction in response following LPS depletion was due
specifically to the reduction in the LPS content. Secondly, it demonstrated that the
biological activity of the various endotoxins that were removed was comparable to
that of the soluble LPS used for the "add back" experiments, the LPS dose response
experiments detailed in Chapter 2, and the WP+LPS challenges detailed in Chapter
10.
Therefore the inhalation challenges with HDS, HDS fractions and the LPS-depleted
HDS indicated that soluble HDS components acted synergistically with the HDS
particulates, and that at least some of this synergistic activity was due to the LPS
content of the soluble components. The extent of the contribution of LPS to this
response could not be fully assessed, as it was not possible to completely deplete the
HDS of LPS. It was therefore possible that the remaining response to the HDS-LPS
was due either to the remaining LPS or to other soluble components.
The response to challenge with a combination of WP and LPS was not significantly
different from that following challenge with the WP re-suspended in the soluble HDS
fraction, whereby the total endotoxin activity within both combinations was
comparable. It could therefore be concluded that the endotoxin content of the SUP
contributed greatly to the synergism between the SUP and the WP.
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11.4 Summary
Firstly, endotoxin inhalation alone is not responsible for the pulmonary inflammation
and dysfunction in heaves. Therefore heaves susceptibility does not represent an
increased responsiveness to inhaled endotoxin.
Secondly, there is evidence to suggest that P-D-glucan exposure, and thus mould
exposure, is related to the severity of disease. However the fact that the WP contained
most of the HDS P-D-glucan and all of the mould spore content, yet only induced a
minimal inflammatory response, suggests that P-D-glucan or mould spore inhalation
alone is not solely responsible for the induction of heaves.
Thirdly, the endotoxin content of stable dust largely contributes to the pulmonary
inflammation, and to a lesser extent the pulmonary dysfunction, of heaves, but only
when inhaled in combination with dust particulates. As the dust particulates in HDS
were primarily mould spores, it would appear that the combination of mould spores
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Summary
To investigate whether inhaled endotoxin contributes to
airway inflammation and dysfunction in stabled horses,
control (n = 6) and asymptomatic heaves (previously termed
chronic obstructive pulmonary disease) susceptible (n = 7)
horses were given inhalation challenges with 20, 200 and
2000 pg of soluble Salmonella typhimurium Ra60
lipopolysaccharidc (LPS). LPS inhalation induced a dose-
dependent neutrophilic airway inflammatory response in
both groups. Inhalation with 2000 pg of LPS also induced
detectable lung dysfunction in the heaves group. LPS
inhalation did not alter clinical score, tracheal secretion
volume or airway reactivity in either group. The no-response
thresholds were lower for the heaves group (<20 pg for
airway inflammation; 200 to 2000 pg for lung dysfunction)
than for the control group (20 to 200 pg for airway
inflammation; >2000 pg for lung dysfunction). To enable
comparison of these threshold levels with airborne endotoxin
concentrations in stables, horses also received a 5 h duration
hay/straw challenge, during which the total and respirable
airborne endotoxin concentrations were determined.
Comparison of the effects of acute LPS inhalation and
hay/straw challenges suggest that inhaled endotoxin is not
the sole cause of heaves. However, it is likely that it
contributes to airway inflammation, botb in heaves horses in
concert with other inhalants, and in normal horses when
they are exposed to high levels in poor stable environments.
Introduction
Inhaled endotoxins are an important cause of human pulmonary
disease (Jacobs 1997a), with the severity of pulmonary
inflammation and clinical symptoms experienced by subjects
exposed to organic dusts being related to the endotoxin
concentration of the inhaled dust (Rylander and Bergstrom 1993;
Smid et al. 1994; Zejda et al. 1994; Schwartz et al. 1995;
Vogelzang et al. 1998). Additionally, the severity of human
asthma has been related to the level of endotoxin exposure
(Michel et at. 1991, 1996; Rizzo et al. 1997), suggesting that
inhaled endotoxin may potentiate the inflammatory response to
allergens in atopic subjects. In man. considerable efforts have
been made to establish no-response threshold levels for inhaled
endotoxin (Michel et al. 1997) and to identify safety guidelines
for occupational endotoxin exposure (Rylander 1997). Since
horse stables contain high concentrations of airborne endotoxin
(Olenchock et al. 1992; Dutkiewicz et al. 1994; McGorum et al.
1998; Tanner et al. 1998) and, given the similarities between
heaves and inhaled endotoxin mediated lung disease in other
species (McGorum et al. 1998), it is surprising that the role of
ondotoxin in heaves is unknown. The aims of the present study
wore (a) to investigate the rosponse of control and heaves horses
to increasing doses of inhaled LPS, (b) to determine no-response
threshold levels for both control and heaves horses and (c) to
compare no rosponse threshold levels of inhaled soluble LPS
with endotoxin levels encountered in equine stables.
Materials and methods
Horses
Six healthy control horses with no detectable respiratory tract
disorders (all female, median age 6 years, range 4—9 years;
median 320 kg bwt, range 316-356 kg bwt) and 7 horses
(3 geldings, 4 mares; age 17 years, range 8-28 years; 434 kg
bwt, 323-594 kg bwt) with a history and clinical diagnosis of
heaves were used. The disease status of all subjects was
confirmed by hay/straw challenge (vide infra). This challenge
induced BALF neutrophilia (>20%), increased volume of
tracheal secretions and a reduction in PaOz in all heaves horses
and, in some heaves horses, induced coughing, nasal discharge,
hyperpnoea, double expiratory lift, increased isovolumetric and
expiratory lung resistance and decreased dynamic compliance
(Cdyn). All of the above clinical and laboratory abnormalities
reverted to normal when the heaves horses were moved to a low
dust environment (i.e. a well-ventilated stable with wood
shavings bedding and haylage feeding, or at pasture). Hay/straw
challenge did not induce detectable pulmonary inflammation and
dysfunction, or detectable tracheal secretions, in control horses.
Throughout the study all horses were kept in a low dust
environment. The study was approved by the Home Office, and
conducted under a Home Office project licence.
Challenge protocol
All horses received an initial control inhalation challenge with
sterile isotonic saline (Vetivex 0.9%)', followed by 3 separate
increasing doses (20, 200 and 2000 pg) of purified Salmonella
typhimurium Ra60 LPS, followed by a hay/straw challenge.
Although randomisation of the inhalation challenges was
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TABLE 1: Baseline BALF total cell counts (x 105), neutrophil ratios (%) and absolute neutrophil counts (x 105) (median and
range) obtained at t>-7days before LPS (20, 200 and 2000 pg) inhalation challenges and hay/straw exposure
Total BALF cell count (x 105/ml) BALF neutrophil ratio (%) BALF neutrophil count (x 105/ml)
Challenge Fleaves Controls Heaves Controls Heaves Controls
20 pg LPS 4.4 (2.9-9.1) 3.3(2.4-4.6) 2.3(0.7-4.1) 1.0(0.5-1.6) 0.09(0.04-0.25) 0.03(0.01-0.06)
200 pg LPS 5.0(1.5-7.2) 5.4 (3.7-7.0) 2.3(1.8-3.6) 1.1(0.6-2.5) 0.11 (0.03-0.15) 0.06(0.02-0.18)
2000 pg LPS 4.4 (1.8—9.7) 4.1 (2.4—7.3) 1.9(0.7-3.2) 1.5(0.6-2.9) 0.08(0.04-0.18) 0.07(0.03-0.08)
Hay/straw 4.2(2.4-9.1) 2.1 (1.0—2.4) 1.5(0.4-5.5) 0.9(0.7-1.9) 0.06(0.03-0.13) 0.02(0.01-0.03)
TABLE 2: Clinical scoring system
Clinical variable Response Score
Cough Present 0
Absent 1






Respiratory rate <20 breaths/min 0
20-30 breaths/min 1
>30 breaths/min 2
Thoracic auscultation Normal 0
Increased normal 1
Adventitious sounds 2
Marked adventitious noise 3
Pulse rate <50 beats/min 0
50-70 beats/min 1
>70 beats/min 2
Rectal temperature Normal 0
Elevated (>39.5°C) 1
Total score 13
considered, this order was chosen for safety reasons due to the
unknown effects of LPS inhalation in the horse. Several
procedures were performed to minimise potential carry-over
effects of a preceding challenge on subsequent challenges.
Firstly, inhalation challenges were conducted a minimum of 14
days apart and, secondly, all horses were shown to have normal
BALF cytology at least 7 days prior to challenges (Table 1) and
normal clinical findings and lung function immediately prior to
each inhalation challenge. In addition, 6 heaves and 4 control
horses received a repeat inhalation challenge of 200 pg LPS
following completion of the other challenges, both to assess
potential carry-over effects and to determine the repeatability of
LPS inhalation challenge.
LPS was diluted from a stock solution (8.89 mg/ml) in sterile
isotonic saline1 immediately prior to nebulisation. To facilitate
uebulisalion, horses were sedated with 20 pg/kg bwl lumifidine
(Sedivet)2 and 10 pg/kg bwt butorphanol (Torbugesic)3, i.v. The
aerosol was generated using a compressor (Parimaster)4 with a
calibrated output of 7 1/min, connected to a nebuliser cup
(Sidestream)5, the manufacturers of which state that 80% of
aerosol is in the respirable range (<5 pm). The nebuliser cup
contained 2 ml of challenge solution. The aerosol passed via a 'T
piece' system into an airtight facemask, with inspiratory and
expiratory valves to minimise aerosol loss. One ml solution was
delivered to the facemask for each challenge.
For the hay/straw challenge, horses were housed for 5 h in a
poorly ventilated stable (3.7 x 3.7 m) with the bottom and top
doors and all air vents closed, fed a mixture of good quality hay
and hay with visible mould growth, and bedded on deep litter
straw. This environment has previously been shown to induce
airway inflammation, clinical signs and lung dysfunction in
heaves horses (McGorum etal. 1993). During this challenge, time
zero (tO) represented the time when the horse entered the stable. To
quantify endotoxin exposure during the hay/straw challenge, total
and respirable stable dusts were collected using personal samplers
(AFC 124 High Flow Personal Sampler)6 from the breathing zones
of all horses. Samples were collected and prepared for analysis as
described previously (McGorum et al. 1998), except that samples
were not filtered after elution of endotoxin from the filter
membrane. The endotoxin content of the filter eluent was
determined using an endotoxin-specific assay (Endospecy)7 as
described by Thorn (1999). Ten pi of appropriately diluted filter
eluent was placed in a microwell plate, 100 pi specific endotoxin
lysate was added, the mixture incubated at 37°C for 30 min and the
reaction stopped by the addition of 200 pi 0.6 mol/1 acetic acid. The
absorbance of the resulting colour reaction was read
photometrically at 405 nm, and compared to a standard curve. All
samples were analysed in duplicate and the mean value
calculated. Analysis was repeated if (a) the paired values differed
from their mean by >10% of the mean, (b) either of the paired
values exceeded the value of undiluted standard solution, or (c)
either of the paired values were less than the value obtained from
a 1:8 dilution of the standard solution.
Assessment of response to challenges
The response to challenges was assessed as indicated in Figure 1,
including use of a clinical scoring system (Table 2). Lung
mechanics were determined as previously described (McGorum
and Dixon 1992), except that raw data were recorded using data
acquisition software (Labview)8. The following lung mechanics
indices were calculated: Cdyn; maximum transpulmonary
pressure change (dPplmax); isovolumetric lung resistance (RLis0);
inspiratory and expiratory lung resistance at 25, 50 and 75% tidal
volume (RL[25%, RL[50%> RLI75%, RLE25%, RLE50% and
RLE75%, respectively); and total, resistive and elastic work of
breathing (Wbt, Wbres and Wbel, respectively). Airway reactivity
was evaluated by inhalation of saline followed by doubling
concentrations of methacholine chloride9 solution (beginning
with 0.4 mg/ml) for 60 s, with 2 min of data recording following
each inhalation. The provocative concentration of methacholine
(PCCdyn70) was the inhaled concentration (mg/ml) that reduced
Cdyn to 70% of the value recorded following saline inhalation.
All horses were sedated for airway reactivity assessment to
ensure subject safety and compliance. Arterial blood samples
were collected as previously described (Dixon et al. 1995) and
analysed using a blood gas analyser (AVL Opti CCA)10. Venous
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t-7 days t-30 min t+90 min t+4 h t+5h t +6 h t+24 h
Fig 1: Study design. For the 5 h hay/straw challenges, the horses entered the stable at t = 0. BAL = bronchoalveolar lavage.
blood was collected by jugular venipuncture for total leucocyte
and neutrophil counts. BALF was collected transendoscopically
as previously described (Dixon et al. 1995), but without local
anaesthesia of the tracheal carina, and analysed as previously
described (McGorum and Dixon 1992), except differential cell
counts included 1000 cells. The t-7 days and 6 h BALF samples
were both collected from the right accessory lobe, and the 24 h
BALF samples collected from the left ventral segment. Both
sampled lung segments were cranioventral, thereby maximising
the chance of them receiving an aerosol challenge of
similar magnitude. Prior to BALF collection, the volume of
tracheal secretions was graded 0-5 as previously described
(Dixon et al. 1995).
Statistical analyses
The effects of each challenge were determined mostly by
performing within-group analyses. Where prechallenge
measurements were made at t-30 min (arterial blood gas analyses,
peripheral blood leucocyte and neutrophil counts, and lung
mechanics) the postchallenge values were expressed as % of
baseline value, except for clinical scores where actual values were
used. The effect of LPS challenge was assessed, by pairing and
subtracting post-LPS and postsaline data. Where no prechallenge
data was collected, comparisons were made with saline challenge
data. A Friedman test was performed on sets of paired data and,
when significant, a Wilcoxon Rank Sum test was performed on
paired data. Between-group analyses were performed for BALF
neutrophil numbers, using the Mann Whitney test. Significance
was assumed if P<0.05. The 2 separate 200 pg LPS inhalation
challenges were compared using a Wilcoxon Rank Sum test and,
as an indication of repeatability, the differences in paired values
were plotted against their mean as described by Bland and Altman
(1986). Good repeatability was assumed if the calculated
differences in paired values fell within 2 s.d. of the mean of the
differences (Anon 1979). Results are expressed as median and
range. Following correction for any effect of saline inhalation,
changes from baseline are expressed as increase/decrease in
median values, with 95% confidence interval for the difference in
median, calculated for nonparametric data as described by
Campbell and Gardner (1994).
Results
Clinical scores
When compared with baseline values, no significant increase in
clinical scores was detected in either group following any of
the challenges.
Lung mechanics and airway reactivity
LPS inhalation challenges had no significant effect on lung
function of controls. The heaves group had increased RLE5o%
(increase in median 106%, 95% confidence interval (CI)
18-2017; P<0.05) and RLE75% (increase 116%, 34-595;
P<0.05) at 5 h following inhalation of 2000 pg when
compared with baseline values. None of the challenges altered
airway reactivity in either group when compared with saline
inhalation challongo. There was no significant difference in
airway reactivity between the first (median 6.9 mg/ml, range
1.5-19.4) and second (5.2 mg/ml, 2.8-17.1) 200 pg LPS
inhalation challenges. There was good agreement of
PCCdyn70 between the 2 challenges, since all the calculated
differences in paired values fell within 2 s.d. of the mean of
the differences.
Arterial blood analyses
LPS challenges did not significantly alter arterial pH, Pao2 or
Pacc>2 when compared with baseline values in either group. In
the heaves group, hay/straw challenge reduced Pao2 at 90 min
(decrease 6%, 1-17; P<0.05), and increased arterial pH at 4 h
(increase 0.2%, 0.1-0.6; P<0.05). PaC02 was reduced in the
control group at 24 h following hay/straw challenge (decrease
9%, 3-15; P<0.05).
Peripheral blood leucocytes and neutrophils
Inhalation of 2000 pg LPS significantly reduced peripheral
blood total leucocyte counts at 4 h when compared with baseline
in both groups (heaves: reduction 14%, 5-24; P<0.05; controls:
23%, 12-36; P<0.05). Control horses also had a significant, but
minor, reduction in peripheral blood total leucocyte counts at
90 min following inhalation of 200 pg LPS (8%, 0-17: P<0.05).
Compared with baseline values, hay/straw challenge
significantly increased peripheral blood total leucocyte counts in
the controls at 90 min (increase 13%, 1-24; P<0.05). A marked
and significant increase in peripheral blood neutrophil counts
was also noted in the heaves group at 24 h following hay/straw
challenge (increase 34%, 13-75; P<0.05).
BALF cytology
Prechallenge BALF cytology is shown in Table 1. Saline
inhalation did not alter BALF cytology in either group. The
BALF neutrophil counts and ratios at 6 and 24 h after each
challenge are summarised in Table 3. LPS induced a dose-
dependent BALF neutrophilia in both groups (Fig 2). In the
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TABLE 3: Absolute BALF neutrophil counts and BALF neutrophil ratios (median and range) at 6 and 24 h after saline and LPS
(20, 200 and 2000 pg) inhalation challenges and hay/straw exposure in heaves group (n = 7) and control group (n = 6)
BALF neutrophil count (x 105/ml) BALF neutrophil ratio (%)
Heaves Controls Heaves Controls
6 h 24 h 6 h 24 h 6 h 24 h 6 h 24 h
Saline 0.06 0.08 0.06 0.04 2.3 1.7 1.3 1.7
(0.03-0.20) (0.04-0.16) (0.01-0.17) (0.02-0.60) (0.6-4.5) (1.1-11.5) (0.2-3.2) (0.6-17.7)
20 pg LPS 0.28a,b 0.20a,b 0.09b 0.03b 6.1a,c 4.7b 1.7° 1,8b
(0.18-0.53) (0.13-1.04) (0.01-0.17) (0.02-0.18) (5.6-7.2) (2.4-23.6) (0.3-6.2) (0.6-2.6)
200 pg LPS 1.45a 0.77a 0.57a 0.39 23.2a 13.7a 13.9a 12.3
(0.42-2.22) (0.26-1.26) (0.08-2.59) (0.27-3.43) (10.5-41.8) (6.1-21.9) (3.1-28.4) (5.7-41.3)
2000 pg LPS 3.25a 1.28a 1.44a 1.69a 34.2a 33.4a 36.7a 37.9a
(0.57-4.34) (0.76-6.24) (0.52-2.70) (1.12-2.70) (28.4-65.8) (17.8-39.6) (10.9-64.2) (19.0-51.0)
Hay/straw 2.05a,b 0.67a,b 0.17b 0.09b 36.0a'b 17.6a,b 7.0a,b 4.3
(0.74-9.83) (0.27-1.41) (0.01-0.40) (0.06-0.22) (21.0-60.7) (5.4-31.5) (0.3-11.2) (1.9-7.4)
a
= Significantly different from postsaline challenge (P<0.05); b = Significantly different from other group at same time point following
same challenge (P<0.01); c = Significantly different from other group at same time point following same challenge (P<0.05).
heaves group, when compared with saline inhalation, absolute
BALF neutrophil count was significantly increased (P<0.05)
at both 6 and 24 h after 20, 200 and 2000 pg LPS inhalation.
These significant increases were also seen in the BALF
neutrophil ratio, with the exception of the 24 h values
following 20 pg LPS inhalation. In controls, BALF neutrophil
count and ratio was significantly increased (P<0.05) at 6 h
after inhalation of 200 and 2000 pg LPS, and at 24 h after
inhalation of 2000 pg LPS. BALF neutrophil count and ratio
was significantly increased (P<0.05) in the heaves group at
6 and 24 h after hay/straw challenge (Fig 2). No increase in
BALF neutrophil count was seen in the control group at 6 or
24 h after hay/straw challenge; however, a slight, yet
significant (P<0.05) increase in BALF neutrophil ratio was
noted in this group at 6 h. Absolute BALF neutrophil count
was significantly greater (P<0.01) at both 6 and 24 h in the
heaves group compared with the control group, following
inhalation of 20 pg LPS and after hay/straw challenge (Fig 2).
In addition, the heaves group also had a significantly greater
BALF neutrophil ratio following 20 pg LPS inhalation
(P<0.05 at 6 h, P<0.01 at 24 h) and hay/straw challenge
(P<0.01). There was no significant difference in BALF
neutrophil counts between the first (1.3 x 105/ml, 0.3-2.2) and
the second (0.9 x 105/ml, 0.6-1.5) 200 pg LPS inhalation
challenges. Nine of the 10 calculated differences in paired
values fell within 2 s.d. of the mean of the differences. As the
data point falling out with this range was a clear outlier (out
with the lower limit defined as: first quartile minus 1.5 x [third
quartile minus first quartile]), repeatability was considered
good (Bland and Altman 1986).
Due to the influence of a BALF neutrophilia on the ratio of
other BALF cell types, they were considered only as absolute
numbers. Reduced absolute BALF macrophage (1.98 x 105/ml,
0.73-2.80 to 0.91 x 105/ml, 0.17-1.76; P<0.05) and mast cell
(0.25 x 105/ml, 0.06-0.39 to 0.08 x 105/ml, 0.01-0.23; P<0.05)
numbers followed 2000 pg LPS inhalation only in controls, with
heaves horses showing a similar but nonsignificant reduction.
None of the challenges induced significant changes in BALF
total cell count, or absolute lymphocyte, epithelial cell,
basophiloid or eosinophil counts. There was no difference
between the 6 and 24 h BALF total or absolute cell counts
following all challenges, although there was a trend towards a
reduction in all cell types at 24 h.
Tracheal secretions
Compared with saline challenge, LPS challenges did not
significantly increase tracheal secretion scores at 6 h in either
group; however, 2 horses in the heaves group had increased
scores following inhalation of 200 and 2000 pg LPS. The heaves
group had significantly (P<0.05) increased tracheal secretion
scores after hay/straw challenge (median score 2, range 1-3),
when compared with saline (score 0, 0-0).
Dust and endotoxin measurements in hay/straw stable
Total and respirable airborne dust endotoxin concentrations and
dust endotoxin content in the hay/straw challenge stable are
given in Table 4. The biologically active endotoxin dose
received during the 5 h challenge was calculated using the
formula: airborne endotoxin concentration (ng/m3) x
ventilation rate of 3.1 m3/h x duration of challenge (h) x 3
(correction for approximate 3-fold underestimation of
biologically active endotoxin content in dust by the limulus
method [Rylander et al. 1989]).
Discussion
The systemic and pulmonary effects of inhalation with soluble
LPS in control and asymptomatic heaves horses are reported
here for the first time. Consistent with endotoxin inhalation
studies in man and other species (Gordon 1992; Schwartz et al.
1994; Urbain et al. 1996; Michel et al. 1997), inhalation of 20,
200 and 2000 pg soluble Salmonella typhimurium Ra60 LPS
induced a dose-dependent airway neutrophilia, with BALF
neutrophil numbers increasing approximately 50-fold in heaves
horses at 6 h after the high dose challenge. After inhalation of
2000 pg LPS, absolute BALF macrophage and mast cell
numbers were significantly reduced in controls and
nonsignificantly reduced in the heaves group. A reduction in
BALF macrophage numbers occurs following LPS inhalation in
other species, possibly due to LPS-induced macrophage
apoptosis (Michel et al. 1997), or to migration of macrophages
from the lung following antigenic stimulation or phagocytosis
and clearance of apoptotic neutrophils (Brazil 2000).
Peripheral blood total leucocyte counts were reduced at 4 h
following inhalation of 2000 pg LPS in both groups, consistent
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Fig 2: Absolute BALF neutrophil count (x 10^/ml) in heaves (n = 7) and control (n = 6) horses at 6 h following inhalation challenge (saline, 20, 200
and 2000 pg LPS) and hay/straw challenge. Closed circle = heaves group; open circle = control group; hyphen = median values.
with a combined systemic and pulmonary response. This
reduction probably reflects margination and pulmonary
recruitment of leucocytes, as occurs following LPS inhalation in
guinea pigs (Fogelmark et al. 1992).
LPS inhalation challenges had no significant effect on
clinical score in either group. This is not surprising, since many
of the clinical symptoms reported by human subjects following
LPS inhalation, including chest tightness, headaches, joint pains
and tiredness (Rylander et al. 1989, 1999), are subjective and,
therefore, difficult to detect in horses. LPS inhalation had no
significant effect on arterial blood gases and only the high dose
(2000 pg) induced a significant deterioration in lung mechanics
in the heaves group. Interestingly, the study by Michel et al
(1992b) showed that, although the circulating leucocyte
response to inhaled endotoxin was similar in healthy and
asthmatic human subjects, only the asthmatic group had
significant lung dysfunction. Similarly, in healthy human
subjects, only moderate and inconsistent, combined restrictive
and obstructive, lung dysfunction occurs following inhalation of
high doses (>80-200 pg) of LPS (Cavagna et al. 1969; Rylander
et al. 1989; Michel et al. 1995b; Michel 1997). While the
increased RLg5Q% and noted in the heaves group are
consistent with an obstructive component, the relative
insensitivity of pulmonary mechanics testing in the horse may
have prevented the detection of mild restrictive dysfunction. As
in man, where inhaled LPS induces more pronounced lung
dysfunction in atopics and asthmatics (Michel et al. 1989;
Rylander 1996), the control horses in the present study had no
significant lung dysfunction, even after inhalation of 2000 pg
LPS. Since the effects of endotoxin are inflammatory in nature
and not IgE-mediated (Michel 1997), the exaggerated lung
dysfunction in the heaves group may reflect a degree of
undetected pre existing airway inflammation, despite their being
maintained in a low dust environment for several weeks prior to
the challenges. No alteration in airway reactivity was detected in
either group, in contrast to the increased airway reactivity noted
at 6 h after endotoxin inhalation in asthmatics (Michel ct al.
1989, 1992a). Failure to detect increased airway reactivity may
be due to insufficient LPS, or to attenuation of the methacholine-
induced bronchconstriction by the bronchodilatory effects of the
a2-agonist drug (Broadstone et al. 1992) used to sedate horses
for this procedure.
LPS challenges did not significantly increase the tracheal
secretion score in either group, although 2 heaves horses had
increased scores after inhalation of 200 and 2000 pg LPS. In
other species, inhaled endotoxin induces (Gordon and Harkema
1994; Gordon et al. 1996), or is correlated with, airway mucus
hypersecretion (Rylander et al. 1999).
The role of inhaled endotoxin in human occupational
respiratory diseases is well documented (Douwes and Heederik
1997; Jacobs 1997a) and the necessity for dose-response
experiments as a prerequisite for the establishment of a no-
response safety threshold has been recognised (Michel et al.
1997). For the first time, comparisons can be made between the
levels of airborne endotoxin detected in equine environments and
the minimal threshold doses of inhaled LPS required for
induction of lung inflammation and dysfunction in the horse. The
response threshold of LPS for inducing airway inflammation was
lower in the heaves (< 20 pg) than control (20-200 pg) group, and
the magnitude of BALF neutrophilia was, albeit insignificantly,
more marked in heaves horses than controls. The response
thresholds for lung dysfunction in the heaves (200-2000 pg LPS)
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TABLE 4: Airborne respirable and total dust and endotoxin concentrations during hay/straw challenges (median and range)
Total dust Respirable dust
Airborne dust concentration (mg/m3) 2.83 0.5
(0.83-6.83) (0.17-0.83)
Endotoxin content of dust (ng/mg) 56.00 11.86
(31.40-163.92) (4.53-98.22)
Airborne endotoxin concentration (ng/m3) 160.00 3.95
(86.88-580.56) (1.75-61.39)
5 h endotoxin exposure3 (pg) . 2.48 0.06
(1.35-9.00) (0.03-0.95)
5 h biologically active endotoxin exposure15 (pg) 7.44 0.18
(4.04-27.00) (0.08-2.85)
3
= airborne endotoxin concentration (ng/m3) x average hourly ventilation of 13 ponies immediately following hay/straw challenge (m3/h)
x duration of challenge (h);
• average hourly ventilation of 13 ponies immediately following hay/straw challenge = 3.1 m3.
• duration of challenge = 5 h.
b
= a x correction factor of 3 (Rylander et al. 1989) for underestimation of biologically active endotoxin in dust samples using limulus
amoebocyte lysate assay.
and control (>2000 pg LPS) groups were higher than the
response thresholds for inflammation. Consistent with this
finding, markers of inflammation were more sensitive indices of
the effects of inhaled endotoxin than lung dysfunction in other
species (Gordon 1992; Michel etal. 1997).
In this study, the 5 h duration hay/straw challenge exposed
horses to a biologically active respirable dust endotoxin dose of
0.18 (0.08-2.85) pg and a biologically active total dust
endotoxin dose of 7.44 (4.04-27.00) pg. These doses are
generally lower than the thresholds for lung inflammation and
dysfunction in both groups. Similarly, while the role of
endotoxin in occupational organic dust-induced lung disease is
well recognised in man, the threshold dose of soluble LPS in
inhalation studies which causes clinical symptoms (Michel et al.
1989, 1995a) greatly exceeds the level of endotoxin exposure
present in organic dust under certain occupational settings,
which also result in clinical symptoms (Larsson et al. 1994).
This apparent discrepancy may be explained by several factors
that limit direct comparison of the threshold doses for inhaled
endotoxin in acute experimental LPS inhalation challenges and
in natural organic dust exposure. Firstly, other agents present in
stable dust, such as moulds and glucans, may potentiate the
response to endotoxin (Fogelmark et al. 1994; Flunt et al. 1994),
thereby exacerbating the response in the hay/straw challenge.
Since pre-exposure of human asthmatics to allergen potentiates
their response to LPS (Martin et al. 1992), concomitant mould
allergen exposure could increase LPS responsiveness to a greater
extent in heaves horses than in controls. Secondly, the
biologically active endotoxin content of the stable dust may have
been underestimated by the limulus method used in this study,
since this method detects mainly soluble endotoxin and
underestimates the biologically active particulate endotoxin
(Rylander et al. 1989). While the recommended correction
factor of 3 (Rylander et al. 1989) was applied when calculating
the biologically active endotoxin content of stable dust, this
correction factor may be incorrect given the probable variation
in the proportions of soluble and particulate endotoxin in dusts
from different sources. Thirdly, short duration challenges, as
used for soluble LPS inhalation in this study, may produce less
effect than longer duration exposure. Fourthly, the acute LPS
and hay/straw challenges probably differed with respect to the
efficacy of delivery and deposition of aerosol and dust particles,
the anatomical site in which they were deposited and the
mechanisms and rate by which they were cleared. While
approximately 7% of the LPS aerosol generated by the jet
nebuliser may have been deposited in the lung during the LPS
inhalation (Votion et al. 1997), the proportion of respirable and
total airborne stable dust reaching the lungs during the hay/straw
challenge could not be determined. Finally, it is unclear whether
the endotoxin concentration in respirable or total airborne stable
dust should be considered when making a comparison with the
threshold dose of soluble LPS. While the majority of endotoxin
in respirable stable dust probably reached the lower airways in
the hay/straw challenge, as endotoxin in the nonrespirable
fraction may cause inflammation and dysfunction of the larger
airways (Jacobs 1997b), it may also have contributed to the
response to hay/straw challenge.
Despite the aforementioned problems in comparing
endotoxin levels in the hay/straw challenge and the threshold
dose for soluble LPS inhalations, several observations suggest
that inhaled endotoxin was not the sole cause of lung
inflammation and dysfunction in the heaves group following
hay/straw challenge. Firstly, the dose of endotoxin encountered
in the hay/straw challenge was markedly lower than the
threshold dose of soluble LPS (200-2000 pg) required to induce
a similar degree of BALF neutrophilia. Secondly, the hay/straw
challenge did not induce BALF neutrophilia in controls, while
inhalation of > 200 pg LPS induced BALF neutrophilia in both
groups. Thirdly, in contrast to LPS inhalation, hay/straw
challenge significantly increased tracheal mucus score in the
heaves group. Therefore, it is probable that other pro¬
inflammatory agents in stable dust (e.g. moulds) contribute to
the aetiopathogenesis of heaves. However, it is likely that
endotoxin per se causes airway inflammation in horses housed
in stables with very poor air hygiene, since respirable endotoxin
concentrations may be as high as 3437 ng/m3 (Dutkiewicz et al.
1994). A 5 h exposure to this concentration equates to a dose
(160 pg) which exceeds the threshold dose of LPS which causes
inflammation in horses with asymptomatic heaves (20 pg), and
may exceed that which causes inflammation in control horses
(between 20 and 200 pg).
In this study, as in human studies (Michel et al. 1997), all
horses were given LPS in increasing rather than randomised
doses. This order was selected because of safety reasons, given
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the absence of data on the effects of acute LPS inhalation in
horses, and given the potential for significant individual-
dependent variability in LPS responsiveness (Michel 1997;
Kline et al. 1999). It could be argued that randomisation of
challenge order may have minimised potential carry-over
effects from prior challenges. Carry-over effects could include
potentiation due to persistence of inflammation, early-phase
tolerance and late-phase (occurring after several weeks)
tolerance due to production of anti-endotoxin antibodies
(Johnston and Greisman 1985; Ulmer 1997). However, the good
repeatibility of inflammatory (BALF neutrophilia) and
functional (PCCDyn70) changes following repeated 200 pg
LPS challenge, suggests that carry-over effects were
insignificant. Further, since early-phase tolerance to inhaled
endotoxin lasts no more than 2 days (Johnston and Greisman
1985), it was unlikely to have influenced the response to
subsequent challenges that were separated by at least 2 weeks.
There are 2 main advantages in using LPS from the
Salmonella R60 mutant in the current study. Firstly, the LPS is
of Ra chemotype (i.e. complete core oligosaccharide plus lipid
A). It is of homogeneous molecular mass, in comparison to
smooth-form LPS which has extremely heterogeneous chain
lengths due to the O-polysaccharide, and thus heterogeneous
biological activity. It should, therefore, give reproducible
results in experimental challenge studies. Secondly, it
represents a structure shared by many of the
Enterobacteriaceae, including all Escherichia coli and
Salmonella species, and this common structure is responsible
for a major part of the biological activity of LPS (I. R. Poxton,
personal communication). It is probable that this structure is
present in large concentrations in a deep litter management
system, as was used for the hay/straw challenges.
In conclusion, inhaled endotoxin induced neutrophilic
airway inflammation and dysfunction in horses. While this study
suggests that inhaled endotoxin is not the sole cause of heaves,
we hypothesise that it contributes to its aetiopathogenesis.
Furthermore, it is likely to result in lung inflammation in normal
horses when housed in environments with high airborne
endotoxin concentrations. The dose-response data described is a
prerequisite to the development of acceptable endotoxin
exposure levels for horse accommodation. Healthy or heaves-
affected horses housed in stables with poor air hygiene may be
exposed to airborne endotoxin levels exceeding the threshold
dose levels that induce airway inflammation. These potentially
detrimental effects of inhaled endotoxin may be minimised by
optimising air hygiene in stables.
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Erratum
The following table, which appeared in the article Relationships ofage and shape of the navicular bone to the development
of navicular disease: a radiological study by K. J. Dik, A. J. M. van den Belt and J. van den Broek, was misprinted in
Equine Veterinary Journal Volume 33, Number 3 (March 2001), for which we apologise. The correct version of Table 5
appears below.
TABLE 5: Association navicular bone shape - character of simple grades 3 and 4 features in clinically affected horses
Inverted flask-shaped channels Enthesophytes Cystic lesions
Aae (vearsl Aae (vearst Aae (vears)
Shape No. No. 3-4 5-9 10-14 15-19 No. 3-4 5-9 10-14 15-19 No. 3-4 5-9 10-14 15-19
1 27 14 0 8 4 2 11 0 2 8 1 2 0 0 2 0
(52%) (41%) (7%)
2 42 23 2 12 7 2 16 2 3 10 1 3 0 2 1 0
(55%) (38%) (7%)
3 16 4 0 0 3 1 9 0 2 6 1 3 0 2 1 0
(25%) (56%) (19%)
4 4 1 0 0 1 0 2 0 0 2 0 10 0 10
(25%) (50%) (25%)
Total 42 2 20 15 5 38 2 7 26 3 9 0 4 5 0
(5%) (49%) (35%) (11%) (5%) (19%) (68%) (8%) (0%) (44%) 56%) (0%)
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Appendix 2.1: Pressure (mmH20) within the oesophageal balloon
plotted against volume (ml) within the oesophageal balloon,
indicating the range of high compliance of the balloon (between
arrows).
305
Appendix 2.2: Flow (l/min) plotted against voltage indicating linearity of flow
readings over working range.
306
Appendix 2.3: Pressure (mm H20) plotted against voltage indicating linearity of
pressure readings overworking range.
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Appendix 2.4a: Example of phase matching of sinusoidal pressure traces at 8Hz. One pressure trace reflects the
pressure at one side of the pneumotachograph and the other pressure trace reflects pressure within the balloon
catheter. Pressure waves through the catheter attached to the pneumotachograph were delayed by reduction of the
diameter of the catheter until the plot of the sinusoidal pressure traces against each other resulted in a straight line
(arrow). The same procedure was repeated for phase matching of the pressure waves within the balloon catheter with
those from the opposite side of the pneumotachograph (Appendix 2.4b).
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Appendix 2.5: Clinical scores in control (C1-6) and heaves (H1-7) horses prior to (0) and at 90, 240 and 1440min following inhalation challenge with saline, 20, 200
and 2000pg LPS, and 5h hay straw challenge (H/S). Score based on: a (tracheal auscultation), b (thoracic auscultation), c (rectal temperature), d (dyspnoea) and e
(respiratory rate).
SALINE 20pg LPS 200pg LPS 2000.ug LPS H/S
TIME PT
(min) 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440
C1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
C5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
C6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 c 0 0 0 1 0
H1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
H2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
H3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
H4 0 0 0 0 0 0 0 0 0 0 0 0 0 1 b 1 b 1 b 0 1 d 0 0
H5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 a 0 1 d 2 d,e 0
H6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
H7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 d,e 1 a
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Appendix 2.6a: Arterial blood pH in control (C1-6) and heaves (H1-7) horses prior to (0) and at 90, 240 and 1440min following inhalation challenge with saline, 20,
200 and 2000pg LPS, and 5h hay straw challenge (H/S). MED. = median value, MIN. = minimum value, MAX. = maximum value.
SALINE 20ng LPS 200^ LPS 2000ng LPS H/S
TIME PT. 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440
C1 7.40 7.41 7.39 7.39 7.36 7.37 7.39 7.37 7.38 7.34 7.42 7.38 7.42 7.37 7.34 7.42 7.45 7.47 7.44 7.38
C2 7.36 7.42 7.35 7.37 7.35 7.35 7.35 7.33 7.40 7.38 7.42 7.37 7.41 7.38 7.39 7.36 7.34 7.38 7.37 7.33
C3 7.38 7.37 7.38 7.38 7.44 7.38 7.39 7.41 7.42 7.36 7.36 7.33 7.39 7.40 7.39 7.41 7.38 7.38 7.41 7.37
C4 7.40 7.39 7.42 7.43 7.34 7.35 7.40 7.42 7.44 7.39 7.40 7.38 7.45 7.38 7.39 7.39 7.45 7.48 7.43 7.43
C5 7.36 7.35 7.36 7.41 7.35 7.33 7.36 7.34 7.38 7.37 7.42 7.38 7.36 7.39 7.37 7.35 7.40 7.38 7.39 7.40
C6 7.39 7.39 7.39 7.38 7.39 7.37 7.36 7.38 7.42 7.41 7.39 7.39 7.38 7.39 7.41 7.36 7.42 7.42 7.42 7.40
MED. 7.39 7.39 7.39 7.39 7.36 7.36 7.37 7.38 7.41 7.38 7.41 7.38 7.40 7.38 7.39 7.38 7.41 7.40 7.42 7.39
MIN. 7.36 7.35 7.35 7.37 7.34 7.33 7.35 7.33 7.38 7.34 7.36 7.33 7.36 7.37 7.34 7.35 7.34 7.38 7.37 7.33
MAX. 7.40 7.42 7.42 7.43 7.44 7.36 7.40 7.42 7.44 7.41 7.42 7.39 7.45 7.40 7.41 7.42 7.45 7.48 7.44 7.43
H1 7.36 7.38 7.38 7.42 7.34 7.37 7.38 7.37 7.42 7.38 7.38 7.39 7.39 7.40 7.39 7.37 7.45 7.47 7.45 7.40
H2 7.35 7.36 7.36 7.32 7.37 7.38 7.36 7.36 7.35 7.34 7.36 7.38 7.38 7.38 7.34 7.40 7.41 7.43 7.42 7.35
H3 7.40 7.34 7.41 7.37 7.36 7.36 7.37 7.37 7.37 7.37 7.37 7.44 7.37 7.36 7.37 7.41 7.38 7.42 7.39 7.38
H4 7.39 7.34 7.35 7.36 7.39 7.33 7.35 7.35 7.35 7.36 7.36 7.33 7.35 7.37 7.38 7.41 7.38 7.42 7.39 7.40
H5 7.37 7.37 7.37 7.33 7.37 7.35 7.37 7.36 7.31 7.33 7.35 7.35 7.35 7.35 7.38 7.38 7.39 7.37 7.43 7.37
H6 7.42 7.38 7.36 7.39 7.34 7.35 7.36 7.39 7.42 7.39 7.40 7.34 7.36 7.37 7.40 7.36 7.40 7.47 7.46 7.39
H7 7.41 7.40 7.43 7.39 7.73 7.41 7.39 7.41 7.39 7.38 7.38 7.41 7.35 7.38 7.36 7.39 7.37 7.41 7.39 7.41
MED. 7.39 7.37 7.37 7.37 7.37 7.36 7.37 7.37 7.37 7.37 7.37 7.38 7.36 7.37 7.38 7.39 7.39 7.42 7.42 7.39
MIN. 7.35 7.34 7.35 7.32 7.34 7.33 7.35 7.35 7.31 7.33 7.35 7.33 7.35 7.35 7.34 7.36 7.37 7.37 7.39 7.35
MAX. 7.42 7.40 7.43 7.42 7.73 7.41 7.39 7.41 7.42 7.39 7.40 7.44 7.39 7.40 7.40 7.41 7.45 7.47 7.46 7.41
Appendix 2.6b: Arterial blood pC02 (mmHg) in control (C1-6) and heaves (H1-7) horses prior to (0) and at 90, 240 and 1440min following inhalation challenge with
SALINE 20pig LPS 200m LPS 2000MgLPS H/S
TIME PT. 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440.0
C1 46.0 46,0 49.0 45.0 44.0 45.0 44.0 44.0 48.0 48.0 43.0 44.0 44.4 46.9 49.2 47.9 40.0 42.0 42.0 39.0
C2 45.0 50.0 48.0 46.0 45.0 46.0 44.0 43.0 41.0 44.0 43.0 40.0 42.0 47.0 47.0 46.0 45.0 45.0 45.0 41.0
C3 46.5 50.1 46.6 47.5 52.1 53.5 52.3 51.9 46.1 53.3 52.2 53.1 50.8 50.3 53.9 48.3 59.8 59.8 53.3 51.0
C4 50.1 48.6 44.7 44.9 50.1 51.1 48.0 48.6 43.8 51.0 48.1 46.0 42.0 45.1 44.1 43.4 45.5 46.1 45.1 41.0
C5 41.0 40.0 39.0 38.0 40.0 45.0 42.0 47.0 45.5 47.6 44.1 49.1 50.6 49.5 49.1 41.6 45.0 40.0 41.0 39.0
C6 40.0 45.0 41.0 44.0 44.0 42.0 44.0 45.0 48.8 48.2 47.2 47.7 48.0 46.6 42.9 46.2 41.0 41.0 39.0 38.0
MED. 45.5 47.3 45.7 45.0 44.5 45.5 44.0 46.0 45.8 48.1 45.7 46.9 46.2 47.0 48.1 46.1 45.0 43.5 43.5 40.0
MIN. 40.0 40.0 39.0 38.0 40.0 42.0 42.0 43.0 41.0 44.0 43.0 40.0 42.0 45.1 42.9 41.6 40.0 40.0 39.0 38.0
MAX. 50.1 50.1 49.0 47.5 52.1 53.5 52.3 51.9 48.8 53.3 52.2 53.1 50.8 50.3 53.9 48.3 59.8 59.8 53.3 51.0
H1 45.0 40.0 40.0 40.0 41.0 39.0 39.0 42.0 39.0 42.0 39.0 36.0 37.0 43.0 40.0 36.0 35.0 32.0 36.0 32.0
H2 47.0 46.0 46.0 46.0 46.0 43.0 46.0 43.0 45.0 48.0 43.0 43.0 50.0 47.0 50.0 39.0 41.0 46.0 43.0 44.0
H3 42.0 46.0 37.0 40.0 45.0 44.0 42.0 41.0 42.0 43.0 43.0 41.0 44.0 43.0 47.0 42.0 42.0 39.0 40.0 39.0
H4 43.0 45.0 45.0 43.0 45.0 48.0 41.0 45.0 43.0 40.0 44.0 41.0 40.0 39.0 43.0 38.0 41.0 41.0 45.0 39.0
H5 53.0 44.0 43.0 45.0 47.0 47.0 46.0 47.0 39.0 38.0 43.0 45.0 43.0 46.0 46.0 44.0 47.0 48.0 40.0 42.0
H6 48.4 48.7 47.6 52.9 54.2 57.3 54.1 49.5 52.0 60.5 56.8 52.0 54.7 56.7 47.2 54.6 49.7 51.0 47.1 45.9
H7 46.0 43.0 45.0 43.0 44.0 40.0 41.0 46.0 42.0 46.0 45.0 41.0 41.0 47.0 40.0 35.0 47.0 43.0 44.0 40.0
MED. 46.0 45.0 45.0 43.0 45.0 44.0 42.0 45.0 42.0 43.0 43.0 41.0 43.0 46.0 46.0 39.0 42.0 43.0 43.0 40.0
MIN. 42.0 40.0 37.0 40.0 41.0 39.0 39.0 41.0 39.0 38.0 39.0 36.0 37.0 39.0 40.0 35.0 35.0 32.0 36.0 32.0
MAX. 53.0 48.7 47.6 52.9 54.2 57.3 54.1 49.5 52.0 60.5 56.8 52.0 54.7 56.7 50.0 54.6 49.7 51.0 47.1 45.9
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Appendix 2.6c: Arterial blood p02 (mmHg) in control (C1-6) and heaves (H1-7) horses prior to (0) and at 90, 240 and 1440min following inhalation challenge with
saline, 20, 200 and 2000|ig LPS, and 5h hay straw challenge (H/S). MED. = median value, MIN. = minimum value, MAX. = maximum value.
SALINE 20\ig LPS 200^ 3 LPS 2000|ig LPS H/S
TIME PT. 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440
C1 100.0 103.0 114.0 105.0 101.0 94.0 93.0 110.0 96.0 100.0 110.0 95.0 90.8 110.4 98.7 91.9 94.0 106.0 98.0 106.0
C2 103.0 100.0 115.0 104.0 91.0 97.0 94.0 94.0 92.0 93.0 86.0 100.0 109.0 111.0 101.0 102.0 88.0 81.0 86.0 88.0
(.3 106.5 97.5 104.6 100.7 94.6 103.3 110.9 93.8 93.0 105.5 113.8 123.0 108.3 115.9 109.9 97.2 82.9 96.0 107.7 119.6
C4 90.6 106.2 88.0 93.8 86.4 97.5 93.5 85.4 95.0 100.8 84.8 100.7 89.9 99.8 100.5 94.8 84.2 100.0 100.0 95.4
-•.5 105.0 99.0 110.0 99.0 98.0 93.0 115.0 93.0 128.0 99.8 104.1 104.2 101.0 109.3 111.0 110.1 105.0 95.0 96.0 106.0
C6 93.0 92.0 104.0 94.0 92.0 104.0 94.0 93.0 96.0 100.9 103.1 105.6 87.7 105.3 79.3 83.5 105.0 93.0 101.0 110.0
MED. 101.5 99.5 107.3 99.9 93.3 97.3 94.0 93. t 95.5 100.4 103.6 102.5 j75.9 109.9 < i/0.8 96.0 91.0 96.5 99.0 106.0
MIN. 90.6 92.0 88.0 93.8 86.4 93.0 93.0 85.4 92.0 93.0 84.8 95.0 87.7 99.8 79.3 83.5 82.9 81.0 86.0 88.0
MAX. 106.5 106.2 115.0 105.0 101.0 104.0 115.0 110.0 128.0 105.5 113.8 123.0 109.0 115.9 111.0 110.1 105.0 106.0 107.7 119.6
H1 99.0 99.0 98.0 107.0 99.0 101.0 106.0 104.0 102.0 102.0 106.0 114.0 94.0 96.0 92.0 92.0 114.0 106.0 107.0 111.0
H2 116.0 99.0 102.0 106.0 82.0 98.0 85.0 99.0 93.0 99.0 99.0 101.0 92.0 92.0 95.0 94.0 94.0 93.0 86.0 89.0
H3 94.0 98.0 98.0 98.0 110.0 108.0 100.0 95.0 101.0 92.0 102.0 107.0 98.0 113.0 93.0 89.0 98.0 97.0 90.0 98.0
H4 102.0 101.0 97.0 97.0 98.0 100.0 102.0 96.0 92.0 96.0 94.0 96.0 87.0 111.0 93.0 99.0 103.0 100.0 89.0 92.0
"5 94.U 93.0 83.0 114.0 95.0 99.0 88.0 102.0 89.0 100.0 93.0 98.0 93.0 93.0 100.0 96.0 105.0 85.0 106.0 103.0
M6 90.5 107.3 94.5 80.3 75.6 73.7 78.8 89.8 80.6 107.6 83.4 85.7 109.1 97.3 110.8 104.6 103.5 86.1 104.0 98.0
H7 100.0 109.0 109.0 111.0 94.0 103.0 117.0 102.0 123.0 106.0 115.0 114.0 99.0 104.0 105.0 129.0 97.0 94.0 94.0 107.0
MED. 99.0 99.0 98.0 106.0 95.0 100.0 100.0 99.0 93.0 100.0 99.0 101.0 94.0 97.3 95.0 96.0 103.0 94.0 94.0 98.0
MIN. 90.5 93.0 83.0 80.3 75.6 73.7 78.8 89.8 80.6 92.0 83.4 85.7 87.0 92.0 92.0 89.0 94.0 85.0 86.0 89.0
/AX. 116.0 109.0 109.0 114.0 110.0 108.0 117.0 104.0 123.0 107.6 115.0 114.0 109.1 113.0 , iC.8 129.0 114.0 106.0 107.0 111.0
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Appendix 2.7a (i and ii): Lung function measurements in control (C1-6) and heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with saline.
TP = time point, MED. = median value, MIN. = minimum value, MAX. = maximum value
Cdyn (i/kPa) dPpl(kPa) RLiso (kPa/l/sec) RR (breaths/min.) VT (i) Wb' (J/min) RLE25% (kPa/l/sec) Ri-E5o% (kPa/i/sec) RLe75% (kPa/l/sec) RLi25% (kPa/I/sec) RUo%(kPa/l/sec) RLi75% (kPa/l/sec)
TP Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h 0h 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h
C1 9.26 6.10 0.85 1.38 0.07 0.06 10.55 9.85 5.18 5.72 13.62 17.55 0.01 0.01 0.02 0.01 0.04 0.02 0.21 0.28 0.10 0.14 0.09 0.09
C2 28.68 13.50 0.58 0.72 0.03 0.06 10.05 10.70 6.42 6.27 11.55 16.39 0.01 0.05 0.01 0.01 0.03 0.03 0.06 0.09 0.05 0.09 0.05 0.08
C3 12.50 8.87 0.54 0.79 0.06 0.06 11.15 10.00 4.19 4.61 9.93 11.70 0.06 0.05 0.04 0.01 0.04 0.02 0.10 0.18 0.08 0.16 0.08 0.12
C4 6.72 8.29 1.02 1.06 0.11 0.19 11.60 9.65 3.12 3.89 16.14 19.76 0.12 0.16 0.10 0.14 0.09 0.16 0.20 0.28 0.19 0.22 0.17 0.19
C5 17.51 27.62 0.31 0.41 0.03 0.04 18.75 10.20 2.71 4.48 7.43 8.62 0.03 0.04 0.03 0.02 0.05 0.06 0.03 0.06 0.04 0.04 0.05 0.05
C6 10.32 6.72 0.80 1.07 0.11 0.14 9.00 8.75 4.44 4.40 13.97 14.83 0.09 0.08 0.08 0.02 0.09 0.07 0.15 0.33 0.16 0.25 0.13 0.17
MED. 11.41 8.58 0.69 0.93 0.06 0.06 10.85 9.93 4.31 4.54 12.59 15.61 0.05 0.05 0.04 0.02 0.04 0.05 0.13 0.23 0.09 0.15 0.09 0.11
MIN. 6.72 6.10 0.31 0.41 0.03 0.04 9.00 8.75 2.71 3.89 7.43 8.62 0.01 0.01 0.01 0.01 0.03 0.02 0.03 0.06 0.04 0.04 0.05 0.05
MAX. 28.68 27.62 1.02 1.38 0.11 0.19 18.75 10.70 6.42 6.27 16.14 19.76 0.12 0.16 0.10 0.14 0.09 0.16 0.21 0.33 0.19 0.25 0.17 0.19
H1 15.09 11.44 0.62 0.82 0.04 0.03 10.40 11.50 6.35 6.40 16.27 16.14 0.05 0.03 0.05 0.03 0.08 0.04 0.07 0.08 0.06 0.06 0.06 0.05
H2 21.95 23.02 0.67 0.75 0.07 0.07 8.80 8.50 6.28 7.71 19.71 22.90 0.04 0.06 0.06 0.06 0.07 0.07 0.08 0.06 0.08 0.06 0.08 0.07
H3 11.44 9.12 0.50 0.95 0.06 0.11 8.50 5.30 3.96 6.57 9.90 14.50 0.09 0.03 0.08 0.00 0.08 0.05 0.09 0.23 0.10 0.33 0.08 0.25
H4 32.99 31.80 0.53 0.49 0.06 0.05 7.10 6.40 7.72 8.74 15.70 13.38 0.07 0.03 0.06 0.04 0.08 0.05 0.08 0.06 0.06 0.06 0.07 0.06
H5 20.73 20.17 1.09 0.66 0.03 0.05 14.95 10.15 11.19 7.52 76.09 22.03 0.04 0.05 0.05 0.06 0.06 0.07 0.01 0.04 0.02 0.05 0.03 0.05
H6 22.73 13.17 0.31 0.80 0.03 0.05 14.20 6.90 2.85 5.71 4.37 10.18 0.04 0.05 0.11 0.08 0.15 0.06 0.03 0.18 0.03 0.19 0.03 0.14
H7 8.56 8.45 0.84 0.87 0.08 0.06 13.40 12.85 4.93 5.40 22.731 21.01 0.06 0.03 0.07 0.03 0.08 0.05 0.10 0.13 0.10 0.10 0.09 0.08
MED. 21.34 15.80 0.58 0.79 0.05 0.05 10.40 9.33 6.32 7.04 15.98 18.58 0.05 0.03 0.06 0.04 0.08 0.05 0.07 0.07 0.06 0.06 0.07 0.06
MIN. 11.44 8.45 0.31 0.49 0.03 0.03 7.10 5.30 2.85 5.40 4.37 13.38 0.04 0.03 0.05 0.00 0.06 0.04 0.01 0.04 0.02 0.05 0.03 0.05
MAX. 32.99 31.80 1.09 0.95 0.07 0.11 14.95 12.85 11.19 8.74 76.09 22.90 0.09 0.06 0.11 0.06 0.15 0.07 0.09 0.23 0.10 0.33 0.08 0.25
te(sec) Ti (sec) T,:Te V'e (l/min) V Emax (i/seC) V',max (l/sec) Wb a. (J) Wbr as (J) Wbgres («J) Wblres<J) Wb,
TP Oh 5h 0h 5h Oh 5h 0h 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h
C1 3.01 2.88 3.30 3.04 1.14 1.12 54.71 56.16 2.86 3.33 3.17 3.43 1.50 2.92 1.41 1.73 0.40 0.03 1.02 1.70 2.52 4.62
C2 3.30 3.45 2.67 2.60 0.82 | 0.76 64.53 66.64 3.29 2.95 3.49 3.47 0.78 1.47 1.13 1.65 0.33 0.41 0.80 1.23 1.58 2.71
C3 2.85 3.02 2.59 2.97 0.93 1.01 46.70 46.15 2.78 2.90 2.44 2.85 0.72 1.32 0.89 1.15 0.28 0.11 0.60 1.04 1.33 2.35
C4 2.44 3.24 2.33 2.95 2.29 0.92 36.56 37.65 2.12 2.07 2.50 2.26 0.79 0.95 1.26 2.05 0.35 0.77 0.92 1.28 1.71 2.23
C5 1.83 3.21 1.41 2.54 0.77 0.79 50.69 45.52 3.35 2.74 3.05 2.79 0.23 0.37 0.41 0.83 0.15 0.32 0.26 0.51 0.48 0.89
C6 3.50 3.17 3.42 3.43 1.02 2.59 40.07 38.38 2.84 2.26 2.37 2.11 1.03 1.45 1.61 1.77 0.61 0.43 1.00 1.34 2.03 2.79
MED. 2.93 3.19 2.63 2.96 0.98 0.96 48.69 45.83 2.85 2.82 2.78 2.82 0.79 1.38 1.20 1.69 0.34 0.36 0.86 1.26 1.65 2.53
MIN. 1.83 2.88 1.41 2.54 0.77 0.76 36.56 37.65 2.12 2.07 2.37 2.11 0.23 0.37 0.41 0.83 0.15 0.03 0.26 0.51 0.48 0.89
MAX. 3.50 3.45 3.42 3.43 2.29 2.59 64.53 66.64 3.35 3.33 3.49 3.47 1.50 2.92 1.61 2.05 0.61 0.77 1.02 1.70 2.52 4.62
H1 2.78 2.31 3.10 2.68 1.14 1.17 65.79 73.34 4.55 6.27 3.04 3.46 1.36 1.68 1.59 1.36 0.77 0.51 0.82 0.86 2.18 2.54
H2 3.84 3.97 2.91 3.12 0.78 0.79 55.72 65.68 3.46 3.46 ■ 3.55 3.59 0.90 1.33 2.19 2.70 1.05 1.21 1.14 r 1.50 2.04 2.83
H3 2.99 6.57 3.02 4.56 1.20 0.70 39.83 34.77 2.13 2.57 3.55 3.39 1.00 2.30 0.96 2.66 0.27 0.60 0.69 2.06 1.69 4.37
H4 5.06 5.03 3.72 4.16 0.94 1.02 53.25 55.75 2.73 3.21 2.97 4.17 1.01 1.33 2.32 2.06 1.10 0.95 1.22 1.11 2.23 2.45
H5 2.14 3.27 2.06 2.77 0.99 1.00 169.96 74.37 8.95 3.87 7.92 4.44 3.25 1.57 4.74 2.28 2.95 1.24 1.78 1.04 5.04 2.61
H6 1.96 3.78 2.09 5.50 3.52 1.45 40.26 39.51 2.86 3.32 3.49 3.21 0.20 1.28 0.31 1.56 0.12 0.51 0.19 1.05 0.39 2.32
H7 2.29 2.24 2.23 2.42 0.98 1.09 65.99 69.32 3.32 3.79 3.10 3.19 1.42 1.75 1.72 1.64 0.63 0.42 1.08 1.21 2.51 2.96
MED. 2.88 3.62 2.97 2.94 1.06 1.01 55.72 67.50 3.16 3.63 3.52 3.53 1.00 1.62 1.89 2.17 0.91 0.77 0.98 1.16 2.11 2.72
MIN. 1.96 2.24 2.06 2.42 0.78 0.70 40.26 34.77 2.13 2.57 2.97 3.19 0.20 1.33 0.31 1.36 0.12 0.42 0.19 0.86 0.39 2.45
MAX. 5.06 6.57 3.72 4.56 3.52 1.17 169.96 74.37 8.95 6.27 7.92 4.44 3.25 2.30 4.74 2.70 2.95 1.24 1.78 2.06 5.04 4.37
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Appendix 2.7b (i and ii): Lung function measurements in control (C1-6) and heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with 20|ig
LPS. TP = time point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (l/kPa) dppl (kPa) RUso (kPa/l/sec) BR (breaths/min.) VT (I) Wb* (J/min) RLE25% (kPa/i/sec) RLe5o% (kPa/i/sec) RLe7s% (kPa/l/sec) RU>5% (kPa/i/sec) RLi5o% (KPa/i/sec) RL|75% (kPa/l/sec)
TP Oh 5h Oh 5h 0h 5h 0h 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h
C1 5.03 6.48 1.43 1.00 0.10 0.09 7.10 9.40 5.61 4.71 11.02 16.20 0.00 0.03 0.00 0.03 0.00 0.06 0.63 0.24 0.29 0.20 0.19 0.15
C2 37.57 17.38 0.50 0.80 0.04 0.03 8.85 8.3 5.84 8.57 13.16 17.80 0.03 0.002 0.04 0 0.05 0.01 0.04 0.14 0.05 0.14 0.06 0.08
C3 20.80 12.55 0.41 0.65 0.04 0.08 10.30 7.90 4.42 4.82 7.83 9.42 0.06 0.09 0.08 0.04 0.06 0.06 0.04 0.11 0.04 0.10 0.05 0.07
C4 5.25 4.98 1.20 1.32 0.22 0.24 9.00 9.05 3.56 3.81 16.87 19.68 0.19 0.22 0.11 0.19 0.16 0.18 0.35 0.34 0.29 0.26 0.25 0.25
C5 20.76 18.69 0.30 0.44 0.04 0.06 20.90 15.70 2.68 3.08 9.82 12.34 0.04 0.06 0.04 0.06 0.05 0.06 0.03 0.05 0.04 0.06 0.05 0.08
C6 16.64 10.56 0.61 0.78 0.06 0.10 11.00 8.70 4.30 4.88 12.03 13.08 0.07 0.05 0.06 0.03 0.06 0.06 0.06 0.12 0.08 0.13 0.08 0.11
MED. 18.70 10.56 0.55 0.78 0.05 0.09 9.65 9.05 4.36 4.71 11.52 13.08 0.05 0.06 0.05 0.04 0.06 0.06 0.05 0.12 0.06 0.13 0.07 0.11
MIN. 5.03 4.98 0.30 0.44 0.04 0.06 7.10 7.90 2.68 3.08 7.83 9.42 0.00 0.03 0.00 0.03 0.00 0.06 0.03 0.05 0.04 0.06 0.05 0.07
MAX. 37.57 18.69 1.43 1.32 0.22 0.24 20.90 15.70 5.84 4.88 16.87 19.68 0.19 0.22 0.11 0.19 0.16 0.18 0.63 0.34 0.29 0.26 0.25 0.25
H1 20.82 12.57 0.60 0.83 0.04 0.06 7.00 7.10 8.37 8.19 14.87 18.58 0.07 0.09 0.06 0.11 0.05 0.10 0.08 0.10 0.06 0.08 0.06 0.06
H2 26.68 20.33 0.81 0.73 0.12 0.07 5.55 6.75 7.50 6.93 17.67 15.13 0.11 0.09 0.11 0.05 0.14 0.09 0.12 0.08 0.10 0.08 0.09 0.07
H3 17.04 9.39 0.54 0.92 0.06 0.09 12.30 7.65 4.40 6.65 16.45 16.31 0.06 0.05 0.06 0.00 0.07 0.05 0.05 0.14 0.06 0.19 0.06 0.13
H4 18.16 14.90 0.72 0.98 0.07 0.08 7.00 7.05 7.40 8.88 14.53 22.45 0.06 0.04 0.05 0.02 0.07 0.05 0.08 0.11 0.07 0.11 0.06 0.07
H5 16.91 17.02 0.75 0.87 0.07 0.06 5.45 5.35 9.75 9.17 15.78 18.74 0.04 0.07 0.07 0.10 0.09 0.11 0.12 0.07 0.10 0.07 0.09 0.07
H6 17.08 8.76 0.54 0.70 0.09 0.10 6.50 5.5 4.69 4.12 6.83 5.352 0.08 0.12 0.05 0.04 0.07 0.13 0.03 0.21 0.06 0.24 0.03 0.11
H7 8.32 5.57 1.14 1.31 0.11 0.11 8.95 11.30 6.19 5.65 24.96 26.42 0.07 0.03 0.06 0.04 0.10 0.07 0.18 0.18 0.16 0.19 0.14 0.14
MED. 17.08 13.73 0.72 0.89 0.07 0.08 7.00 7.08 7.40 7.56 15.78 18.66 0.07 0.06 0.06 0.05 0.07 0.08 0.08 0.10 0.07 0.09 0.06 0.07
MIN. 8.32 5.57 0.54 0.73 0.04 0.06 5.45 5.35 4.40 5.65 6.83 15.13 0.04 0.03 0.05 0.00 0.05 0.05 0.03 0.07 0.06 0.07 0.03 0.06
MAX. 26.68 20.33 1.14 1.31 0.12 0.11 12.30 11.30 9.75 9.17 24.96 26.42 0.11 0.09 0.11 0.11 0.14 0.11 0.18 0.18 0.16 0.19 0.14 0.14
TE(sec) T| (sac) TI:Te V6 (l/min) V'emax (l/sec) V imax (l/SeC) Wbe,(J) Wbres (J) WbgreS (J) Wblre5 (J) : Wb, ot (J)
TP 0h 5h Oh 5h 0h 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h 0h 5h
C1 3.88 3.11 4.49 3.26 1.16 1.10 39.70 44.31 2.50 2.99 2.52 2.75 3.14 1.85 1.49 1.70 0.80 0.34 2.28 1.35 5.42 3.21
C2 3.34 4.27 2.87 3.28 1.21 0.80 51.77 70.67 2.77 3.49 3.21 4.92 0.53 2.30 1.29 2.16 0.58 0.20 0.71 2.36 1.24 4.66
C3 3.27 3.97 2.56 3.58 0.79 0.91 45.16 38.22 2.59 2.60 2.69 2.60 0.49 0.92 0.76 1.19 0.38 0.53 0.38 0.66 0.87 1.58
C4 3.66 3.67 2.97 3.18 0.82 0.88 32.11 34.56 1.68 1.66 1.91 1.86 1.22 1.52 1.86 2.25 0.59 0.73 1.27 1.51 2.49 3.03
C5 1.66 2.17 1.30 1.70 0.80 0.79 54.92 48.20 3.15 2.92 3.50 3.02 0.18 0.28 0.48 0.78 0.17 0.30 0.30 0.48 0.49 0.76
C6 3.33 3.95 2.39 2.97 0.75 0.76 47.43 42.54 2.70 2.29 3.28 2.89 0.66 1.15 1.12 1.49 0.44 0.37 0.68 1.12 1.34 2.27
MED. 3.33 3.67 2.71 3.18 0.81 0.88 46.29 42.54 2.65 2.60 2.95 2.75 0.59 1.15 1.20 1.49 0.41 0.37 0.70 1.12 1.29 2.27
MIN. 1.66 2.17 1.30 1.70 0.75 0.76 32.11 34.56 1.68 1.66 1.91 1.86 0.18 0.28 0.48 0.78 0.17 0.30 0.30 0.48 0.49 0.76
MAX. 3.88 3.97 4.49 3.58 1.21 1.10 54.92 48.20 3.15 2.99 3.50 3.02 3.14 1.85 1.86 2.25 0.80 0.73 2.28 1.51 5.42 3.21
H1 4.08 4.18 4.53 4.28 1.14 1.04 58.50 58.06 4.46 5.02 3.37 3.30 1.67 2.70 2.10 2.61 1.11 1.41 0.99 1.20 2.66 3.90
H2 5.67 4.89 5.04 4.04 0.89 0.83 41.70 46.68 2.78 3.12 2.69 3.78 1.06 1.20 3.15 2.26 1.95 1.31 1.20 0.95 2.26 2.15
H3 2.36 4.19 2.44 3.74 1.06 0.91 54.68 50.36 3.52 3.31 3.30 3.69 0.59 2.37 1.25 2.16 0.74 0.59 0.52 1.57 1.11 3.94
H4 5.26 5.15 3.74 3.49 0.72 0.69 51.38 62.65 2.92 3.63 3.88 4.93 1.65 2.70 2.17 3.24 1.12 1.08 1.06 2.16 2.71 4.86
H5 5.96 6.09 4.97 3.92 0.83 0.63 53.12 49.04 2.99 3.34 3.90 3.81 2.72 2.47 2.87 3.03 1.16 1.74 1.72 1.29 4.44 3.76
H6 3.52 4.72 2.67 6.44 0.82 1.36 27.00 22.71 3.10 1.520 2.31 1.71 0.39 1.01 0.94 0.99 0.63 0.546 0.30 0.44 0.70 1.45
H7 2.99 2.41 3.62 2.78 1.22 1.15 55.30 63.74 2.92 3.48 2.59 3.35 2.30 2.87 2.74 2.29 1.14 0.64 1.60 1.65 3.89 4.52
MED. 4.08 4.54 3.74 3.83 0.89 \ 0.87 53.12 54.21 2.99 3.41 3.30 3.73 1.65 2.58 2.17 2.45 1.12 1.19 1.06 1.43 2.66 3.92
MIN. 2.36 2.41 2.44 2.78 0.72 0.63 27.00 46.68 2.78 3.12 2.31 3.30 0.39 1.20 0.94 2.16 0.63 0.59 0.30 0.95 0.70 2.15
MAX. 5.96 6.09 5.04 4.28 1.22 1.15 58.50 63.74 4.46 5.02 3.90 4.93 2.72 2.87 3.15 3.24 1.95 1.74 1.72 2.16 4.44 4.86
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Appendix 2.7c (i and ii): Lung function measurements in control (C1-6) and heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with 200pg
LPS. TP = time point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (l/kPa) dPp! (kPa) RUo (kPa/l/sec) RR (breaths/min.) mm Wb' (J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/i/sec) RLe?s% (kPa/l/sec) RLi25% (kPa/l/sec) RLi5o% (kPa/l/sec) RLi75% (kPa/f/sec)
TP Oh 5h 0h 5h Oh 5h Oh 5h 0h 5h 0h 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h
C1 5.98 7.65 1.07 1.11 0.09 0.10 11.05 7.40 4.02 5.48 12.58 12.80 0.00 0.04 0.01 0.00 0.03 0.03 0.25 0.20 0.16 0.19 0.12 0.13
C2 9.91 14.37 1.00 0.85 0.08 0.07 9.25 8.45 6.37 7.53 23.51 23.10 0.04 0.04 0.02 0.02 0.04 0.04 0.15 0.11 0.14 0.10 0.12 0.09
C3 18.95 14.93 0.54 0.55 0.05 0.07 8.35 7.45 5.60 4.67 10.56 8.77 0.06 0.09 0.05 0.05 0.05 0.07 0.07 0.11 0.06 0.09 0.06 0.09
C4 4.06 5.26 0.93 1.05 0.15 0.23 9.75 10.55 2.98 3.05 8.99 17.24 0.13 0.20 0.10 0.24 0.08 0.23 0.25 0.25 0.23 0.23 0.20 0.22
C5 17.27 22.32 0.44 0.43 0.05 0.05 17.45 11.20 3.08 3.89 13.98 9.10 0.05 0.05 0.05 0.06 0.06 0.07 0.05 0.04 0.06 0.06 0.07 0.06
C6 11.89 9.68 0.66 0.78 0.13 0.12 5.85 6.05 4.83 5.33 7.14 8.60 0.03 0.04 0.02 0.01 0.08 0.07 0.17 0.21 0.16 0.19 0.14 0.14
MED. 10.90 12.02 0.80 0.81 0.08 0.09 9.50 7.95 4.42 5.00 11.57 10.95 0.05 0.05 0.04 0.04 0.05 0.07 0.16 0.16 0.15 0.14 0.12 0.11
MIN. 4.06 5.26 0.44 0.43 0.05 0.05 5.85 6.05 2.98 3.05 7.14 8.60 0.00 0.04 0.01 0.00 0.03 0.03 0.05 0.04 0.06 0.06 0.06 0.06
MAX. 18.95 22.32 1.07 1.11 0.15 0.23 17.45 11.20 6.37 7.53 23.51 23.10 0.13 0.20 0.10 0.24 0.08 0.23 0.25 0.25 023 0.23 0.20 0.22
H1 24.10 22.59 0.54 0.58 0.03 0.03 8.35 8.45 9.87 10.64 18.82 21.85 0.05 0.05 0.06 0.05 0.05 0.05 0.03 0.03 0.02 0.02 0.02 0.02
H2 31.32 15.42 0.95 0.88 0.09 0.12 6.25 6.15 7.74 7.27 23.41 20.26 0.05 0.17 0.10 0.10 0.16 0.12 0.13 0.14 0.10 0.12 0.09 0.10
H3 12.50 12.65 0.53 0.65 0.06 0.11 6.25 5.30 4.33 4.63 6.34 9.11 0.08 0.12 0.04 0.06 0.08 0.10 0.13 0.15 0.23 0.27 0.20 0.12
H4 18.86 18.83 0.54 0.69 0.08 0.07 7.45 6.40 5.67 8.16 12.10 16.05 0.03 0.02 0.07 0.04 0.08 0.07 0.09 0.07 0.09 0.07 0.08 0.07
H5 17.70 20.31 0.62 0.58 0.06 0.06 5.75 5.75 8.39 7.95 10.78 10.43 0.04 0.05 0.07 0.07 0.08 0.08 0.05 0.05 0.05 0.07 0.07 0.07
H6 15.98 13.62 0.56 0.66 0.07 0.08 5.25 6.10 4.47 5.01 3.90 6.29 0.09 0.08 0.07 0.09 0.10 0.12 0.16 0.05 0.06 0.08 0.07 0.04
H7 8.76 7.38 1.06 0.83 0.09 0.06 15.15 18.95 5.49 4.29 46.69 30.46 0.08 0.05 0.10 0.07 0.11 0.08 0.10 0.08 0.10 0.07 0.10 0.07
MED. 17.70 15.42 0.56 0.66 0.07 0.07 6.25 6.15 5.67 7.27 12.10 16.05 0.05 0.05 0.07 0.07 0.08 0.08 0.10 0.07 0.09 0.07 0.08 0.07
MIN. 8.76 7.38 0.53 0.58 0.03 0.03 5.25 5.30 4.33 4.29 3.90 6.29 0.03 0.02 0.04 0.04 0.05 0.05 0.03 0.03 0.02 0.02 0.02 0.02
MAX. 31.32 22.59 1.06 0.88 0.09 0.12 15.15 18.95 9.87 10.64 46.69 30.46 0.09 0.17 0.10 0.10 0.16 0.12 0.16 0.15 0.23 0.27 0.20 0.12
TE(sec) Ti(sec) T.:TE V'e (l/min) V Emax (I/S6C) Vimax (l/sec) Wb i (J) Wbres (J) WbEfes(J) Wbires (J) Wb, o«(J)
TP 0h 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h
C1 2.88 4.19 2.74 4.07 0.95 0.97 43.26 40.47 1.96 2.23 2.99 3.07 1.46 2.01 1.22 1.75 0.03 0.34 1.19 1.40 2.65 3.41
C2 3.56 4.21 2.81 3.01 0.80 0.73 58.90 63.62 3.08 3.22 3.16 3.48 2.05 1.99 2.46 2.69 0.48 0.72 1.98 1.97 4.04 3.96
C3 3.44 4.10 3.41 3.89 1.00 0.95 46.61 34.87 3.35 2.33 2.68 2.39 0.80 0.76 1.21 1.07 0.64 0.49 0.57 0.58 1.37 1.34
C4 3.38 3.13 3.00 2.59 0.90 0.84 29.01 32.24 1.45 1.59 1.58 1.80 1.08 0.89 0.93 1.62 0.27 0.69 0.66 0.93 1.74 1.82
C5 1.90 2.84 1.51 2.51 0.81 0.89 53.74 43.80 3.31 2.80 3.25 2.62 0.30 0.37 0.77 0.76 0.30 0.36 0.47 0.41 0.76 0.78
C6 5.76 5.40 4.48 4.89 0.80 0.93 28.27 32.29 1.45 1.70 1.84 2.23 1.02 1.52 1.21 1.47 0.34 0.46 0.87 1.01 1.89 2.53
MED. 3.41 4.14 2.91 3.45 0.85 0.91 44.94 37.67 2.52 2.28 2.83 2.50 1.05 1.20 1.21 1.55 0.32 0.48 0.76 0.97 1.81 2.18
MIN. 1.90 2.84 1.51 2.51 0.80 0.73 28.27 32.24 1.45 1.59 1.58 1.80 0.30 0.37 0.77 0.76 0.03 0.34 0.47 0.41 0.76 0.78
MAX. 5.76 5.40 4.48 4.89 1.00 0.97 58.90 63.62 3.35 3.22 3.25 3.48 2.05 2.01 2.46 2.69 0.64 0.72 1.98 1.97 4.04 3.96
H1 3.33 3.44 3.80 3.71 1.17 1.09 81.99 89.74 6.07 6.91 3.70 4.18 2.14 2.55 2.20 2.58 1.37 1.50 0.84 1.08 2.97 3.63
H2 5.31 5.32 4.40 4.40 0.83 0.83 48.51 44.96 3.20 2.29 2.59 2.96 0.88 1.74 3.78 3.27 2.46 1.74 1.33 1.52 2.21 3.26
H3 4.87 4.18 4.82 5.47 1.08 1.81 26.94 24.40 2.03 2.62 2.64 2.94 0.85 1.13 0.99 1.45 0.41 0.55 0.58 0.91 1.44 2.04
H4 4.69 5.64 3.29 3.57 0.72 0.64 42.21 52.43 2.49 3.07 3.02 3.68 0.88 1.79 1.63 2.46 0.87 1.22 0.76 1.24 1.64 3.03
H5 5.99 6.00 4.26 4.48 0.72 0.76 47.85 45.59 2.41 2.31 3.46 3.37 2.00 1.60 1.84 1.82 0.90 0.85 0.94 0.97 2.94 2.57
H6 4.73 4.91 6.50 4.85 1.40 0.99 23.51 30.42 1.52 1.77 1.70 1.95 0.66 0.93 0.73 1.02 0.42 0.75 0.31 0.27 0.97 1.19
H7 1.79 1.46 2.17 1.72 1.22 1.18 83.35 81.18 4.06 4.31 3.81 3.96 1.81 1.30 3.07 1.62 1.65 0.81 1.42 0.80 3.23 2.11
MED. 4.73 4.91 4.26 4.40 1.08 0.99 47.85 45.59 2.49 2.62 3.02 3.37 0.88 1.60 1.84 1.82 0.90 0.85 0.84 0.97 2.21 2.57
MIN. 1.79 1.46 2.17 1.72 0.72 0.64 23.51 24.40 1.52 1.77 1.70 1.95 0.66 0.93 0.73 1.02 0.41 0.55 0.31 0.27 0.97 1.19
MAX. 5.99 6.00 6.50 5.47 1.40 1.81 83.35 89.74 6.07 6.91 3.81 4.18 2.14 2.55 3.78 3.27 2.46 1.74 1.42 1.52 3.23 3.63
315
Appendix 2.7c (i and ii): Lung function measurements in control (C1-6) and heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with 2000pg
LPS. TP = time point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (t/kPa) dPpi(kPa) RLiS0 (kPa/i/sec) RR (breaths/min.) VT (I) Wb' (J/min) RLe25% (kPa/l/sec) RIeso% (kPa/l/sec) RLe7s% (kPa/l/sec) RLi2s%(kPa/l/sec) RLi5o% (kPa/l/sec) RLi75% (kPa/I/sec)
TP Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h 0h 5h Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h 0h 5h
C1 13.13 9.56 0.62 0.89 0.05 0.08 8.40 8.60 5.09 5.05 8.47 12.60 0.01 0.02 0.00 0.01 0.02 0.02 0.16 0.22 0.15 0.14 0.09 0.11
C2 18.13 12.04 0.62 0.76 0.08 0.09 6.25 6.10 6.41 6.13 11.52 10.72 0.01 0.00 0.00 0.00 0.05 0.02 0.17 0.22 0.17 0.21 0.11 0.15
C3 13.58 13.64 0.52 0.55 0.06 0.06 17.20 11.75 3.53 4.42 16.45 11.84 0.06 0.06 0.06 0.07 0.06 0.06 0.06 0.06 0.07 0.06 0.08 0.07
C4 5.14 4.99 1.06 1.19 0.22 0.25 8.40 10.2 2.80 2.80 10.27 15.32 0.09 0.19 0.03 0.15 0.13 0.18 0.42 0.50 0.35 0.38 0.25 0.34
C5 19.77 18.99 0.29 0.36 0.03 0.07 17.90 9.15 2.69 2.84 6.63 4.14 0.04 0.03 0.05 0.04 0.05 0.08 0.02 0.09 0.03 0.09 0.04 0.08
C6 11.64 6.36 0.71 1.25 0.09 0.18 8.05 8.60 4.60 4.47 10.00 18.52 0.05 0.08 0.01 0.03 0.04 0.08 0.21 0.31 0.15 0.25 0.13 0.20
MED. 13.58 11.60 0.62 0.72 0.08 0.07 8.40 8.88 3.53 4.44 10.27 12.22 0.05 0.05 0.02 0.03 0.05 0.07 0.17 0.16 0.15 0.12 0.11 0.09
MIN. 5.14 6.36 0.29 0.36 0.03 0.06 6.25 8.60 2.69 2.84 6.63 4.14 0.01 0.02 0.00 0.01 0.04 0.02 0.02 0.06 0.03 0.06 0.04 0.07
MAX. 19.77 18.99 1.06 1.25 0.22 0.18 17.90 11.75 6.41 5.05 16.45 18.52 0.09 0.08 0.06 0.07 0.13 0.08 0.42 0.31 0.35 0.25 0.25 0.20
H1 23.17 25.91 0.61 0.73 0.05 0.08 4.90 5.70 9.53 9.81 12.86 15.42 0.09 0.12 0.05 0.10 0.05 0.10 0.13 0.10 0.12 0.07 0.07 0.07
H2 38.44 26.89 0.30 1.07 0.02 0.16 7.15 6.55 7.57 6.68 5.90 25.90 0.00 0.16 0.00 0.16 0.02 0.20 0.03 0.13 0.04 0.13 0.02 0.12
H3 12.76 11.93 0.66 0.68 0.10 0.11 7.05 4.50 5.31 5.20 9.96 9.83 0.10 0.09 0.05 0.05 0.09 0.09 0.11 0.19 0.11 0.25 0.10 0.17
H4 24.51 30.49 0.49 0.52 0.06 0.06 7.15 10.30 6.66 5.23 10.03 14.59 0.00 0.03 0.04 0.06 0.06 0.08 0.06 0.06 0.05 0.06 0.05 0.06
H5 21.41 20.95 0.62 0.78 0.05 0.10 5.00 4.60 10.12 11.15 13.18 19.76 0.09 0.07 0.08 0.12 0.09 0.13 0.06 0.11 0.05 0.09 0.05 0.09
H6 8.80 9.84 0.64 0.93 0.09 0.12 9.50 10.60 3.59 4.58 9.24 22.25 0.10 0.14 0.14 0.12 0.12 0.12 0.09 0.09 0.07 0.10 0.08 0.12
H7 7.67 9.20 1.07 1.21 0.08 0.11 8.90 9.00 6.24 6.68 18.06 29.20 0.03 0.06 0.01 0.03 0.04 0.09 0.23 0.19 0.20 0.15 0.14 0.13
MED. 21.41 20.95 0.62 0.78 0.06 0.11 7.15 6.55 6.66 6.68 10.03 19.76 0.09 0.09 0.05 0.10 0.06 0.10 0.09 0.11 0.07 0.10 0.07 0.12
MIN. 7.67 9.20 0.30 0.52 0.02 0.06 4.90 4.50 3.59 4.58 5.90 9.83 0.00 0.03 0.00 0.03 0.02 0.08 0.03 0.06 0.04 0.06 0.02 0.06
MAX. 38.44 30.49 1.07 1.21 0.10 0.16 9.50 10.60 10.12 11.15 18.06 29.20 0.10 0.16 0.14 0.16 0.12 0.20 0.23 0.19 0.20 0.25 0.14 0.17
TE(sec) T| (sac) TY.Te V'E (J/min) V Emax (J/SeC) ; Vimax (J/SeC) Wb Wbr WbEre.,(J) Ita Wblras (J) Wb, ol(J)
TP Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h 0h 5h
C1 3.78 3.76 3.42 3.30 0.91 0.89 42.81 43.20 2.33 2.29 2.14 2.30 0.99 1.41 1.02 1.47 0.14 0.26 0.89 1.21 1.87 2.62
C2 5.91 5.89 3.81 3.92 0.66 0.67 40.12 37.20 2.13 2.24 2.67 2.48 1.21 1.58 1.86 1.75 0.35 0.07 1.52 1.67 2.73 3.25
C3 1.84 2.81 1.71 2.46 0.95 0.92 60.68 52.02 3.57 3.07 3.05 3.02 0.50 0.76 0.97 1.02 0.42 0.43 0.55 0.59 1.05 1.35
C4 4.11 3.33 2.99 2.70 0.74 0.81 23.42 28.65 1.24 1.28 1.62 1.39 0.90 0.78 1.19 1.54 0.31 0.52 0.88 1.02 1.78 1.80
C5 1.97 3.69 1.45 2.74 0.75 0.74 47.23 26.04 2.92 1.54 2.93 1.77 0.21 0.25 0.37 0.44 0.16 0.15 0.21 0.29 0.42 0.55
C6 3.73 3.63 3.63 3.42 1.00 0.96 37.10 38.31 2.02 2.02 2.46 2.05 0.90 1.56 1.22 2.18 0.23 0.65 1.00 1.53 1.90 3.09
MED. 3.73 3.66 2.99 3.02 0.75 0.90 40.12 40.76 2.13 2.15 2.67 2.18 0.90 1.08 1.19 1.25 0.31 0.35 0.88 0.90 1.78 1.99
MIN. 1.84 2.81 1.45 2.46 0.66 0.74 23.42 26.04 1.24 1.54 1.62 1.77 0.21 0.25 0.37 0.44 0.16 0.15 0.21 0.29 0.42 0.55
MAX. 5.91 3.76 3.81 3.42 1.00 0.96 60.68 52.02 3.57 3.07 3.05 3.02 1.21 1.56 1.86 2.18 0.42 0.65 1.52 1.53 2.73 3.09
H1 5.47 5.58 6.75 6.73 1.27 1.23 46.77 55.94 3.43 2.74 3.58 2.62 2.10 2.01 2.59 3.16 1.32 1.92 1.27 1.24 3.36 3.24
H2 4.92 4.94 3.57 4.20 0.73 0.85 54.03 43.86 3.58 2.75 3.77 2.34 0.78 1.09 0.83 3.95 0.34 2.25 0.48 1.70 1.26 2.79
H3 4.98 5.15 4.16 5.18 0.84 1.33 37.64 23.43 2.38 1.98 2.83 2.73 1.13 1.51 1.52 1.66 0.75 0.41 0.77 1.25 1.90 2.76
H4 4.81 3.15 3.73 2.66 0.78 0.85 47.71 53.82 2.82 3.01 3.09 3.00 0.93 0.46 1.43 1.41 0.77 0.80 0.66 0.61 1.58 1.07
H5 6.88 8.07 4.63 4.94 0.71 0.62 50.64 51.09 2.68 2.40 4.00 3.47 2.45 3.01 2.48 4.27 1.29 1.93 1.19 2.34 3.64 5.35
H6 2.96 2.77 3.42 2.92 1.18 1.06 33.93 48.58 2.89 2.58 2.42 2.78 0.75 1.07 0.97 2.11 0.49 0.98 0.48 1.14 1.23 2.20
H7 3.26 3.13 3.85 3.54 1.19 1.15 55.31 60.57 2.96 2.97 2.73 2.69 2.60 2.45 2.15 3.18 0.46 1.17 1.69 2.01 4.29 4.46
MED. 4.92 4.94 3.85 4.20 0.84 1.06 47.71 51.09 2.89 2.74 3.09 2.73 1.13 1.51 1.52 3.16 0.75 1.17 0.77 1.25 1.90 2.79
MIN. 2.96 2.77 3.42 2.66 0.71 0.62 33.93 23.43 2.38 1.98 2.42 2.34 0.75 0.46 0.83 1.41 0.34 0.41 0.48 0.61 1.23 1.07
MAX. 6.88 8.07 6.75 6.73 1.27 1.33 55.31 60.57 3.58 3.01 4.00 3.47 2.60 3.01 2.59 4.27 1.32 2.25 1.69 2.34 4.29 5.35
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Appendix 2.7c (i and ii): Lung function measurements in control (C1-6) and heaves (H1-7) horses prior to (Oh) and at 5h following initiation of 5h hay/straw
challenge. TP = time point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (f/kPa) dPpI (kPa) RLjfio (kPa/l/sec) RR (breaths/min.) VT (I) WbHJ/min) RLe25% (kPa/l/sec) RUso% (kPa/l/sec) RLe?5% (kPa/l/sec) RL,25% (kPa/l/sec) RLi5o%(kPa/l/sec) RLi75% (kPa/l/sec)
TP Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h 0h 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h
C1 5.31 8.81 1.38 0.86 0.06 0.09 7.00 8.45 5.85 4.53 11.68 9.68 0.00 0.01 0.00 0.02 0 00 0.05 039 0.13 0.12 0.12 0.11 0.11
C2 12.37 14.75 0.82 0.82 0.11 0.11 5.50 5.30 6.45 6.65 10.63 12.17 0.04 0.10 0.00 0.08 0.05 0.13 0.26 0.13 0.23 0.12 0.16 0.12
C3 31.49 21.02 0.61 0.55 0.04 0.04 6.65 5.55 10.97 7.93 18.12 6.59 0.04 0.05 0.03 0.05 0.04 0.06 0.04 0.05 0.03 0.04 0.05 0.04
C4 4.05 6.23 1.30 0.73 0.20 0.15 16.60 13.85 2.81 2.29 35.25 11.07 0.18 0.07 0.21 0.08 0.26 0.12 0.22 0.18 0.23 0.20 0.22 0.16
C5 36.57 13.34 0.25 0.45 0.02 0.02 33.00 26.10 2.59 3.15 13.63 14.79 0.02 0.03 0.03 0.05 0.04 0.06 0.02 0.02 0.02 0.02 0.03 0.03
C6 11.25 9.99 0.68 0.49 0.05 0.05 13.95 20.65 3.89 2.65 11.22 13.62 0.05 0.03 0.04 0.05 0.05 0.10 0.10 0.07 0.09 0.09 0.08 0.06
MED. 11.81 11.67 0.75 0.64 0.06 0.07 10.48 11.15 4.87 3.84 12.66 11.62 0.04 0.04 0.03 0.05 0.04 0.08 0.16 0.10 0.10 0.10 0.10 0.09
MIN. 4.05 6.23 0.25 0.45 0.02 0.02 5.50 5.30 2.59 2.29 10.63 6.59 0.00 0.01 0.00 0.02 0.00 0.05 0.02 0.02 0.02 0.02 0.03 0.03
MAX. 36.57 21.02 1.38 0.86 0.20 0.15 33.00 26.10 10.97 7.93 35.25 14.79 0.18 0.10 0.21 0.08 0.26 0.13 0.39 0.18 0.23 0.20 0.22 0.16
H1 27.12 26.47 1.02 0.66 0.16 0.06 4.95 7.55 8.14 7.50 22.64 19.24 0.17 0.08 0.13 0.07 0.19 0.08 0.15 0.06 0.15 0.06 0.21 0.08
H2 46.49 20.52 0.43 0.76 0.05 0.09 7.60 9.45 6.03 5.66 9.70 18.75 0.03 0.05 0.05 0.06 0.06 0.09 0.05 0.07 0.05 0.08 0.06 0.11
H3 10.91 14.23 0.69 0.57 0.10 0.07 8.70 5.85 4.98 4.68 11.06 6.15 0.03 0.00 0.03 0.01 0.07 0.06 0.17 0.12 0.22 0.13 0.13 0.03
H4 25.75 31.19 0.43 0.38 0.05 0.03 7.20 9.50 5.70 5.84 8.08 8.58 0.02 0.03 0.04 0.03 0.07 0.05 0.06 0.04 0.06 0.04 0.06 0.07
H5 21.88 20.48 0.51 0.55 0.06 0.07 8.10 6.85 6.84 7.13 13.96 11.91 0.02 0.04 0.04 0.07 0.07 0.07 0.07 0.03 0.08 0.06 0.08 0.05
H6 9.60 14.87 0.81 0.50 0.10 0.06 8.50 10.10 4.82 4.07 15.68 6.40 0.08 0.04 0.12 0.04 0.07 0.05 0.12 0.04 0.07 0.04 0.07 0.16
H7 33.40 21.49 0.55 0.91 0.06 0.14 19.55 14.50 4.17 4.25 28.45 35.06 0.05 0.11 0.06 0.13 0.07 0.14 0.05 0.12 0.06 0.14 0.07 0.07
MED. 26.44 20.52 0.53 0.57 0.06 0.07 8.10 9.45 5.86 5.66 12.51 11.91 0.03 0.04 0.05 0.06 0.07 0.07 0.06 0.06 0.07 0.06 0.08 0.03
MIN. 10.91 14.23 0.43 0.38 0.05 0.03 4.95 5.85 4.17 4.07 8.08 6.15 0.02 0.00 0.03 0.01 0.06 0.05 0.05 0.03 0.05 0.04 0.06 0.16
MAX. 46.49 31.19 1.02 0.91 0.16 0.14 19.55 14.50 8.14 7.50 28.45 35.06 0.17 0.11 0.13 0.13 0.19 0.14 0.17 0.12 0.22 0.14 0.21
Te (sec) T( (S6C) T,:Te VWI/min) V'Emax (i/sec) V'imax (l/sec) Wb Wbres(J) Wbfc-fes(J) Wblres(J) Wb„of(J)
TP Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h • Oh 5h Oh 5h
C1 4.35 3.80 4.37 3.52 1.01 0.94 39.00 38.17 2.21 1.88 2.27 2.59 3.53 1.17 1.67 1.19 0.24 0.28 1.91 0.91 5.44 2.08
C2 5.72 6.07 5.28 5.10 0.93 0.86 35.49 35.20 1.98 2.00 2.08 2.18 1.66 1.47 1.94 2.24 0.41 1.15 1.53 1.09 3.19 2.56
C3 5.36 5.78 4.18 5.11 0.78 0.89 74.86 43.93 3.31 1.98 4.18 2.33 1.99 1.52 2.56 1.19 1.17 0.67 1.39 0.53 3.38 2.05
C4 2.11 2.70 1.52 1.73 0.75 0.64 46.50 31.59 2.34 1.25 2.73 2.29 1.05 0.42 2.09 0.81 0.83 0.20 1.26 0.61 2.31 1.03
C5 1.07 1.32 0.79 1.02 0.78 0.80 85.36 81.88 4.11 4.39 5.00 4.67 0.10 0.44 0.42 0.58 0.19 0.34 0.23 0.24 0.33 0.68
C6 2.36 1.60 2.10 1.35 0.90 0.85 53.81 54.12 3.93 3.84 3.17 3.52 0.87 0.42 0.80 0.69 0.27 0.23 0.53 0.46 1.40 0.88
MED. 3.35 3.25 3.14 2.63 0.84 0.85 50.16 41.05 2.83 1.99 2.95 2.46 1.35 0.81 1.80 1.00 0.34 0.31 1.33 0.57 2.75 1.54
MIN. 1.07 1.32 0.79 1.02 0.75 0.64 35.49 31.59 1.98 1.25 2.08 2.18 0.10 0.42 0.42 0.58 0.194 0.20 0.23 0.24 0.33 0.68
MAX. 5.72 6.07 5.28 5.11 1.01 0.94 85.36 81.88 4.11 4.39 5.00 4.67 3.53 1.52 2.56 2.24 1.17 1.15 1.91 1.09 5.44 2.56
H1 5.67 4.00 6.18 3.82 1.10 0.99 40.19 56.47 2.13 3.41 1.76 3.00 1.25 1.05 4.38 2.44 2.18 1.26 2.20 1.17 3.45 2.22
H2 4.72 3.72 3.11 2.70 0.66 0.73 45.65 53.25 2.55 3.12 3.01 2.84 0.39 0.79 1.28 2.01 0.61 1.00 0.66 1.01 1.06 1.81
H3 3.88 6.66 3.98 3.49 1.03 0.55 43.03 27.33 2.53 2.00 2.37 2.13 1.18 0.87 1.46 1.02 0.48 0.33 0.98 0.69 2.15 1.56
H4 4.55 3.32 3.65 3.05 0.81 0.92 41.02 55.47 2.52 3.09 2.67 3.36 0.64 0.52 1.10 0.91 0.59 0.56 0.51 0.36 1.16 0.88
H5 4.09 5.19 3.34 3.87 0.82 0.75 55.61 48.86 2.85 2.68 3.52 3.16 1.28 1.37 1.71 1.81 0.60 1.00 1.11 0.80 2.39 2.17
H6 3.02 3.02 2.87 3.06 0.95 1.02 30.00 41.09 2.91 2.38 3.65 2.70 1.31 0.58 1.55 0.64 0.428 0.30 1.12 0.35 2.42 0.93
H7 1.57 2.23 1.56 1.93 1.01 0.88 81.68 61.07 3.36 2.31 4.06 2.93 0.32 0.47 1.45 2.46 0.73 1.05 0.72 1.41 1.04 1.88
MED. 4.32 3.72 3.49 3.06 0.91 0.88 43.03 53.25 2.54 2.68 2.84 2.93 0.91 0.79 1.45 1.81 0.61 1.00 0.85 0.80 1.65 1.81
MIN. 1.57 2.23 1.56 1.93 0.66 0.55 30.00 27.33 2.13 2.00 1.76 2.13 0.32 0.47 1.10 0.64 0.48 0.30 0.51 0.35 1.04 0.88
MAX. 5.67 6.66 6.18 3.87 1.10 1.02 81,68 61.07 3.36 3.41 4.06 3.36 1.28 1.37 4.38 2.46 2.18 1.26 2.20 1.41 3.45 2.22
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Appendix 2.8: PCCdyn70 values (mg/ml) in control (C1-6)
and heaves (H1-7) horses at 5h following inhalation
challenge with saline 20, 200 and 2000pg LPS and 5h
hay/straw challenge (H/S). MED. = median value, MIN. =
minimum value, MAX. = maximum value.
SALINE 20jig LPS 200fig LPS 2000^ig LPS H/S
C1 3.82 2.47 3.39 2.93 4.44
C2 9.91 6.60 8.61 5.89 8.38
C3 3.46 24.53 10.18 11.14 11.02
C4 2.82 8.04 3.63 3.84 2.82
C5 3.87 8.53 7.58 4.71 4.71
C6 2.29 2.19 1.47 36.38 2.73
MED. 3.64 7.32 5.60 5.30 4.57
MIN. 2.29 2.19 1.47 2.93 2.73
MAX. 9.91 24.53 10.18 36.38 11.02
H1 7.86 2.93 6.17 11.81 4.98
H2 3.06 10.12 3.80 1.24 2.15
H3 5.64 8.93 9.32 8.33 4.66
H4 10.53 10.82 19.40 6.18 14.04
H5 6.40 6.39 2.20 8.90 9.02
H6 2.46 2.56 1.79 2.29 2.41
H7 5.63 5.34 7.69 2.10 6.10
MED. 5.64 6.39 6.17 6.18 4.98
MIN. 2.46 2.56 1.79 1.24 2.15
MAX. 10.53 10.82 19.40 11.81 14.04
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Appendix 2.9 (a) BALF total nucleated cell counts (x105/ml) in control (C1-6) and heaves (H1-7) at 6h and 24h
following challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (H/S). MED. = median
value, MINI. = minimum value, MAX. = maximum value.
SALINE SALINE 20ug 20\ig 200m 200ng 2000ng 2000ng 200p.gR 200pgR H/S H/S
TIME PT 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h
C1 5.10 4.90 3.50 4.30 4.30 8.30 7.30 5.00 6.30 NP 2.20 5.20
C2 3.90 3.70 3.50 3.70 2.70 4.80 4.90 5.90 6.20 NP 2.90 4.60
C3 2.00 3.00 1.90 1.90 2.90 3.30 1.50 4.80 NP NP 2.10 2.90
C4 2.90 1.40 2.00 4.50 3.60 2.50 3.30 4.80 NP NP 3.20 1.80
C5 9.60 3.40 6.40 4.30 5.20 3.40 3.90 4.20 4.00 NP 4.60 2.00
C6 3.80 2.90 11.10 7.00 9.40 3.00 4.20 5.30 3.00 NP 2.20 1.70
MED. 3.85 3.20 3.50 4.30 3.95 3.35 4.05 4.90 2.55 2.45
MIN 2.00 1.40 1.90 1.90 2.70 2.50 1.50 4.20 2.10 1.70
MAX 9.60 4.90 11.10 7.00 9.40 8.30 7.30 5.90 4.60 5.20
H1 5.60 9.00 6.30 5.60 4.90 6.20 4.10 4.60 NP NP 6.20 3.40
H2 3.40 2.90 3.20 4.40 5.70 2.50 7.20 3.40 3.50 NP 4.20 3.00
H3 3.80 3.90 4.10 4.50 5.30 4.20 5.20 3.30 4.30 NP 2.80 6.30
H4 5.50 3.90 5.40 5.10 8.20 8.60 12.40 5.60 3.80 NP 7.00 5.00
H5 3.20 4.80 4.60 4.90 4.50 8.20 6.60 16.00 2.30 NP 16.20 3.80
H6 1.30 0.60 2.90 2.90 4.00 4.20 1.70 4.50 NP NP 5.70 6.70
H7 5.20 3.85 7.40 4.85 4.20 5.60 9.30 7.20 6.40 NP 6.50 2.60
MED. 3.80 3.90 4.60 4.85 4.90 5.60 6.60 4.60 6.20 3.80
MIN 1.30 0.60 2.90 2.90 4.00 2.50 1.70 3.30 2.80 2.60
MAX 5.60 9.00 7.40 5.60 8.20 8.60 12.40 16.00 16.20 6.70
Appendix 2.9 (c) BALF macrophage counts (x105/ml) in control (C1-6) and heaves (H1-7) at 6h and 24h
following challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (H/S). MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE SALINE 20m 20ng 200pg 200pg 2000pg 2000pg 200pgR 200pgR H/S HIS
TIME PT 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h
C1 2.80 2.56 2.01 2.15 1.65 1.95 1.40 1.35 2.76 NP 1.35 1.46
C2 2.25 2.30 1.89 1.91 1.12 2.15 1.76 1.91 3.25 NP 1.89 2.32
C3 0.73 0.91 0.33 0.44 0.51 0.48 0.17 0.82 NP NP 0.66 0.76
C4 1.71 0.86 1.19 2.16 1.25 1.21 1.21 2.28 NP NP 1.89 1.12
C5 2.57 0.58 0.92 2.15 1.12 1.41 0.50 0.86 1.18 NP 0.98 0.87
C6 1.14 1.07 3.94 2.84 4.18 1.37 0.61 1.11 0.83 NP 1.17 0.98
MED. 1.98 0.99 1.54 2.15 1.19 1.39 0.91 1.23 1.97 1.26 1.05
MIN 0.73 0.58 0.33 0.44 0.51 0.48 0.17 0.82 0.83 0.66 0.76
MAX 2.80 2.56 3.94 2.84 4.18 2.15 1.76 2.28 3.25 1.89 2.32
H1 1.96 3.46 2.26 2.14 1.06 2.44 0.77 1.21 1.56 NP 1.44 1.07
H2 1.58 1.42 0.88 0.90 1.69 0.72 0.68 1.06 0.44 NP 0.90 1.02
H3 1.24 2.10 1.68 1.65 1.58 1.97 1.15 1.30 1.12 NP 1.35 2.41
H4 2.96 2.13 2.57 2.05 2.48 2.69 3.94 1.31 1.10 NP 3.16 2.43
H5 1.27 2.26 1.15 1.39 0.61 2.90 0.72 4.61 0.53 NP 2.03 1.30
H6 0.34 0.24 0.70 0.54 1.02 1.20 0.23 1.07 NP NP 1.04 1.53
H7 2.40 1.77 1.94 1.43 1.06 1.64 1.23 1.43 1.31 NP 2.57 0.95
MED. 1.58 2.10 1.68 1.43 1.06 1.97 0.77 1.30 1.11 1.44 1.30
MIN 0.34 0.24 0.70 0.54 0.61 0.72 0.23 1.06 0.44 0.90 0.95
MAX 2.96 3.46 2.57 2.14 2.48 2.90 3.94 4.61 1.56 3.16 2.43
Appendix 2.9 (b) BALF lymphocyte counts (x105/ml) in control (C1-6) and heaves (H1-7) at 6h and 24h
following challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (H/S). MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE SALINE 20jxg 20m 200ng; zoom | 2000{j.g 2000jxg 200(igR 200ngR H/S HIS
TIME PT 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h
C1 1.89 1.95 0.99 1.74 2.03 2.78 3.69 1.22 2.55 NP 0.61 3.28
C2 1.28 1.17 1.44 1.52 1.37 2.20 2.45 2.70 2.59 NP 0.99 1.97
C3 0.99 1.53 1.30 1.21 1.71 2.16 0.71 1.88 NP NP 1.07 1.67
C4 0.99 0.47 0.64 2.07 1.17 0.95 0.68 1.16 NP NP 0.76 0.53
C5 6.22 2.06 5.24 1.74 3.02 1.41 1.35 1.45 1.94 NP 3.09 0.90
C6 2.41 1.68 6.22 3.26 2.40 0.84 0.87 1.45 1.32 NP 0.79 0.54
MED. 1.59 1.61 1.37 1.74 1.87 1.78 1.11 1.45 2.24 0.89 1.29
MIN 0.99 0.47 0.64 1.21 1.17 0.84 0.68 1.16 1.32 0.61 0.53
MAX 6.22 2.06 6.22 3.26 3.02 2.78 3.69 2.70 2.59 3.09 3.28
H1 3.33 4.64 3.45 2.97 2.60 2.60 1.78 1.93 2.07 NP 1.44 1.48
H2 1.54 1.15 2.04 2.36 1.94 1.15 2.55 1.44 1.52 NP 0.71 0.99
H3 2.09 1.25 1.88 2.35 1.26 1.27 0.68 0.81 1.20 NP 0.60 2.63
H4 2.36 1.59 2.45 2.64 3.83 4.51 4.56 2.02 1.50 NP 2.30 2.13
H5 1.64 2.39 2.93 2.76 2.37 3.80 1.47 4.85 0.64 NP 4.26 1.73
H6 0.80 0.24 1.93 2.04 2.12 2.28 0.73 1.56 NP NP 2.46 3.34
H7 2.57 1.90 4.83 3.19 2.40 3.48 5.39 4.41 4.28 NP 2.32 1.15
MED. 2.09 1.59 2.45 2.64 2.37 2.60 1.78 1.93 1.51 2.30 1.73
MIN 0.80 0.24 1.88 2.04 1.26 1.15 0.68 0.81 0.64 0.60 0.99
MAX 3.33 4.64 4.83 3.19 3.83 4.51 5.39 4.85 4.28 4.26 3.34
Appendix 2.9 (d) BALF neutrophil counts (x105/ml) in control (C1-6) and heaves (H1-7) at 6h and 24h following
challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (H/S). MED. = median value, MIN.
= minimum value, MAX. = maximum value.
SALINE SALINE 20m 20|ig 200ng 200m 2000ng 2000ng 200ngR 200ngR HIS HIS
TIME PT 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h
C1 0.04 0.19 0.06 0.03 0.28 3.43 1.61 2.25 0.64 NP 0.02 0.22
C2 0.01 0.02 0.01 0.02 0.08 0.27 0.53 1.12 0.18 NP 0.01 0.09
C3 0.02 0.02 0.12 0.03 0.40 0.35 0.52 1.50 NP NP 0.24 0.21
C4 0.09 0.03 0.08 0.12 1.02 0.31 1.27 1.22 NP NP 0.35 0.10
C5 0.17 0.60 0.10 0.03 0.73 0.42 1.86 1.87 0.69 NP 0.40 0.06
C6 0.09 0.05 0.17 0.18 2.59 0.73 2.70 2.70 0.79 NP 0.11 0.07
MED. 0.06 0.04 0.09 0.03 0.57 0.39 1.44 1.69 0.67 0.17 0.09
MIN 0.01 0.02 0.01 0.02 0.08 0.27 0.52 1.12 0.18 0.01 0.06
MAX 0.17 0.60 0.17 0.18 2.59 3.43 2.70 2.70 0.79 0.40 0.22
H1 0.20 0.12 0.39 0.13 1.14 0.77 1.40 1.17 1.18 NP 3.14 0.54
H2 0.08 0.08 0.20 1.04 1.90 0.55 3.92 0.76 1.49 NP 2.47 0.95
H3 0.17 0.16 0.23 0.26 2.22 0.86 3.25 1.10 1.86 NP 0.74 1.12
H4 0.03 0.04 0.30 0.20 1.82 1.18 3.83 2.15 1.17 NP 1.47 0.27
H5 0.06 0.08 0.28 0.67 1.45 1.26 4.34 6.24 1.08 NP 9.83 0.67
H6 0.06 0.07 0.18 0.14 0.42 0.26 0.57 1.78 NP NP 2.05 1.41
H7 0.06 0.04 0.53 0.14 0.58 0.35 2.64 1.28 0.74 NP 1.41 0.39
MED. 0.06 0.08 0.28 0.20 1.45 0.77 3.25 1.28 1.17 2.05 0.67
MIN 0.03 0.04 0.18 0.13 0.42 0.26 0.57 0.76 0.74 0.74 0.27
MAX 0.20 0.16 0.53 1.04 2.22 1.26 4.34 6.24 1.86 9.83 1.41
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Appendix 2.9 (e) BALF masl cell counts (x105/ml) in control (C1-6) and heaves (H1-7) at 6h AND 24h following
challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (H/S). MED. = median value, MIN.
= minimum value, MAX. = maximum value.
SALINE SALINE 20jig 20ng 200fig 200ng 2000ng 2000jig 200|igR 200^gR H/S HIS
TIME PT 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h
C1 0.23 0.19 0.32 0.33 0.28 0.12 0.23 0.14 0.20 NP 0.11 0.20
C2 0.30 0.19 0.12 0.21 0.10 0.11 0.12 0.11 0.16 NP 0.01 0.20
C3 0.26 0.50 0.12 0.16 0.26 0.24 0.08 0.30 NP NP 0.11 0.20
C4 0.06 0.04 0.05 0.05 0.04 0.03 0.04 0.07 NP NP 0.07 0.05
C5 0.39 0.15 0.10 0.19 0.09 0.10 0.09 0.00 0.16 NP 0.12 0.17
C6 0.09 0.08 0.20 0.19 0.06 0.05 0.00 0.04 0.04 NP 0.11 0.10
MED. 0.25 0.17 0.12 0.19 0.10 0.10 0.08 0.09 0.16 0.11 0.18
MIN 0.06 0.04 0.05 0.05 0.04 0.03 0.00 0.00 0.04 0.01 0.05
MAX 0.39 0.50 0.32 0.33 0.28 0.24 0.23 0.30 0.20 0.12 0.20
H1 0.11 0.75 0.18 0.34 0.10 0.39 0.05 0.24 0.09 NP 0.12 0.32
H2 0.15 0.25 0.07 0.04 0.06 0.08 0.03 0.13 0.03 NP 0.11 0.05
H3 0.19 0.38 0.30 0.24 0.24 0.10 0.10 0.09 0.10 NP 0.10 0.14
H4 0.13 0.12 0.07 0.12 0.07 0.19 0.05 0.05 0.03 NP 0.08 0.17
H5 0.09 0.07 0.08 0.08 0.05 0.22 0.01 0.27 0.01 NP 0.08 0.10
H6 0.10 0.04 0.07 0.12 0.40 0.45 0.17 0.07 NP NP 0.10 0.31
H7 0.17 0.12 0.06 0.07 0.02 0.13 0.03 0.07 0.03 NP 0.10 0.09
MED. 0.13 0.12 0.07 0.12 0.07 0.19 0.05 0.09 0.03 0.10 0.14
MIN 0.09 0.04 0.06 0.04 0.02 0.08 0.01 0.05 0.01 0.08 0.05
MAX 0.19 0.75 0.30 0.34 0.40 0.45 0.17 0.27 0.10 0.12 0.32
Appendix 2.9 (g) BALF eosinophil counts (x105/ml) in control (C1-6) and heaves (H1-7) at 6h AND 24h
following challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (H/S). MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE SALINE 20|ig 20(xg 20(Hig 200ng 2000fig 2000|xg 200jigR 200ngR H/S H/S
TIME PT 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h
C1 0.05 0.02 0.00 0.02 0.00 0.02 0.34 0.01 0.12 NP 0.01 0.04
C2 0.06 0.03 0.01 0.04 0.01 0.07 0.02 0.05 0.00 NP 0.00 0.00
C3 0.00 0.01 0.00 0.01 0.00 0.04 0.01 0.20 NP NP 0.00 0.00
C4 0.00 0.00 0.00 0.08 0.01 0.00 0.03 0.02 NP NP 0.02 0.00
C5 0.02 0.01 0.02 0.04 0.21 0.03 0.09 0.03 0.00 NP 0.01 0.00
C6 0.06 0.02 0.58 0.55 0.16 0.01 0.02 0.00 0.01 NP 0.00 0.01
MED. 0.03 0.01 0.01 0.04 0.01 0.03 0.03 0.02 0.00 0.01 0.00
MIN 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00
MAX 0.06 0.03 0.58 0.55 0.21 0.07 0.34 0.20 0.12 0.02 0.04
H1 0.00 0.04 0.01 0.00 0.00 0.01 0.10 0.00 0.00 NP 0.01 0.00
H2 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 NP 0.00 0.00
H3 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 NP 0.00 0.01
H4 0.01 0.00 0.00 0.09 0.00 0.03 0.00 0.06 0.00 NP 0.00 0.00
H5 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.03 0.03 NP 0.00 0.01
H6 0.01 0.00 0.00 0.06 0.03 0.02 0.01 0.01 NP NP 0.02 0.09
H7 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 NP 0.02 0.02
MED. 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.01
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.01 0.04 0.01 0.09 0.03 0.03 0.10 0.06 0.03 0.02 0.09
Appendix 2.9 (f) BALF basophiloid cell counts (x105/ml) in control (C1-6) and heaves (H1-7) at 6h and 24h
following challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (H/S). MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE SALINE 20ng 20ng 200|ig 200f*g 2000ng 2000^ig 200jigR 200figR HIS H/S
TIME PT 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h
C1 0.07 0.00 0.09 0.03 0.06 0.01 0.04 0.04 0.03 NP 0.09 0.02
C2 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.02 NP 0.00 0.01
C3 0.00 0.04 0.03 0.05 0.02 0.03 0.01 0.09 NP NP 0.03 0.05
C4 0.03 0.00 0.03 0.02 0.10 0.01 0.07 0.05 NP NP 0.12 0.01
C5 0.22 0.00 0.02 0.02 0.03 0.02 0.02 0.00 0.03 NP 0.00 0.00
C6 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 NP 0.00 0.00
MED. 0.02 0.00 0.03 0.02 0.02 0.01 0.02 0.03 0.02 0.02 0.01
MIN 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00
MAX 0.22 0.04 0.09 0.05 0.10 0.03 0.07 0.09 0.03 0.12 0.05
H1 0.01 0.00 0.00 0.02 0.00 0.00 0.00 0.04 0.00 NP 0.04 0.00
H2 0.05 0.00 0.01 0.02 0.09 0.00 0.01 0.00 0.02 NP 0.01 0.00
H3 0.11 0.00 0.01 0.00 0.01 0.00 0.02 0.00 0.02 NP 0.01 0.01
H4 0.01 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.00 NP 0.00 0.02
H5 0.02 0.00 0.12 0.00 0.00 0.01 0.05 0.00 0.01 NP 0.00 0.00
H6 0.00 0.00 0.02 0.01 0.01 0.00 0.00 0.01 NP NP 0.03 0.00
H7 0.01 0.01 0.01 0.01 0.15 0.00 0.01 0.01 0.04 NP 0.08 0.00
MED. 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.00
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.11 0.02 0.12 0.02 0.15 0.01 0.05 0.04 0.04 0.08 0.02
Appendix 2.9 (h) BALF epithelial cell counts (x105/ml) in control (C1-6) and heaves (H1-7) at 6h and 24h
following challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (H/S). MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE SALINE 20fig 20jag 200ng 200ng 2000fxg 2000}ig 200{*gR 200ngR HIS HIS
TIME PT 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h 6h 24h
C1 0.03 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 NP 0.00 0.00
C2 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 NP 0.00 0.00
C3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NP NP 0.00 0.00
C4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NP NP 0.00 0.00
C5 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NP 0.00 0.00
C6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NP 0.00 0.00
MED. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.03 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
H1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NP 0.00 0.00
H2 0.00 0.00 0.00 0.05 0.02 0.01 0.00 0.01 0.00 NP 0.00 0.00
H3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NP 0.00 0.00
H4 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 NP 0.00 0.00
H5 0.10 0.00 0.05 0.00 0.00 0.00 0.00 0.00 0.00 NP 0.00 0.00
H6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NP NP 0.00 0.00
H7 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 NP 0.00 0.00
MED. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.10 0.00 0.05 0.05 0.02 0.01 0.00 0.01 0.00 0.00 0.00
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Appendix 2.10a: Peripheral venous blood total leukocyte concentrations (x109/l) in control (C1-6) and heaves (H1-7) horses prior to (0) and at 90, 240 and 1440min
following inhalation challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (HIS), med. = median value, mini. = minimum value, max. = maximum value.
SALINE 20uq LPS 200uq LPS 2000iiq LPS H/S
TIME PT. 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440
C1 8.5 9.2 9.5 12.7 9.4 9.7 106 11.5 9.1 9.8 10.6 11.2 7.7 8.3 7.7 5.3 7.2 8.9 7.5 9.9
C2 10.6 10.3 12.1 13.3 8.9 8.5 9.2 13.5 12.9 12.2 12.0 12.7 10.3 9.6 10.5 12.1 8.5 9.4 9.1 10.1
C3 8.1 8.1 9.1 13.5 8.9 7.8 8.8 9.2 10.4 8.6 9.6 11.3 7.6 7.1 7.3 9.1 7.4 8.5 8.9 7.0
C4 8.5 7.6 10.1 8.2 8.8 8.2 9.5 12.4 7.9 7.0 8.2 9.6 8.4 8.0 7.7 10.3 6.4 6.9 6.2 9.5
C5 8.1 7.5 9.0 12.1 9.5 8.1 8.5 11.2 9.2 7.3 8.0 6.9 8.5 7.1 6.6 11.3 6.6 7.7 8.0 8.0
C6 7.2 7.1 7.4 9.8 8.5 7.1 8.0 10.8 7.8 6.5 7.5 8.2 6.1 4.7 4.1 6.5 7.7 7.8 8.9 10.5
MED. 8.3 7.9 9.3 12.4 8.9 8.2 9.0 11.4 9.2 8.0 8.9 10.4 8.1 7.6 7.5 9.7 7.3 8.2 8.5 9.7
MIN. 7.2 7.1 7.4 8.2 8.5 7.1 8.0 9.2 7.8 6.5 7.5 6.9 6.1 4.7 4.1 5.3 6.4 6.9 6.2 7.0
MAX. 10.6 10.3 12.1 13.5 9.5 9.7 10.6 13.5 12.9 12.2 12.0 12.7 10.3 9.6 10.5 12.1 8.5 9.4 9.1 10.5
H1 9.3 9.1 10.7 10.3 11.5 11.8 12.7 10.8 9.1 11.0 11.4 10.0 10.7 10.5 9.1 10.9 8.6 7.3 8.6 10.9
H2 6.0 6.3 6.8 8.2 6.8 6.4 6.6 8.0 5.5 4.5 5.6 8.7 3.6 4.0 3.7 7.3 5.5 6.2 6.2 6.1
H3 9.4 8.8 9.0 11.7 9.5 7.6 8.5 10.2 8.4 6.5 6.7 8.4 8.0 6.3 6.2 7.3 9.1 9.0 9.4 11.4
H4 9.2 7.9 9.3 9.1 7.9 7.9 9.1 8.9 7.7 9.0 9.3 11.8 8.8 9.1 7.4 10.1 6.9 7.3 7.2 9.2
H5 10.6 10.5 12.2 11.9 12.1 11.6 10.5 12.4 14.5 14.0 13.2 13.4 14.2 13.5 13.8 19.2 9.7 8.8 9.1 14.6
H6 7.3 6.3 7.2 10.0 6.8 7.5 7.2 13.4 7.0 6.1 6.5 8.2 8.2 6.7 7.3 8.0 7.0 7.5 7.1 7.4
H7 10.5 10.0 11.0 13.5 10.3 10.7 11.1 12.7 10.4 11.3 13.2 12.7 10.0 10.4 10.5 13.5 9.3 9.5 10.4 7.8
MED. 9.3 8.8 9.3 10.3 9.5 7.9 9.1 10.8 8.4 9.0 9.3 10.0 8.8 9.1 7.4 10.1 8.6 7.5 8.6 9.2
MIN. 6.0 6.3 6.8 8.2 6.8 6.4 6.6 8.0 5.5 4.5 5.6 8.2 3.6 4.0 3.7 7.3 5.5 6.2 6.2 6.1
MAX. 10.6 10.5 12.2 13.5 12.1 11.8 12.7 13.4 14.5 14.0 13.2 13.4 14.2 13.5 13.8 19.2 9.7 9.5 10.4 14.6
Appendix 2.10b: Peripheral venous blood neutrophil concentration (x109/l) in control (C1-6) and heaves (H1-7) horses prior to (0) and at 90, 240 and 1440min
following inhalation challenge with saline, 20, 200 and 2000pg LPS, and 5h hay straw challenge (H/S). med. = median value, mini. = minimum value, max. = maximum value.
SALINE 20uq LPS 200n LPS 2000uq LPS H/S
TIME PT. 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440 0 90 240 1440
C1 4.3 4.4 6.0 7.2 5.5 5.5 6.6 7.1 5.0 5.3 7.3 6.7 2.8 4.2 2.9 4.1 4.3 4.5 5.0 6.6
C2 5.3 5.7 7.6 6.0 3.2 4.2 3.3 8.8 7.2 6.5 7.0 7.9 6.3 5.8 6.5 6.9 3.9 4.8 4.3 6.5
C3 2.4 4.0 4.0 7.7 4.0 3.2 4.3 5.2 5.2 5.4 4.8 6.7 3.4 2.6 2.6 4.7 3.6 3.7 4.0 3.1
C4 3.7 4.9 4.1 4.3 3.7 3.9 4.0 9.2 2.8 2.6 3.3 4.3 4.0 3.4 4.3 5.7 2.4 2.0 1.6 5.4
C5 4.6 4.1 3.6 10.2 6.1 4.4 5.0 6.8 5.2 4.2 4.4 4.6 4.7 4.1 3.8 5.8 3.9 4.5 4.3 5.8
C6 3.2 4.3 3.1 6.0 3.8 4.1 4.6 7.6 5.6 3.9 4.2 6.0 4.2 2.9 2.1 3.4 3.2 5.1 4.8 7.6
MED. 4.0 4.3 4.1 6.6 3.9 4.1 4.5 7.4 5.2 4.7 4.6 6.3 4.1 3.8 3.4 5.2 3.8 4.5 4.3 6.1
MIN. 2.4 4.0 3.1 4.3 3.2 3.2 3.3 5.2 2.8 2.6 3.3 4.3 2.8 2.6 2.1 3.4 2.4 2.0 1.6 3.1
MAX. 5.3 5.7 7.6 10.2 6.1 5.5 6.6 9.2 7.2 6.5 7.3 7.9 6.3 5.8 6.5 6.9 4.3 5.1 5.0 7.6
H1 6.1 6.5 8.5 6.6 7.9 8.3 7.6 4.6 5.4 7.4 9.1 5.0 9.4 9.0 7.6 8.0 4.5 4.3 4.1 7.7
H2 4.0 3.5 4.1 6.0 4.0 3.9 4.0 5.8 3.7 2.9 3.9 6.8 2.2 3.2 2.5 5.5 3.1 2.8 3.6 4.1
H3 6.3 6.7 6.3 7.8 5.9 5.4 6.4 6.3 4.5 3.6 4.4 6.2 5.5 3.7 4.3 5.0 6.0 5.8 6.9 7.1
H4 5.1 4.8 6.5 6.2 5.5 5.4 5.9 5.6 4.5 5.9 7.0 8.3 5.6 5.7 5.6 7.5 4.3 4.8 5.3 5.8
H5 7.1 7.5 8.1 9.2 7.1 9.2 7.1 9.4 10.7 10.4 9.1 8.7 9.8 10.0 12.3 14.6 5.5 5.6 5.6 11.8
H6 3.9 4.0 4.9 5.6 2.7 4.1 3.2 9.5 3.2 3.4 3.3 5.3 2.4 2.7 3.0 4.4 3.7 3.5 3.3 4.6
H7 6.5 6.0 6.7 9.5 5.6 6.4 6.2 8.8 6.3 7.8 8.7 7.5 5.5 7.9 6.7 9.6 5.0 5.4 6.1 5.1
MED. 6.1 6.0 6.5 6.6 5.6 5.4 6.2 6.3 4.5 5.9 7.0 6.8 5.5 5.7 5.6 7.5 4.5 4.8 5.3 5.8
MIN. 3.9 3.5 4.1 5.6 2.7 3.9 3.2 4.6 3.2 2.9 3.3 5.0 2.2 2.7 2.5 4.4 3.1 2.8 3.3 4.1
MAX. 7.1 7.5 8.5 9.5 7.9 9.2 7.6 9.5 10.7 10.4 9.1 8.7 9.8 10.0 12.3 14.6 6.0 5.8 6.9 11.8
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Appendix 3.1: Clinical scores in heaves (HI-5 and 7) horses prior to (0) and at 90, 240 and 1440min following initiation of 5h hay straw challenges H/S A and H/S B. Score based on:
a (tracheal auscultation), d (dyspnoea) and e (respiratory rate).
CHALLENGE H/S A H/SB
TIME PT. (min) P 90 240 1440 0 90 ro
\
1440
H1 0 0 2 d,e 0 0 0 0 0
H2 0 0 0 0 0 0 0 0
H3 0 0 0 0 0 0 0 0
H4 0 0 1 d 0 0 1 d 0 0
H5 0 0 2 d,e 0 0 1 d 2 d,e 0
H7 0 1 e 1 d 1 d 0 0 2 d,e 1 a
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Appendix 3.2a (i and ii): Lung function measurements in heaves (H1-5 and 7) horses prior to (Oh) and at 5h following initiation of 5h hay/straw challenge HIS A. TP
= time point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (1/kPa) dPpl(KPa) RUo (kPa/l/sec) RR (breaths/min.) VT(I) Wb' (J/min) RLe25% (kPa/l/sec) Rl-E5o% (kPa/i/sec) RLe?s% (kPa/l/sec) RLi2s%(kPa/l/sec) RLi5o% (kPa/l/sec) RLi75% (kPa/i/sec)
TP Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h
H1 27.96 25.85 0.58 0.59 0.04 0.04 6.10 7.45 9.01 8.63 12.59 15.30 0.06 0.05 0.04 0.05 0.06 0.05 0.07 0.02 0.06 0.03 0.05 0.03
H2 31.37 28.53 0.43 0.42 0.06 0.04 6.85 7.75 5.18 5.86 7.59 7.82 0.07 0.01 0.06 0.02 0.07 0.04 0.06 0.05 0.05 0.05 0.05 0.05
H3 14.21 11.46 0.51 0.50 0.03 0.06 7.20 8.00 4.73 3.60 7.68 6.23 0.07 0.02 0.03 0.02 0.03 0.04 0.10 0.10 0.11 0.11 0.08 0.12
H4 24.59 36.76 0.40 0.42 0.05 0.04 10.25 11.80 0.00 0.00 11.45 16.12 0.02 0.02 0.04 0.04 0.05 0.05 0.05 0.04 0.05 0.04 0.05 0.04
H5 25.23 30.14 0.58 0.49 0.04 0.04 6.95 8.10 8.94 8.42 14.18 14.713 0.05 0.02 0.05 0.03 0.06 0.04 0.03 0.03 0.03 0.03 0.04 0.04
H7 15.60 23.38 0.54 0.36 0.04 0.04 22.25 14.00 4.19 4.06 25.06 10.26 0.03 0.02 0.04 0.04 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
MED. 24.91 25.85 0.53 0.42 0.04 0.04 6.95 9.78 4.96 4.06 12.02 10.26 0.05 0.02 0.04 0.04 0.06 0.05 0.05 0.05 0.05 0.05 0.05 0.05
MIN. 14.21 11.46 0.40 0.36 0.03 0.04 6.10 7.45 0.00 0.00 7.59 6.23 0.02 0.01 0.03 0.02 0.03 0.04 0.03 0.02 0.03 0.03 0.04 0.03
MAX. 31.37 36.76 0.58 0.59 0.06 0.06 22.25 14.00 9.01 8.63 25.06 16.12 0.07 0.05 0.06 0.05 0.07 0.05 0.10 0.10 0.11 0.11 0.08 0.12
TE(sec) Ti (sec) T.:Te VE (I/min) V'Emax (i/SeC) V (max (l/sec) Wbm Wbr ss(J) WbE es(J) : Wbires(J) Whoot(J)
TP Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h
H1 4.61 3.57 5.52 4.13 1.23 1.20 54.88 64.25 3.80 5.57 3.40 3.69 1.50 1.12 2.12 1.99 1.25 1.46 0.87 0.53 2.37 1.64
H2 4.84 4.80 3.82 2.97 0.79 0.62 35.87 45.52 2.48 2.82 2.86 3.62 0.44 0.60 1.08 1.01 0.60 0.46 0.48 0.54 0.92 1.14
H3 3.16 3.82 4.55 3.06 1.99 0.96 41.25 33.35 1.73 1.87 2.64 2.76 1.21 0.68 0.95 0.74 0.25 0.21 0.70 0.53 1.91 1.21
H4 3.25 2.91 2.46 2.25 0.75 0.79 54.83 67.08 2.94 3.78 3.56 4.05 0.67 0.50 1.10 1.37 0.51 0.71 0.59 0.66 1.26 1.16
H5 5.18 4.38 3.21 3.09 0.64 0.722 62.24 68.29 3.16 3.65 3.86 4.33 1.41 1.31 1.93 1.83 1.00 0.78 0.93 1.05 2.34 2.37
H7 1.38 1.97 1.46 2.28 1.05 1.16 91.76 56.46 4.14 2.90 4.34 2.78 0.63 0.38 1.18 0.74 0.53 0.35 0.65 0.39 1.28 0.76
MED. 3.93 3.57 3.52 2.97 0.92 0.96 54.88 60.35 3.05 2.90 3.48 3.62 0.94 0.60 1.14 1.01 0.57 0.46 0.67 0.53 1.59 1.16
MIN. 1.38 1.97 1.46 2.25 0.64 0.62 35.87 45.52 1.73 1.87 2.64 2.76 0.44 0.38 0.95 0.74 0.25 0.21 0.48 0.39 0.92 0.76
MAX. 5.18 4.80 5.52 4.13 1.99 1.20 91.76 67.08 4.14 5.57 4.34 4.05 1.50 1.12 2.12 1.99 1.25 1.46 0.93 0.66 2.37 1.64
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Appendix 3.2 (i and ii): Lung function measurements in heaves (H1-5 and 7) horses prior to (Oh) and at 5h following initiation of 5h hay/straw challenge H/S B. TP =
time point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (l/kPa) dPpi (kPa) RLjS0 (kPa/l/sec) RR (breaths/min.) VT(I) Wb' (J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/l/sec) RLe7s% (kPa/l/sec) RLi2s% (kPa/f/sec) RLiso%(KPa/l/sec) RLi75% (kPa/i/sec)
TP Oh 5h Oh 5h 0h 5h 0h 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h
H1 27.12 26.47 1.02 0.66 0.16 0.06 4.95 7.55 8.14 7.50 22.64 19.24 0.17 0.08 0.13 0.07 0.19 0.08 0.15 0.06 0.15 0.06 0.21 0.07
H2 46.49 20.52 0.43 0.76 0.05 0.09 7.60 9.45 6.03 5.66 9.70 18.75 0.03 0.05 0.05 0.06 0.06 0.09 0.05 0.07 0.05 0.08 0.06 0.08
H3 10.91 14.23 0.69 0.57 0.10 0.07 8.70 5.85 4.98 4.68 11.06 6.15 0.03 0.00 0.03 0.01 0.07 0.06 0.17 0.12 0.22 0.13 0.13 0.11
H4 25.75 31.19 0.43 0.38 0.05 0.03 7.20 9.50 5.70 5.84 8.08 8.58 0.02 0.03 0.04 0.03 0.07 0.05 0.06 0.04 0.06 0.04 0.06 0.03
H5 21.88 20.48 0.51 0.55 0.06 0.07 8.10 6.85 6.84 7.13 13.96 11.91 0.02 0.04 0.04 0.07 0.07 0.07 0.07 0.03 0.08 0.06 0.08 0.07
H7 33.40 21.49 0.55 0.91 0.06 0.14 19.55 14.50 4.17 4.25 28.45 35.06 0.05 0.11 0.06 0.13 0.07 0.14 0.05 0.12 0.06 0.14 0.07 0.16
MED. 26.44 21.00 0.53 0.62 0.06 0.07 7.85 8.50 5.86 5.75 12.51 15.33 0.03 0.05 0.05 0.06 0.07 0.07 0.06 0.07 0.07 0.07 0.08 0.08
MIN. 10.91 14.23 0.43 0.38 0.05 0.03 4.95 5.85 4.17 4.25 8.08 6.15 0.02 0.00 0.03 0.01 0.06 0.05 0.05 0.03 0.05 0.04 0.06 0.03
MAX. 46.49 31.19 1.02 0.91 0.16 0.14 19.55 14.50 8.14 7.50 28.45 35.06 0.17 0.11 0.13 0.13 0.19 0.14 0.17 0.12 0.22 0.14 0.21 0.16
Te(sec) Ti (sec) T.:TE V'E (l/min) V'Emax (l/sec) V Imax (l/sec) Wbm Wbres (J) WbEfes(J) Wblres(J) WbHot(J)
TP Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h
H1 5.67 4.00 6.18 3.82 1.10 0.99 40.19 56.47 2.13 3.41 1.76 3.00 1.25 1.05 4.38 2.44 2.18 1.26 2.20 1.17 3.45 2.22
H2 4.72 3.72 3.11 2.70 0.66 0.73 45.65 53.25 2.55 3.12 3.01 2.84 0.39 0.79 1.28 2.01 0.61 1.00 0.66 1.01 1.06 1.81
H3 3.88 6.66 3.98 3.49 1.03 0.55 43.03 27.33 2.53 2.00 2.37 2.13 1.18 0.87 1.46 1.02 0.48 0.33 0.98 0.69 2.15 1.56
H4 4.55 3.32 3.65 3.05 0.81 0.92 41.02 55.47 2.52 3.09 2.67 3.36 0.64 0.52 1.10 0.91 0.59 0.56 0.51 0.36 1.16 0.88
H5 4.09 5.19 3.34 3.87 0.82 0.75 55.61 48.86 2.85 2.68 3.52 3.16 1.28 1.37 1.71 1.81 0.60 1.00 1.11 0.80 2.39 2.17
H7 1.57 2.23 1.56 1.93 1.01 0.88 81.68 61.07 3.36 2.31 4.06 2.93 0.32 0.47 1.45 2.46 0.73 1.05 0.72 1.41 1.04 1.88
MED. 4.32 3.86 3.49 3.27 0.91 0.81 44.34 54.26 2.54 2.88 2.84 2.96 0.91 0.83 1.45 1.91 0.61 1.00 0.85 0.91 1.65 1.85
MIN. 1.57 2.23 1.56 1.93 0.66 0.55 40.19 27.23 2.13 2.00 1.76 2.13 0.32 0.47 1.10 0.91 0.48 0.33 0.51 0.36 1.04 0.88
MAX. 5.67 6.66 6.18 3.87 1.10 0.99 81.68 61.07 3.36 3.41 4.06 3.36 1.28 1.37 4.38 2.46 2.18 1.26 2.20 1.41 3.45 2.22
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Appendix 3.3: PCCdyn70 values
(mg/ml) in heaves (H1-5 and 7)
horses at 5h following initiation
of 5h hay/straw challenges H/S
A and H/S B. MED. = median
value, MIN. = minimum value,
MAX. = maximum value.
Appendix 3.4: BALF total nucleated cell (TCC), lymphocyte (L), macrophage (M), neutrophil (N), mast cell (Ma),
basiphiloid cell (B), eosinophil (Eo) and epithelial cell (Ep) counts (x105/ml) in heaves (H1-5 and 7) at 6h following













TCC M H N a B Eo E D
H/S A H/S B H/S A H/S B H/S A H/S B H/S A H/S B H/S A H/S B H/S A H/S B H/S A H/S B H/S A H/S B
H1 5.10 6.20 3.34 1.44 0.98 1.44 0.53 3.14 0.25 0.12 0.00 0.04 0.01 0.01 0.00 0.00
H2 4.00 4.20 1.81 0.71 1.68 0.90 0.37 2.47 0.12 0.11 0.02 0.01 0.00 0.00 0.00 0.00
H3 5.00 2.80 2.02 0.60 1.97 1.35 0.58 0.74 0.38 0.10 0.05 0.01 0.01 0.00 0.00 0.00
H4 8.20 7.00 3.06 2.30 4.49 3.16 0.37 1.47 0.28 0.08 0.00 0.00 0.01 0.00 0.00 0.00
H5 9.80 16.20 4.32 4.26 4.66 2.03 0.70 9.83 0.11 0.08 0.01 0.00 0.01 0.00 0.00 0.00
H7 2.10 6.50 0.86 2.32 0.78 2.57 0.34 1.41 0.08 0.10 0.03 0.08 0.01 0.02 0.00 0.00
MED. 5.05 6.35 2.54 1.87 1.82 1.73 0.45 1.97 0.18 0.10 0.01 0.01 0.01 0.00 0.00 0.00
MIN 2.10 2.80 0.86 0.60 0.78 0.90 0.34 0.74 0.08 0.08 0.00 0.00 0.00 0.00 0.00 0.00
MAX 9.80 16.20 4.32 4.26 4.66 3.16 0.70 9.83 0.38 0.12 0.05 0.08 0.01 0.02 0.00 0.00
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Appendix 4.1: Clinical scores in heaves (H1-5 and 7) horses prior to (0) and at 240min following inhalation challenge with saline, 0.5, 1.6
and 5.0mg Aspergillus fumigatus extract (AFE). Score based on: b (thoracic auscultation).
CHALLENGE SALINE 0.5 mg AFE 1.6 mg AFE
■
5.0 mg AFE
TIME PT. (min) 0 240 0 240 0 240 0 240
H1 0 0 0 0 0 0 0 0
H2 0 0 0 0 0 0 0 0
H3 0 0 0 0 0 0 0 0
LI AH4 0 0 0 0 0 0 0 0
H5 0 0 0 0 0 0 0 0
H7 0 0 0 0 0 0 0 1 b
Appendix 4.2a: Arterial blood pH, pC02 (mmHg) and p02 (mmHg) in heaves (H1-5 and 7) horses prior to (0) and at 240min following inhalation challenge with
saline, 0.5, 1.6 and 5.0mg Aspergillus fumigatus extract (AFE). MED. = median value, MIN. = minimum value, MAX. = maximum value.
PH pC02 po2
SALINE 0.5ms AFE 1.6mg AFE 5.0mg AFE SALINE 0.5mg AFE 1.6mg AFE 5.0mg AFE SALINE 0.5mg AFE 1.6mg AFE 5.0mg AFE
HORSE 0 240 0 240 0 240 0 240 o 240 0 240 0 240 0 240 0 240 0 240 0 240 0 240
H1 7.36 7.38 7.41 7.40 7.38 7.37 7.36 7.35 45.0 40.0 45.6 46.9 41.6 43.0 43.9 48.5 99.0 98.0 94 3 96.4 113.5 1103 109.9 98 1
H2 7.35 7.36 7.37 7.40 7.36 7.39 7.33 7.35 47.0 46.0 50.9 53.8 48.7 53.1 52.8 54.4 116.0 102.0 102.6 100.8 116.2 99.3 87.8 87.8
H3 7.40 7.41 7.35 7.40 7.38 7.37 7.39 7.39 42.0 37.0 49.5 48.3 52.4 50.9 50.5 47.6 94.0 98.0 107.1 97.2 111.3 99.6 99.5 108.7
H4 7.39 7.35 7.38 7.41 7.41 7.41 7.38 7.38 43.0 45.0 48.1 46.2 48.5 50.3 45.2 47.1 102.0 97.0 101.8 93.0 102.7 101.5 104.5 102.6
H5 7.37 7.37 7.39 7.41 7.37 7.43 7.37 7.39 53.0 43.0 48.4 50.2 51.0 46.2 48.1 46.5 94.0 83.0 100.4 101.0 114.6 104.3 106.3 102.5
H7 7.41 7.43 7.41 7.42 7.38 7.37 7.37 7.40 46.0 45.0 45.6 46.0 41.6 43.0 48.3 50.0 100.0 109.0 113.6 112.1 113.5 110.3 106.7 101.3
MED. 7.38 7.38 7.39 7.40 7.38 7.38 7.37 7.39 45.5 44.0 48.3 47.6 48.6 48.3 48.2 48.1 99.5 98.0 102.2 99.0 113.5 102.9 105.4 101.9
MIN. 7.35 7.35 7.35 7.40 7.36 7.37 7.33 7.35 42.0 37.0 45.6 46.0 41.6 43.0 43.9 46.5 94.0 83.0 94.3 93.0 102.7 99.3 87.8 87.8
MAX. 7.41 7.43 7.41 7.42 7.41 7.43 7.39 7.40 53.0 46.0 50.9 53.8 52.4 53.1 52.8 . 54.4 116.0 109.0 113.6 112.1 116.2 110.3 109.9 108.7
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Appendix 4.3a (i and ii): Lung function measurements in heaves (H1-5 and 7) horses prior to (Oh) and at 5h following inhalation challenge with saline. TP = time
point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (i/kPa) dPpl(kPa) RL,so (kPa/l/sec) RR (breaths/min.) VT (I) Wb' (J/min) RIe25% (kPa/l/sec) RLE5o% (kPa/l/sec) RLe7s% (kPa/l/sec) RLi2s% (kPa/l/sec) RLi5b% (kPa/l/sec) RLi75% (kPa/l/sec)
TP Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h
H1 15.09 11.44 0.62 0.82 0.04 0.03 10.40 11.50 6.35 6.40 16.27 16.14 0.05 0.03 0.05 0.03 0.08 0.04 0.07 0.08 0.06 0.06 0.06 0.05
H2 21.95 23.02 0.67 0.75 0.07 0.07 8.80 8.50 6.28 7.71 19.71 22.90 0.04 0.06 0.06 0.06 0.07 0.07 0.08 0.06 0.08 0.06 0.08 0.07
H3 11.44 9.12 0.50 0.95 0.06 0.11 8.5 5.30 3.96 6.57 9.90 14.50 0.09 0.03 0.08 0.00 0.08 0.05 0.09 0.23 0.10 0.33 0.08 0.25
H4 32.99 31.80 0.53 0.49 0.06 0.05 7.10 6.40 7.72 8.74 15.70 13.38 0.07 0.03 0.06 0.04 0.08 0.05 0.08 0.06 0.06 0.06 0.07 0.06
H5 20.73 20.17 1.09 0.66 0.03 0.05 14.95 10.15 11.19 7.52 76.09 22.03 0.04 0.05 0.05 0.06 0.06 0.07 0.01 0.04 0.02 0.05 0.03 0.05
H7 8.56 8.45 0.835 0.87 0.08 0.06 13.4 12.85 4.93 5.40 22.731 21.01 0.06 0.03 0.07 0.03 0.08 0.05 0.10 0.13 0.10 0.10 0.09 0.08
MED. 20.73 15.80 0.62 0.79 0.06 0.05 9.60 9.33 6.35 7.04 16.27 18.58 0.05 0.03 0.06 0.04 0.08 0.05 0.08 0.07 0.06 0.06 0.07 0.06
MIN. 11.44 8.45 0.50 0.49 0.03 0.03 7.10 5.30 3.96 5.40 9.90 13.38 0.04 0.03 0.05 0.00 0.06 0.04 0.01 0.04 0.02 0.05 0.03 0.05
MAX. 32.99 31.80 1.09 0.95 0.07 0.11 14.95 12.85 11.19 8.74 76.09 22.90 0.09 0.06 0.08 0.06 0.08 0.07 0.09 0.23 0.10 0.33 0.08 0.25
TE (sec) Ti(sec) T.:TE VE (l/min) V'Emax (l/sec) V (max l/sec) Wb ,(J) Wbr .(J) WbE Wbires(J) i Wb|;m
TP 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h
H1 2.78 2.31 3.10 2.68 1.14 1.17 65.79 73.34 4.55 6.27 3.04 3.46 1.36 1.68 1.59 1.36 0.77 0.51 0.82 0.86 2.18 2.54
H2 3.84 3.97 2.91 3.12 0.78 0.79 55.72 65.68 3.46 3.46 3.55 3.59 0.90 1.33 2.19 2.70 1.05 1.21 1.14 1.50 2.04 2.83
H3 2.99 6.57 3.02 4.56 1.20 0.70 39.83 34.77 2.13 2.57 3.55 3.39 1.00 2.30 0.96 2.66 0.27 0.60 0.69 2.06 1.69 4.37
H4 5.06 5.03 3.72 4.16 0.94 1.02 53.25 55.75 2.73 3.21 2.97 4.17 1.01 1.33 2.32 2.06 1.10 0.95 1.22 1.11 2.23 2.45
H5 2.14 3.27 2.06 2.77 0.99 1.00 169.96 74.37 8.95 3.87 7.92 4.44 3.25 1.57 4.74 2.28 2.95 1.24 1.78 1.04 5.04 2.61
H7 2.29 2.24 2.23 2.42 0.98 1.09 65.99 69.32 3.321 3.79 3.102 3.19 1.422 1.75 1.72 1.64 0.63 0.42 1.08 1.21 2.51 2.96
MED. 2.99 3.62 3.02 2.94 0.99 1.01 60.76 67.50 3.46 3.63 3.55 3.53 1.01 1.62 2.19 2.17 1.05 0.77 1.14 1.16 2.18 2.72
MIN. 2.14 2.24 2.06 2.42 0.78 0.70 53.25 34.77 2.13 2.57 2.97 3.19 0.90 1.33 0.96 1.36 0.27 0.42 0.69 0.86 1.69 2.45
MAX. 5.06 6.57 3.72 4.56 1.20 1.17 169.96 74.37 8.95 6.27 7.92 4.44 3.25 2.30 4.74 2.70 2.95 1.24 1.78 2.06 5.04 4.37
327
Appendix 4.3b (i and ii): Lung function measurements in heaves (H1-5 and 7) horses prior to (Oh) and at 5h following inhalation challenge with 0.5mg Aspergillus
fumigatus extract (AFE). TP = time point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (f/kPa) dPpl(kPa) RL,so (kPa/l/sec) RR (breaths/min.) VT (I) Wb'(J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/l/sec) RLe7s% (kPa/l/sec) RLi25% (kPa/l/sec) Rliso% (kPa/i/sec) RLi75% (kPa/I/sec)
TP Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h 0h 5h Oh 5h 0h 5h 0h 5h Oh 5h Oh 5h Oh 5h
H1 22.44 17.02 0.52 0.72 0.05 0.06 7.50 5.50 6.01 8.15 11.78 13.25 0.06 0.10 0.07 0.10 0.07 0.07 0.07 0.114 0.06 0.091 0.07 0.09
H2 50.77 38.90 0.58 0.53 0.04 0.05 7.20 8.10 6.97 5.66 12.28 9.58 0.03 0.03 0.05 0.04 0.08 0.05 0.06 0.40 0.06 0.39 0.06 0.45
H3 13.47 14.30 0.73 0.52 0.10 0.04 6.25 3.90 5.91 4.28 10.09 8.75 0.07 0.06 0.03 0.07 0.07 0.14 0.12 0.12 0.16 0.138 0.11 0.13
H4 29.11 37.02 0.44 0.40 0.04 0.03 9.65 10.70 6.27 5.94 12.06 10.84 0.01 0.02 0.03 0.04 0.05 0.05 0.04 0.04 0.04 0.03 0.04 0.04
H5 32.06 37.14 0.39 0.39 0.04 0.04 7.15 6.75 7.48 6.83 8.56 8.24 0.03 0.04 0.05 0.04 0.06 0.05 0.04 0.05 0.05 0.05 0.05 0.05
H7 15.67 30.36 0.61 0.70 0.06 0.07 13.40 22.30 5.23 4.38 19.75 47.29 0.05 0.07 0.05 0.07 0.06 0.08 0.06 0.06 0.06 0.07 0.07 0.08
MED. 25.78 37.08 0.55 0.47 0.05 0.05 7.35 9.40 6.14 5.80 11.92 10.21 0.04 0.03 0.05 0.04 0.06 0.05 0.06 0.06 0.06 0.06 0.06 0.06
MIN. 13.47 30.36 0.39 0.39 0.04 0.03 6.25 6.75 5.23 4.38 8.56 8.24 0.01 0.02 0.03 0.04 0.05 0.05 0.04 0.04 0.04 0.03 0.04 0.04
MAX. 50.77 38.90 0.73 0.70 0.10 0.07 13.40 22.30 7.48 6.83 19.75 47.29 0.07 0.07 0.07 0.07 0.08 0.08 0.12 0.40 0.16 0.39 0.11 0.45
Te (sec) T| (sec) T,:Te V'E (l/min) V'Emax (i/SeC) V imax (l/sec) Wb .(J) Wbr «<J> WbE Wbires(J) Wbttof (J)
TP Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h
H1 3.50 5.37 4.15 5.36 1.25 0.10 44.90 44.69 3.49 3.6 2.66 2.97 0.87 1.936 1.48 2.368 0.81 1.258 0.67 1.11 1.54 3.047
H2 4.71 4.40 3.56 3.19 0.76 0.71 50.31 45.63 2.77 2.55 3.07 2.94 0.88 0.44 1.69 1.72 0.84 1.14 0.85 0.58 1.74 1.02
H3 5.53 3.62 4.58 4.52 0.85 1.25 36.89 16.88 2.49 1.79 3.15 3.14 1.35 1.44 1.69 1.19 0.71 0.10 0.98 1.09 2.33 2.53
H4 3.36 3.04 2.83 2.80 0.86 0.94 60.75 63.59 3.52 3.59 3.87 3.51 0.67 0.51 1.22 1.07 0.67 0.55 0.55 0.52 1.22 1.03
H5 5.00 5.53 3.57 3.33 0.72 0.63 53.09 46.10 2.78 2.20 3.27 3.56 0.90 0.68 1.22 1.20 0.46 0.38 0.76 0.82 1.66 1.50
H7 2.27 1.31 2.30 1.43 1.02 1.10 69.74 97.70 3.06 4.24 3.11 3.96 0.92 0.32 1.52 2.16 0.71 1.18 0.81 0.98 1.73 1.30
MED. 4.11 3.72 3.56 3.00 0.85 0.82 51.70 54.84 2.92 3.07 3.13 3.54 0.89 0.47 1.50 1.46 0.71 0.84 0.79 0.70 1.70 1.16
MIN. 2.27 1.31 2.30 1.43 0.72 0.63 36.89 45.63 2.49 2.20 2.66 2.94 0.67 0.32 1.22 1.07 0.46 0.38 0.55 0.52 1.22 1.02
MAX. 5.53 5.53 4.58 3.33 1.25 1.10 69.74 97.70 3.52 4.24 3.87 3.96 1.35 0.68 1.69 2.16 0.84 1.18 0.98 0.98 2.33 1.50
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Appendix 4.3c (i and ii): Lung function measurements in heaves (H1-5 and 7) horses prior to (Oh) and at 5h following inhalation challenge with 1.6mg Aspergillus
fumigatus extract (AFE). TP = time point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (l/kpa) dPpl (kPa) RLiso (kPa/l/sec) RR (breaths/min.) VT (I) Wb' (J/min) RLe25% (kPa/l/sec) RUsos. (kPa/l/sec) RLe7s% (kPa/l/sec) RLi2s% (kPa/l/sec) RLiso%(kPa/i/sec) RLi75% (kPa/l/sec)
TP Oh 5h Oh 5h 0h 5h 0h 5h Oh 5h 0h 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h Oh 5h
H1 19.69 17.10 0.68 0.94 0.05 0.10 6.60 5.55 7.87 8.24 14.38 19.36 0.06 0.13 0.02 0.08 0.06 0.13 0.11 0.13 0.11 0.12 0.08 0.12
H2 35.84 33.67 0.56 0.60 0.05 0.08 8.65 7.70 6.81 6.69 14.45 15.89 0.03 0.06 0.04 0.06 0.06 0.08 0.04 0.07 0.04 0.07 0.06 0.08
H3 14.10 8.07 0.62 0.68 0.07 0.15 6.65 3.95 4.88 3.66 10.68 10.62 0.06 0.09 0.03 0.12 0.06 0.11 0.15 0.19 0.17 0.31 0.12 0.25
H4 24.40 23.55 0.60 0.62 0.07 0.06 6.10 9.30 6.98 7.23 12.02 15.52 0.01 0.04 0.06 0.08 0.08 0.08 0.08 0.09 0.09 0.06 0.10 0.08
H5 22.81 31.44 0.53 0.38 0.04 0.03 9.20 8.5 6.97 6.15 12.31 7.75 0.02 0.03 0.04 0.03 0.05 0.05 0.03 0.03 0.04 0.03 0.06 0.05
H7 16.33 15.81 0.61 0.71 0.06 0.08 12.75 10.05 4.98 5.10 17.95 16.66 0.04 0.04 0.03 0.05 0.06 0.09 0.08 0.10 0.08 0.10 0.07 0.09
MED. 21.25 20.32 0.61 0.65 0.05 0.08 7.65 7.70 6.89 6.42 13.34 15.71 0.03 0.05 0.03 0.07 0.06 0.09 0.08 0.09 0.08 0.09 0.08 0.09
MIN. 14.10 8.07 0.53 0.38 0.04 0.03 6.10 3.95 4.88 3.66 10.68 7.75 0.01 0.03 0.02 0.03 0.05 0.05 0.03 0.03 0.04 0.03 0.06 0.05
MAX. 35.84 33.67 0.68 0.94 0.07 0.15 12.75 10.05 7.87 8.24 17.95 19.36 0.06 0.13 0.06 0.12 0.08 0.13 0.15 0.19 0.17 0.31 0.12 0.25
Te (sec) Ti(sec) T,:TE V'E (l/min) VEmax (l/sec) V imax l/sec) Wb .(J) Wb, es(J) WbE es(J) Wb, es(J) Wbt,ot(J)
TP 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h
H1 4.19 4.92 4.88 5.67 1.17 1.16 51.74 45.82 3.69 2.81 3.22 246 1.53 1.98 2.18 3.42 1.09 1.93 1.09 1.49 2.62 3.47
H2 4.01 4.73 2.93 3.24 0.73 0.69 59.13 51.43 3.44 2.88 3.29 2.98 0.67 0.68 1.67 2.09 0.80 0.95 0.87 1.13 1.54 1.81
H3 4.19 2.40 4.10 5.14 1.25 2.15 32.75 14.40 2.38 1.87 3.41 2.65 1.14 1.70 1.47 1.33 0.35 0.12 1.12 1.21 2.26 2.91
H4 5.07 4.26 4.55 4.22 0.90 1.16 42.38 64.20 2.92 3.28 3.40 3.98 0.98 1.44 1.93 2.21 1.06 0.87 0.87 1.33 1.85 2.77
H5 3.76 4.06 2.95 2.79 0.82 0.69 63.72 52.73 3.73 2.83 4.03 3.58 1.15 0.78 1.37 0.92 0.47 0.33 0.91 0.59 2.06 1.37
H7 2.28 2.90 2.33 3.01 1.02 1.05 63.33 51.41 3.19 2.67 3.02 2.63 0.75 0.85 1.38 1.64 0.51 0.77 0.87 0.87 1.62 1.72
MED. 4.10 4.16 3.53 3.73 0.96 1.11 55.44 51.41 3.32 2.82 3.34 2.82 1.06 1.14 1.57 1.86 0.65 0.82 0.89 1.17 1.95 2.29
MIN. 2.28 2.40 2.33 2.79 0.73 0.69 32.75 14.40 2.38 1.87 3.02 2.46 0.67 0.68 1.37 0.92 0.35 0.12 0.87 0.59 1.54 1.37
MAX. 5.07 4.92 4.88 5.67 1.25 2.15 63.72 64.20 3.73 3.28 4.03 3.98 1.53 1.98 2.18 3.42 1.09 1.93 1.12 1.49 2.62 3.47
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Appendix 4.3d (i and ii): Lung function measurements in heaves (H1-5 and 7) horses prior to (Oh) and at 5h following inhalation challenge with 5.0mg Aspergillus
fumigatus extract (AFE). TP = time point, MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (f/kPa) dPpI (kPa) RL1S0 (kPa/i/sec) RR (breaths/min.) VT (I) Wb' <J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/l/sec) RLe?5% (kPa/i/sec) RL-25% (kPa/l/sec) RLi5o% (kPa/i/sec); RLi75% (kPa/i/sec)
TP Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h
H1 17.79 16.53 0.58 0.71 0.05 0.06 7.60 7.40 7.00 8.02 13.38 17.69 0.06 0.07 0.06 0.08 0.04 0.07 0.09 0.09 0.07 0.06 0.07 0.05
H2 33.11 33.32 0.33 0.57 0.04 0.07 10.15 6.80 5.56 7.40 7.21 13.91 0.01 0.07 0.02 0.06 0.03 0.08 0.03 0.05 0.04 0.06 0.04 0.06
H3 11.96 11.95 0.88 0.74 0.07 0.11 6.70 4.55 6.22 6.57 11.10 9.54 0.03 0.05 0.00 0.00 0.05 0.06 0.17 0.21 0.18 0.26 0.12 0.16
H4 44.04 29.11 0.28 0.43 0.03 0.04 13.40 11.85 4.83 5.28 9.29 10.87 0.02 0.02 0.03 0.03 0.04 0.03 0.03 0.04 0.03 0.04 0.03 0.04
H5 26.56 28.02 0.47 0.49 0.05 0.04 8.70 8.40 6.34 6.88 11.01 12.08 0.03 0.04 0.05 0.05 0.06 0.06 0.04 0.03 0.04 0.04 0.06 0.05
H7 14.48 17.56 0.58 0.70 0.06 0.07 14.30 11.50 4.26 5.93 16.70 24.56 0.04 0.07 0.04 0.07 0.06 0.08 0.08 0.07 0.08 0.07 0.07 0.08
MED. 22.17 22.79 0.53 0.64 0.05 0.06 9.43 7.90 5.89 6.72 11.06 13.00 0.03 0.06 0.03 0.06 0.05 0.06 0.06 0.06 0.06 0.06 0.06 0.06
MIN. 11.96 11.95 0.28 0.43 0.03 0.04 6.70 4.55 4.26 5.28 7.21 9.54 0.01 0.02 0.00 0.00 0.03 0.03 0.03 0.03 0.03 0.04 0.03 0.04
MAX. 44.04 33.32 0.88 0.74 0.07 0.11 14.30 11.85 7.00 8.02 16.70 24.56 0.06 0.07 0.06 0.08 0.06 0.08 0.17 0.21 0.18 0.26 0.12 0.16
TE(sec) Ti(sec) T,:Te V'E (J/min) VEmax (i/sec) (l/sec) Wb»(J) Wbres(J) Wb^sU) Wblfes(J) Wbt,ot(J)
TP Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh ill 5h Oh 5h Oh 5h
H1 3.94 3.77 3.95 4.50 1.02 1.27 52.88 59.55 4.56 5.23 3.10 3.49 1.38 1.95 1.76 2.36 0.73 1.26 1.03 1.10 2.41 3.04
H2 3.39 5.25 2.56 3.33 0.76 0.74 56.31 50.08 3.04 3.00 3.64 3.20 0.48 0.87 0.71 1.98 0.29 0.91 0.42 1.08 0.90 1.95
H3 5.04 7.88 4.27 5.40 0.94 0.69 42.49 29.78 2.72 2.11 3.22 2.86 1.57 1.82 1.62 2.09 0.61 0.57 1.01 1.52 2.58 3.34
H4 2.50 2.82 2.20 2.32 0.88 0.82 61.84 61.77 2.95 3.03 3.68 3.73 0.29 0.51 0.70 0.91 0.32 0.42 0.38 0.49 0.67 1.00
H5 3.72 4.04 3.17 3.20 0.86 0.80 55.07 57.75 2.78 2.92 3.46 3.81 0.82 0.89 1.28 1.45 0.51 0.53 0.76 0.92 1.58 1.81
H7 2.07 2.48 2.19 2.80 1.06 1.14 60.35 68.06 2.70 3.53 2.90 3.16 0.82 1.06 1.23 2.11 0.41 1.08 0.82 1.03 1.64 2.09
MED. 3.55 3.90 2.86 3.26 0.91 0.81 55.69 58.65 2.87 3.02 3.34 3.35 0.82 0.98 1.25 2.03 0.46 0.74 0.79 1.05 1.61 2.02
MIN. 2.07 2.48 2.19 2.32 0.76 0.69 42.49 29.78 2.70 2.11 2.90 2.86 0.29 0.51 0.70 0.91 0.29 0.42 0.38 0.49 0.67 1.00
MAX. 5.04 7.88 4.27 5.40 1.06 1.27 61.84 68.06 4.56 5.23 3.68 3.81 1.57 1.95 1.76 2.36 0.73 1.26 1.03 1.52 2.58 3.34
Appendix 4.4: PCCdyn70 values (mg/ml) in heaves (H1-5 and 7)
horses at 5h following inhalation challenge with saline 0.5, 1.6
and 5.0mg Aspergillus fumigatus extract (AFE). MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE 0.5mg AFE 1.6mg AFE 5mg AFE
H1 7.86 7.58 5.97 5.72
H2 3.06 9.88 5.77 5.45
H3 5.64 6.10 0.72 4.18
H4 10.53 24.57 9.57 11.02
H5 6.40 7.01 4.53 5.49
H7 5.63 2.45 3.09 7.19
MED. 6.02 7.30 5.15 5.60
MIN. 3.06 2.45 0.72 4.18
MAX. 10.53 24.57 9.57 11.02
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Appendix 4.5: BALF total nucleated cell (TCC), lymphocyte, macrophage, neutrophil, mast cell, basiphiloid cell, eosinophil and epithelial cell counts (x105/ml) in
heaves (H1-5 and 7) at 6h following inhalation challenge with saline, 0.5, 1.6 and 5.0mg Aspergillus fumigatus extract (AFE). MED. = median value, MIN. =
minimum value, MAX. = maximum value.
TCC
SALINE 0.5mg AFE I.SmgAFE S.Omg AFE
H1 5.60 3.50 2.70 6.60
H2 3.40 2.30 3.90 2.00
H3 3.80 1.50 3.30 4.50
H4 5.50 3.40 6.00 4.40
H5 3.20 5.10 3.80 4.20
H7 5.20 3.60 9.40 4.60
MED. 4.50 3.45 3.85 4.45
MIN 3.20 1.50 2.70 ; 2.00
MAX 5.60 5.10 9.40 6.60
Mast cells
SALINE 0.5mg AFE 1.6mg AFE S.Omg AFE
H1 0.11 0.11 0.06 0.14
H2 0.15 0.05 0.04 0.02
H3 0.19 0.04 0.08 0.08
H4 0.13 0.05 0.10 0.04
H5 0.09 0.03 0.04 0.05
H7 0.17 0.03 0.05 0.04
MED. 0.14 0.04 0.05 0.05
MIN 0.09 0.03 0.04 0.02
MAX 0.19 0.11 0 10 0 14
Lymphocytes
SALINE 0.5mg AFE 1.6mg AFE 5.0mg AFE
HI 3.33 1.68 0.85 2.38
H2 1.54 1.18 1.02 0.74
H3 2.09 0.36 0.56 1.48
H4 2.36 1.38 2.44 2.23
H5 1.64 2.01 1.41 0.89
H7 2.57 1.38 6.04 2.32
MED. 2.22 1.38 1.21 1.86
MIN ; 1.54 0.36 0.56 0.74
MAX 3.33 2.01 6.04 2.38
Basiphiloid cells
SALINE O.Smg AFE 1.6mg AFE 5.0mg AFE
H1 0.01 0.00 000 0.00
H2 0.05 0.00 0.02 0.01
H3 0.11 0.00 0.00 0.00
H4 0.01 0.00 0.00 0.00
H5 0.02 0.01 0.00 0.01
H7 0.01 0.02 0.01 0.00
MED 0.01 0.00 0.00 : 0.00
MIN 0.01 0.00 0 00 0.00
MAX 0.11 0.02 0.02 0.01
Macrophages
SALINE O.Smg AFE i.6mg AFE S.Omg AFE
H1 1.96 1.55 0.93 2.69
H2 1.58 0.85 0.72 0.33
H3 1.24 0.86 1.63 1.67
H4 2.96 1.90 2.78 1.56
H5 1.27 2.56 1.50 1.40




MIN 1.24 0.85 0.72 0.33
MAX 2.96 2.56 2.78 2.69
Eosinophils
SAUNE 0.5mg AFE 1.6mg AFE 5 Omg AFE
H1 0.00 0.00 0.00 0.00
H2 0.00 0.01 0.00 0.00
H3 0.01 0.00 0.00 0.01
H4 0.01 0.00 0.01 0.02
H5 0.01 0.02 0.00 0.02
H7 0.00 0.00 0.01 0.01
MED. 0.00 0.00 0.00 0 01
MIN : 0.00 0.00 0.00 0.00
MAX 0.01 0.02 0.01 0 02
Neutrophils
SALINE O.Smg AFE I.SmgAFE S.Omg AFE
H1 0.20 0.15 0.86 1.39
H2 0.08 0.21 2.10 0.89
H3 0.17 0.24 1.03 1.26
H4 0.03 0.07 0.68 0.55
H5 0.06 0.48 0.85 1.83
H7 0.06 0.08 1.08 0.36
MED. 0.07 0.18 0.94 108
MIN | 0.03 0.07 0.68 0.36
MAX 0.20 0.48 2.10 . 1.83
Epithelial cells
SALINE 0.5mg AFE 1.6mg AFE 5.0mg AFE
H1 0.00 0.00 0.00 0.00
H2 0.00 0.00 0.00 0.00
H3 0.00 0.00 0.00 0.00
H4 0.00 0.00 0.00 0.00
H5 0.10 0.00 0.00 0.00
H7 0.00 0.00 0.00 0.00
MED. 0.00 0.00 0.00 0 00
MIN 0.00 0.00 0.00 0.00
MAX 0.10 0.00 0.00 0.00
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Appendix 5.1: Clinical scores in heaves (H1-5 and 7) horses prior to (0) and at 240min following inhalation challenge with saline, 1.6mg
Aspergillus fumigatus extract (AFE) and 1.6mg LPS depleted Aspergillus fumlgatus extract (AFE-LPS).
CHALLENGE SALINE 1.6 mg AFE 1.6 mg AFE-LPS
TIME PT. (min) 0 240 0 240 240
H1 0 0 0 0 0 0
H2 0 0 0 0 0 0
COX:■ 0 0 0 0 0 0
H4 0 0 0 0 0 0
H5 0 0 0 0 0 0
H7 0 0 0 0 0 0
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Appendix 5.2: Arterial blood pH, pC02 (mmHg) and p02 (mmHg) in heaves (H1-5 and 7) horses prior to (0) and at 240min following inhalation challenge with saline,
1.6mg Aspergillus fumigatus extract (AFE) and 1.6mg LPS-depleted Aspergillus fumigatus extract (AFE-LPS). MED. = median value, MIN. = minimum value, MAX.
= maximum value.
pH pco2 P02
PH SALINE AFE AFE-LPS SALINE AFE AFE-LPS SALINE FC1.6 FC-LPS
HORSE 0 240 0 240 0 240 0.0 240.0 0.0 240.0 0.0 240.0 o 240 0 240 0 240
H1 7.36 7.38 7.38 7.37 7.38 7.39 45.0 40.0 41.6 43.0 44.6 48.0 99.0 98.0 113.5 110.3 101.4 102.4
H2 7.35 7.36 7.36 7.39 7.39 7.36 47.0 46.0 48.7 53.1 54.9 51.8 116.0 102.0 116.2 99.3 96.8 100.9
H3 7.40 7.41 7.38 7.37 7.39 7.37 42.0 37.0 52.4 50.9 50.0 49.4 94.0 98.0 111.3 99.6 89.3 103.6
H4 7.39 7.35 7.41 7.41 7.41 7.43 43.0 45.0 48.5 50.3 49.4 47.2 102.0 97.0 102.7 101.5 98.3 103.2
H5 7.37 7.37 7.37 7.43 7.39 7.40 53.0 43.0 51.0 46.2 51.6 49.2 94.0 83.0 114.6 104.3 100.2 101.6
H7 7.41 7.43 7.38 7.37 7.37 7.39 46.0 45.0 41.6 43.0 43.3 43.8 100.0 109.0 113.5 110.3 104.4 111.0
MED. 7.38 7.38 7.38 7.38 7.39 7.39 45.5 44.0 48.6 48.3 49.7 48.6 99.5 98.0 113.5 102.9 99.3 102.8
MIN. 7.35 7.35 7.36 7.37 7.37 7.36 42.0 37.0 41.6 43.0 43.3 43.8 94.0 83.0 102.7 99.3 89.3 100.9
MAX. 7.41 7.43 7.41 7.43 7.41 7.43 53.0 46.0 52.4 53.1 54.9 51.8 116.0 109.0 116.2 110.3 104.4 111.0
Appendix 5.3: Lung function measurements in heaves (H1-5 and 7) horses prior to (Oh) and at 5h following inhalation challenge with 1.6mg LPS-depleted
Aspergillus fumigatus extract (AFE-LPS). MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (i/kPa) dPpl(kPa) RLjS0 (kPa/l/sec) RR (breaths/min.) VT (I) Wb' (J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/l/sec) RLE75%(kPa/l/sec) RL.i25%(kPa/j/sec) RLt5o%(kPa/i/sec) RL|75% (kPa/l/sec)
TP 0h 5h 0h 5h Oh 5h 0h 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h
H1 24.16 18.04 0.65 0.71 0.06 0.08 7.45 5.35 7.54 8.23 16.14 12.57 0.07 0.10 0.06 0.06 0.08 0.08 0.06 0.11 0.05 0.09 0.06 0.09
H2 84.83 28.72 0.48 0.92 0.05 0.12 9.40 6.10 6.28 8.01 15.59 22.98 0.05 0.10 0.07 0.11 0.07 0.14 0.04 0.12 0.04 0.09 0.05 0.12
H3 13.53 14.44 0.84 0.82 0.17 0.16 4.60 4.70 5.84 6.50 11.15 11.76 0.01 0.04 0.09 0.05 0.17 0.15 0.24 0.20 0.31 0.25 0.25 0.18
H4 25.29 31.66 0.57 0.54 0.07 0.07 6.10 7.05 7.03 6.22 14.90 14.84 0.03 0.03 0.06 0.06 0.08 0.08 0.08 0.09 0.09 0.09 0.09 0.10
H5 22.22 26.65 0.70 0.65 0.05 0.05 5.60 6.60 9.58 9.44 17.19 18.84 0.08 0.06 0.10 0.08 0.10 0.10 0.07 0.06 0.09 0.06 0.07 0.06
H7 20.81 33.33 0.54 0.81 0.06 0.09 10.85 10.50 5.40 5.59 15.70 24.77 0.07 0.09 0.06 0.10 0.06 0.13 0.06 0.09 0.05 0.09 0.06 0.10
MED. 23.19 27.69 0.61 0.76 0.06 0.08 6.78 6.35 6.66 7.25 15.64 16.84 0.06 0.07 0.06 0.07 0.08 0.11 0.07 0.10 0.07 0.09 0.07 0.10
MIN. 13.53 14.44 0.48 0.54 0.05 0.05 4.60 4.70 5.40 5.59 11.15 11.76 0.01 0.03 0.06 0.05 0.06 0.08 0.04 0.06 0.04 0.06 0.05 0.06
MAX. 84.83 33.33 0.84 0.92 0.17 0.16 10.85 10.50 9.58 9.44 17.19 24.77 0.08 0.10 0.10 0.11 0.17 0.15 0.24 0.20 0.31 0.25 0.25 0.18
TE(sec) Tj (sec) T,:Te V'e (l/min) V'Emax (l/SeC) V imax (I/Sec) Wb .(J) Wbr Wberes (J) Wbires(J) WbB0{(J)
TP Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h
H1 3.66 5.77 4.54 5.57 1.29 0.97 55.91 43.78 3.92 3.02 3 49 3.08 1.24 1.90 2.18 2.36 1.28 1.26 0.90 1.10 2.14 3.00
H2 3.29 5.43 2.90 4.31 1.02 0.80 59.01 49.02 3.17 2.97 3.46 2.76 0.29 1.17 1.63 3.75 0.86 2.09 0.76 1.65 1.05 2.83
H3 6.64 6.79 6.55 5.96 1.00 0.89 26.88 30.36 1.96 2.17 2.09 2.54 1.25 1.50 2.42 2.50 1.16 1.10 1.27 1.41 2.52 2.91
H4 4.90 4.35 4.22 3.78 1.93 1.09 43.02 43.77 2.70 2.44 3.33 3.60 1.04 0.77 2.21 1.96 1.17 0.86 1.04 1.11 2.08 1.88
H5 6.49 5.55 4.17 3.61 0.66 0.65 53.56 62.67 3.46 3.58 4.06 4.27 2.13 1.80 2.92 2.82 1.08 1.12 1.84 1.70 3.97 3.50
H7 2.73 2.80 2.76 3.04 1.02 1.09 58.65 58.73 3.05 3.16 2.86 2.90 0.71 0.47 1.42 2.40 0.76 1.37 0.66 1.03 1.38 1.50
MED. 4.28 5.49 4.19 4.04 1.02 0.93 54.73 46.40 3.11 2.99 3.40 2.99 1.14 1.34 2.20 2.45 1.12 1.19 0.97 1.26 2.11 2.87
MIN. 2.73 2.80 2.76 3.04 0.66 0.65 26.88 30.36 1.96 2.17 2.09 2.54 0.29 0.47 1.42 1.96 0.76 0.86 0.66 1.03 1.05 1.50
MAX. 6.64 6.79 6.55 5.96 1.93 1.09 59.01 62.67 3.92 3.58 4.06 4.27 2.13 1.90 2.92 3.75 1.28 2.09 1.84 1.70 3.97 3.50
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Appendix 5.4: PCCdyn70 values (mg/ml) in heaves
(H1-5 and 7) horses at 5h following inhalation
challenge with saline, 1.6mg Aspergillus fumigatus
extract (AFE) and 1.6mg LPS-depleted Aspergillus
fumigatus extract (AFE-LPS). MED. = median value,
MIN. = minimum value, MAX. = maximum value.
SALINE AFE AFE-LPS
H1 7.86 5.97 7.66
H2 3.06 5.77 8.12
H3 5.64 0.72 4.42
H4 10.53 9.57 11.24
H5 6.40 4.53 10.33
H7 5.63 3.09 4.67
MED. 6.02 5.15 7.89
MIN. 3.06 0.72 4.42
MAX. 10.53 9.57 11.24
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Appendix 5.5: BALF total nucleated cell (TCC), lymphocyte, macrophage, neutrophil, mast cell, basiphiloid cell, eosinophil and epithelial cell counts (x10 /ml) in
heaves (H1-5 and 7) at 6h following inhalation challenge with saline, 1.6mg Aspergillus fumigatus extract (AFE) and 1.6mg LPS-depleted Aspergillus fumigatus
extract (AFE-LPS). MED. = median value, MIN. = minimum value, MAX. = maximum value.
TCC
SALINE AFE AFE-LPS
H1 5.60 2.70 4.20
H2 3.40 3.90 4.00
H3 3.80 3.30 3.10
H4 5.50 6.00 5.60
H5 3.20 3.80 2.70
H7 5.20 9.40 3.70
MED. 4.50 3.85 3.85
MIN 3.20 2.70 2.70
MAX 5.60 9.40 5.60
Lymphocyte:
SALINE AFE AFE-LPS
H1 3.33 0.85 1.33
H2 1.54 1.02 1.27
H3 2.09 0.56 1.09
H4 2.36 2.44 2.37
H5 1.64 1.41 1.13
H7 2.57 6.04 1.72
MED. 2.22 1.21 1.30
MIN 1.54 0.56 1.09
MAX 3.33 6.04 2.37
Macropha ges
SALINE AFE AFE-LPS
H1 1.96 0.93 2.00
H2 1.58 0.72 0.76
H3 1.24 1.63 1.75
H4 2.96 2.78 2.61
H5 1.27 1.50 1.13
H7 2.40 2.21 1.42
MED. 1.77 1.57 1.58
MIN 1.24 0.72 0.76
MAX 2.96 2.78 2.61
Neutrophils
SALINE AFE AFE-LPS
H1 0.20 0.86 0.76
H2 0.08 2.10 1.90
H3 0.17 1.03 0.16
H4 0.03 0.68 0.46
H5 0.06 0.85 0.38
H7 0.06 1.08 0.43
MED. 0.07 0.94 0.44
MIN 0.03 0.68 0.16
MAX 0.20 2.10 1.90
Mast cells
SALINE AFE AFE-LPS
H1 0.11 0.06 0.11
H2 0.15 0.04 0.06
H3 0.19 0.08 0.11
H4 0.13 0.10 0.15
H5 0.09 0.04 0.05
H7 0.17 0.05 0.07
MED. 0.14 0.05 0.09
MIN 0.09 0.04 0.05
MAX 0.19 0.10 0.15
Basophiloid cells
SALINE AFE AFE-LPS
H1 0.01 0.00 0.00
H2 0.05 0.02 0.00
H3 0.11 0.00 0.00
H4 0.01 0.00 0.02
H5 0.02 0.00 0.01
H7 0.01 0.01 0.06
MED. 0.01 0.00 0.01
MIN 0.01 0.00 0.00
MAX 0.11 0.02 0.06
Eosinophils
SALINE AFE AFE-LPS
H1 0.00 0.01 0.01
H2 0.00 0.00 0.00
H3 0.01 0.00 0.00
H4 0.01 0.01 0.00
H5 0.01 0.00 0.01
H7 0.00 0.01 0.00
MED. 0.00 0.00 0.00
MIN 0.00 0.00 0.00
MAX 0.01 0.01 0.01
Epithelial cells
SALINE AFE AFE-LPS
H1 0.00 0.00 0.00
H2 0.00 0.00 0.00
H3 0.00 0.00 0.00
H4 0.00 0.00 0.00
H5 0.10 0.00 0.00
H7 0.00 0.00 0.00
MED. 0.00 0.00 0.00
MIN 0.00 0.00 0.00
MAX 0.10 0.00 0.00
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Appendix 7.1: Clinical scores in control (C1-6) and heaves (H1-7) horses prior to (0) and at 240min following inhalation challenge with
saline and 3 separate doses of HDS-1 (HDS-1 [31], HDS-1 [57], HDS-1 [100] and HDS-1 [316]). Score based on: a (tracheal
auscultation), d (dyspnoea) and e (respiratory rate). NP = challenge not performed, NM = clinical score not measured.
CHALLENGE SALINE HDS-1 [31] HDS-1 [57] HDS-1 [100] HDS-1 [316]
TIME PT. (min) 0 240 o 240 0 240 9 240 0 240
C1 0 0 NP NP 0 0 0 0 NM NM
C2 0 0 NP NP 0 0 0 0 NM NM
C3 0 0 NP NP 1 e 0 1 e 0 NM NM
C4 0 0 NP NP 0 0 0 0 NM NM
C5 0 0 NP NP 0 0 0 0 NM NM
C6 0 0 NP NP 0 0 0 0 NM NM
H1 0 0 0 0 0 0 0 0 NP NP
H2 0 0 0 0 0 0 0 1 d NP NP
COX 0 0 0 0 1 a 0 0 0 NP NP
■
H4 0 0 0 0 0 0 0 0 NP NP
H5 0 0 0 0 0 0 0 0 NP NP
H6 0 0 0 0 0 0 0 0 NP NP
H? 0 0 0 0 0 0 0 0 NP NP
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Appendix 7.2: (a) BALF total nucleated cell counts (x105/ml) in control (C1-6)
and heaves (H1-7) at 6h following challenge with saline, HDS-1[31], HDS-
1 [57], HDS-1[100], HDS-1 [316], HDS-2, HDS-2[R] and HDS-3. MED. =
median value, MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1 [31] HDS-1 [57] HDS-1 [100] HDS-1 [316] HDS-2 HDS-2[R] HDS-3
C1 5.10 NP 3.00 3.00 4.90 4.30 NP NP
C2 3.90 NP 3.90 4.30 0.00 2.60 NP NP
C3 2.00 NP 2.30 1.60 2.20 1.70 NP NP
C4 2.90 NP 1.80 8.00 4.30 3.20 NP NP
C5 9.60 NP 4.10 5.00 6.90 3.70 NP NP
C6 3.80 NP 3.80 5.10 4.40 2.50 NP NP
MED. 3.85 3.40 4.65 4.35 2.90
MIN 2.00 1.80 1.60 0.00 1.70
MAX 9.60 4.10 8.00 6.90 4.30
H1 5.60 3.80 7.70 4.00 NP 4.30 7.30 9.10
H2 3.40 3.40 2.90 3.70 NP 7.90 8.10 8.90
H3 3.80 3.30 4.90 6.20 NP 8.70 6.30 8.10
H4 5.50 3.00 7.60 4.10 NP 7.30 4.00 15.20
H5 3.20 8.00 8.80 7.00 NP 9.10 21.80 12.60
H6 1.30 3.20 2.00 2.10 NP 3.70 0.00 10.10
H7 5.20 4.50 5.10 4.10 NP 8.40 11.10 19.00
MED. 3.80 3.40 5.10 4.10 7.90 7.30 10.10
MIN 1.30 3.00 2.00 2.10 3.70 0.00 8.10
MAX 5.60 8.00 8.80 7.00 9.10 21.80 19.00
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Appendix 7.2: (b) BALF lymphocyte counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1[31], HDS-1[57],
HDS-1[100], HDS-1[316], HDS-2, HDS-2[R] and HDS-3. MED. = median
value. MIN, = minimum value. MAX. = maximum value.
SALINE HDS-1 [31] HDS 1 [57] HDS-1 [100] HDS-1.[316] i HDS-2 HDS 2[8j HDS-3
C1 1.89 ND 1.04 0.66 1.32 2.37 NP NP
C2 1.28 ND 1.15 1.24 0.92 NP NP
C3 0.99 ND 1.31 0.83 0.85 1.07 NP NP
C4 0.99 ND 0.61 1.74 1.42 1.13 NP NP
C5 6.22 ND 2.06 2.29 1.79 1.51 NP NP
C6 2.41 ND 1.02 2.23 0.62 0.96 NP NP
MED. 1.59 1.10 1.49 1.32 1.10
MIN 0.99 0.61 0.66 0.62 0.92
MAX 6.22 2.06 2.29 1.79 2.37
H1 3.33 1.80 3.60 1.62 NP 1.64 1.41 0.98
H2 1.54 1.45 0.95 0.61 NP 0.56 0.49 0.63
H3 2.09 1.03 2.12 1.19 NP 0.56 0.59 0.36
H4 2.36 1.23 4.23 1.75 NP 2.34 1.16 2.14
H5 1.64 2.52 2.55 1.86 NP 2.20 2.07 1.17
H6 0.80 2.10 104
J
0.81 NP 0.51 NP 1.19
H7 2.57 2.20 1.71 1.12 NP 1.53 2.24 1.86
MED. 2.09 1.80 2.12 1.19 1.53 1.28 1.17
MIN 0.80 1.03 0.95 0.61 0.51 0.49 0.36
MAX 3.33 2.52 4.23 1.86 2.34 2.24 2.14
Appendix 7.2: (c) BALF macrophage counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1 [31 ], HDS-1[57],
HDS-1 [100], HDS-1 [316], HDS-2, HDS-2[R] and HDS-3. MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1 [31] HDS-1 [57] HDS-1 [100] HDS-1 [316] HDS-2 HDS-2[R} HDS-3
C1 2.80 NP 1.76 1.72 1.43 1.43 NP NP
C2 2.25 NP 2.55 2.75 1.46 NP NP
C3 0.73 NP 0.78 0.51 0.37 0.30 NP NP
C4 1.71 NP 0.77 4.19 0.94 1.62 NP NP
C5 2.57 NP 1.80 1.91 0.76 1.39 NP NP
C6 1.14 NP 2.33 2.46 0.63 1.20 NP NP
MED. 1.98 1.78 2.18 0.76 1.41
MIN 0.73 0.77 0.51 0.37 0.30
MAX 2.80 2.55 4.19 1.43 1.62
H1 1.96 1.77 2.80 1.16 NP 0.84 1.90 0.66
H2 1.58 1.09 0.65 0.41 NP 0.71 0.83 0.53
H3 1.24 1.15 1.68 1.75 NP 1.22 0.88 0.72
H4 2.96 1.63 2.55 1.48 NP 1.78 1.59 1.93
H5 1.27 3.06 2.80 1.18 NP 1.66 2.27 0.92
H6 0.34 0.90 0.33 0.50 NP 0.39 0.24
H7 2.40 1.90 1.26 0.77 NP 1.19 1.78 0.78
MED. 1.58 1.63 1.68 1.16 1.19 1.68 0.72
MIN 0.34 0.90 0.33 0.41 0.39 0.83 0.24
MAX 2.96 3.06 2.80 1.75 1.78 2.27 1.93
Appendix 7.2: (d) BALF neutrophil counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1 [31], HDS-1 [57],
HDS-1 [100], HDS-1[316], HDS-2, HDS-2[R] and HDS-3. MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1 [31] HDS-1 [57] HDS-1 [100] HDS-1 [316] HDS-2 HDS-2[R] HDS-3
C1 0.04 NP 0.01 0.29 1.70 0.14 NP NP
C2 0.01 NP 0.06 0.12 0.02 NP NP
C3 0.02 NP 0.02 0.08 0.90 0.17 NP NP
C4 0.09 NP 0.05 0.56 1.72 0.16 NP NP
C5 0.17 NP 0.05 0.66 4.28 0.41 NP NP
C6 0.09 NP 0.24 0.28 3.12 0.19 NP NP
MED. 0.06 0.05 0.28 1.72 0.16
MIN 0.01 0.01 0.08 0.90 0.02
MAX 0.17 0.24 0.66 4.28 0.41
H1 0.20 0.12 0.43 1.11 NP 1.68 3.80 7.37
H2 0.08 0.81 1.23 2.60 NP 6.47 6.73 7.65
H3 0.17 1.02 1.01 3.14 NP 6.61 4.73 6.92
H4 0.03 0.08 0.57 0.80 NP 3.12 1.13 10.84
H5 0.06 2.30 3.32 3.81 NP 4.95 17.29 10.47
H6 0.06 0.06 0.50 0.54 NP 2.71 8.55
H7 0.06 0.14 2.02 2.17 NP 5.52 6.87 16.30
MED. 0.06 0.14 1.01 2.17 4.95 5.73 8.55
MIN 0.03 0.06 0.43 0.54 1.68 1.13 6.92
MAX 0.20 2.30 3.32 3.81 6.61 17.29 16.30
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Appendix 7.2: (e) BALF mast cell counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1 [31 ], HDS-1[57],
HDS-1[100], HDS-1 [316], HDS-2, HDS-2[R] and HDS-3. MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1 [31] HDS-1 [57] HDS-1 [100] HDS-1 [316] HDS-2 HDS-2[R] HDS-3
C1 0.23 NP 0.19 0.13 0.18 0.23 NP NP
C2 0.30 NP 0.12 0.18 0.12 NP NP
C3 0.26 NP 0.16 0.12 0.08 0.15 NP NP
C4 0.06 NP 0.05 0.24 0.09 0.06 NP NP
C5 0.39 NP 0.18 0.15 0.08 0.33 NP NP
C6 0.09 NP 0.08 0.11 0.03 0.13 NP NP
MED. 0.25 0.14 0.14 0.08 0.14
MIN 0.06 0.05 0.11 0.03 0.06
MAX 0.39 0.19 0.24 0.18 0.33
H1 0.11 0.07 0.30 0.08 NP 0.13 0.11 0.06
H2 0.15 0.04 0.06 0.07 NP 0.10 0.06 0.06
H3 0.19 0.08 0.09 0.11 NP 0.29 0.10 0.09
H4 0.13 0.05 0.08 0.05 NP 0.04 0.05 0.08
H5 0.09 0.06 0.02 0.02 NP 0.04 0.00 0.00
H6 0.10 0.12 0.12 0.14 NP 0.06 0.09
H7 0.17 0.16 0.06 0.02 NP 0.08 0.12 0.06
MED. 0.13 0.07 0.0B 0.07 0.08 0.08 0.06
MIN 0.09 0.04 0.02 0.02 0.04 0.00 0.00
MAX 0.19 0.16 0.30 0.14 0.29 0.12 0.09
Appendix 7.2: (f) BALF basiphiloid cell counts (x105/ml) in control (C1-6) and
heaves (H1 -7) at 6h following challenge with saline, HDS-1[31], HDS-1[57],
HDS-1 [100], HDS-1[316], HDS-2, HDS-2[R] and HDS-3. MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1 [31] HDS-1 [57] HDS-1 [100] HDS-1 [316] HDS-2 HDS-2[R] HDS-3
C1 0.07 NP 0.00 0.20 024 0.09 NP NP
C2 0.01 NP 0.00 0.00 0.08 NP NP
C3 0.00 NP 0.03 0.03 0.01 0.00 NP NP
C4 0.03 NP 0.03 1.04 0.00 0.08 NP NP
C5 0.22 NP 0.02 0.00 0.00 0.01 NP NP
C6 0.01 NP 0.00 0.00 0.00 0.00 NP NP
MED. 0.02 0.01 0.02 0.00 0.04
MIN 0.00 0.00 0.00 0.00 0.00
MAX 0.22 0.03 1.04 0.24 0.09
H1 0.01 0.00 0.00 0.00 NP 0.01 0.07 0.00
H2 0.05 0.01 0.01 0.00 NP 0.06 0.00 0.02
H3 0.11 0.02 0.00 0.00 NP 0.03 0.00 0.02
H4 0.01 0.02 0.02 0.00 NP 0.00 0.00 0.00
H5 0.02 0.00 0.02 0.00 NP 0.00 0.02 0.03
H6 0.00 0.02 0.00 0.10 NP 0.02 0.00
H7 0.01 0.01 0.02 0.00 NP 0.03 0.04 0.00
MED. 0.01 0.01 0.01 0.00 0.02 0.01 0.00
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.11 0.02 0.02 0.10 0.06 0.07 0.03
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Appendix 7.2: (g) BALF eosinophil counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1 [31 ], HDS-1[57],
HDS-1[100], HDS-1[316], HDS-2, HDS-2[R] and HDS-3. MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1 [31] HDS-1 [57] HDS-1 [100] HDS-1 [316] HDS-2 HDS-2[R] HDS-3
C1 0.05 NP 0.00 0.00 0.04 0.05 NP NP
C2 0.06 NP 0.02 0.01 0.00 NP NP
C3 0.00 NP 0.00 0.04 0.00 0.01 NP NP
C4 0.00 NP 0.29 0.23 0.14 0.15 NP NP
C5 0.02 NP 0.00 0.00 0.00 0.06 NP NP
C6 0.06 NP 0.14 0.02 0.00 0.03 NP NP
MED. 0.03 0.01 0.01 0.00 0.04
MIN 0.00 0.00 0.00 0.00 0.00
MAX 0.06 0.29 0.23 0.14 0.15
H1 0.00 0.03 0.57 0.03 NP 0.00 0.01 0.02
H2 0.00 0.00 0.00 0.00 NP 0.00 0.00 0.00
H3 0.01 0.00 0.00 0.00 NP 0.00 0.01 0.00
H4 0.01 0.00 0.14 0.01 NP 0.02 0.07 0.21
H5 0.01 0.07 0.10 0.13 NP 0.25 0.15 0.01
H6 0.01 0.00 0.01 0.01 NP 0.00 0.02
H7 0.00 0.10 0.02 0.02 NP 0.05 0.04 0.00
MED. 0.01 0.00 0.02 0.01 0.00 0.03 0.01
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.01 0.10 0.57 0.13 0.25 0.15 0.21
Appendix 7.2: (h) BALF epithelial cell counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1[31], HDS-1[57],
HDS-1[100], HDS-1[316], HDS-2, HDS-2[R] and HDS-3. MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1 [31] HDS-1 [57] HDS-1 [100] HDS-1 [316] HDS-2 HDS-2[R] HDS-3
C1 0.03 NP 0.00 0.00 0.00 0.00 NP NP
C2 0.00 NP 0.00 0.00 0.00 NP NP
C3 0.00 NP 0.00 0.00 0.00 0.00 NP NP
C4 0.00 NP 0.00 0.00 0.00 0.00 NP NP
C5 0.00 NP 0.00 0.00 0.00 0.00 NP NP
C6 0.00 NP 0.00 0.00 0.00 0.00 NP NP
MED. 0.00 0.00 0.00 0.00 0.00
MIN 0.00 0.00 0.00 0.00 0.00
MAX 0.03 0.00 0.00 0.00 0.00
H1 0.00 0.00 0.00 0.00 NP 0.00 0.00 0.00
H2 0.00 0.00 0.00 0.00 NP 0.00 0.00 0.00
H3 0.00 0.00 0.00 0.00 NP 0.00 0.00 0.00
H4 0.00 0.00 0.00 0.00 NP 0.00 0.00 0.00
H5 0.10 0.00 0.00 0.00 NP 0.00 0.00 0.00
H6 0.00 0.00 0.00 0.00 NP 0.00 0.00
H7 0.00 0.00 0.00 0.00 NP 0.00 0.00 0.00
MED. 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.10 0.00 0.00 0.00 0.00 0.00 0.00
Appendix 7.3: Clinical scores in control (C1-6) and heaves (H1-7) horses prior to (0) and at 240min following inhalation challenge with
saline and 3 separate batches of HDS (HDS-1 [100], HDS-2 [100] and HDS-3 [100]) and a repeat inhalation challenge with HDS-2 [100]
(HDS-2 [100]R). Score based on: a (tracheal auscultation), d (dyspnoea), e (respiratory rate) and f (mucopurulent nasal discharge). NP =
challenge not performed, NM = clinical score not measured.
CHALLENGE SALINE HDS-1 [100] HDS-2 [100] HDS-2 [100]R HDS-3 [100]
TIME PT. (min) 0 240 0 240 0 240 0 240 0 240
C1 0 0 0 0 0 0 NP NP NP NP
C2 0 0 0 0 0 0 NP NP NP NP
C3 0 0 0 0 0 0 NP NP NP NP
C4 0 0 0 0 0 0 NP NP NP NP
C5 0 0 0 0 0 0 NP NP NP NP
C6 0 0 0 0 0 0 NP NP NP NP
H1 0 0 0 0 0 0 NM NM 0 0
H2 0 0 0 1 d 0 1 e NM NM 0 1 a
H3 0 0 0 0 0 0 NM NM 0 0
H4 0 0 0 0 0 0 NM NM 0 0
H5 0 0 0 0 0 1 f NM NM 0 0
H6 0 0 0 0 0 0 NP NP 0 0
H7 0 0 0 0 1 e 1 e NM NM 0 0
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Appendix 7.4: Arterial blood pH, pC02 (mmHg) and p02 (mmHg) in control (Cl-6) and heaves (Hl-7) horses prior to (0) and at 240min following inhalation challenge with saline,
HDS-1[100], HDS-2[100] and HDS-3[100]. MED. = median value, MIN. = minimum value, MAX. = maximum value.
pH pC02 p02
SALINE HDS-1[100J HDS-2 [100] HDS-3 [100] SALINE HDS-1[100] HDS-2 [100] HDS-3 (100} SALINE HDS-1[100] HDS-2 (100] HDS-3 [100]
TIME PT. 0 240 0 240 0 240 0 240 0 240 0.0 240.0 0.0 240.0 0.0 240.0 0 240 0 240 0 240 0 240
C1 7.40 7.39 7.37 7.37 7.40 7.43 ND ND 46.0 49.0 53.5 48.9 52.2 50.5 ND ND 100.0 114.0 100.0 97.7 94.7 99.8 ND ND
C2 7.36 7.35 7.32 7.36 7.40 7.40 ND ND 45.0 48.0 54.0 56.0 44.9 49.1 ND ND 103.0 115.0 90.4 88.0 101.3 94.7 ND ND
C3 7.38 7.38 7.42 7.41 7.41 7.42 ND ND 46.5 46.6 46.4 46.3 51.2 48.8 ND ND 106.5 104.6 113.3 103.7 89.6 99.1 ND ND
C4 7.40 7.42 7.36 7.41 7.42 7.40 ND ND 50.1 44.7 49.2 49.1 43.7 47.3 ND ND 90.6 88.0 80.7 74.6 86.4 102.3 ND ND
C5 7.36 7.36 7.43 7.41 7.39 7.41 ND ND 41.0 39.0 51.0 48.5 48.2 45.0 ND ND 105.0 110.0 125.0 118.0 93.4 90.9 ND ND
C6 7.39 7.39 7.43 7.40 7.40 7.40 ND ND 40.0 41.0 50.0 43.5 48.0 46.8 ND ND 93.0 104.0 98.0 109.3 98.9 108.7 ND ND
MED. 7.39 7.39 7.39 7.40 7.40 7.41 45.5 45.7 50.5 48.7 48.1 48.1 101.5 107.3 99.0 100.7 J 94.1 99.5
MIN. 7.36 7.35 7.32 7.36 7.39 7.40 40.0 39.0 46.4 43.5 43.7 45.0 90.6 88.0 80.7 74.6 86.4 90.9
MAX. 7.40 7.42 7.43 7.41 7.42 7.43 50.1 49.0 54.0 56.0 52.2 50.5 106.5 115.0 125.0 118.0 101.3 108.7
H1 7.36 7.38 7.34 7.39 7.38 7.35 7.35 7.35 45.0 40.0 45.2 46.7 47.0 45.3 50.2 52.4 99.0 98.0 104.4 121.8 124.3 110.8 118.0 116.2
H2 7.35 7.36 7.34 7.38 7.34 7.33 7.38 7.38 47.0 46.0 48.9 50.8 56.8 53.5 56.8 54.3 116.0 102.0 100.8 101.5 108.0 113.8 112.2 103.5
H3 7.40 7.41 7.41 7.39 7.42 7.38 7.37 7.42 42.0 37.0 50.0 48.2 49.1 52.5 50.2 51.9 94.0 98.0 92.0 117.6 116.7 113.8 121.3 112.6
H4 7.39 7.35 7.42 7.43 7.40 7.37 7.42 7.44 43.0 45.0 43.4 46.0 42.0 46.0 43.2 42.3 102.0 97.0 104.1 124.0 116.4 92.4 100.8 101.7
H5 7.37 7.37 7.37 7.37 7.37 7.41 53.0 43.0 51.0 55.6 51.8 52.5 94.0 83.0 97.0 85.7 90.7 95.6
H6 7.42 7.36 7.37 7.40 7.33 7.32 7.33 7.36 48.4 47.6 51.3 56.4 66.9 61.1 63.7 55.2 90.5 94.5 98.4 81.4 84.5 99.7 87.1 107.5
H7 7.41 7.43 7.36 7.40 7.35 7.35 7.43 7.34 46.0 45.0 43.0 44.4 53.0 48.1 52.0 48.4 100.0 109.0 109.2 108.0 125.8 118.6 96.8 123.3
MED. 7.39 7.37 7.37 7.39 7.37 7.35 7.38 7.37 46.0 45.0 48.9 48.2 51.8 52.5 51.1 52.2 99.0 98.0 100.8 108.0 116.4 110.8 106.5 110.1
MIN. 7.35 7.35 7.34 7.37 7.33 7.32 7.33 7.34 42.0 37.0 43.0 44.4 42.0 45.3 43.2 42.3 90.5 83.0 92.0 81.4 84.5 92.4 87.1 101.7
MAX. 7.42 7.43 7.42 7.43 7.42 7.41 7.43 7.44 53.0 47.6 51.3 56.4 66.9 61.1 63.7 55.2 116.0 109.0 109.2 124.0 125.8 118.6 121.3 123.3
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Appendix 7.5(a): Lung function measurements in control (C1-6) and heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with HDS-1[100],
MED. = median value, MIN. = minimum value, MAX. = maximum value.
Gdyn f/kPa) dPpl(kPa) RLifio (kPa/l/sec) RR (breaths/min.) VT( I) Wb' (J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/i/sec) RLe75% (kPa/l/sec) RLi25% (kPa/l/sec) RL.,50% (kPa/l/sec) RLi7s% (kPa/l/sec)
TP Oh 5h Oh 5h 0h 5h 0h 5h Oh 5h 0h 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h
C1 4.87 3.98 1.05 1.51 0.12 0.09 9.40 8.40 3.71 4.95 13.03 14.23 0.09 0.03 0.10 0.01 0.11 0.04 0.20 0.28 0.18 0.20 0.16 0.13
C2 11.13 15.45 0.54 0.54 0.04 0.05 8.35 8.55 4.38 4.73 6.21 8.08 0.06 0.05 0.05 0.04 0.03 0.03 0.12 0.15 0.08 0.09 0.07 0.08
C3 14.67 13.51 0.47 0.74 0.04 0.06 15.20 10.15 3.97 6.05 11.77 16.49 0.03 0.06 0.02 0.04 0.03 0.02 0.07 0.10 0.06 0.09 0.06 0.07
C4 5.33 4.97 1.47 1.83 0.35 0.41 7.15 7.15 3.77 3.88 17.84 22.75 0.29 0.39 0.19 0.27 0.28 0.35 0.43 0.47 0.38 0.40 0.31 0.36
C5 18.89 18.88 0.36 0.52 0.05 0.08 10.70 6.40 3.59 4.78 6.38 6.63 0.04 0.09 0.05 0.09 0.05 0.09 0.03 0.09 0.04 0.07 0.05 0.07
C6 16.23 8.63 0.61 0.84 0.08 0.06 8.40 8.25 4.61 4.15 8.76 9.42 0.03 0.04 0.04 0.10 0.07 0.07 0.12 0.18 0.09 0.23 0.09 0.10
MED. 12.90 11.07 0.58 0.79 0.06 0.07 8.90 8.25 3.87 4.75 10.26 11.83 0.05 0.05 0.05 0.06 0.06 0.06 0.12 0.17 0.08 0.14 0.08 0.09
MIN. 4.87 3.98 0.36 0.52 0.04 0.05 7.15 6.40 3.59 3.88 6.21 6.63 0.03 0.03 0.02 0.01 0.03 0.02 0.03 0.09 0.04 0.07 0.05 0.07
MAX. 18.89 18.88 1.47 1.83 0.35 0.41 15.20 10.15 4.61 6.05 17.84 22.75 0.29 0.39 0.19 0.27 0.28 0.35 0.43 0.47 0.38 0.40 0.31 0.36
H1 22.62 25.23 0.62 0.61 0.05 0.07 7.25 5.25 7.81 8.26 14.61 11.59 0.06 0.09 0.06 0.09 0.05 0.10 0.11 0.07 0.07 0.06 0.05 0.08
H2 43.80 46.18 0.34 0.41 0.04 0.05 8.05 7.05 5.34 5.87 6.38 7.58 0.01 0.04 0.04 0.04 0.05 0.06 0.04 0.05 0.04 0.05 0.05 0.06
H3 19.80 16.26 0.40 0.70 0.04 0.09 4.55 4.00 4.26 6.81 5.36 7.90 0.04 0.00 0.02 0.01 0.06 0.08 0.12 0.15 0.13 0.24 0.09 0.14
H4 40.77 28.59 0.28 0.37 0.04 0.06 10.85 9.40 4.19 4.11 6.26 7.22 0.01 0.03 0.04 0.05 0.04 0.07 0.04 0.07 0.04 0.07 0.04 0.06
H5 28.55 27.38 0.50 0.63 0.04 0.04 8.05 8.90 7.02 8.29 11.50 22.56 0.05 0.04 0.04 0.05 0.06 0.05 0.05 0.04 0.03 0.03 0.04 0.06
H6 9.20 9.83 0.91 0.88 0.11 0.09 8.30 8.50 5.12 5.77 16.19 15.79 0.12 0.08 0.11 0.08 0.12 0.09 0.15 0.13 0.10 0.11 0.11 0.08
H7 27.43 38.35 0.57 0.64 0.06 0.07 15.95 10.65 4.72 5.24 25.36 22.74 0.06 0.07 0.06 0.08 0.07 0.10 0.05 0.07 0.06 0.07 0.07 0.08
MED. 27.43 27.38 0.50 0.63 0.04 0.07 8.05 8.50 5.12 5.87 11.50 11.59 0.05 0.04 0.04 0.05 0.06 0.08 0.05 0.07 0.06 0.07 0.05 0.08
MIN. 9.20 9.83 0.28 0.37 0.04 0.04 4.55 4.00 4.19 4.11 5.36 7.22 0.01 0.00 0.02 0.01 0.04 0.05 0.04 0.04 0.03 0.03 0.04 0.06
MAX. 43.80 46.18 0.91 0.88 0.11 0.09 15.95 10.65 7.81 8.29 25.36 22.74 0.12 0.09 0.11 0.09 0.12 0.10 0.15 0.15 0.13 0.24 0.11 0.14
Tl(sec) Ti (sec) T.:Te V'E (l/min) V'Emax (l/SeC) V |max (l/sec) ' Wb .(J) Wbr *(J) WbE es(J) Wbtres(J) : Wb|tot<J)
TP 0h 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h
C1 2.94 3.37 3.36 3.44 1.16 1.02 34.55 42.058 2.09 2.61 1.94 3.30 1.37 3.22 1.38 1.60 0.53 0.10 0.85 1.70 2.22 4.92
C2 3.92 3.58 3.31 3.51 0.84 0.99 36.66 40.32 2.58 2.62 2.09 2.18 0.92 0.93 0.74 0.90 0.12 0.23 0.62 0.68 1.54 1.61
C3 2.15 3.38 1.83 2.59 0.86 0.77 60.20 61.04 2.89 3.55 3.38 3.65 0.55 1.42 0.78 1.65 0.21 0.45 0.57 1.21 1.12 2.62
C4 4.61 4.62 3.85 3.71 0.84 0.81 26.89 27.55 1.33 1.30 1.47 1.60 1.36 1.51 2.52 3.14 1.04 1.34 1.48 1.80 2.85 3.31
C5 3.07 5.24 2.63 4.05 0.88 0.78 39.19 30.64 2.44 1.95 2.42 2.17 0.36 0.64 0.54 1.03 0.23 0.44 0.31 0.59 0.68 1.23
C6 4.34 4.10 3.50 3.24 0.86 0.76 38.73 33.01 2.07 1.93 2.55 2.27 0.81 1.09 1.17 1.14 0.42 0.40 0.75 0.75 1.56 1.84
MED. 3.49 3.84 3.33 3.47 0.86 0.80 37.70 33.01 2.27 2.28 2.26 2.22 0.86 1.25 0.98 1.37 0.32 0.42 0.69 0.98 1.55 2.23
MIN. 2.15 3.37 1.83 2.59 0.84 0.76 26.89 27.55 1.33 1.30 1.47 1.60 0.36 0.64 0.54 0.90 0.12 0.10 0.31 0.59 0.68 1.23
MAX. 4.61 5.24 3.85 4.05 1.16 1.02 60.20 61.04 2.89 3.55 3.38 3.65 1.37 3.22 2.52 3.14 1.04 1.34 1.48 1.80 2.85 4.92
H1 3.67 5.38 4.71 6.32 1.29 1.20 56.24 42.96 4.75 2.92 3.32 2.90 1.40 1.41 2.03 2.25 1.02 1.32 1.00 0.93 2.40 2.34
H2 4.11 5.02 3.37 3.56 0.82 0.72 42.94 41.15 2.43 2.44 2.80 2.82 0.33 0.42 0.79 1.09 0.43 0.52 0.37 0.56 0.70 0.98
H3 3.95 8.58 5.66 6.15 1.92 0.72 19.65 27.41 1.70 2.45 2.53 2.74 0.73 1.33 0.84 1.94 0.22 0.84 0.62 1.10 1.35 2.43
H4 2.82 3.38 2.50 3.02 0.89 0.89 44.97 38.02 2.24 2.10 2.76 2.38 0.23 0.32 0.56 0.77 0.27 0.38 0.29 0.39 0.51 0.71
H5 4.08 3.36 3.20 2.88 0.79 0.87 56.43 73.40 3.28 4.74 3.91 5.08 0.89 1.22 1.39 2.28 0.59 0.99 0.80 1.29 1.68 2.51
H6 2.97 3.11 4.27 3.86 1.46 1.25 42.15 48.98 3.00 3.01 2.40 2.89 1.45 1.70 1.94 1.84 1.06 0.92 0.88 0.92 2.33 2.62
H7 1.94 2.55 1.87 3.04 0.99 1.22 74.85 56.93 3.61 3.08 3.69 3.07 0.44 0.44 1.58 1.88 0.79 1.04 0.79 0.84 1.23 1.29
MED. 3.67 3.38 3.37 3.56 0.99 0.89 44.97 42.96 3.00 2.92 2.80 2.89 0.73 1.22 1.39 1.88 0.59 0.92 0.79 0.92 1.35 2.34
MIN. 1.94 2.55 1.87 2.88 0.79 0.72 19.65 27.41 1.70 2.10 2.40 2.38 0.23 0.32 0.56 0.77 0.22 0.38 0.29 0.39 0.51 0.71
MAX. 4.11 8.58 5.66 6.32 1.92 1.25 74.85 73.40 4.75 4.74 3.91 5.08 1.45 1.70 2.03 2.28 1.06 1.32 1.00 1.29 2.40 2.62
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Appendix 7.5(b): Lung function measurements in control (C1-6) and heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with HDS-2[100],
MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (l/kPa) dPpi (kPa) RLiso (kPa/l/sec) RR (breaths/min.) VT (I) Wb' (J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/l/sec) RLe?5% (kPa/l/sec) RLi25% (kPa/l/sec) RL.,50% (kPa/l/sec) RLi75% (kPa/l/sec)
TP Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h Oh 5h
C1 5.52 7.60 0.75 0.83 0.07 0.09 10.1 7.05 3.01 4.26 7.10 7.22 0.04 0.05 0.02 0.03 0.08 0.05 0.16 0.22 0.09 0.13 0.08 0.15
C2 24.18 12.92 0.47 0.69 0.05 0.12 9.80 7.05 5.07 4.81 11.19 10.63 0.05 0.11 0.03 0.11 0.04 0.13 0.07 0.10 0.06 0.12 0.08 0.13
C3 10.25 13.44 0.75 0.63 0.10 0.08 9.60 9.30 4.06 4.63 12.84 11.46 0.12 0.09 0.10 0.08 0.10 0.07 0.13 0.10 0.13 0.09 0.11 0.09
C4 9.67 9.03 0.73 0.92 0.14 0.20 9.75 7.35 3.40 3.76 11.61 11.52 0.09 0.13 0.05 0.06 0.11 0.18 0.20 0.27 0.21 0.26 0.16 0.19
C5 16.34 15.23 0.49 0.57 0.05 0.09 11.35 7.00 4.16 5.03 8.64 7.83 0.04 0.12 0.03 0.05 0.06 0.08 0.04 0.10 0.04 0.10 0.06 0.06
C6 14.10 12.87 0.50 0.54 0.04 0.06 8.90 9.90 4.73 4.83 7.46 12.16 0.03 0.07 0.00 0.07 0.01 0.07 0.11 0.08 0.16 0.08 0.08 0.08
MED. 12.18 12.90 0.61 0.66 0.06 0.09 9.75 7.20 4.11 4.72 9.92 11.04 0.04 0.10 0.03 0.06 0.07 0.08 0.12 0.10 0.11 0.11 0.08 0.11
MIN. 5.52 7.60 0.47 0.54 0.04 0.06 8.90 7.00 3.01 3.76 7.10 7.22 0.03 0.05 0.00 0.03 0.01 0.05 0.04 0.08 0.04 0.08 0.06 0.06
MAX. 24.18 15.23 0.75 0.92 0.14 0.20 11.35 9.90 5.07 5.03 12.84 12.16 0.12 0.13 0.10 0.11 0.11 0.18 0.20 0.27 0.21 0.26 0.16 0.19
H1 27.70 20.54 0.47 0.71 0.02 0.05 10.40 7.05 6.81 8.80 13.46 18.80 0.04 0.08 0.03 0.10 0.04 0.06 0.03 0.06 0.03 0.05 0.05 0.06
H2 76.18 20.94 0.38 1.65 0.03 0.17 10.40 13.85 6.65 5.94 12.89 90.89 0.03 0.16 0.03 0.15 0.04 0.17 0.03 0.16 0.03 0.18 0.04 0.19
H3 13.16 8.76 0.57 0.67 0.05 0.12 5.80 5.50 4.55 3.64 5.27 4.94 0.00 0.06 0.00 0.00 0.04 0.05 0.13 0.21 0.19 0.28 0.17 0.20
H4 36.29 27.00 0.48 0.50 0.04 0.05 11.90 11.70 5.92 5.60 16.01 16.37 0.03 0.03 0.04 0.05 0.05 0.06 0.03 0.04 0.04 0.05 0.05 0.05
H5 25.13 19.55 0.48 0.59 0.03 0.06 11.55 12.75 6.52 5.17 14.90 19.88 0.03 0.04 0.04 0.05 0.04 0.06 0.03 0.05 0.03 0.07 0.04 0.07
H6 11.06 10.73 0.77 0.74 0.10 0.09 10.35 11.40 4.65 4.73 17.67 19.84 0.08 0.09 0.09 0.10 0.10 0.10 0.12 0.08 0.11 0.08 0.10 0.08
H7 24.26 21.84 0.48 0.62 0.05 0.07 12.75 9.65 4.67 5.37 13.92 14.18 0.05 0.05 0.06 0.06 0.07 0.09 0.04 0.08 0.04 0.08 0.06 0.07
MED. 25.13 20.54 0.48 0.67 0.04 0.07 10.40 11.40 5.92 5.37 13.92 18.80 0.03 0.06 0.04 0.06 0.04 0.06 0.03 0.08 0.04 0.08 0.05 0.07
MIN. 11.06 8.76 0.38 0.50 0.02 0.05 5.80 5.50 4.55 3.64 5.27 4.94 0.00 0.03 0.00 0.00 0.04 0.05 0.03 0.04 0.03 0.05 0.04 0.05
MAX. 76.18 27.00 0.77 1.65 0.10 0.17 12.75 13.85 6.81 8.80 17.67 90.89 0.08 0.16 0.09 0.15 0.10 0.17 0.13 0.21 0.19 0.28 0.17 0.20
Te (sec) Ti(sec) T,:Te V'e (l/min) V'emax (l/sec) Vlmax (l/sec) m ,(J) Wb, *<J) Wbe es(J) Wbires (J) Wb„ot(J)
TP 0h 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h
C1 2.53 4.12 2.50 4.27 0.97 1.07 40.93 29.98 1.84 1.70 2.45 1.91 0.83 1.22 0.62 1.01 0.14 0.24 0.48 0.78 1.31 1.99
C2 3.52 4.98 2.57 3.50 0.77 0.73 49.54 33.86 2.74 1.61 2.93 1.93 0.55 0.94 1.11 1.48 0.31 0.53 0.81 0.95 1.35 1.89
C3 3.09 3.42 3.12 3.07 1.02 0.90 38.97 42.93 2.41 2.31 1.96 2.55 0.84 0.80 1.33 1.24 0.64 0.53 0.68 0.71 1.53 1.51
C4 3.66 4.69 2.72 3.53 0.77 0.76 32.87 27.60 1.47 1.43 2.02 1.73 0.61 0.80 1.21 1.57 0.39 0.63 0.83 0.94 1.44 1.74
C5 3.10 4.97 2.16 3.41 0.70 0.69 46.84 35.13 2.81 1.82 2.83 2.75 0.54 0.82 0.75 1.13 0.28 0.47 0.47 0.65 1.01 1.47
C6 3.83 3.06 2.95 2.96 0.77 0.99 42.14 47.71 3.23 3.98 2.92 2.99 0.79 0.92 0.84 1.21 0.03 0.49 0.81 0.72 1.60 1.64
MED. 3.31 4.41 2.64 3.45 0.77 0.83 42.14 34.49 2.57 1.76 2.64 2.24 0.70 0.87 0.98 1.23 0.29 0.51 0.74 0.75 1.40 1.69
MIN. 2.53 3.06 2.16 2.96 0.70 0.69 32.87 27.60 1.47 1.43 1.96 1.73 0.54 0.80 0.62 1.01 0.03 0.24 0.47 0.65 1.01 1.47
MAX. 3.83 4.98 3.12 4.27 1.02 1.07 49.54 47.71 3.23 3.98 2.93 2.99 0.84 1.22 1.33 1.57 0.64 0.63 0.83 0.95 1.60 1.99
H1 2.95 4.33 2.99 4.07 1.05 0.95 69.87 61.99 5.32 5.09 3.67 3.61 0.83 1.88 1.34 2.64 0.65 1.50 0.69 1.14 1.52 3.02
H2 3.18 2.58 2.62 1.76 0.83 0.68 69.17 82.17 4.24 3.90 4.00 5.11 0.34 0.86 1.25 6.59 0.56 2.34 0.69 4.25 1.02 5.10
H3 5.35 6.78 4.43 4.25 1.03 0.64 26.43 20.18 1.99 1.65 2.84 1.78 0.87 0.75 0.85 0.84 0.23 0.26 0.62 0.59 1.50 1.34
H4 2.68 2.86 2.29 2.29 0.87 0.81 70.55 65.31 3.73 3.37 4.22 4.01 0.52 0.62 1.31 1.41 0.69 0.74 0.62 0.67 1.14 1.28
H5 3.06 2.85 2.07 1.87 0.69 0.68 75.17 65.66 3.53 3.24 4.76 4.02 0.87 0.70 1.27 1.57 0.43 0.45 0.84 1.12 1.71 1.82
H6 2.74 2.56 2.87 2.70 1.05 1.06 48.26 54.17 2.83 3.02 2.46 2.99 0.97 1.05 1.66 1.74 0.71 0.78 0.95 0.96 1.92 2.01
H7 2.31 3.04 2.45 3.22 1.07 1.06 59.36 51.70 2.75 2.69 2.85 2.71 0.46 0.66 1.09 1.48 0.61 0.78 0.48 0.70 0.94 1.37
MED. 2.95 2.86 2.62 2.70 1.03 0.81 69.17 61.99 3.53 3.24 3.67 3.61 0.83 0.75 1.27 1.57 0.61 0.78 0.69 0.96 1.50 1.82
MIN. 2.31 2.56 2.07 1.76 0.69 0.64 26.43 20.18 1.99 1.65 2.46 1.78 0.34 0.62 0.85 0.84 0.23 0.26 0.48 0.59 0.94 1.28
MAX. 5.35 6.78 4.43 4.25 1.07 1.06 75.17 82.17 5.32 5.09 4.76 5.11 0.97 1.88 1.66 6.59 0.71 2.34 0.95 4.25 1.92 5.10
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Appendix 7.5(c): Lung function measurements in heaves (H1-5 and 7) horses prior to (Oh) and at 5h following inhalation challenge with HDS-2[R], MED. = median
value, MIN. = minimum value, MAX. = maximum value.
Cdyn (l/kPa) dPpI (kPa) RLiso (kPa/I/sec) RR (breaths/min.) VT(!) Wb' (J/min) Ri-E25% (kPa/I/sec) Ri-E5o% (kPa/I/sec) Rl-E7s% (kPa/l/sec) RL}25% (kPa/i/sec) Rli5o%(kPa/l/sec) RLl75%(kPa/l/$ec)
TP Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h Oh 5h
H1 27.72 16.87 0.79 0.93 0.07 0.09 9.30 8.45 7.73 7.49 30.59 29.14 0.09 0.13 0.09 0.12 0.09 0.10 0.05 0.06 0.07 0.08 0.08 0.09
H2 84.77 16.02 0.37 1.39 0.03 0.13 13.60 13.50 5.15 4.98 11.52 49.52 0.02 0.10 0.03 0.11 0.04 0.14 0.02 0.11 0.03 0.13 0.05 0.15
H3 9.52 7.63 1.02 0.97 0.12 0.10 5.70 5.20 6.93 4.79 13.46 7.69 0.03 0.12 0.00 0.00 0.03 0.09 0.19 0.28 0.38 0.35 0.15 0.21
H4 37.74 35.45 0.50 0.50 0.06 0.05 11.50 12.90 5.27 5.63 14.40 17.48 0.04 0.03 0.05 0.05 0.05 0.06 0.04 0.04 0.05 0.04 0.05 0.05
H5 22.05 29.78 0.41 0.48 0.03 0.04 9.45 7.00 5.65 7.76 7.58 10.61 0.04 0.04 0.04 0.05 0.05 0.06 0.03 0.04 0.03 0.04 0.03 0.05
H7 13.61 9.79 0.75 1.25 0.08 0.13 12.70 14.45 4.88 5.34 24.42 53.36 0.09 0.13 0.08 0.14 0.08 0.14 0.09 0.12 0.09 0.13 0.10 0.13
MED. 24.89 16.44 0.63 0.95 0.06 0.09 10.48 10.68 5.46 5.48 13.93 23.31 0.04 0.11 0.05 0.08 0.05 0.10 0.04 0.08 0.06 0.10 0.07 0.11
MIN. 9.52 7.63 0.37 0.48 0.03 0.04 5.70 5.20 4.88 4.79 7.58 7.69 0.02 0.03 0.00 0.00 0.03 0.06 0.02 0.04 0.03 0.04 0.03 0.05
MAX. 84.77 35.45 1.02 1.39 0.12 0.13 13.60 14.45 7.73 7.76 30.59 53.36 0.09 0.13 0.09 0.14 0.09 0.14 0.19 0.28 0.38 0.35 0.15 0.21
TE(sec) T|(sec) Tt:TE V'e (l/min) V'Emax (J/SeC) ; V',max (l/sec) Wb ,(J) Wbr*fJ) WbEres (J) Wblres(J) Wb,tot (J)
TP Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h
H1 3.26 3.58 3.18 3.58 0.98 1.02 71.66 62.99 5.17 4.50 3.53 2.93 1.10 1.65 3.27 3.43 1.77 1.96 1.51 1.47 2.61 3.12
H2 2.40 2.51 2.10 1.88 0.89 0.75 69.19 66.85 3.32 3.41 3.67 4.22 0.19 0.81 0.88 3.70 0.40 1.55 0.48 2.15 0.67 2.96
H3 5.49 6.80 4.75 4.92 0.88 0.73 39.58 24.84 2.96 1.65 3.59 2.06 2.58 1.43 2.26 1.48 0.29 0.49 1.98 0.99 4.55 2.42
H4 2.91 2.55 2.45 2.13 0.84 0.84 59.72 72.75 4.15 3.62 3.68 4.18 0.39 0.47 1.29 1.34 0.66 0.66 0.64 0.68 1.02 1.15
H5 3.51 5.34 2.77 3.31 0.77 0.63 52.64 54.37 2.87 2.98 3.41 3.69 0.78 1.01 0.81 1.53 0.37 0.54 0.44 0.99 1.22 2.00
H7 2.31 2.23 2.43 1.97 1.06 0.88 62.19 77.31 3.18 3.56 2.93 3.51 0.92 1.51 1.93 3.73 0.86
llliiiil!
1.80 1.08 1.94 1.99 3.45
MED. 3.08 3.06 2.61 2.72 0.88 0.79 60.95 64.92 3.25 : 3.49 3.56 3.60 0.85 1.22 1.61 2.48 : 1 10 0.86 1.23 1.61 2.69
MIN. 2.31 2.23 !;f 2.10 1.88 0.77 0.63 39.58 24.84 2.87 1.65 2.93 2.06 0.19 0.47 0.81 1.34 0.29 0.49 0.44 0.68 0.67 1.15
MAX. 5.49 ■ 6.80 4.75 4.92 1.06 1.02 71.66 77:31 5.17 4.50 3.68 4.22 2.58 1.65 3.27 3.73 1.77 1.96 1.98 2.15 4.55 3.45
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Appendix 7.5(d): Lung function measurements in heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with HDS-3[100]. MED. = median
value, MIN. = minimum value, MAX. = maximum value.
Cdyn (f/kPa) dPpI (kPa) RLiSo (kPa/l/sec) RR (breaths/min.) VT(I) Wb' (J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/l/sec) RLe7s% (kPa/l/sec) Ri-i2s%{kPa/i/sec) RL,so% (kPa/l/sec) RLi75% (kPa/i/sec)
TP Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h Oh 5h Oh 5h Oh 5h
H1 21.27 19.81 0.77 0.97 0.06 0.11 7.30 9.80 8.84 6.64 22.41 35.06 0.10 0.14 0.13 0.13 0.08 0.11 0.04 0.08 0.03 0.11 0.05 0.13
H2 50.26 12.57 0.56 1.71 0.05 0.18 9.60 10.60 6.48 6.39 16.57 64.60 0.07 0.17 0.05 0.16 0.06 0.17 0.04 0.14 0.04 0.17 0.07 0.18
H3 10.54 7.75 0.97 0.94 0.07 0.19 5.50 5.55 6.18 4.90 7.21 9.37 0.06 0.11 0.01 0.05 0.03 0.11 0.16 0.24 0.32 0.38 0.15 0.23
H4 39.62 43.75 0.44 0.46 0.03 0.05 11.70 15.20 5.66 3.98 13.50 15.41 0.03 0.03 0.03 0.05 0.05 0.07 0.03 0.05 0.03 0.05 0.04 0.06
H5 31.96 24.16 0.48 0.68 0.04 0.04 10.65 12.10 7.56 7.36 15.94 26.34 0.02 0.05 0.04 0.05 0.05 0.06 0.02 0.02 0.03 0.03 0.04 0.05
H6 10.40 3.68 0.67 1.33 0.08 0.20 11.90 20.60 3.79 2.81 15.79 45.80 0.09 0.21 0.09 0.25 0.10 0.27 0.11 0.17 0.09 0.16 0.10 0.15
H7 25.29 18.64 0.47 0.80 0.05 0.09 12.35 7.70 4.89 6.32 13.10 17.91 0.05 0.07 0.06 0.05 0.06 0.11 0.04 0.12 0.04 0.11 0.05 0.10
MED. 25.29 18.64 0.56 0.94 0.05 0.11 10.65 10.60 6.18 6.32 15.79 26.34 0.06 0.11 0.05 0.05 0.06 0.11 0.04 0.12 0.04 0.11 0.05 0.13
MIN. 10.40 3.68 0.44 0.46 0.03 0.04 5.50 5.55 3.79 2.81 7.21 9.37 0.02 0.03 0.01 0.05 0.03 0.06 0.02 0.02 0.03 0.03 0.04 0.05
MAX. 50.26 43.75 0.97 1.71 0.08 0.20 12.35 20.60 8.84 7.36 22.41 64.60 0.10 0.21 0.13 0.25 0.10 0.27 0.16 0.24 0.32 0.38 0.15 0.23
TE (sec) T i (sec) T«:TE VE (l/min) V'Em3x (i/sec) VImax (l/SeC) Wb ..(J) Wbr3S(J) Wbaes(J) Wb, es(J) Wb„m
TP Oh 5h 0h 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh i 5h
H1 4.24 3.14 4.09 3.22 0.97 1.04 64.61 64.33 4.71 4.15 3.44 2.88 1.87 1.17 3.12 3.68 2.00 1.95 1.12 1.73 2.99 2.90
H2 3.51 3.35 2.86 2.31 0.84 0.69 61.54 67.88 3.64 3.29 3.47 4.35 0.44 1.66 1.76 6.11 0.89 2.27 0.87 3.84 1.31 5.50
H3 6.58 6.22 4.92 4.80 0.76 0.77 34.03 27.09 2.91 1.69 2.90 2.11 2.42 1.55 1.41 1.71 0.39 0.62 1.02 1.08 3.44 2.64
H4 2.84 2.19 2.14 1.77 0.76 0.82 66.14 60.49 3.53 2.93 4.20 3.31 0.46 0.19 1.12 1.01 0.57 0.52 0.56 0.49 1.02 0.68
H5 3.30 2.96 2.65 2.18 0.81 0.76 79.97 89.31 4.11 4.70 4.51 5.18 0.93 1.23 1.58 2.22 0.59 0.99 0.99 1.22 1.92 2.45
H6 2.27 1.50 2.74 1.45 1.22 0.98 44.98 57.88 3.69 3.24 2.86 2.97 0.70 1.11 1.31 2.31 0.57 1.26 0.74 1.05 1.44 2.16
H7 2.46 4.02 2.48 3.76 1.02 0.94 60.02 48.71 2.74 2.59 3.31 2.50 0.51 1.08 1.08 2.31 0.61 1.08 0.47 1.23 0.98 2.31
MED. 3.30 3.14 2.74 2.31 0.84 0.82 61.54 60.49 3.64 3.24 3.44 2.97 0.70 1.17 1.41 2.31 0.59 1.08 0.87 1.22 1.44 2.45
MIN. 2.27 1.50 2.14 1.45 0.76 0.69 34.03 27.09 2.74 1.69 2.86 2.11 0.44 0.19 1.08 1.01 0.39 0.52 0.47 0.49 0.98 0.68
MAX. 6.58 6.22 4.92 4.80 1.22 1.04 79.97 89.31 4.71 4.70 4.51 5.18 2.42 1.66 3.12 6.11 2.00 2.27 1.12 3.84 3.44 5.50
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Appendix 8.1: Clinical scores in control (C1-6) and heaves (H1-7) horses prior to (0) and at 240min following inhalation challenge with
saline, HDS-1 supernatant (SUP), HDS-1 washed particulates (WP), HDS-1 wash fraction (WF), WP and SUP administered seperately
(WP/SUP[s]), WP resuspended in SUP (WP/SUP[m]) and HDS-1. Score based on: a (tracheal auscultation), d (dyspnoea) and f
(mucopurulent nasal discharge). NP = challenge not performed, NM = clinical score not measured.
CHALLENGE SALINE SUP IMIIIII I ■HIMIIII1II if WP/SUP[s] WP/SUP[m] HDS-1
TIME PT.
(min) 0 240 0 240 0 240 0 240 0 240 n 240 Q 240
C1 0 0 0 0 NP NP NP NP NP NP NP NP 0 0
C2 0 0 0 0 NP NP NP NP NP NP NP NP 0 0
C3 0 0 0 0 NP NP NP NP NP NP NP NP 0 0
C4 0 0 0 0 NP NP NP NP NP NP NP NP 0 0
C5 0 0 0 0 NP NP NP NP NP NP NP NP 0 0
C6 0 0 0 0 NP NP NP NP NP NP NP NP 0 0
H1 0 0 0 1 a 0 0 0 0 NM NM NM NM 0 0
H2 0 0 0 0 0 0 0 0 NM NM NM NM 0 1 d
H3 0 0 0 0 0 o 0 0 NM NM NM NM 0 0
H4 0 0 0 0 0 1 d 0 0 NM NM NM NM 0 0
H5 0 0 0 0 1 f 1 f 0 0 NM NM NM NM 0 0
H6 0 0 0 0 0 0 0 0 NM NM NM NM 0 0
H7 0 0 0 0 0 1 d 0 0 NM NM NM NM 0 0
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Appendix 8.2: Arterial blood pH, pC02 (mmHg) and p02 (mmHg) in control (C1-6) and heaves (H1-7) horses prior to (0) and at 240min following inhalation
challenge with saline, HDS-1[100], SUP and WP. MED. = median value, MIN. = minimum value, MAX. = maximum value.
pH pC02 p02
SALINE HDS-1[100] SUP WP SALINE ... HDS-1[100] SUP lilliiiliiiilliil SALINE ; ; > HDS-1[100] SUP WP
TIME PT. 0 240 0 240 0 240 0 240 0 240 0 240 0 240 0 240 0 240 0 240 0 240 0 240
C1 7.40 7.39 7.37 7.37 7.46 7.38 NP NP 46.0 49.0 53.5 48.9 44.9 55.9 NP NP 100.0 114.0 100.0 97.7 102.3 92.1 NP NP
C2 7.36 7.35 7.32 7.36 7.34 7.39 NP NP 45.0 48.0 54.0 56.0 51.1 50.1 NP NP 103.0 115.0 90.4 88.0 96.2 95.8 NP NP
C3 7.38 7.38 7.42 7.41 7.37 7.40 NP NP 46.5 46.6 46.4 46.3 47.0 52.0 NP NP 106.5 104.6 113.3 103.7 110.0 95.0 NP NP
C4 7.40 7.42 7.36 7.41 7.39 7.39 NP NP 50.1 44.7 49.2 49.1 48.2 51.9 NP NP 90.6 88.0 80.7 74.6 95.2 81.6 NP NP
C5 7.36 7.36 7.43 7.41 7.41 7.43 NP NP 41.0 39.0 51.0 48.5 51.6 49.2 NP NP 105.0 110.0 125.0 118.0 89.5 99.3 NP NP
C6 7.39 7.39 7.43 7.40 7.41 7.42 NP NP 40.0 41.0 50.0 43.5 47.7 48.0 NP NP 93.0 104.0 98.0 109.3 90.4 91.6 NP NP
MED. 7.39 7.39 7.39 7.40 7.40 7.39 45.5 45.7 50.5 48.7 48.0 51.0 101.5 107.3 99.0 100.7 95.7 93.6
MIN. 7.36 7.35 7.32 7.36 7.34 7.38 40.0 39.0 46.4 43.5 44.9 48.0 90.6 88.0 80.7 74.6 89.5 81.6
MAX. 7.40 7.42 7.43 7.41 7.46 7.43 50.1 49.0 54.0 56.0 51.6 55.9 106.5 115.0 125.0 118.0 110.0 99.3
H1 7.36 7.38 7.34 7.39 7.38 7.41 7.41 7.39 45.0 40.0 45.2 46.7 47.7 49.7 46.9 49.8 99.0 98.0 104.4 121.8 99.9 103.2 105.7 94.8
H2 7.35 7.36 7.34 7.38 7.38 7.39 7.37 7.38 47.0 46.0 48.9 50.8 51.5 52.7 48.5 51.5 116.0 102.0 100.8 101.5 91.4 90.3 98.9 96.4
H3 7.40 7.41 7.41 7.39 7.42 7.44 7.42 7.44 42.0 37.0 50.0 48.2 49.9 44.8 47.6 46.9 94.0 98.0 92.0 117.6 93.0 94.2 107.4 92.8
H4 7.39 7.35 7.42 7.43 7.40 7.43 7.38 7.40 43.0 45.0 43.4 46.0 48.0 44.8 46.6 48.3 102.0 97.0 104.1 124.0 92.4 102.6 97.7 99.1
H5 7.37 7.37 7.37 7.37 7.39 7.35 7.39 7.41 53.0 43.0 51.0 55.6 51.5 55.5 51.9 49.0 94.0 83.0 97.0 85.7 95.4 90.1 88.8 95.9
H6 7.42 7.36 7.37 7.40 7.37 7.41 7.38 7.40 48.4 47.6 51.3 56.4 55.7 51.3 47.3 49.4 90.5 94.5 98.4 81.4 95.3 88.6 98.3 96.2
H7 7.41 7.43 7.36 7.40 7.41 7.41 7.41 7.44 46.0 45.0 43.0 44.4 44.6 48.1 49.9 47.6 100.0 109.0 109.2 108.0 99.2 97.9 98.1 98.9
MED. 7.39 7.37 7.37 7.39 7.39 7.41 7.39 7.40 46.0 45.0 48.9 48.2 49.9 49.7 47.6 49.0 99.0 98.0 100.8 108.0 95.3 94.2 98.3 96.2
MIN. 7.35 7.35 7.34 7.37 7.37 7.35 7.37 7.38 42.0 37.0 43.0 44.4 44.6 44.8 46.6 46.9 90.5 83.0 92.0 81.4 91.4 88.6 88.8 92.8
MAX. 7.42 7.43 7.42 7.43 7.42 7.44 7.42 7.44 53.0 47.6 51.3 56.4 55.7 55.5 51.9 51.5 116.0 109.0 109.2 124.0 99.9 103.2 107.4 99.1
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Appendix 8.3: Lung function measurements in control (C1-6) and heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with SUP. MED. =
median value, MIN. = minimum value, MAX. = maximum value.
Cdyn fl/kPa) dPpI(kPa) RLiS0 (kPa/l/sec) RR (breaths/min.) VT (I) Wb' (J/min) RLe25% (kPa/l/sec) RLE5o%(kPa/l/sec) RLe75% (kPa/l/sec) RLi25% (kPa/1/sec) RL|5o% (kPa/i/sec) RL|75% (kPa/l/sec)
TP Oh 5h Oh 5h 0h 5h 0h 5h Oh 5h 0h 5h Oh 5h 0h 5h 0h 5h Oh 5h Oh 5h 0h 5h
C1 4.51 4.82 1.26 1.34 0.15 0.16 8.15 8.10 4.35 4.92 11.82 16.53 0.06 0.07 0.02 0.08 0.05 0.08 0.27 0.25 0.22 0.19 0.17 0.16
C2 10.00 8.05 0.88 1.05 0.08 0.09 7.90 9.35 6.17 5.44 16.82 20.70 0.08 0.10 0.06 0.07 0.05 0.07 0.16 0.17 0.14 0.15 0.13 0.14
C3 15.86 32.39 0.61 0.54 0.07 0.07 10.00 10.50 5.10 4.96 12.53 16.249 0.08 0.23 0.07 0.23 0.07 0.47 0.06 0.05 0.07 0.05 0.06 0.06
C4 11.08 3.70 0.57 0.82 0.02 0.08 6.60 7.25 6.01 2.85 2.09 2.82 0.01 0.10 0.00 0.02 0.00 0.01 0.08 0.32 0.13 0.20 0.07 0.14
C5 13.49 19.27 1.20 0.92 0.17 0.13 5.55 6.00 7.54 7.21 22.65 20.36 0.16 0.09 0.15 0.13 0.19 0.16 0.19 0.15 0.15 0.11 0.13 0.11
C6 9.05 7.35 0.81 0.90 0.06 0.08 8.95 8.10 5.69 5.58 13.02 12.00 0.04 0.07 0.01 0.05 0.01 0.03 0.14 0.16 0.16 0.20 0.11 0.13
MED. 10.54 7.35 0.84 0.92 0.07 0.09 8.03 8.10 5.85 5.44 12.77 16.53 0.07 0.09 0.04 0.07 0.05 0.07 0.15 0.17 0.14 0.19 0.12 0.14
MIN. 4.51 3.70 0.57 0.82 0.02 0.08 5.55 6.00 4.35 2.85 2.09 2.82 0.01 0.07 0.00 0.02 0.00 0.01 0.06 0.15 0.07 0.11 0.06 0.11
MAX. 15.86 19.27 1.26 1.34 0.17 0.16 10.00 9.35 7.54 7.21 22.65 20.70 0.16 0.10 0.15 0.13 0.19 0.16 0.27 0.32 0.22 0.20 0.17 0.16
H1 17.02 32.45 0.77 0.72 0.06 0.05 7.60 5.85 8.26 12.44 19.64 22.69 0.08 0.08 0.10 0.07 0.08 0.07 0.07 0.04 0.06 0.04 0.06 0.06
H2 60.46 43.03 0.53 0.54 0.05 0.05 6.75 7.60 7.24 6.88 13.43 12.08 0.02 0.88 0.06 0.65 0.07 0.54 0.05 0.06 0.05 0.05 0.06 0.05
H3 7.36 8.59 0.74 1.04 0.13 0.09 5.75 5.35 4.40 7.43 6.84 16.00 0.07 0.03 0.02 0.01 0.09 0.02 0.19 0.18 0.25 0.29 0.22 0.23
H4 24.11 20.94 0.62 0.65 0.05 0.06 7.40 6.30 7.74 8.26 13.90 14.55 0.03 0.00 0.04 0.04 0.06 0.07 0.05 0.06 0.05 0.06 0.06 0.05
H5 22.12 20.50 0.94 1.13 0.09 0.06 4.55 4.80 12.03 14.42 19.52 34.24 0.13 0.12 0.15 0.13 0.16 0.14 0.06 0.10 0.04 0.06 0.06 0.07
H6 13.42 11.71 0.70 0.66 0.07 0.08 9.00 8.30 5.37 4.88 14.24 9.09 0.08 0.07 0.07 0.05 0.07 0.08 0.10 0.11 0.08 0.15 0.08 0.08
H7 21.85 18.46 0.55 0.87 0.06 0.06 9.75 9.40 5.13 8.08 11.79 28.72 0.06 0.06 0.06 0.05 0.07 0.08 0.06 0.08 0.06 0.07 0.07 0.07
MED. 21.85 20.50 0.70 0.72 0.06 0.06 7.40 6.95 7.24 8.08 13.90 16.00 0.07 0.07 0.06 0.05 0.07 0.08 0.06 0.08 0.06 0.06 0.06 0.07
MIN. 7.36 8.59 0.53 0.54 0.05 0.05 4.55 5.35 4.40 4.88 6.84 9.09 0.02 0.00 0.02 0.01 0.06 0.02 0.05 0.04 0.04 0.04 0.06 0.05
MAX. 60.46 43.03 0.94 1.13 0.13 0.09 9.75 9.40 12.03 14.42 19.64 34.24 0.13 0.88 0.15 0.65 0.16 0.54 0.19 0.18 0.25 0.29 0.22 0.23
TE(sec) Ti (sec) T.:TE V'E (l/min) VEmax (l/sec) Vlmax l/sec) Wb ,(J) Wbres(J) WbEres(J) Wb,res(J) Wb, ot(J)
TP Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h
C1 3.96 3.63 3.72 3.79 0.95 1.05 35.11 39.76 1.78 2.02 2.26 2.29 2.10 2.52 1.50 2.04 0.24 0.58 1.27 1.46 3.36 3.98
C2 4.33 3.72 3.29 2.84 0.76 0.79 48.58 50.46 2.72 2.81 2.66 2.71 1.90 1.88 2.14 2.27 0.47 0.56 1.67 1.71 3.57 3.59
C3 2.94 2.24 3.10 3.05 1.06 6.80 50.95 52.04 2.66 3.72 2.69 3.13 0.82 0.49 1.26 1.50 0.70 0.928 0.56 0.57 1.38 1.06
C4 5.03 4.58 4.13 3.66 0.83 0.81 39.54 20.66 2.20 1.16 2.73 1.27 1.65 1.09 0.31 0.39 0.24 0.00 0.55 0.39 2.20 1.48
C5 6.15 5.39 4.79 4.58 0.78 0.85 41.87 43.30 2.17 2.18 2.62 3.07 2.11 1.36 4.06 3.37 2.10 1.72 1.96 1.65 4.06 3.01
C6 3.47 3.84 3.25 3.59 0.96 0.95 50.86 45.23 3.18 3.84 3.25 2.79 1.78 2.12 1.41 1.48 0.13 0.18 1.28 1.30 3.06 3.42
MED. 4.15 3.84 3.50 3.66 0.89 0.85 45.23 43.30 2.43 2.18 2.67 2.71 1.84 1.88 1.46 2.04 0.35 0.56 1.27 1.46 3.21 3.42
MIN. 2.94 3.63 3.10 2.84 0.76 0.79 35.11 20.66 1.78 1.16 2.26 1.27 0.82 1.09 0.31 0.39 0.13 0.00 0.55 0.39 1.38 1.48
MAX. 6.15 5.39 4.79 4.58 1.06 1.05 50.95 50.46 3.18 3.84 3.25 3.07 2.11 2.52 4.06 3.37 2.10 1.72 1.96 1.71 4.06 3.98
H1 3.39 4.40 4.55 6.04 1.35 1.40 62.47 72.45 4.79 4.43 3.58 4.32 2.03 2.45 2.60 3.96 1.63 2.84 0.97 1.12 2.99 3.57
H2 5.42 4.36 3.48 3.05 0.65 4.72 48.67 52.25 3.42 3.27 4.15 4.14 0.47 0.68 1.98 1.63 1.10 0.73 0.89 0.89 1.35 1.57
H3 6.08 5.83 4.67 4.50 0.79 0.97 25.37 39.65 1.56 2.77 2.12 4.17 1.32 3.76 1.17 2.55 0.41 0.15 0.76 2.40 2.09 6.16
H4 4.69 5.70 3.54 3.78 0.76 0.70 57.59 52.59 3.33 3.35 3.97 3.65 1.29 1.68 1.90 2.28 1.07 1.32 0.83 0.96 2.12 2.64
H5 7.32 7.34 5.75 5.07 0.79 0.70 54.50 63.71 2.78 4.02 4.06 4.64 3.42 4.16 4.21 7.07 2.64 4.64 1.57 2.43 4.99 6.59
H6 2.85 3.15 3.88 4.21 1.38 1.33 48.37 40.55 3.85 2.92 2.77 2.39 1.08 1.01 1.60 1.11 0.79 0.49 0.81 0.62 1.89 1.63
H7 3.15 3.32 3.04 3.07 0.97 0.93 50.11 75.70 2.49 3.49 2.38 4.04 0.62 1.79 1.22 3.04 0.61 1.46 0.61 1.59 1.23 3.38
MED. 4.69 4.40 3.88 4.21 0.79 0.97 50.11 52.42 3.33 3.35 3.58 4.14 1.29 1.79 1.90 2.55 1.07 1.32 0.83 1.12 2.09 3.38
MIN. 2.85 3.15 3.04 3.05 0.65 0.70 25.37 39.65 1.56 2.77 2.12 2.39 0.47 0.68 1.17 1.11 0.41 0.15 0.61 0.62 1.23 1.57
MAX. 7.32 7.34 5.75 6.04 1.38 4.72 62.47 75.70 4.79 4.43 4.15 4.64 3.42 4.16 4.21 7.07 2.64 4.64 1.57 2.43 4.99 6.59
349
Appendix 8.3: Lung function measurements in heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with WP. MED. = median value, MIN. =
minimum value, MAX. = maximum value.
Cdyn (l/kPa) dPpI (kPa) RLiso (kPa/l/sec) RR (breaths/min.) VT(i) Wb' (J/min) RLe25% (kPa/i/sec) Rl~E5o% (kPa/l/sec) RLg7s% (kPa/l/sec) RLi2s% (kPa/l/sec) RLiso% (kPa/l/sec) RLi75% (kPa/l/sec)
TP Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h Oh 5h
H1 17.53 20.05 1.62 1.27 0.15 0.12 4.75 5.10 13.26 12.35 46.49 37.63 0.19 0.12 0.17 0.13 0.17 0.16 0.11 0.14 0.09 0.11 0.11 0.11
H2 50.27 32.00 0.50 0.54 0.03 0.05 9.85 7.00 8.04 7.48 18.12 12.05 0.05 0.01 0.04 0.04 0.05 0.06 0.03 0.05 0.02 0.05 0.03 0.05
H3 8.13 9.04 1.02 0.98 0.11 0.13 4.95 4.80 6.25 7.18 12.19 13.22 0.09 0.01 0.05 0.01 0.12 0.11 0.17 0.20 0.23 0.32 0.20 0.25
H4 28.46 22.70 0.51 0.50 0.04 0.06 15.50 8.05 5.85 5.76 23.89 9.81 0.03 0.03 0.04 0.06 0.05 0.08 0.03 0.05 0.04 0.06 0.04 0.05
H5 32.71 21.75 0.53 0.84 0.06 0.07 4.45 4.55 9.24 11.64 11.13 19.09 0.07 0.09 0.09 0.11 0.10 0.11 0.08 0.07 0.08 0.07 0.07 0.07
H6 9.95 12.12 0.87 0.74 0.12 0.09 11.35 9.90 4.03 5.31 19.68 16.42 0.13 0.07 0.11 0.06 0.11 0.06 0.13 0.09 0.13 0.06 0.14 0.06
H7 17.56 14.70 1.11 0.93 0.14 0.07 6.30 8.40 7.34 7.26 23.82 22.43 0.15 0.08 0.16 0.07 0.22 0.09 0.14 0.09 0.11 0.06 0.13 0.06
MED. 17.56 20.05 0.87 0.84 0.11 0.07 6.30 7.00 7.34 7.26 19.68 16.42 0.09 0.07 0.09 0.06 0.11 0.09 0.11 0.09 0.09 0.06 0.11 0.06
MIN. 8.13 9.04 0.50 0.50 0.03 0.05 4.45 4.55 4.03 5.31 11.13 9.81 0.03 0.01 0.04 0.01 0.05 0.06 0.03 0.05 0.02 0.05 0.03 0.05
MAX. 50.27 32.00 1.62 1.27 0.15 0.13 15.50 9.90 13.26 12.35 46.49 37.63 0.19 0.12 0.17 0.13 0.22 0.16 0.17 0.20 0.23 0.32 0.20 0.25
Te (sec) T i (sec) TI-TE VE (l/min) VEmax (i/Sec) VIrnax (l/sec) WbM Wbr *(J) WbE es(J) Wb(res(J) Wb,tot(J)
TP Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h szo 5h Oh 5h Oh 5h
H1 5.57 5.37 6.90 6.37 1.27 1.19 62.73 62.56 3.58 3.28 2.98 3.41 5.03 3.87 9.49 7.37 6.69 4.64 2.80 2.73 7.83 6.60
H2 3.30 5.10 2.82 3.56 0.86 0.70 78.78 52.01 4.38 3.36 5.03 4.14 0.65 0.87 1.87 1.74 1.08 0.97 0.79 0.77 1.44 1.63
H3 5.98 7.64 5.43 5.06 1.07 0.67 31.42 34.48 2.12 2.39 2.85 3.19 2.70 2.72 2.26 2.77 0.94 0.87 1.32 1.90 4.02 4.63
H4 2.06 4.20 1.77 3.19 0.87 0.77 90.79 46.34 4.35 2.42 4.83 2.83 0.66 0.73 1.51 1.20 0.76 0.65 0.75 0.54 1.41 1.27
H5 7.14 7.60 5.40 5.00 1.13 0.67 40.97 52.58 2.26 2.99 3.18 4.25 1.40 3.27 2.24 3.79 0.96 1.61 1.28 2.17 2.67 5.44
H6 2.67 2.83 2.66 2.94 1.00 1.11 45.50 52.70 2.84 3.15 2.51 3.38 0.80 1.21 1.75 1.63 0.72 0.79 1.03 0.84 1.83 2.05
H7 4.83 3.44 4.76 3.63 0.99 1.06 46.10 60.90 2.32 3.31 2.16 3.42 1.55 1.79 3.81 2.64 2.31 1.57 1.49 1.07 3.05 2.86
MED. 4.83 5.10 4.76 3.63 1.00 0.77 46.10 52.58 2.84 3.15 2.98 3.41 1.40 1.79 2.24 2.64 0.96 0.97 1.28 1.07 2.67 2.86
MIN. 2.06 2.83 1.77 2.94 0.86 0.67 31.42 34.48 2.12 2.39 2.16 2.83 0.65 0.73 1.51 1.20 0.72 0.65 0.75 0.54 1.41 1.27
MAX. 7.14 7.64 6.90 6.37 1.27 1.19 90.79 62.56 4.38 3.36 5.03 4.25 5.03 3.87 9.49 7.37 6.69 4.64 2.80 2.73 7.83 6.60
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Appendix 8.4: PCCdyn70 values (mg/ml) in control (C1-6) and
heaves (H1-7) horses at 5h following inhalation challenge with
saline, SUP, WP and HDS-1[100]. MED. = median value, MIN. =
minimum value, MAX. = maximum value.
SALINE SUP WP HDS-1T1001
C1 3.82 1.35 NP 3.17
C2 9.91 4.22 NP 7.08
C3 3.46 8.85 NP 5.25
C4 2.82 1.83 NP 2.07
C5 3.87 1.69 NP 4.69
C6 2.29 4.58 NP 2.65
MED. 3.64 3.03 4.69
MIN. 2.29 1.35 2.07
MAX. 9.91 8.85 7.08
H1 7.86 0.72 5.63 8.16
H2 3.06 2.40 4.54 6.91
H3 5.64 4.85 5.74 4.26
H4 10.53 20.13 13.66 11.43
H5 6.40 3.23 3.48 9.96
H6 2.46 4.04 2.89 4.27
H7 5.63 7.12 4.39 6.20
MED. 5.64 4.04 4.54 6.91
MIN. 2.46 0.72 2.89 4.26
MAX. 10.53 20.13 13.66 11.43
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Appendix 8.5: (a) BALF total nucleated cell counts (x105/ml) in control (C1-
6) and heaves (H1-7) at 6h following challenge with saline, HDS-1[100],
SUP, WP, WP[R], WF, WP/SUP[s], WP/SUP[m] and H/S B. MED. = median
value, MIN. = minimum value, MAX. = maximum value.
SALINE HDS-11100] SUP WP WP[RJ WF WP/SUPfs] WP/SUPfmJ H/S B
C1 5.10 3.00 6.60 NP NP NP NP NP 2.20
C2 3.90 4.30 4.30 NP NP NP NP NP 2.90
C3 2.00 1.60 1.80 NP NP NP NP NP 2.10
C4 2.90 8.00 2.90 NP NP NP NP NP 3.20
C5 9.60 5.00 3.70 NP NP NP NP NP 4.60
C6 3.80 5.10 2.40 NP NP NP NP NP 2.20
MED. 3.85 4.65 3.30 2.55
MIN 2.00 1.60 1.80 2.10
MAX 9.60 8.00 6.60 4.60
H1 5.60 4.00 5.50 5.50 3.10 5.00 5.50 5.40 6.20
H2 3.40 3.70 7.40 4.80 3.70 3.90 5.90 4.70 4.20
H3 3.80 6.20 4.70 5.00 3.50 3.10 13.70 10.20 2.80
H4 5.50 4.10 9.40 5.60 5.30 3.20 7.30 5.70 7.00
H5 3.20 7.00 8.20 7.80 3.90 7.70 19.00 7.80 16.20
H6 1.30 2.10 3.40 2.00 3.50 2.30 2.90 2.30 5.70
H7 5.20 4.10 7.30 9.10 NP 4.90 4.40 5.30 6.50
MED. 3.80 4.10 7.30 5.50 3.90 5.90 5.40 6.20
MIN 1.30 2.10 3.40 2.00 2.30 2.90 2.30 2.80
MAX 5.60 7.00 9.40 9.10 7.70 19.00 10.20 16.20
Appendix 8.5: (b) BALF lymphocyte counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1[100], SUP, WP,
WP[R], WF, WP/SUP[s], WP/SUP[m] and H/S B. MED. = median value,
MIN. = minimum value, MAX. = maximum value.
SALINE HDS-11100] SUP WP WP[R] WF WP/SUP[s] WP/SUPlm] H/SB
C1 1.89 0.66 2.96 NP NP NP NP NP 0.61
C2 1.28 1.24 1.49 NP NP NP NP NP 0.99
C3 0.99 0.83 1.07 NP NP NP NP NP 1.07
C4 0.99 1.74 0.88 NP NP NP NP NP 0.76
C5 6.22 2.29 2.25 NP NP NP NP NP 3.09
C6 2.41 2.23 0.94 NP NP NP NP NP 0.79
MED. 1.59 1.49 1.28 0.89
MIN 0.99 0.66 0.88 0.61
MAX 6.22 2.29 2.96 3.09
H1 3.33 1.62 2.94 3.29 0.78 2.16 2.94 2.39 1.44
H2 1.54 0.61 2.76 2.21 1.19 2.17 1.33 1.09 0.71
H3 2.09 1.19 1.63 2.19 0.72 1.16 2.42 2.83 0.60
H4 2.36 1.75 4.32 1.98 1.81 0.68 2.47 2.33 2.30
H5 1.64 1.86 5.61 3.49 1.27 3.08 4.20 1.79 4.26
H6 0.80 0.81 2.33 0.95 1.52 1.28 1.56 1.14 2.46
H7 2.57 1.12 4.37 5.20 NP 2,64 2.36 2.39 2.32
MED. 2.09 1.19 2.94 2.21 1.23 2.16 2.42 2.33 2.30
MIN 0.80 0.61 1.63 0.95 0.72 0.68 1.33 1.09 0.60
MAX 3.33 1.86 5.61 5.20 1.81 3.08 4.20 2.83 4.26
Appendix 8.5: (c) BALF macrophage counts (x10s/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1 [100], SUP, WP,
WP[R], WF, WP/SUP[s], WP/SUP[m] and H/S B. MED. = median value,
MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1[10G] SUP WP WP[RJ WF WP/SUPJsJ WP/SUP[mJ H/SB
C1 2.80 1.72 2.61 NP NP NP NP NP 1.35
C2 2.25 2.75 2.46 NP NP NP NP NP 1.89
C3 0.73 0.51 0.52 NP NP NP NP NP 0.66
C4 1.71 4.19 1.66 NP NP NP NP NP 1.89
C5 2.57 1.91 1.08 NP NP NP NP NP 0.98
C6 1.14 2.46 1.21 NP NP NP NP NP 1.17
MED. 1.98 2.18 1.43 1.26
MIN 0.73 0.51 0.52 0.66
MAX 2.80 4.19 2.61 1.89
H1 1.96 1.16 1.98 1.68 2.15 2.16 1.78 2.21 1.44
H2 1.58 0.41 2.85 2.29 2.13 1.42 1.57 1.19 0.90
H3 1.24 1.75 1.96 1.99 2.47 1.37 5.14 4.81 1.35
H4 2.96 1.48 4.21 3.18 3.22 2.31 4.08 2.10 3.16
H5 1.27 1.18 1.45 3.92 1.82 2.98 5.30 1.37 2.03
H6 0.34 0.50 0.55 0.71 1.67 0.65 0.68 0.38 1.04
H7 2.40 0.77 2.09 1.65 NP 1.76 1.67 1.46 2.57
MED. 1.58 1.16 1.98 1.99 2.14 1.76 1.78 1.46 1.44
MIN 0.34 0.41 0.55 0.71 1.67 0.65 0.68 0.38 0.90
MAX 2.96 1.75 4.21 3.92 3.22 2.98 5.30 4.81 3.16
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Appendix 8.5: (d) BALF neutrophil counts (x105/ml) in control (C1-6) and
heaves (H1 -7) at 6h following challenge with saline, HDS-1 [100], SUP, WP,
WP[R], WF, WP/SUP[s], WP/SUP[m] and H/S B. MED. = median value,
MIN. = minimum value, MAX. = maximum value.
SALINE HDSrlJIOp]: SUP WP WP[RJ WF WP/SUP(sJ WP/SUPJm] H/SB
C1 0.04 0.29 0.25 NP NP NP NP NP 0.02
C2 0.01 0.12 0.06 NP NP NP NP NP 0.01
C3 0.02 0.08 0.04 NP NP NP NP NP 0.24
C4 0.09 0.56 0.18 NP NP NP NP NP 0.35
C5 0.17 0.66 0.17 NP NP NP NP NP 0.40
C6 0.09 0.28 0.12 NP NP NP NP NP 0.11
MED. 0.06 0.28 0.15 0.17
MIN 0.01 0.08 0.04 0.01
MAX 0.17 0.66 0.25 0.40
H1 0.20 1.11 0.28 0.21 0.08 0.40 0.27 0.43 3.14
H2 0.08 2.60 1.64 0.14 0.24 0.12 2.83 2.34 2.47
H3 0.17 3.14 0.98 0.65 0.20 0.40 5.90 2.35 0.74
H4 0.03 0.80 0.53 0.19 0.19 0.05 0.47 1.04 1.47
H5 0.06 3.81 0.98 0.19 0.79 1.54 9.29 4.55 9.83
H6 0.06 0.54 0.28 0.10 0.23 0.21 0.43 0.63 2.05
H7 0.06 2.17 0.31 0.56 NP 0.35 0.12 1.36 1.41
MED. 0.06 2.17 0.53 0.19 0.22 0.35 0.47 1.36 2.05
MIN 0.03 0.54 0.28 0.10 0.08 0.05 0.12 0.43 0.74
MAX 0.20 3.81 1.64 0.65 0.79 1.54 9.29 4.55 9.83
Appendix 8.5: (e) BALF mast cell counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1[100], SUP, WP,
WP[R], WF, WP/SUP[s], WP/SUP[m] and H/S B. MED. = median value,
MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1[100) SUP WP WPfRJ WF WP/SUPts] WP/SUP[mJ H/S B
C1 0.23 0.13 0.28 NP NP NP NP NP 0.11
C2 0.30 0.18 0.25 NP NP NP NP NP 0.01
C3 0.26 0.12 0.16 NP NP NP NP NP 0.11
C4 0.06 0.24 0.08 NP NP NP NP NP 0.07
C5 0.39 0.15 0.16 NP NP NP NP NP 0.12
C6 0.09 0.11 0.10 NP NP NP NP NP 0.11
MED. 0.25 0.14 0.16 0.11
MIN 0.06 0.11 0.08 0.01
MAX 0.39 0.24 0.28 0.12
H1 0.11 0.08 0.23 0.23 0.07 0.18 0.30 0.24 0.12
H2 0.15 0.07 0.13 0.12 0.13 0.19 0.17 0.07 0.11
H3 0.19 0.11 0.09 0.14 0.11 0.16 0.22 0.21 0.10
H4 0.13 0.05 0.11 0.09 0.07 0.13 0.14 0.03 0.08
H5 0.09 0.02 0.02 0.11 0.02 0.03 0.02 0.02 0.08
H6 0.10 0.14 0.23 0.19 0.06 0.15 0.19 0.14 0.10
H7 0.17 0.02 0.20 0.15 NP 0.07 0.19 0.08 0.10
MED. 0.13 0.07 0.13 0.14 0.07 0.15 0.19 0.08 0.10
MIN 0.09 0.02 0.02 0.09 0.02 0.03 0.02 0.02 0.08
MAX 0.19 0.14 0.23 0.23 0.13 0.19 0.30 0.24 0.12
Appendix 8.5: (f) BALF basiphiloid cell counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1[100], SUP, WP,
WP[R], WF, WP/SUP[s], WP/SUP[m] and H/S B. MED. = median value,
MIN. = minimum value, MAX. = maximum value.
SALINE HDS-1[1Q0] SUP WP WPfRJ WF WP/SUP[sJ WP/SUPJm] H/S B
C1 0.07 0.20 0.36 NP NP NP NP NP 0.09
C2 0.01 0.00 0.03 NP NP NP NP NP 0.00
C3 0.00 0.03 0.00 NP NP NP NP NP 0.03
C4 0.03 1.04 0.04 NP NP NP NP NP 0.12
C5 0.22 0.00 0.01 NP NP NP NP NP 0.00
C6 0.01 0.00 0.00 NP NP NP NP NP 0.00
MED. 0.02 0.02 0.02 0.02
MIN 0.00 0.00 0.00 0.00
MAX 0.22 1.04 0.36 0.12
H1 0.01 0.00 0.01 0.02 0.01 0.11 0.00 0.00 0.04
H2 0.05 0.00 0.00 0.02 0.00 0.00 0.00 0.01 0.01
H3 0.11 0.00 0.03 0.00 0.00 0.01 0.01 0.00 0.01
H4 0.01 0.00 0.00 0.02 0.00 0.02 0.00 0.00 0.00
H5 0.02 0.00 0.02 0.02 0.00 0.01 0.00 0.02 0.00
H6 0.00 0.10 0.00 0.04 0.01 0.01 0.02 0.00 0.03
H7 0.01 0.00 0.01 0.02 NP 0.05 0.02 0.00 0.08
MED. 0.01 0.00 0.01 0.02 0.00 0.01 0.00 0.00 0.01
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.11 0.10 0.03 0.04 0.01 0.11 0.02 0.02 0.08
Appendix 8.5: (g) BALF eosinophil counts (x10s/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1[100], SUP, WP,
WP[R], WF, WP/SUP[s], WP/SUP[m] and H/S B. MED. = median value,
MIN. = minimum value, MAX. = maximum value.
saline hds-1[100] SUP WP WPfRJ WF WP/SUP[s] WP/SUP[mJ H/SB
c1 0.05 0.00 0.13 np np np np np 0.01
c2 0.06 0.01 0.02 np np np np np 0.00
c3 0.00 0.04 0.00 np np np np np 0.00
c4 0.00 0.23 0.07 np np np np np 0.02
c5 0.02 0.00 0.03 np np np np np 0.01
c6 0.06 0.02 0.03 np np np np np 0.00
MED. 0.03 0.01 0.03 0.01
MIN 0.00 0.00 0.00 0.00
MAX 0.06 0.23 0.13 0.02
h1 0.00 0.03 0.07 0.07 0.00 0.00 0.21 0.12 0.01
h2 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00
h3 0.01 0.00 0.01 0.04 0.00 0.00 0.00 0.00 0.00
h4 0.01 0.01 0.23 0.13 0.01 0.00 0.14 0.20 0.00
h5 0.01 0.13 0.11 0.08 0.00 0.06 0.19 0.06 0.00
h6 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.02
h7 0.00 0.02 0.33 1.54 np 0.02 0.03 0.01 0.02
MED. 0.01 0.01 0.07 0.07 0.00 0.00 0.03 0.01 0.00
MIN 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.01 0.13 0.33 1.54 0.01 0.06 0.21 0.20 0.02
Appendix 8.5: (h) BALF epithelial cell counts (x105/ml) in control (C1-6) and
heaves (H1-7) at 6h following challenge with saline, HDS-1[100], SUP, WP,
WP[R], WF, WP/SUP[s], WP/SUP[m] and H/S B. MED. = median value,
MIN. = minimum value, MAX. = maximum value.
saline hds-11100] sup wp iiiwpirj wf wp/sup[s! wp/supcml h/sb
c1 0.03 0.00 0.00 np np np np np 0.00
c2 0.00 0.00 0.00 np np np np np 0.00
c3 0.00 0.00 0.00 np np np np np 0.00
c4 0.00 0.00 0.00 np np np np np 0.00
c5 0.00 0.00 0.00 np np np np np 0.00
c6 0.00 0.00 0.00 np np np np np 0.00
MED. 0.00 0.00 0.00 0.00
MIN 0.00 0.00 0.00 0.00
MAX 0.03 0.00 0.00 0.00
h1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
h2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
h3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
h4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
h5 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
h6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
h7 0.00 0.00 0.00 0.00 np 0.00 0.00 0.00 0.00
MED. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
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Appendix 9.1: Clinical scores in control (C1-6) and heaves (H1-7) horses prior to (0) and at 240min following inhalation challenge with saline, HDS-1 (HDS), LPS
depleted HDS-1 (HDS-LPS) and LPS depleted HDS-1 with added back LPS (HDS-LPS+LPS). Score based on: a (tracheal auscultation), d (dyspnoea) and f
(mucopurulent nasal discharge). NP = challenge not performed.
CHALLENGE SALINE HDS HDS-LPS HDS-LPS+LPS
TIME PT. (min) 0 240 nu 240 o 240 240
C1 0 0 0 0 0 0 NP NP
C2 0 0 0 0 0 0 NP NP
C3 0 0 0 0 0 0 NP NP
C4 0 0 0 0 0 0 NP NP
C5 0 0 0 0 0 0 NP NP
C6 0 0 0 0 0 0 NP NP
H1 0 0 0 0 0 0 0 0
H2 0 0 0 1 d 0 1 a 0 0
H3 0 0 0 0 0 0 0 0
H4 0 0 0 0 0 0 0 0
H5 0 0 0 0 0 0 0 2 a, f
H6 0 0 0 0 0 0 NP NP
H7 0 0 0 0 0 0 0 0
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Appendix 9.2a (i and ii): Lung function measurements in control (C1-6) and heaves (H1-5 and 7) horses prior to (Oh) and at 5h following inhalation challenge with
HDS-1[100], MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (l/kPa) dPpl(kPa) RLiso (KPa/l/sec) RR (breaths/min.) VT (I) Wb' (J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/l/sec) RLe?s% (kPa/l/sec) RLi2s% (kPa/l/sec) RLi5o% (kPa/l/sec) RL|75%(kPa/j/sec)
TP Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h 0h 5h
C1 4.87 3.98 1.05 1.51 0.12 0.09 9.40 8.4 3.71 4.95 13.03 14.23 0.09 0.03 0.10 0.01 0.11 0.04 020 0 28 0.18 0.20 0.16 0.13
C2 11.13 15.45 0.54 0.54 0.04 0.05 8.35 8.55 4.38 4.73 6.21 8.08 0.06 0.05 0.05 0.04 0.03 0.03 0.12 0.15 0.08 0.09 0.07 0.08
C3 14.67 13.51 0.47 0.74 0.04 0.06 15.20 10.15 3.97 6.05 11.77 16.49 0.03 0.06 0.02 0.04 0.03 0.02 0.07 0.10 0.06 0.09 0.06 0.07
C4 5.33 4.97 1.47 1.83 0.35 0.41 7.15 7.15 3.77 3.88 17.84 22.75 0.29 0.39 0.19 0.27 0.28 0.35 0.43 0.47 0.38 0.40 0.31 0.36
C5 18.89 18.88 0.36 0.52 0.05 0.08 10.70 6.40 3.59 4.78 6.38 6.63 0.04 0.09 0.05 0.09 0.05 0.09 0.03 0.09 0.04 0.07 0.05 0.07
C6 16.23 8.63 0.61 0.84 0.08 0.06 8.40 8.25 4.61 4.15 8.76 9.42 0.03 0.04 0.04 0.10 0.07 0.07 0.12 0.18 0.09 0.23 0.09 0.10
MED. 12.90 11.07 0.58 0.79 0.06 0.07 8.90 8.25 3.87 4.75 10.26 11.83 0.05 0.05 0.05 0.06 0.06 0.06 0.12 0.17 0.08 0.14 0.08 0.09
MIN. 4.87 3.98 0.36 0.52 0.04 0.05 7.15 6.40 3.59 3.88 6.21 6.63 0.03 0.03 0.02 0.01 0.03 0.02 0.03 0.09 0.04 0.07 0.05 0.07
MAX. 18.89 18.88 1.47 1.83 0.35 0.41 15.20 10.15 4.61 6.05 17.84 22.75 0.29 0.39 0.19 0.27 0.28 0.35 0.43 0.47 0.38 0.40 0.31 0.36
H1 22.62 25.23 0.62 0.61 0.05 0.07 7.25 5.25 7.81 8.26 14.61 11.59 0.06 0.09 0.06 0.09 0.05 0.10 0.11 0.07 0.07 0.06 0.05 0.08
H2 43.80 46.18 0.34 0.41 0.04 0.05 8.05 7.05 5.34 5.87 6.38 7.58 0.01 0.04 0.04 0.04 0.05 0.06 0.04 0.05 0.04 0.05 0.05 0.06
H3 19.80 16.26 0.40 0.70 0.04 0.09 4.55 4.00 4.26 6.81 5.36 7.90 0.04 0.00 0.02 0.01 0.06 0.08 0.12 0.15 0.13 0.24 0.09 0.14
H4 40.77 28.59 0.28 0.37 0.04 0.06 10.85 9.40 4.19 4.11 6.26 7.22 0.01 0.03 0.04 0.05 0.04 0.07 0.04 0.07 0.04 0.07 0.04 0.06
H5 28.55 27.38 0.50 0.63 0.04 0.04 8.05 8.90 7.02 8.29 11.50 22.56 0.05 0.04 0.04 0.05 0.06 0.05 0.05 0.04 0.03 0.03 0.04 0.06
H7 27.43 38.35 0.57 0.64 0.06 0.07 15.95 10.65 4.72 5.24 25.36 22.74 0.06 0.07 0.06 0.08 0.07 0.10 0.05 0.07 0.06 0.07 0.07 0.08
MED. 27.99 27.98 0.45 0.62 0.04 0.07 8.05 7.98 5.03 6.34 8.94 9.74 0.04 0.04 0.04 0.05 0.06 0.08 0.05 0.07 0.05 0.06 0.05 0.07
MIN. 19.80 16.26 0.28 0.37 0.04 0.04 4.55 4.00 4.19 4.11 5.36 7.22 0.01 0.00 0.02 0.01 0.04 0.05 0.04 0.04 0.03 0.03 0.04 0.06
MAX. 43.80 46.18 0.62 0.70 0.06 0.09 15.95 10.65 7.81 8.29 25.36 22.74 0.06 0.09 0.06 0.09 0.07 0.10 0.12 0.15 0.13 0.24 0.09 0.14
Te (sec) Ti(sec) T«:Te VE (l/min) VEmax (l/sec) V,m3X (l/sec) Wb ,(J) Wbres(J) WbE,eS(J) Wbues(J) Wb,at (J)
TP 0h 5h Oh 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h
C1 2.94 3.37 3.36 3.44 1.16 1.02 34.55 42.06 2.09 2.61 1.94 3.30 1.37 322 1.38 1.60 0.53 0.10 0.85 1.70 2.22 4.92
C2 3.92 3.58 3.31 3.51 0.84 0.99 36.66 40.32 2.58 2.62 2.09 2.18 0.92 0.93 0.74 0.90 0.12 0.23 0.62 0.68 1.54 1.61
C3 2.15 3.38 1.83 2.59 0.86 0.77 60.20 61.04 2.89 3.55 3.38 3.65 0.55 1.42 0.78 1.65 0.21 0.45 0.57 1.21 1.12 2.62
C4 4.61 4.62 3.85 3.71 0.84 0.81 26.89 27.55 1.33 1.30 1.47 1.60 1.36 1.51 2.52 3.14 1.04 1.34 1.48 1.80 2.85 3.31
C5 3.07 5.24 2.63 4.05 0.88 0.78 39.19 30.64 2.44 1.95 2.42 2.17 0.36 0.64 0.54 1.03 0.23 0.44 0.31 0.59 0.68 1.23
C6 4.34 4.10 3.50 3.24 0.86 0.76 38.73 33.01 2.07 1.93 2.55 2.27 0.81 1.09 1.17 1.14 0.42 0.40 0.75 0.75 1.56 1.84
MED. 3.49 3.84 3.33 3.47 0.86 0.80 37.70 33.01 2.27 2.28 2.26 2.22 0.86 1.25 0.98 1.37 0.32 0.42 0.69 0.98 1.55 2.23
MIN. 2.15 3.37 1.83 2.59 0.84 0.76 26.89 27.55 1.33 1.30 1.47 1.60 0.36 0.64 0.54 0.90 0.12 0.10 0.31 0.59 0.68 1.23
MAX. 4.61 5.24 3.85 4.05 1.16 1.02 60.20 61.04 2.89 3.55 3.38 3.65 1.37 3.22 2.52 3.14 1.04 1.34 1.48 1.80 2.85 4.92
H1 3.67 5.38 4.71 6.32 1.29 1.20 56.24 42.96 4.75 2.92 3.32 2.90 1.40 1.41 2.03 2.25 1.02 1.32 1.00 0.93 2.40 2.34
H2 4.11 5.02 3.37 3.56 0.82 0.72 42.94 41.15 2.43 2.44 2.80 2.82 0.33 0.42 0.79 1.09 0.43 0.52 0.37 0.56 0.70 0.98
H3 3.95 8.58 5.66 6.15 1.92 0.72 19.65 27.41 1.70 2.45 2.53 2.74 0.73 1.33 0.84 1.94 0.22 0.84 0.62 1.10 1.35 2.43
H4 2.82 3.38 2.50 3.02 0.89 0.89 44.97 38.02 2.24 2.10 2.76 2.38 0.23 0.32 0.56 0.77 0.27 0.38 0.29 0.39 0.51 0.71
H5 4.08 3.36 3.20 2.88 0.79 0.87 56.43 73.40 3.28 4.74 3.91 5.08 0.89 1.22 1.39 2.28 0.59 0.99 0.80 1.29 1.68 2.51
H7 1.94 2.55 1.87 3.04 0.99 1.22 74.85 56.93 3.61 3.08 3.69 3.07 0.44 0.44 1.58 1.88 0.79 1.04 0.79 0.84 1.23 1.29
MED. 3.81 4.20 3.29 3.30 0.94 0.88 50.61 42.05 2.86 2.69 3.06 2.86 0.58 0.83 1.12 1.91 0.51 0.92 0.71 0.89 1.29 1.81
MIN. 1.94 2.55 1.87 2.88 0.79 0.72 19.65 27.41 1.70 2.10 2.53 2.38 0.23 0.32 0.56 0.77 0.22 0.38 0.29 0.39 0.51 0.71
MAX. 4.11 8.58 5.66 6.32 1.92 1.22 74.85 73.40 4.75 4.74 3.91 5.08 1.40 1.41 2.03 2.28 1.02 1.32 1.00 1.29 2.40 2.51
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Appendix 9.2b (i and ii): Lung function measurements in control (C1-6) and heaves (H1-5 and 7) horses prior to (Oh) and at 5h following inhalation challenge with
LPS-depleted HDS (HDS-LPS). MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (l/kPa) dPpI (kPa) RUo (kPa/i/sec) RR (breaths/min.) VT (I) Wb' (J/min) RLe25% (kPa/l/sec) RLE50% (kPa/l/sec) RLe?s% (kPa/l/sec) RLi2s% (kPa/l/sec) RL.50% (kPa/l/sec) RLi75% (kPa/i/sec)
TP Oh 5h Oh 5h Oh 5h 0h 5h Oh 5h 0h 5h 0h 5h Oh 5h 0h 5h 0h 5h 0h 5h 0h 5h
C1 8.59 6.30 0.67 0.69 0.08 0.09 9.95 21.30 3.64 2.04 7.81 11.13 0.02 0.08 0.02 0.09 0.05 0.11 0.15 0.08 0.12 0.10 0 10 0 11
C2 26.29 14.69 0.59 0.56 0.08 0.06 7.00 6.80 5.06 5.13 9.66 7.78 0.07 0.07 0.06 0.05 0.09 0.01 0.12 0.18 0.10 0.11 0.12 0.10
C3 12.35 6.78 0.55 0.90 0.05 0.08 12.65 12.95 3.83 4.07 10.38 17.62 0.06 0.06 0.05 0.04 0.05 0.05 0.07 0.15 0.06 0.15 0.06 0.13
C4 10.08 8.41 0.59 0.89 0.14 0.18 6.40 5.75 3.76 4.34 5.43 8.79 0.00 0.09 0.01 0.00 0.05 0.04 0.27 0.39 0.26 0.34 0.15 0.23
C5 16.30 16.38 0.57 0.40 0.04 0.06 12.45 11.25 4.92 3.13 11.06 5.94 0.04 0.04 0.06 0.05 0.07 0.07 0.04 0.05 0.03 0.06 0.05 0.08
C6 17.35 19.12 0.40 0.69 0.03 0.07 54.70 34.60 1.66 2.89 14.67 19.07 0.03 0.07 0.03 0.06 0.04 0.06 0.01 0.16 0.02 0.15 0.02 0.08
MED. 14.32 11.55 0.58 0.69 0.06 0.07 11.20 12.10 3.79 3.60 10.02 9.96 0.04 0.07 0.04 0.05 0.05 0.06 0.09 0.16 0.08 0.13 0.08 0.10
MIN. 8.59 6.30 0.40 0.40 0.03 0.06 6.40 5.75 1.66 2.04 5.43 5.94 0.00 0.04 0.01 0.00 0.04 0.01 0.01 0.05 0.02 0.06 0.02 0.08
MAX. 26.29 19.12 0.67 0.90 0.14 0.18 54.70 34.60 5.06 5.13 11.06 19.07 0.07 0.09 0.06 0.09 0.09 0.11 0.27 0.39 0.26 0.34 0.15 0.23
H1 18.65 23.72 0.68 0.64 0.06 0.07 6.50 5.75 8.05 8.86 14.68 15.64 0.09 0.10 0.10 0.15 0.07 0.09 0.08 0.05 0.06 0.05 0.05 0.06
H2 51.39 36.40 0.51 1.24 0.06 0.079 5.50 6.9 7.96 7.56 11.41 19.79 0.03 0.08 0.05 0.08 0.07 0.11 0.06 0.085 0.06 0.149 0.05 0.079
H3 12.46 9.21 0.64 0.82 0.09 0.09 6.65 5.55 4.77 5.32 9.11 10.24 0.08 0.06 0.05 0.02 0.06 0.05 0.71 0.15 0.69 0.20 0.78 0.15
H4 23.87 23.10 0.51 0.53 0.05 0.05 6.60 7.85 7.17 7.19 9.50 9.48 0.01 0.01 0.04 0.04 0.06 0.05 0.06 0.06 0.06 0.06 0.05 0.08
H5 22.47 23.32 0.61 0.47 0.04 0.04 10.40 5.5 7.78 7.52 11.64 5.76 0.09 0.06 0.08 0.06 0.11 0.07 0.05 0.03 0.03 0.03 0.04 0.03
H7 15.82 18.05 0.80 0.75 0.08 0.09 10.10 9.40 6.14 5.96 23.19 24.48 0.07 0.09 0.06 0.09 0.08 0.11 0.09 0.10 0.08 0.11 0.08 0.11
MED. 20.56 23.10 0.63 0.64 0.06 0.07 6.63 6.80 7.47 7.19 11.52 10.24 0.08 0.06 0.06 0.06 0.07 0.07 0.07 0.06 0.06 0.06 0.05 0.08
MIN. 12.46 9.21 0.51 0.47 0.04 0.04 5.50 5.55 4.77 5.32 9.11 5.76 0.01 0.01 0.04 0.02 0.06 0.05 0.05 0.03 0.03 0.03 0.04 0.03
MAX. 51.39 23.72 0.80 0.82 0.09 0.09 10.40 9.40 8.05 8.86 23.19 24.48 0.09 0.10 0.10 0.15 0.11 0.11 0.71 0.15 0.69 0.20 0.78 0.15
TE(sec) Ti(sec) T,:Te VE (l/min) V'Emax (i/SeC) V,max (l/sec) Wbe.(J) Wbres (J) WbEres (J) Wblres(J) Wbnot(J)
TP Oh 5h 0h 5h Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h 0h 5h
C1 2.92 1.92 3.24 1.65 1.14 1.03 36.55 37.08 1.90 1.69 2.31 3.07 0.81 0.41 0 79 0.62 0.15 0.18 0.64 0.44 1.45 0.85
C2 4.89 4.96 3.74 3.79 0.79 0.76 35.37 34.96 1.90 2.45 2.25 2.44 0.50 0.94 1.35 1.13 0.46 0.22 0.90 0.91 1.40 1.86
C3 2.35 2.38 2.36 2.23 1.05 0.94 48.31 52.83 3.16 3.58 3.03 2.92 0.63 1.24 0.79 1.35 0.35 0.30 0.44 1.05 1.07 2.29
C4 5.37 6.39 4.04 4.21 0.77 0.67 24.19 24.82 1.33 1.35 1.60 1.86 0.68 1.11 0.84 1.55 0.17 0.24 0.67 1.31 1.34 2.42
C5 2.66 3.11 2.27 2.26 0.86 0.73 60.95 35.11 3.30 1.85 3.36 2.09 0.80 0.31 0.91 0.53 0.41 0.18 0.50 0.35 1.30 0.66
C6 0.52 1.65 0.49 2.06 1.02 1.24 92.24 62.02 5.73 3.36 4.84 3.02 0.15 0.74 0.19 0.90 0.01 0.22 0.18 0.68 0.03 1.42
MED. 2.79 2.74 2.80 2.24 0.94 0.85 42.43 36.10 2.53 2.15 2.67 2.68 0.65 0.84 0.82 1.02 0.26 0.22 0.57 0.80 1.32 1.64
MIN. 0.52 1.65 0.49 1.65 0.77 0.67 24.19 24.82 1.33 1.35 1.60 1.86 0.15 0.31 0.19 0.53 0.01 0.18 0.18 0.35 0.03 0.66
MAX. 5.37 6.39 4.04 4.21 1.14 1.24 92.24 62.02 5.73 3.58 4.84 3.07 0.81 1.24 1.35 1.55 0.46 0.30 0.90 1.31 1.45 2.42
H1 4.46 5.24 4.90 5.24 1.14 1.04 52.28 50.88 4.26 3.95 3.03 2.86 1.79 1.70 2.26 2.66 1.37 1.68 0.89 0.98 2.69 2.68
H2 6.26 5.06 4.64 4.03 0.74 1.020 43.80 45.50 2.92 2.594 4.02 3.980 0.63 2.65 2.07 2.95 1.16 1.15 0.91 1.800 1.53 4.448
H3 5.23 5.62 3.63 4.19 0.79 1.69 31.68 29.42 2.58 1.90 3.04 2.87 0.93 1.68 1.81 1.57 1.10 0.42 0.71 1.15 1.63 2.83
H4 5.32 5.06 4.08 4.19 0.78 0.84 47.35 55.95 2.69 2.99 3.42 3.67 1.12 1.09 1.46 1.47 0.80 0.75 0.66 0.72 1.78 1.81
H5 4.99 6.46 4.92 4.35 1.04 0.67 79.27 38.69 2.20 2.08 2.85 3.13 1.59 1.38 1.91 1.04 1.08 0.48 0.82 0.56 2.41 1.94
H7 2.90 2.78 3.05 3.61 1.06 1.31 62.49 56.35 3.24 3.09 3.35 2.58 1.25 1.05 2.26 2.49 1.00 1.39 1.26 1.11 2.51 2.15
MED. 5.11 5.24 4.36 4.19 0.92 1.04 49.82 48.19 2.81 2.99 3.20 2.87 1.18 1.38 1.99 1.57 1.09 0.75 0.86 0.98 2.10 2.15
MIN. 2.90 2.78 3.05 3.61 0.74 0.67 31.68 29.42 2.20 1.90 2.85 2.58 0.63 1.05 1.46 1.04 0.80 0.42 0.66 0.56 1.53 1.81
MAX. 6.26 6.46 4.92 5.24 1.14 1.69 79.27 56.35 4.26 3.95 4.02 3.67 1.79 1.70 2.26 2.66 1.37 1.68 1.26 1.15 2.69 2.83
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Appendix 9.2c (i and ii): Lung function measurements in heaves (H1-5 and 7) horses prior to (Oh) and at 5h following inhalation challenge with HDS-LPS with added
back LPS (HDS-LPS+LPS). MED. = median value, MIN. = minimum value, MAX. = maximum value.
Cdyn (J/kPa) dPpl(kPa) RLiso (kPa/l/sec) RR (breaths/rain.) VT (I) Wbli/min) RLe25% (kPa/l/sec) RLe5o% (kPa/l/sec) RLe7s% (kPa/l/sec) RLi25% (kPa/l/sec) Rliso%(kPa/l/sec) RLi75% (kPa/i/sec)
TP Oh 5h Oh 5h 0h 5h 0h 5h Oh 5h 0h 5h Oh 5h 0h 5h Oh 5h Oh 5h oh 5h Oh 5h
H1 25.00 18.96 0.78 0.92 0.07 0.07 7.40 7.55 8.00 9.44 21.68 31.56 0.11 0.11 0.10 0.11 0.10 0.10 0.05 0.05 0.06 0.06 0.07 0.06
H2 76.89 32.02 0.44 0.84 0.04 0.11 10.45 7.05 6.19 6.30 14.80 18.90 0.02 0.10 0.04 0.10 0.06 0.14 0.04 0.10 0.04 0.10 0.05 0.13
H3 9.77 6.95 0.77 1.03 0.09 0.18 6.50 5.85 5.09 4.94 9.08 11.10 0.07 0.12 0.02 0.00 0.06 0.11 0.15 0.25 0.25 0.41 0.14 0.23
H4 37.44 19.65 0.41 0.70 0.04 0.11 10.75 11.60 5.77 4.13 11.19 17.91 0.04 0.10 0.06 0.10 0.05 0.13 0.03 0.07 0.03 0.09 0.04 0.12
H5 28.22 23.45 0.49 0.58 0.04 0.04 7.55 7.00 7.56 8.03 11.66 12.19 0.03 0.05 0.05 0.06 0.06 0.08 0.03 0.03 0.04 0.03 0.05 0.06
H7 23.29 14.70 0.60 0.81 0.05 0.08 13.55 9.80 6.01 6.02 24.74 21.86 0.05 0.10 0.05 0.09 0.06 0.09 0.04 0.07 0.05 0.08 0.06 0.09
MED. 26.61 19.31 0.54 0.82 0.05 0.09 9.00 7.30 6.10 6.16 13.23 18.41 0.05 0.10 0.05 0.09 0.06 0.10 0.04 0.07 0.04 0.08 0.06 0.11
MIN. 9.77 6.95 0.41 0.58 0.04 0.04 6.50 5.85 5.09 4.13 9.08 11.10 0.02 0.05 0.02 0.00 0.05 0.08 0.03 0.03 0.03 0.03 0.04 0.06
MAX. 76.89 32.02 0.78 1.03 0.09 0.18 13.55 11.60 8.00 9.44 24.74 31.56 0.11 0.12 0.10 0.11 0.10 0.14 0.15 0.25 0.25 0.41 0.14 0.23
TE(sec) Ti(sec) T,:Te V'e (l/min) V'eiyiqx (l/sec) V'imax (l/sec) Wb >i(J) Wbr .(J) WbE es(J) Wb!res(J) 8 Wb, ot(J)
TP
H1
Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h I Oh 5h
3.78 3.77 4.31 4.29 1.15 1.14 59.05 70.91 4.05 5.92 2.93 3.29 1.27 2.35 2.94 4.26 1.83 2.70 1.11 1.56 2.38 3.91
H2 3.23 5.13 2.50 3.46 0.79 0.68 64.40 44.14 3.23 2.35 3.68 2.57 0.26 0.64 1.42 2.71 0.61 1.27 0.81 1.45 1.06 2.09
H3 4.53 5.53 4.59 4.79 2.17 0.87 33.39 28.80 2.40 2.01 3.05 2.38 1.61 1.76 1.36 1.90 0.36 0.62 1.00 1.28 2.61 3.04
H4 3.13 3.15 2.54 2.16 0.82 0.70 61.81 47.82 3.27 2.05 3.59 2.70 0.48 0.48 1.06 1.53 0.52 0.68 0.53 0.85 1.02 1.32
H5 4.70 4.96 3.03 3.38 0.64 0.69 57.41 55.88 3.70 3.76 4.29 4.01 0.96 1.39 1.43 1.70 0.62 0.58 0.81 1.13 1.77 2.51
H7 2.30 3.17 2.15 2.97 0.95 0.94 81.53 59.00 3.92 3.11 4.10 2.77 0.79 1.24 1.85 2.20 0.83 1.12 1.01 1.08 1.80 2.32
MED. 3.50 4.36 2.79 3.42 0.89 0.78 60.43 51.85 3.48 2.73 3.64 2.74 0.87 1.31 1.42 2.05 0.62 0.90 0.90 1.20 1.78 2.42
MIN. 2.30 3.15 2.15 2.16 0.64 0.68 33.39 28.80 2.40 2.01 2.93 2.38 0.26 0.48 1.06 1.53 0.36 0.58 0.53 0.85 1.02 1.32
MAX. 4.70 5.53 4.59 4.79 2.17 1.14 81.53 70.91 4.05 5.92 4.29 4.01 1.61 2.35 2.94 4.26 1.83 2.70 1.11 1.56 2.61 3.91
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Appendix 9.3: PCCdyn70 values (mg/ml) in control
(C1-6) and heaves (H1-5 and 7) horses at 5h
following inhalation challenge with HDS-1[100],
LPS-depleted HDS (HDS-LPS) and HDS-LPS with
added back LPS (HDS-LPS+LPS). MED. = median
value, MIN. = minimum value, MAX. = maximum
value.
HDS-1f100] HDS-LPS I HDS-LPS+LPS
C1 3.17 1.67 NP
C2 7.08 3.32 NP
C3 5.25 3.43 NP
C4 2.07 2.70 NP
C5 4.69 0.34 NP




H1 8.16 9.21 6.18
H2 6.91 1.39 2.71
H3 4.26 3.98 4.46
H4 11.43 10.88 7.16
H5 9.96 12.02 4.71
H7 6.20 4.69 5.34
MED. 7.53 6.95 5.02
MIN. 4.26 1.39 2.71
MAX. 11.43 12.02 7.16
360
Appendix 9.4: BALF total nucleated cell (TCC), lymphocyte, macrophage, neutrophil, mast cell, basiphiloid cell, eosinophil and epithelial cell counts (x105/ml) in
heaves (H1-5 and 7) at 6h following inhalation challenge with saline, HDS-1 [100], LPS-depleted HDS (HDS-LPS) and HDS-LPS with added back LPS (HDS-L+L).
MED. = median value, MIN. = minimum value, MAX. = maximum value.
TCC
SAUNE HDS-1 [100] HDS-LPS HDS-L+L
C1 5.10 3.00 1.80 NP
C2 3.90 4.30 3.20 NP
C3 2.00 1.60 3.20 NP
C4 2.90 8.00 3.80 NP
C5 9.60 5.00 4.40 NP
C6 3.80 5.10 2.80 NP
MED. 3.85 4.65 3.20
MIN 2.00 1.60 1.80
MAX 9.60 8.00 4.40
H1 5.60 4.00 3.20 5.50
H2 3.40 3.70 4.10 3.90
H3 3.80 6.20 3.00 4.00
H4 5.50 4.10 4.50 3.40
H5 3.20 7.00 6.20 6.00
H6 1.30 2.10 4.60 NP
H7 5.20 4.10 3.40 4.10
MED. 3.80 4.10 4.10 4.00
MIN 1.30 2.10 3.00 0.00
MAX 5.60 7.00 6.20 6.00
Lymphocytes
SALINE HDS-1 [100] HDS-LPS HDS-L+L
C1 1.89 0.66 0.54 NP
C2 1.28 1.24 0.84 NP
C3 0.99 0.83 1.87 NP
C4 0.99 1.74 1.25 NP
C5 6.22 2.29 1.67 NP
C6 2.41 2.23 1.16 NP
MED. 1.59 1.49 1.20
MIN 0.99 0.66 0.54
MAX 6.22 2.29 1.87
H1 3.33 1.62 1.16 2.35
H2 1.54 0.61 0.90 0.61
H3 2.09 1.19 1.13 0.78
H4 2.36 1.75 1.85 1.36
H5 1.64 1.86 2.43 0.68
H6 0.80 0.81 2.42 NP
H7 2.57 1.12 1.58 1.99
MED. 2.09 1.19 1.58 1.07
MIN 0.80 0.61 0.90 0.61
MAX 3.33 1.86 2.43 2.35
Macrophages
SALINE HDS-1 [100] HDS-LPS HDS-L+L
C1 2.80 1.72 1.00 NP
C2 2.25 2.75 2.13 NP
C3 0.73 0.51 0.78 NP
C4 1.71 4.19 2.19 NP
C5 2.57 1.91 2.11 NP
C6 1.14 2.46 1.39 NP
MED. 1.98 2.18 1.75
MIN 0.73 0.51 0.78
MAX 2.80 4.19 2.19
H1 1.96 1.16 1.37 1.18
H2 1.58 0.41 0.67 0.66
H3 1.24 1.75 1.23 1.10
H4 2.96 1.48 2.16 1.38
H5 1.27 1.18 2.11 1.01
H6 0.34 0.50 0.84 NP
H7 2.40 0.77 1.18 1.03
MED. 1.58 1.16 1.23 1.07
MIN 0.34 0.41 0.67 0.66
MAX 2.96 1.75 2.16 1.38
Neutrophils
SALINE : HDS-1[100] HDS-LPS HDS-L+L
C1 0.04 0.29 0.08 NP
C2 0.01 0.12 0.04 NP
C3 0.02 0.08 0.11 NP
C4 0.09 0.56 0.07 NP
C5 0.17 0.66 0.15 NP
C6 0.09 0.28 i 0.18 NP
MED. 0.06 0.28 0.09
MIN 0.01 0.08 0.04
MAX 0.17 0.66 0.18
H1 0.20 1.11 0.48 1.78
H2 0.08 2.60 2.48 2.55
H3 0.17 3.14 0.47 1.95
H4 0.03 0.80 0.44 0.56
H5 0.06 3.81 1.62 4.28
H6 0.06 0.54 1.07 NP
H7 0.06 2.17 0.61 0.94
MED. 0.06 2.17 0.61 1.87
MIN 0.03 0.54 0.44 0.56
MAX 0.20 3.81 2.48 4.28
Mast cells
SALINE HDS-1 [100] HDS-LPS HDS-L+L
C1 0.23 0.13 0.17 NP
C2 0.30 COCD 0.12 NP
C3 0.26 0.12 0.30 NP
C4 0.06 0.24 0.06 NP
C5 0.39 0.15 0.25 NP
C6 0.09 0.11 0.05 NP
MED. 0.25 0.14 0.15
MIN 0.06 0.11 0.05
MAX 0.39 0.24 0.30
H1 0.11 0.08 0.10 0.18
H2 0.15 0.07 0.05 0.08
H3 0.19 0.11 0.14 0.14
H4 0.13 0.05 0.03 0.05
H5 0.09 0.02 0.04 0.00
H6 0.10 0.14 0.21 NP
H7 0.17 0.02 0.01 0.05
MED. 0.13 0.07 0.05 0.07
MIN 0.09 0.02 0.01 0.00
MAX 0.19 0.14 0.21 0.18
Basiphiloid cells
SALINE HDS-1 [100J HDS-LPS HDS-L+L
C1 0.07 0.20 0.01 NP
C2 0.01 0.00 0.06 NP
C3 0.00 0.03 0.00 NP
C4 0.03 1.04 0.17 NP
C5 0.22 0.00 0.21 NP
C6 0.01 0.00 0.01 NP
MED. 0.02 0.02 0.04
MIN 0.00 0.00 0.00
MAX 0.22 1.04 0.21
H1 0.01 0.00 0.08 0.00
H2 0.05 0.00 0.00 0.00
H3 0.11 0.00 0.04 0.02
H4 0.01 0.00 0.01 0.01
H5 0.02 0.00 0.00 0.02
H6 0.00 0.10 0.00 NP
H7 0.01 0.00 0.03 0.05
MED. 0.01 0.00 0.01 0.01
MIN 0.00 0.00 0.00 0.00
MAX 0.11 0.10 0.08 0.05
Eosinophils
SAUNE HDS-1 [100] HDS-LPS HDS-L+L
C1 0.05 0.00 0.00 NP
C2 0.06 0.01 0.00 NP
C3 0.00 0.04 0.14 NP
C4 0.00 0.23 0.06 NP
C5 0.02 0.00 0.01 NP
C6 0.06 0.02 0.00 NP
MED. 0.03 0.01 0.00
MIN 0.00 0.00 0.00
MAX 0.06 0.23 0.14
H1 0.00 0.03 0.01 0.01
H2 0.00 0.00 0.00 0.00
H3 0.01 0.00 0.00 0.00
H4 0.01 0.01 0.00 0.04
H5 0.01 0.13 0.00 0.01
H6 0.01 0.01 0.06 NP
H7 0.00 0.02 0.00 0.03
MED. 0.01 0.01 0.00 0.01
MIN 0.00 0.00 0.00 0.00
MAX 0.01 0.13 0.06 0.04
Epithelial cells
SALINE HDS-1 [100] HDS-LPS HDS-L+L
C1 0.03 0.00 0.00 NP
C2 0.00 0.00 0.00 NP
C3 0.00 0.00 0.00 NP
C4 0.00 0.00 0.00 NP
C5 0.00 0.00 0.00 NP
C6 0.00 0.00 0.00 NP
MED. 0.00 0.00 0.00
MIN 0.00 0.00 0.00
MAX 0.03 0.00 0.00
H1 0.00 0.00 0.00 0.00
H2 0.00 0.00 0.00 0.00
H3 0.00 0.00 0.00 0.00
H4 0.00 0.00 0.00 0.00
H5 0.10 0.00 0.00 0.00
H6 0.00 0.00 0.00 NP
H7 0.00 0.00 o.oo ' 0.00
MED. 0.00 0.00 0.00 0.00
MIN 0.00 0.00 0.00 0.00
MAX 0.10 0.00 0.00 0.00
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Appendix 10.1 (i and ii): Lung function measurements in heaves (H1-7) horses prior to (Oh) and at 5h following inhalation challenge with WP+LPS. MED. - median
value, MIN. = minimum value, MAX. = maximum value.
Cdyn (l/kRa) dPpl(kPa) RLjfio (kPa/l/sec) RR (breaths/min.) VT (!) Wb' (J/min) RLe25% (kPa/l/sec) RLe5o% (kPa/l/sec) RLE75% (kPa/l/sec) RLl25%(kPa/l/sec) RLi5o% (kPa/l/sec) RLj75% (kPa/l/sec)
TP Oh 5h 0h 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h 0h 5h 0h 5h 0h 5h Oh 5h Oh 5h
H1 21.48 17.29 0.73 0.96 0.06 0.09 8.35 7.85 7.81 7.69 19.81 25.00 0.08 0.12 0.09 0.12 0.06 0.09 0.04 0.08 0.04 0.07 0.05 0.05
H2 46.81 20.39 0.47 1.19 0.05 0.14 7.50 6.90 6.12 7.56 10.52 31.39 0.04 0.15 0.06 0.12 0.09 0.18 0.06 0.12 0.05 0.13 0.05 0.15
H3 7.96 9.21 0.86 0.80 0.11 0.14 5.40 5.05 4.94 5.42 10.83 7.87 0.05 0.11 0.02 0.03 0.10 0.11 0.22 0.19 0.35 0.31 0.26 0.16
H4 27.98 22.11 0.76 0.61 0.06 0.05 7.85 6.40 7.34 6.98 15.64 11.61 0.09 0.14 0.07 0.08 0.08 0.09 0.07 0.07 0.05 0.03 0.05 0.06
H5 18.68 22.50 0.60 0.56 0.05 0.05 7.10 9.40 7.34 6.33 9.97 13.79 0.04 0.05 0.06 0.06 0.07 0.06 0.04 0.03 0.04 0.05 0.04 0.06
H6 9.17 6.81 0.70 0.97 0.11 0.15 10.45 8.30 4.17 3.95 11.19 13.21 0.09 0.13 0.10 0.14 0.10 0.18 0.25 0.26 0.24 0.16 0.08 0.15
H7 19.20 13.80 0.73 0.67 0.06 0.07 9.95 8.30 6.96 6.12 22.04 13.37 0.05 0.08 0.05 0.06 0.07 0.07 0.07 0.08 0.07 0.08 0.07 0.07
MED. 19.20 17.29 0.73 0.80 0.06 0.09 7.85 7.85 6.96 6.33 11.19 13.37 0.05 0.12 0.06 0.08 0.08 0.09 0.07 0.08 0.05 0.08 0.05 0.07
MIN. 7.96 6.81 0.47 0.56 0.05 0.05 5.40 5.05 4.17 3.95 9.97 7.87 0.04 0.05 0.02 0.03 0.06 0.06 0.04 0.03 0.04 0.03 0.04 0.05
MAX. 46.81 22.50 0.86 1.19 0.11 0.15 10.45 9.40 7.81 7.69 22.04 31.39 0.09 0.15 0.10 0.14 0.10 0.18 0.25 0.26 0.35 0.31 0.26 0.16
Te (sec) Ti (sec) T,:Te Ve (l/min) V'Emax (l/SeC) V'imax [[/sec) Wb i (J) Wb,« (J) WbE «(J) Wbtres (J) . Wbttot(J)
TP Oh 5h 0h 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h Oh 5h
H1 3.27 3.32 4.13 4.40 1.32 1.37 65.02 60.13 4.93 4.84 3.77 3.05 1.40 1.74 2.39 3.18 1.60 2.12 0.79 1.06 2.20 2.80
H2 4.32 4.72 3.87 4.00 0.90 0.85 45.70 52.25 2.67 2.54 2.88 2.58 0.45 1.43 1.43 4.57 0.83 2.39 0.61 2.18 1.06 3.61
H3 5.48 6.24 5.12 5.54 1.22 0.89 26.77 27.59 1.82 1.58 2.47 2.34 1.70 1.61 1.82 1.54 0.64 0.63 1.19 0.91 2.89 2.52
H4 4.78 5.05 3.76 4.41 0.81 0.87 57.53 44.57 3.57 2.63 3.87 3.00 0.97 1.14 2.19 1.81 1.33 1.15 0.87 0.66 1.84 1.80
H5 5.17 3.67 3.32 2.63 0.65 0.73 52.38 59.25 2.90 3.37 3.90 3.88 1.45 0.90 1.40 1.44 0.52 0.58 0.88 0.86 2.32 1.76
H6 3.02 3.09 3.74 4.16 1.26 1.36 43.43 32.75 3.01 2.27 1.94 1.72 0.95 1.15 1.30 1.57 0.62 0.70 0.68 0.87 1.63 2.02
H7 2.81 3.47 3.19 3.67 1.14 1.06 69.45 50.80 3.78 2.79 3.25 2.53 1.25 1.39 2.21 1.59 1.11 0.81 1.10 0.78 2.35 2.17
MED. 4.32 3.67 3.76 4.16 1.14 0.89 52.38 50.80 3.01 2.63 3.25 2.58 1.25 1.39 1.82 1.59 0.83 0.81 0.87 0.87 2.20 2.17
MIN. 2.81 3.09 3.19 2.63 0.65 0.73 26.77 27.59 1.82 1.58 1.94 1.72 0.45 0.90 1.30 1.44 0.52 0.58 0.61 0.66 1.06 1.76
MAX. 5.48 6.24 5.12 5.54 1.32 1.37 69.45 60.13 4.93 4.84 3.90 3.88 1.70 1.74 2.39 4.57 1.60 2.39 1.19 2.18 2.89 3.61
Appendix 10.2: PCCdyn70 values (mg/ml) in
heaves (H1-7) horses at 5h following inhalation
challenge with saline, WP+LPS and HDS-1[100],
MED. = median value, MIN. = minimum value,
MAX. = maximum value.
SALINE HDS-1[100] WP+LPS
H1 7.86 8.16 5.63
H2 3.06 6.91 4.54
H3 5.64 4.26 5.74
H4 10.53 11.43 13.66
H5 6.40 9.96 3.48
H6 2.46 4.27 2.89
H7 5.63 6.20 4.39
MED. 5.64 6.91 4.54
MIN. 2.46 4.26 2.89
MAX.. 10.53 11.43 13.66
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Appendix 10.3(a): BALF total nucleated cell counts (x105/ml) in heaves (H1-
7) horses at 6h following challenge with saline, 20pg LPS, HDS-1 [100], WP,
WP[R], WP+LPS, WP+LPS[R], WP/SUP[m] and WP/SUP[s], MED. =
median value, MIN. = minimum value, MAX. = maximum value.
SALINE 20fig LPS HDS-1 WP WP[R] WP+LPS wp+lps[r] wp/sup[m] wp/sup[sj
H1 5.60 6.30 4.00 5.50 3.10 2.80 3.30 5.40 5.50
H2 3.40 3.20 3.70 4.80 3.70 2.90 4.50 4.70 5.90
H3 3.80 4.10 6.20 5.00 3.50 4.20 11.00 10.20 13.70
H4 5.50 5.40 4.10 5.60 5.30 4.20 4.20 5.70 7.30
H5 3.20 4.60 7.00 7.80 3.90 3.80 4.40 7.80 19.00
H6 1.30 2.90 2.10 2.00 3.50 2.30 2.30 2.30 2.90
H7 5.20 7.40 4.10 9.10 NP 3.90 NP 5.30 4.40
MED. 3.80 4.60 4.10 5.50 3.80 5.40 5.90
MIN 1.30 2.90 2.10 2.00 2.30 2.30 2.90
MAX 5.60 7.40 7.00 9.10 4.20 10.20 19.00
Appendix 10.3(c): BALF macrophage counts (x105/ml) in heaves (H1-7)
horses at 6h following challenge with saline, 20pg LPS, HDS-1 [100], WP,
WP[R], WP+LPS, WP+LPS[R], WP/SUP[m] and WP/SUP[s], MED. =
median value, MIN. = minimum value, MAX. = maximum value.
SALINE 20fig LPS HDS-1 WP WP[R] WP+LPS wp+lps[rj wp/supfm] wp/sup[s]
H1 1.96 2.26 1.16 1.68 2.15 0.89 1.28 2.21 1.78
H2 1.58 0.88 0.41 2.29 2.13 0.60 1.64 1.19 1.57
H3 1.24 1.68 1.75 1.99 2.47 1.23 3.18 4.81 5.14
H4 2.96 2.57 1.48 3.18 3.22 1.51 2.36 2.10 4.08
H5 1.27 1.15 1.18 3.92 1.82 0.75 0.88 1.37 5.30
H6 0.34 0.70 0.50 0.71 1.67 0.36 0.63 0.38 0.68
H7 2.40 1.94 0.77 1.65 NP 1.15 NP 1.46 1.67
MED. 1.58 1.68 1.16 1.99 2.14 0.89 1.46 1.46 1.78
MIN 0.34 0.70 0.41 0.71 1.67 0.36 0.63 0.38 0.68
MAX 2.96 2.57 1.75 3.92 3.22 1.51 3.18 4.81 5.30
Appendix 10.3(b): BALF lymphocyte counts (x105/ml) in heaves (H1-7)
horses at 6h following challenge with saline, 20pg LPS, HDS-1 [100], WP,
WP[R], WP+LPS, WP+LPS[R], WP/SUP[m] and WP/SUP[s], MED. =
median value, MIN. = minimum value, MAX. = maximum value.
SALINE 20|ig LPS HDS-1 WP WP[R] WP+LPS wp+lps[r] wp/supcm] wp/sup[s]
H1 3.33 3.45 1.62 3.29 0.78 1.07 1.42 2.39 2 94
H2 1.54 2.04 0.61 2.21 1.19 0.81 1.06 1.09 1.33
H3 2.09 1.88 1.19 2.19 0.72 1.21 2.51 2.83 2.42
H4 2.36 2.45 1.75 1.98 1.81 2.05 1.22 2.33 2.47
H5 1.64 2.93 1.86 3.49 1.27 1.46 0.76 1.79 4.20
H6 0.80 1.93 0.81 0.95 1.52 1.38 0.94 1.14 1.56
H7 2.57 4.83 1.12 5.20 NP 2.08 NP 2.39 2.36
MED. 2.09 2.45 1.19 2.21 1.23 1.38 1.14 2.33 2.42
MIN 0.80 1.88 0.61 0.95 0.72 0.81 0.76 1.09 1.33
MAX 3.33 4.83 1.86 5.20 1.81 2.08 2.51 2.83 4.20
Appendix 10.3(d): BALF neutrophil counts (x105/ml) in heaves (H1-7) horses
at 6h following challenge with saline, 20pg LPS, HDS-1 [100], WP, WP[R],
WP+LPS, WP+LPS[R], WP/SUP[m] and WP/SUP[s], MED. = median value,
MIN. = minimum value, MAX. = maximum value.
SALINE 20fig LPS HDS-1 WP WP[R] WP+LPS wp+lps[r] wp/supjm] wp/supcsj
H1 0.20 0.39 1.11 0.21 0.08 0.71 0.45 0.43 0.27
H2 0.08 0.20 2.60 0.14 0.24 1.35 1.70 2.34 2.83
H3 0.17 0.23 3.14 0.65 0.20 1.62 5.08 2.35 5.90
H4 0.03 0.30 0.80 0.19 0.19 0.55 0.53 1.04 0.47
H5 0.06 0.28 3.81 0.19 0.79 1.54 2.74 4.55 9.29
H6 0.06 0.18 0.54 0.10 0.23 0.40 0.63 0.63 0.43
H7 0.06 0.53 2.17 0.56 NP 0.56 NP 1.36 0.12
MED. 0.06 0.28 2.17 0.19 0.22 0.71 1.16 1.36 0.47
MIN 0.03 0.18 0.54 0.10 0.08 0.40 0.45 0.43 0.12
MAX 0.20 0.53 3.81 0.65 0.79 1.62 5.08 4.55 9.29
Appendix 10.3(e): BALF mast cell counts (x105/ml) in heaves (H1-7) horses
at 6h following challenge with saline, 20pg LPS, HDS-1[100], WP, WP[R],
WP+LPS, WP+LPS[R], WP/SUP[m] and WP/SUP[s]. MED. = median value,
MIN. = minimum value, MAX. = maximum value.
SALINE 20pg LPS HDS-1 WP WP[R] WP+LPS WP+LPS [RJ WP/SUP[M] WP/SUP[S]
H1 0.11 0.18 0.08 0.23 0.07 0.13 0.15 0.24 0.30
H2 0.15 0.07 0.07 0.12 0.13 0.09 0.08 0.07 0.17
H3 0.19 0.30 0.11 0.14 0.11 0.13 0.23 0.21 0.22
H4 0.13 0.07 0.05 0.09 0.07 0.09 0.08 0.03 0.14
H5 0.09 0.08 0.02 0.11 0.02 0.00 0.02 0.02 0.02
H6 0.10 0.07 0.14 0.19 0.06 0.14 0.11 0.14 0.19
H7 0.17 0.06 0.02 0.15 NP 0.08 NP 0.08 0.19
MED. 0.13 0.07 0.07 0.14 0.07 0.09 0.09 0.08 0.19
MIN 0.09 0.06 0.02 0.09 0.02 0.00 0.02 0.02 0.02
MAX 0.19 0.30 0.14 0.23 0.13 0.14 0.23 0.24 0.30
Appendix 10.3(g): BALF eosinophil counts (x105/ml) in heaves (H1-7)
horses at 6h following challenge with saline, 20pg LPS, HDS-1[100], WP,
WP[R], WP+LPS, WP+LPS[R], WP/SUP[m] and WP/SUP[s], MED. =
median value, MIN. = minimum value, MAX. = maximum value.
SALINE 20fig LPS HDS-1 WP WP[R] WP+LPS WP+LPS [RJ WP/SUP[M] WP/SUP[S]
H1 0.00 0.01 0.03 0.07 0.00 0.00 0.00 0.12 0.21
H2 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00
H3 0.01 0.00 0.00 0.04 0.00 0.00 0.00 0.00 0.00
H4 0.01 0.00 0.01 0.13 0.01 0.00 0.00 0.20 0.14
H5 0.01 0.00 0.13 0.08 0.00 0.03 0.00 0.06 0.19
H6 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01
H7 0.00 0.01 0.02 1.54 NP o.di NP 0.01 0.03
MED. 0.01 0.00 0.01 0.07 0.00 0.01 0.00 0.01 0.03
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MAX 0.01 0.01 0.13 1.54 0.01 0.03 0.00 0.20 0.21
Appendix 10.3(f): BALF basiphiloid cell counts (x10b/ml) in heaves (F11-7)
horses at 6h following challenge with saline, 20pg LPS, HDS-1[100], \J\lP,
WP[R], WP+LPS, WP+LPS[R], WP/SUP[m] and WP/SUP[s], MED. -
median value, MIN. = minimum value, MAX. = maximum value.
SALINE 20ng LPS HDS-1 WP WP[R] WP+LPS WP+LPS [R] WP/SUPJMJ wp/sufQ
H1 0.01 0.00 0.00 0.02 0.01 0.00 0.00 0.00 O.oU
H2 0.05 0.01 0.00 0.02 0.00 0.03 0.02 0.01 o.oU
H3 0.11 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0-0l_
H4 0.01 0.01 0.00 0.02 0.00 0.00 0.00 0.00 0.oU
H5 0.02 0.12 0.00 0.02 0.00 0.02 0.00 0.02 o.ocu
H6 0.00 0.02 0.10 0.04 0.01 0.01 0.00 0.00 o.oU
H7 0.01 0.01 0.00 0.02 NP 0.02 NP 0.00 O.oU
MED. 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0-0U
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 O.QO^
MAX 0.11 0.12 0.10 0.04 0.01 0.03 0.02 0.02 O.oU
Appendix 10.3(h): BALF epithelial cell counts (x10b/ml) in heaves (H1-7)
horses at 6h following challenge with saline, 20pg LPS, HDS-1[100], WP>
WP[R], WP+LPS, WP+LPS[R), WP/SUP[m] and WP/SUP[s], MED. ~
median value, MIN. = minimum value, MAX. = maximum value.
SALINE 20(ig LPS HDS-1 WP WP[R] WP+LPS WP+LPS[RJ WP/SUP[MJ WP/SUPR
H1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.ocu
H2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.oiu
H3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 °o<U
H4 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 O.oU
H5 0.10 0.05 0.00 0.00 0.00 0.00 0.00 0.00 o.ocu
H6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.ocU
H7 0.00 0.02 0.00 0.00 NP 0.00 NP 0.00 o.ocu
MED. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.ocu
MIN 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 o.otU
MAX 0.10 0.05 0.00 0.00 0.00 0.00 0.00 0.00 o.ocu
